HEPATITIS B A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2004 by ICON Group International, Inc. Copyright ©2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Hepatitis B: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83979-4 1. Hepatitis B-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on hepatitis B. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON HEPATITIS B .............................................................................................. 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Hepatitis B .................................................................................. 32 E-Journals: PubMed Central ....................................................................................................... 88 The National Library of Medicine: PubMed .............................................................................. 125 CHAPTER 2. NUTRITION AND HEPATITIS B .................................................................................. 173 Overview.................................................................................................................................... 173 Finding Nutrition Studies on Hepatitis B ................................................................................. 173 Federal Resources on Nutrition ................................................................................................. 179 Additional Web Resources ......................................................................................................... 180 CHAPTER 3. ALTERNATIVE MEDICINE AND HEPATITIS B............................................................ 181 Overview.................................................................................................................................... 181 National Center for Complementary and Alternative Medicine................................................ 181 Additional Web Resources ......................................................................................................... 201 General References ..................................................................................................................... 203 CHAPTER 4. DISSERTATIONS ON HEPATITIS B.............................................................................. 205 Overview.................................................................................................................................... 205 Dissertations on Hepatitis B ...................................................................................................... 205 Keeping Current ........................................................................................................................ 207 CHAPTER 5. CLINICAL TRIALS AND HEPATITIS B ........................................................................ 209 Overview.................................................................................................................................... 209 Recent Trials on Hepatitis B ...................................................................................................... 209 Keeping Current on Clinical Trials ........................................................................................... 221 CHAPTER 6. PATENTS ON HEPATITIS B......................................................................................... 223 Overview.................................................................................................................................... 223 Patents on Hepatitis B ............................................................................................................... 223 Patent Applications on Hepatitis B ........................................................................................... 249 Keeping Current ........................................................................................................................ 282 CHAPTER 7. BOOKS ON HEPATITIS B ............................................................................................ 283 Overview.................................................................................................................................... 283 Book Summaries: Federal Agencies............................................................................................ 283 Book Summaries: Online Booksellers......................................................................................... 286 The National Library of Medicine Book Index ........................................................................... 290 Chapters on Hepatitis B ............................................................................................................. 291 CHAPTER 8. MULTIMEDIA ON HEPATITIS B ................................................................................. 297 Overview.................................................................................................................................... 297 Video Recordings ....................................................................................................................... 297 Audio Recordings....................................................................................................................... 299 Bibliography: Multimedia on Hepatitis B.................................................................................. 300 CHAPTER 9. PERIODICALS AND NEWS ON HEPATITIS B .............................................................. 303 Overview.................................................................................................................................... 303 News Services and Press Releases.............................................................................................. 303 Newsletters on Hepatitis B ........................................................................................................ 307 Newsletter Articles .................................................................................................................... 308 Academic Periodicals covering Hepatitis B................................................................................ 310 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 311 Overview.................................................................................................................................... 311 U.S. Pharmacopeia..................................................................................................................... 311 Commercial Databases ............................................................................................................... 312
viii Contents
Researching Orphan Drugs ....................................................................................................... 313 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 317 Overview.................................................................................................................................... 317 NIH Guidelines.......................................................................................................................... 317 NIH Databases........................................................................................................................... 319 Other Commercial Databases..................................................................................................... 326 The Genome Project and Hepatitis B ......................................................................................... 326 APPENDIX B. PATIENT RESOURCES ............................................................................................... 331 Overview.................................................................................................................................... 331 Patient Guideline Sources.......................................................................................................... 331 Associations and Hepatitis B ..................................................................................................... 357 Finding Associations.................................................................................................................. 358 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 361 Overview.................................................................................................................................... 361 Preparation................................................................................................................................. 361 Finding a Local Medical Library................................................................................................ 361 Medical Libraries in the U.S. and Canada ................................................................................. 361 ONLINE GLOSSARIES................................................................................................................ 367 Online Dictionary Directories ................................................................................................... 370 HEPATITIS B DICTIONARY...................................................................................................... 371 INDEX .............................................................................................................................................. 451
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with hepatitis B is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about hepatitis B, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to hepatitis B, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on hepatitis B. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to hepatitis B, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on hepatitis B. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON HEPATITIS B Overview In this chapter, we will show you how to locate peer-reviewed references and studies on hepatitis B.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and hepatitis B, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “hepatitis B” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Treatment of Chronic Hepatitis B in Australia and New Zealand Source: Journal of Gastroenterology and Hepatology. 15(Supplement): E79-E82. May 2000. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Acute and chronic infections with hepatitis B virus (HBV) are a major public health problem in Australia and New Zealand. This article reviews the treatment of chronic hepatitis B in these countries. Although both countries have a low prevalence of the population with chronic HBV (less than 2 percent) infection, both have certain population groups with a high prevalence of the disease. In Australia, the highest rates
4
Hepatitis B
are found among Aborigines and Torres Strait Islanders (approximately 10 to 25 percent) and immigrants from Southeast Asia and the Pacific Islands (5 to 15 percent). In New Zealand the cases of chronic HBV infection vary among groups: Chinese (10 percent), Maori (5.43 percent), Pacific Islanders (4.4 percent) and Europeans (0.43 percent). In New Zealand, a universal vaccination program was introduced, with hepatitis B vaccine being incorporated into the national childhood vaccination schedule in 1988. In both New Zealand and Australia, pregnant women are screened and HBV vaccine is administered to children of chronically infected mothers. Seronegative household members of families containing a member found to be acutely or chronically infected with HBV are vaccinated. Interferon therapy has been available since the late 1980s and is fully subsidized. Lamivudine has been prescribe preliver and postliver transplant as part of an international compassionate use program. Interferon, usually without steroid priming, has been the standard therapy, with trials showing a 41 percent response rate. 26 references. •
Hepatitis B Vaccine Recommended for All Children Source: FDA Consumer. 25(5): 2-3. June 1991. Summary: All children should be vaccinated against hepatitis B, according to the Immunization Practices Advisory Committee of the U.S. Public Health Service. Immunization experts made this recommendation in February 1991, after strategies to vaccinate adults at high risk for hepatitis B failed to achieve sufficient coverage. This brief article reviews the reasons behind this decision and the potential benefits of universal immunization. 2 references. (AA-M).
•
Risk Factors for Viral Hepatitis B and C Help Identify Disease Source: Practical Gastroenterology. 22(1): 10-12, 19-22, 25-26. January 1998. Contact: Available from Shugar Publishing, Inc. 99B Main Street, Westhampton Beach, NY 11978. (631) 288-4404. Fax (631) 288-4435. E-Mail:
[email protected]. Summary: An estimated 200,000 to 300,000 people in the US become infected each year with the hepatitis B virus, and 150,000 become infected with the hepatitis C virus. Identification of the modes of transmission is of primary importance in efforts to curtail the spread of these infections. This article reviews the risk factors, both common and rare, that have been identified to date. The authors note that, in individual cases, knowledge of risk factors for transmission helps physicians to identify and counsel patients at risk, to identify those whose history indicates the possibility of infection, and, for those who are seropositive, to determine how and when infection occurred, which may have implications for prognosis and treatment. Topics include sexual contact, household and other social contacts, risks of HBV transmission in institutional settings, the maternal-fetal interface, blood and blood product transfusions, hemodialysis, transplantation associated risk, physicians as a risk to their patients, transmission from medical devices, occupational risk factors, social and recreational transmission, intravenous drug abuse, cosmetic transmission (ear piercing, tattooing, barber shop shaving, manicurists), the risk factor associated with certain sports, and insect-borne infection. 2 figures. 4 tables. 28 references. (AA-M).
•
Prevention of Hepatitis B Virus in Athletic Training Source: Journal of Athletic Training. 29(2): 107-112. June 1994.
Studies
5
Summary: Because of exposure to blood-borne pathogens and potentially infectious materials, athletic training is an allied health care profession with an increased risk of exposure to hepatitis B virus (HBV). This article considers the prevention of HBV in athletic training. Topics include the pathogenesis and epidemiology of HBV; signs and symptoms; transmission; and preventive measures, including immunization, protective equipment, housekeeping, and sharps. The authors stress the importance of information dissemination about prevention of HBV in the athletic training setting to all athletic training staff and students, through in-service training sessions, symposia, and lectures. 1 table. 11 references. (AA-M). •
Management of Patients with Chronic Hepatitis B Source: Journal of Gastroenterology and Hepatology. 17(4): 406-408. April 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Better understanding of hepatitis B virus (HBV) replication and the natural history and immunopathogenesis of chronic hepatitis B, together with the introduction of effective agents with different mechanisms of action, are the basis for better therapeutic strategies against chronic hepatitis B. This article brings readers up to date on the current management of patients with chronic hepatitis B. Among currently available drugs, alpha interferon therapy gives a response rate of 30 to 40 percent, compared with 10 to 20 percent in matched controls, but patients with lower alanine aminotransferase (ALT), higher HBV-DNA, and immunosuppressed patients have a poorer response, and alpha interference can be dangerous in patients with cirrhosis (liver scarring). The author also reports on the use of thymosin alpha 1, lamivudine, and other drugs still in preliminary trials (adefovir dipivoxil, entecavir, emtricitabine, clevudine). The author concludes that further development of new drugs and new strategies, such as combination or sequential therapy, may help to better achieve the goals of treatment for chronic hepatitis B in the future. 1 table. 10 references.
•
Prophylactic Lamivudine Prevents Hepatitis B Reactivation in Chemotherapy Patients Source: Alimentary Pharmacology and Therapeutics. 16(11): 1939-1944. November 2002. Contact: Available from Alimentary Pharmacology and Therapeutics. Blackwell Science Ltd., Osney Mead, Oxford OX2 OEL, UK. +44(0)1865 206206. Fax +44(0)1865 721205. Email:
[email protected]. Website: www.blackwell-science.com. Summary: Chronic hepatitis B virus (HBV) carriers receiving chemotherapy develop a high hepatitis B virus reactivation rate (38 to 53 percent) with a high mortality (37 to 60 percent). Few studies have characterized the efficacy of lamivudine in the treatment of chemotherapy-induced HBV reactivation. This article reports on a study undertaken to determine whether lamivudine prophylaxis reduces chemotherapy-induced HBV reactivation and mortality. The medical records of all hepatitis B surface antigenpositive patients with malignancy treated with chemotherapy since 1995 at the National University Hospital of Singapore were identified and divided into those who received lamivudine prophylaxis before chemotherapy (P, n = 16) and those who did not (NP, n = 19). The baseline characteristics of the two groups were similar. Seven of the 19 patients in the NP group and none of the 16 patients in the P group developed HBV reactivation (36.8 percent versus 0 percent). Six of the seven patients in the NP group who developed reactivation received lamivudine at that time, but five died (mortality, 71.4 percent),
6
Hepatitis B
whilst no patient in the P group died from reactivation. The authors conclude that prophylactic lamivudine appears to prevent hepatitis B virus reactivation and its associated mortality in patients treated with chemotherapy. 3 tables. 11 references. •
Adding to the Hepatitis B Virus Treatment Arsenal: Glucosidase Inhibitor Derivatives (editorial) Source: Hepatology. 33(6): 1544-1546. June 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Chronic hepatitis B virus (HBV) infection is a major cause of cirrhosis (scarring) and hepatocellular carcinoma (liver cancer) in the United States and worldwide. Eradication of the infection and prevention of complications of chronic infection are the dual goals of treatment. This editorial comments on an accompanying article which reports on the use of alfa glucosidase inhibitor derivatives in the drug therapy for HBV infections. The agents under consideration (N nonyl DNJ and N nonyl DGJ) appear to have a mechanism of action that is unique and potentially complementary to that of nucleoside analogues. As new agents for treatment of HBV infection become available for clinical use, combination treatment of chronic HBV infection can be anticipated. The editorial stresses that designing the optimal combination therapy for HBV will need to take into account drug potency, mechanism of drug uptake and activation, sites of drug action, effect on cccDNA, and specific viral mutations arising with prolonged therapy. The author concludes that it remains to be seen whether these imino sugars (N nonyl DNJ and N nonyl DGJ) will join the growing list of anti HBV drugs. However, if the present results can be reproduced in animal studies and clinical trials (with humans), this novel class of agents may be a welcome addition to the arsenal of anti HBV drugs. 1 figure. 1 table. 13 references.
•
Hepatitis B and C: Looking Beyond Traditional Therapy Source: Digestive Health and Nutrition. p. 23-25. November-December 2000. Contact: Available from American Gastroenterological Association. 7910 Woodmont Avenue, 7th Floor, Bethesda, MD 20814. (877) DHN-4YOU or (301) 654-2055, ext. 650. Email:
[email protected]. Summary: For years, both hepatitis B and C have been treated mainly with one drug, interferon, that can cause a host of side effects and helps less than 50 percent of the people who take it. This article describes research into new drugs that indicates that many people with hepatitis C who do not respond to interferon alone may respond when it is combined with other drugs, and that some drugs may even take the place of interferon entirely for the treatment of hepatitis B. The author briefly reviews the different types of hepatitis, then notes the symptoms of hepatitis B and C, how they are transmitted, and prevention strategies. The author then focuses on interferon therapy. Interferon is a natural substance produced by the body to protect itself against infection, but, when infected with hepatitis, the body may not make enough interferon to fight the disease effectively. Injections of artificial interferon help stimulate the immune system to fight hepatitis. The author then describes the use of Rebetron (the trade name for a drug that combines interferon and ribavirin). Alone, ribavirin does not have much antiviral action, however, when taken with interferon, ribavirin boosts sustained response rates in hepatitis C patients to 40 percent. There are considerable side effects, so each patient must be cared for on an individualized plan. The article also describes the use of a modified form of interferon (pegylated interferon) which is expected to be approved by
Studies
7
the Food and Drug Administration (FDA) in 2001 for treatment of hepatitis C (and perhaps later for hepatitis B). Another drug discussed is lamivudine, used to stop hepatitis B virus from reproducing. A final section discusses the role of some of these drugs in helping patients wait longer for a liver transplant. One sidebar reviews the impact of hepatitis on the liver and why it is so important to treat the disease when possible. •
New Treatment Strategies in Hepatitis B and C: Natural History of Chronic Hepatitis B and C Source: Journal of Gastroenterology and Hepatology. 14(Supplement): S1-S5. May 1999. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Hepatitis B virus (HBV) affects more than 300 million individuals worldwide, and in the United States approximately 1.25 million individuals are chronic carriers of HBV. This article reviews the natural history of chronic hepatitis B and C. The risk of becoming a chronic hepatitis B virus surface antigen carrier is dependent upon the mode of acquisition of infection as well as the age of the individual at the time of infection. For those individuals with high levels of virus replication, chronic active hepatitis (CAV) with progression to cirrhosis, liver failure and hepatocellular carcinoma (HCC, liver cancer) is common. Liver transplantation is an excellent treatment option for patients with end stage liver disease from HBV. Patients with chronic HBV infection should be screened periodically for hepatoma, although screening strategies have not been proven to prolong survival. Newer antiviral agents for the treatment of HBV are potent inhibitors of HBV DNA and their long term effect on the natural history of HBV is yet to be proven. The natural history of hepatitis C virus (HCV) infection is less well defined than that of chronic HBV. Certain patients who are chronic carriers of HCV may never develop extensive fibrosis, whereas others will progress to CAV with cirrhosis, HCC, and end stage liver disease. Factors that influence the progression of HCV are those related to the host, including the age at acquisition of infection, gender, and immune status; the disease process is accelerated in patients who consume regular amounts of alcohol. Hepatocellular carcinoma develops frequently in patients with HCV infection and its overall incidence is increasing due to this chronic viral disease. Patients with HCV cirrhosis should be screened regularly for hepatoma and liver transplantation is an effective treatment option for those with end stage disease. The author concludes that the impact of antiviral therapy on the natural history of HCV is still to be determined and should be the focus of large clinical trials. 4 tables. 30 references.
•
Towards Control of Hepatitis B in the Asia-Pacific Region: Natural History of Hepatitis B Virus Infection in Children Source: Journal of Gastroenterology and Hepatology. 15(Supplement): E16-E19. May 2000. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Hepatitis B virus (HBV) infection during childhood can cause acute, fulminant, or chronic hepatitis, liver cirrhosis (scarring), and liver cancer. This article reviews the natural history of hepatitis B infection in children, with a consideration of strategies towards control of hepatitis B in the Asia Pacific region. Approximately 90
8
Hepatitis B
percent of the infants of hepatitis B e antigen (HBeAg) seropositive mothers become hepatitis B surface antigen (HBsAg) carriers. Children chronically infected are mostly asymptomatic. Although liver damage is usually mild during childhood, severe liver disease, including cirrhosis and hepatocellular carcinoma, may develop insidiously for 2 to 7 years. Spontaneous HBeAg seroconversion occurs gradually as the age of the child increases. Viral replication is reduced during this process, which is usually preceded by an elevation of aminotransferases. In a long term followup study, the annual HBeAg seroconversion rate was 4 to 5 percent in children older than 3 years of age and less than 2 percent in children under 3 years. The annual seroconversion rate was very low (0.56 percent). Age at infection, maternal HBeAg and HBeAg status, host immune status, and possibly the HBV strain are the main factors determining the course of HBV infection in children. 22 references. •
Treatment of Chronic Hepatitis B: Case Selection and Duration of Therapy Source: Journal of Gastroenterology and Hepatology. 17(4): 409-414. April 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Hepatitis B virus (HBV) infection is a major health burden in the Asia-Pacific region. This article addresses the treatment of chronic hepatitis B, focusing on case selection and duration of therapy. The author stresses that proper assessment and judicial introduction of therapy can suppress replication of HBV and resolve liver inflammation, thereby preventing the silent progression of chronic liver disease to end stage cirrhosis (liver scarring). The author discusses interferon (IFN) monotherapy, injection based therapies, lamivudine, administration and dosage, patient response, drug resistant mutations, the end point of treatment, combination therapy, herbal medicines, and patient indications for different drug therapies. The author concludes that preliminary data from IFN and lamivudine combination therapy show some promise, but there are conflicting results.
•
Occult Hepatitis B Virus Infection in Patients with Chronic Hepatitis C Liver Disease Source: New England Journal of Medicine. 341(1): 22-26. July 1, 1999. Summary: Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known. This article reports on a study that searched for HBV DNA in liver and serum samples from 200 HBsAg negative patients with hepatitis C virus (HCV) liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). Of the patients, 100 had detectable antibodies to the HBV core antigen; 100 were negative for all HBV markers. Some patients (n = 83) were treated with interferon alfa. The study also included 50 patients with liver disease who were negative both for HBsAg and for HCV markers. Sixty six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C. Among the 66 patients, 46 were anti HBc positive and 20 were negative for all HBV markers. Twenty two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective. The authors conclude that occult hepatitis B infection occurs
Studies
9
frequently in patients with chronic hepatitis C liver disease and may have clinical significance for these patients. 4 tables. 45 references. •
Chronic Hepatitis B and C Source: Postgraduate Medicine. 92(4): 75-80, 82. September 15, 1992. Summary: In this article, the author discusses the results of studies conducted to evaluate therapy with alpha, beta, and gamma interferon as well as with other agents, such as ribavirin, thymosin, and ursodeoxycholic acid. The author notes that at the time this article was written, interferon alfa-2b (Intron-A) is not approved for both indications; however, interferon is not without significant side effects and costs. 2 figures. 1 table. 32 references. (AA-M).
•
Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B Source: New England Journal of Medicine. 333(17): 1099-1105. October 26, 1995. Summary: In this article, the authors describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (FIAU) as therapy for chronic hepatitis B virus infection. Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks. They were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. During the 13th week, lactic acidosis and liver failure suddenly developed in 1 patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function, despite the discontinuation of fialuridine. Of these seven patients, five died and two survived after liver transplantation. The authors conclude that the toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues. 5 figures. 1 table. 43 references. (AA-M).
•
Is Vaccination Against Hepatitis B Efficient? A Review of World Literature Source: Health Economics. 3(1): 25-37. January-February 1994. Contact: Available from John Wiley and Sons Limited. Subscriptions Department, 605 Third Avenue, New York, NY 10157-0228. (212) 850-6000. Summary: In this article, the authors report on the result of a study aimed at assessing the variability of assumptions upon which economic models for the introduction of vaccination against hepatitis B are based. They discuss the conclusions reached and define a minimum set of methodological standards upon which future economic studies on vaccines should be based. The literature review identified 116 published and unpublished works by Medline literature searches, consulting private databases, and corresponding with all authors and researchers active in the economic evaluation of vaccines. All works were assessed, but only the 90 studies that were original economic analyses are reviewed. The authors found profound variability on main parameters of the efficiency equation, including disease incidence, costing methods, use of marginal theory, discounting and study timespan, sensitivity analysis, and reporting methods. They caution against decisions made on biased evidence because of poor research
10
Hepatitis B
methodology and call for the standardization of study methods and procedures. 6 tables. 121 references. (AA-). •
Hampering Hepatitis B Transmission Through Neonatal Therapy Source: National Medical Association News. May-June 1992. p. 3. Summary: In this interview article, Dr. Neil S. Silverman explains his views on hampering hepatitis B transmission through neonatal therapy. He proposes drug screening as a marker for increased risk of HBsAg positivity and empiric initiation of hepatitis B immune globulin (HBIG) prophylaxis for infants born to unregistered women with positive results of urine drug screening whose infants' HBsAg results are unavailable within 12 hours of delivery. In this interview, Dr. Silverman discusses the relationship between hepatitis B prevalence and the unregistered prenatal population; the incidence of hepatitis B in the population of women that use drugs; problems with legalities of a drug screening policy; specific advantages of prenatal testing; risks involved with immunoglobulin administration; statistics on the proposed numbers of hepatitis B cases that could be prevented annually; morbidity for children who become hepatitis carriers; the likelihood of a plan for hepatitis B prophylaxis being implemented; and problems created by the ongoing and increasing substance abuse situation.
•
Hepatitis B Virus Mutant Associated with an Epidemic of Fulminant Hepatitis B Source: Liver Update. 5(1): 7-8. Spring 1991. Contact: Available from American Liver Foundation. 1425 Pompton Avenue, Cedar Grove, NJ 07009. (201) 256-2550 or (800) 223-0179. Summary: Infection with hepatitis B virus (HBV) leads to a wide spectrum of liver injury. Fulminant hepatitis B is a rare disease, but carries a high mortality. This brief article reports on a nosocomial outbreak of five cases of fulminant hepatitis B that occurred in Israel. Investigations by the author suggest that the five patients with fulminant hepatitis were infected by the same virus derived from a common source while a subclinical case was infected by another HBV strain at the same time. This study points to a role for naturally occurring viral mutations in the emergence of HBV viral strains capable of producing more severe liver injury.
•
Potential for the Use of Modified Hepatitis Delta Virus in the Therapy of Chronic Hepatitis B Virus Infections Source: Viral Hepatitis Reviews. 1(1): 47-52. September 1995. Contact: Available from Journals Subscriptions Department, Harcourt Brace and Company Ltd. High Street, Foots Cray, Sidcup, Kent DA14 5HP UK. Telephone +181 300 3322. Summary: Infections by hepatitis B virus (HBV) continue to be a major source of chronic liver disease, despite the great advancements in our understanding of HBV infections and the widespread availability of an effective vaccine. Once a patient has become chronically infected with HBV, the currently available therapies are not particularly effective, and there is a high risk that infection will proceed to cirrhosis and hepatocellular carcinoma. This article evaluates the potential of a novel therapy: the application of modified forms of hepatitis delta virus (HDV) as part of an antiviral strategy for individuals with chronic hepatitis B virus infections. 3 figures. 31 references. (AA-M).
Studies
•
11
Clinical Trial of Lamivudine in Children with Chronic Hepatitis B Source: New England Journal of Medicine. NEJM. 346(22): 1706-1713. May 30, 2002. Summary: Lamivudine therapy is effective for chronic hepatitis B virus (HBV) infection in adults. This article reports on a study that evaluated the efficacy and tolerability of lamivudine as a treatment for chronic infection with HBV in children. Of the 403 children screened, 191 were randomly assigned to receive lamivudine and 97 to receive placebo. The rate of virologic response at week 52 was higher among children who received lamivudine than among those who received placebo (23 percent versus 13 percent). Lamivudine therapy was well tolerated and was also associated with higher rates of seroconversion from hepatitis B e antigen (HBeAg) to hepatitis B e antibody, normalization of alanine aminotransferase levels, and suppression of HBV DNA. 2 figures. 4 tables. 20 references.
•
Review: Hepatitis B and Liver Transplantation Source: Journal of Gastroenterology and Hepatology. 13(3): 217-223. March 1997. Contact: Available from Blackwell Science Pty Ltd. P.O. Box 378, Carlton, Victoria 3053, Australia. Phone: 61 3 9347 0300; Fax: 61 3 9347 5001; Web site: http://www.blacksci.co.uk. Summary: Liver transplantation in hepatitis B virus (HBV) infected patients is very commonly followed by recurrence of infection in the transplanted liver. This review article focuses on new strategies for the prevention and treatment of disease recurrence after transplantation. Most recipients with HBV recurrence will develop chronic hepatitis that follows a more aggressive course than is seen in nonimmunocompromised subjects; this frequently results in graft failure. The presence of hepatitis B e antigen or significant levels of HBV-DNA in the serum is highly predictive of recurrence and this has led to the view that patients, whose serum is positive for these conventional markers of replication, should be excluded from transplantation. The key to improving the results of transplantation in patients with HBV infection lies in the development of effective strategies to prevent reinfection. High dose anti-HBs immunoglobulin is effective in patients who are coinfected with hepatitis D, those transplanted for fulminant hepatitis, and cirrhotic patients who have very low levels of viral replication prior to transplantation. Unfortunately, immunoprophylaxis does not seem to influence the outcome in those patients with higher levels of replication. There are several new orally active nucleoside analogues that are potent inhibitors of hepatitis B replication that may be effective for both the prevention and treatment of recurrent disease. The most promising are lamivudine and famciclovir. Both agents have been extensively evaluated in animal models of HBV and have been shown to rapidly suppress viral replication. The author concludes that the initial experience with these agents in liver transplant recipients has been promising and a number of studies are currently under way to determine whether these drugs, used alone or in combination with immunoprophylaxis, are able to prevent recurrence in those patients at highest risk of posttransplant HBV recurrence. 1 table. 59 references. (AA-M).
•
Efficacy of Granulocyte-Macrophage Colon-Stimulating Factor or Lamivudine Combination with Recombinant Interferon in Non-Responders to Interferon in Hepatitis B Virus-Related Chronic Liver Disease Patients Source: Journal of Gastroenterology and Hepatology. 17(7): 765-771. July 2002.
12
Hepatitis B
Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Non-response to interferon (IFN) monotherapy is a major therapeutic problem in the management of chronic hepatitis B virus (HBV) infection. This article reports on a study in which the effectiveness of combination therapy to enhance the immunomodulatory effect of IFN by combining GMCSF (granulocyte-macrophage colony stimulating factor) or decreasing viral load by adding an antiviral agent such as lamivudine was evaluated prospectively. The study included 24 patients with chronic hepatitis B who were non-responders to previous IFN therapy were randomized to receive an IFN and GMCSF (group A, n = 10) or IFN and lamivudine (group B, n = 14) combination for 6 months. All patients successfully completed both the treatment schedules. At the end of treatment, there was a significant decrease in mean ALT levels. The HBV-DNA and HBeAg loss was seen in six of 10 (60 percent) patients in group ! and seven of 15 (50 percent) patients in group B. During follow up, two of six patients (33 percent) in group A and three of seven (43 percent) patients in group B relapsed with HBV-DNA and HBeAg positivity, which meant an overall sustained response of 40 percent and 28 percent respectively. None of the factors such as HBV viral load, ALT levels or liver histology could predict the non-response to combination therapy or occurrence of relapse. The authors conclude that larger studies using such combination therapies would be helpful in improving treatment strategies for chronic hepatitis B. 4 tables. 34 references. •
Hepatitis B Infection in Patients with Acute Liver Failure in the United States Source: Hepatology. 33(4): 972-976. April 2001. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: Occult (hidden) hepatitis B virus (HBV) infection has been reported in 30 to 50 percent of patients with acute liver failure (ALF) in small case series. This article reports on a study undertaken to determine the prevalence of occult HBV infection in a large series of ALF patients in the United States and the prevalence of precore and core promoter variants in patients with ALF caused by hepatitis B. Sera (blood products) from patients in the US ALF study and liver, when available, were tested using nested polymerase chain reaction (PCR) with primers in the HBV S and precore regions. PCR positive samples were sequenced. Sera and or liver from 139 patients (39 males, 100 females; mean age 42 years) were studied between January 1998 and December 1999. Twelve patients were diagnosed with hepatitis B, one with hepatitis B, C, and D coinfection, and 22 had indeterminate etiology (cause). HBV DNA was detected in the sera of 9 patients (6 percent); all 9 had ALF caused by hepatitis B. HBV genotypes A, B, C, and D were present in 4, 3, 1, and 1 patients, respectively. Seven of these 9 patients had precore or core promoter variants. Liver from 19 patients were examined. HBV DNA was detected in the liver of 3 patients with ALF caused by hepatitis B, but in none of the remaining 16 patients with non B ALF. Contrary to earlier reports, occult HBV infection was not present in this large series of ALF patients in the United States. 1 appendix. 3 tables. 34 references.
•
Chronic Hepatitis B Virus Infection in Asian Countries Source: Journal of Gastroenterology and Hepatology. 15(12): 1356-1361. December 2000.
Studies
13
Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Of the estimated 50 million new cases of hepatitis B virus (HBV) infection diagnosed annually, 5 to 10 percent of adults and up to 90 percent of infants will become chronically infected. Of those who become chronically infected, 75 percent are in Asia where hepatitis B is the leading cause of chronic hepatitis (liver infection), cirrhosis (liver scarring), and hepatocellular carcinoma (liver cancer). This article offers detailed statistics on chronic HBV infection in Asian countries, including Indonesia, the Phillipines, Thailand, China, Taiwan, and Malaysia. In the highly endemic countries in Asia (places where HBV is found on a routine basis in the population), the majority of infections are contracted postnatally or perinatally (during birth). Three phases of chronic HBV infection are recognized: phase 1 patients are HBeAg positive with high levels of virus in the serum (blood) and minimal hepatic (liver) inflammation; phase 2 patients have intermittent or continuous hepatitis of varying degrees of severity; phase 3 is the inactive phase during which viral concentrations are low and there is minimal inflammatory activity in the liver. In general, patients who clear HBeAg have a better prognosis than patients who remain HBeAg positive for prolonged periods of time. The outcome after anti HBe seroconversion depends on the degree of preexisting liver damage and any subsequent HBV reactivation. Without preexisting cirrhosis, there may be only slight fibrosis or mild chronic hepatitis, but with preexisting cirrhosis, further complications may happen. The annual incidence of hepatic decompensation (reduction in liver function) in HBV related cirrhosis varies from 2 to 10 percent and in these patients, the 5 year survival rate drops dramatically to 14 to 35 percent. The annual risk of developing HCC (liver cancer) in patients with cirrhosis varies between 1 and 6 percent. Chronic hepatitis B is not a static disease and the natural history of the disease is affected by both viral and host factors. The prognosis is poor with decompensated cirrhosis and effective treatment options are limited. The authors conclude that prevention of HBV infection through vaccination is still therefore the best strategy for decreasing the incidence of hepatitis B associated cirrhosis and HCC. 1 table. 32 references. •
Hepatitis B Virus Infection Without Immunological Markers After Open-Heart Surgery Source: Lancet. 345(8946): 355-357. February 11, 1995. Summary: Posttransfusion hepatitis is still an important problem, despite the screening of blood donors for hepatitis B virus (HBV) and hepatitis C virus infections. This article reports on a study in which the researchers assessed whether HBV DNA might be detected by PCR in prospectively collected serum samples of patients with unexplained posttransfusion hepatitis but no immunological HBV markers. They found HBV DNA in 4 (20 percent) of 20 patients with unexplained posttransfusion hepatitis and in 5 patients with mildly increased aminotransferases. The clinical course of these HBV infections was usually mild and self-limiting. The researchers conclude that low-titre, immunologically negative HBV infections do exist and might represent a significant cause of post-transfusion hepatitis.
•
Injections Given in Healthcare Settings as a Major Source of Acute Hepatitis B in Moldova Source: International Journal of Epidemiology. 28(4): 782-786. August 1999.
14
Hepatitis B
Contact: Available from Oxford University Press. Journals Subscription Department, Great Clarendon Street, Oxford OX2 6DP, UK. 44 (0)1865 267907. Fax 44 (0)1865 267485. Summary: Reported rates of acute hepatitis B are high in many former Soviet Union republics and modes of transmission are not well defined. This article reports on two case control studies that were undertaken in Moldova to identify risk factors for acute hepatitis B in people aged 2 to 15 years (children) and older than 15 years (adults). Serologically confirmed acute hepatitis B cases occurring between January 1994 and August 1995 were matched on age, sex, and district of residence to three potential control groups who were tested for hepatitis B markers to exclude the immune. In multivariate analysis, compared with the 175 controls, the 70 adult cases (mean age 25 years, 66 percent male) were more likely to report receiving injections in the 6 months before illness during a dental visit, a hospital visit, or a visit to the polyclinic. Among children, receiving injections during a hospital visit was the only exposure reported significantly more often by the 19 cases (mean age 8 years, 68 percent male) compared with the 81 controls. These results, along with reported unsafe injection practices in Moldova, suggest that injections are a major source of hepatitis B virus transmission and highlight the importance of proper infection control procedures in preventing transmission of blood borne infections. 3 tables. 25 references. •
Hepatitis A, Hepatitis B, and Combination Hepatitis Vaccines for Immunoprophylaxis: An Update Source: Digestive Diseases and Sciences. 47(6): 1183-1194. June 2002. Contact: Available from Kluwer Academic Publishers. Customer Service Department, P.O. Box 358, Accord Station, Hingham, MA 02018-0358. (781) 871-6600. Fax (781) 6819045. E-mail:
[email protected]. Website: www.wkap.nl. Distribution Centre, P.O. Box 322, 3300 AH Dordrecht, The Netherlands. 31 78 6392392. Fax: 31 78 6546474. E-mail:
[email protected]. Summary: Since the publication of the last extensive review of hepatitis vaccines, use of inactivated hepatitis A vaccines has been extended to high-risk regions of the United States and specific patient groups, such as those with chronic liver disease, and use of the recombinant hepatitis B vaccines has been recommended for older adolescents. In addition, a combination hepatitis A and B vaccine, recently approved for licensure by the U.S. Food and Drug Administration (FDA), should increase convenience and compliance, reduce the costs of vaccination, and provide prolonged and dual protection for those at risk for hepatitis. This article considers these advances and their use for immunoprophylaxis. The author also briefly comments that although commercially available vaccines for hepatitis C, D, and E remain a distant goal, advances in vaccine and adjuvant technology, including immunization with DNA-based vaccines, hold promise for the future. 5 tables. 85 references.
•
Association Between Administration of Hepatitis B Vaccine at Birth and Completion of the Hepatitis B and 4:3:1:3 Vaccine Series Source: JAMA. Journal of the American Medical Association. 284(8): 978-983. August 2330, 2000. Summary: The association between infant age at initiation of hepatitis B vaccination and completion of the 3 dose hepatitis B vaccination series is unclear. This article reports on a study undertaken to assess the association between administration of the first dose of hepatitis B vaccine within 7 days of birth and completion of the hepatitis B vaccine series and the 4:3:1:3 vaccine series (4 doses of diphtheria tetanus pertussis vaccine, 3 doses of
Studies
15
polio vaccine, 1 dose of measles containing vaccine, and 3 doses of Haemophilus influenzae type b vaccine). The study included an analysis of data from the 1998 National Immunization Survey, a random digit dialing telephone survey (n = 34,480 complete interviews) of parents of children aged 19 to 35 months from 50 states and 28 selected urban areas in the United States that included a provider record check mail survey. Overall, 86.9 percent of children 19 to 35 months of age in 1998 received 3 or more doses of hepatitis B vaccine, and 79.9 percent completed the 4:3:1:3 vaccine series. Analysis indicated that, compared with children who received the first hepatitis B vaccine dose within 7 days of birth, odds ratios for not completing the 3 dose hepatitis B vaccine series increased as the time from birth increased. The authors hypothesize that the significant association between age at administration of the first dose of hepatitis B vaccine and completion of the 3 dose series may reflect clinician concerns about parental resistance to multiple injections during a single visit. The authors conclude that administration of the first dose of hepatitis B vaccine at birth is associated with increased likelihood of completion of the hepatitis B vaccination series. Because of this and other advantages, providers should strongly consider a hepatitis B vaccination schedule that initiates vaccination at birth. 1 figure. 2 tables. 23 references. •
Comparison of Clinical, Virologic and Pathologic Features in Patients with Acute Hepatitis B and C Source: Journal of Gastroenterology and Hepatology. 16(2): 209-214. February 2001. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: The clinical outcomes of adult acquired acute infection of hepatitis C virus (HCV) and hepatitis B virus (HBV) are quite different. This article reports on a comparison of clinical, biochemical, virologic, and pathologic pictures in 22 adults patients with acute hepatitis C and 16 adult patients with acute hepatitis B. Liver biopsies were performed within 3 months of acute onset of the illness in each of these patients. The results showed that a significantly younger age; a higher ratio of the clinical symptoms of jaundice, nausea, vomiting, and poor appetite; a higher mean serum (blood) level of alanine transaminase; aspartate transaminase, and total bilirubin were present in patients with acute hepatitis B, compared to those with acute hepatitis C. There was a significantly higher degree of periportal inflammation and total necroinflammatory activity in the acute hepatitis B patients. Fifteen (68.2 percent) of the 22 patients with acute hepatitis C had detectable serum HCV RNA, but only two (14.3 percent) of the 14 tested patients with acute hepatitis B had detectable serum HCV DNA, detected by using the branched DNA signal amplification assay. Eighteen (82 percent) of the 22 acute hepatitis C patients and none of the 16 acute hepatitis B patients progressed into a chronic hepatitis stage. 3 tables. 35 references.
•
Hepatitis B Immunization and Postimmunization Serology Source: Journal of the Canadian Dental Association. 66(10): 551-552. November 2000. Contact: Available from Canadian Dental Association. 1815 Alta Vista Drive, Ottowa, ON K1G 3Y6. (613) 523-1770. E-mail:
[email protected]. Website: www.cda-adc.ca. Summary: The development of hepatitis vaccines in the 1980s has substantially decreased dental workers' risk of acquiring hepatitis B virus (HBV). This article reports on hepatitis B immunization and postimmunization serology, focusing on dental workers in Canada. A recent survey of dentists in Canada showed that more than 90
16
Hepatitis B
percent had completed an immunization series and an additional 3 percent had natural immunity. However, rates of immunization among dental assistants and hygienists was found to be much lower. The author discusses the vaccines themselves, the antibody levels required for protection, postimmunization testing for immunity, and the potential need for booster doses of hepatitis B vaccine. The author concludes that all nonimmune dental health care workers should receive immunization with recombinant hepatitis B vaccine. Postimmunization serology should be performed to ensure seroconversion and guide further immunization and postexposure prophylaxis. Following seroconversion, booster doses of vaccine are not required. 10 references. •
Impact of Hepatitis B and C Virus on Kidney Transplantation Outcome Source: Hepatology. 29(1): 257-263. January 1999. Contact: Available from W.B. Saunders Company. 6277 Sea Harbor Drive, Orlando, FL 19106-3399. (800) 654-2452 or (407) 345-4000. Summary: The impact of hepatitis B (HBV) and C (HCV) on patient survival after kidney transplantation is controversial. This article reports on a study undertaken to assess the independent prognostic values of hepatitis B surface antigen (HBsAg) and anti-HCV in a large renal transplant population. The study also compared infected and noninfected patients matched for factors possibly associated with graft and patient survival and assessed the prognostic value of biopsy proven cirrhosis. A total of 834 transplanted patients were included: 128 with positive HBsAg (group I), 216 with positive anti-HCV (group II), and 490 without serological markers of HBV and HCV (group III). Fifteen percent of patients were HBsAg positive, and 29 percent were antiHCV positive. Ten year survival of group I (55 percent) and group II (65 percent) were significantly lower than survival of group III (80 percent). At 10 years, among all 834 patients, 4 variables had independent prognostic values in patient survival: age at transplantation, year of transplantation, biopsy proven cirrhosis, and presence of HCV antibodies. In the case control study, comparison of infected patients with their matched controls showed that age at transplantation and anti-HCV were independent prognostic factors. HCV, biopsy proven cirrhosis, and age are independent prognostic factors of 10 year survival in patients with kidney grafts. The authors conclude that a routine liver histological analysis in infected patients would improve selection of patients for renal transplantation. 4 figures. 5 tables. 34 references. (AA-M).
•
Kidney Transplantation in Patients with Chronic Hepatitis B Virus Infection: Is the Prognosis Worse? Source: Digestive Diseases and Sciences. 46(3): 469-475. March 2001. Contact: Available from Kluwer Academic/Plenum Publishers. 233 Spring Street, New York, NY 10013-1578. (212) 620-8000. Fax (212) 807-1047. Summary: The impact of hepatitis B virus (HBV) infection on the long term outcome of kidney transplant patients is controversial. This study included a total of 34 chronic hepatitis B surface antigen (HBsAg) carriers among 143 renal (kidney) allograft recipients (mean follow up period: 5.6 years plus or minus 3.3 years; range 1 to 13 years). During the follow up, one HBsAg positive recipient with preexisting cirrhosis died of liver failure, and seven (21 percent) others developed serious HBV related complications (4 had fulminant hepatitis, 2 hepatocellular carcinoma or liver cancer, and 1 cirrhosis), and four died. Although HBsAg positive recipients had a higher rate of liver related complications and deaths than HBsAg negative recipients did, there were no significant differences in the long term graft and patient survival between the two
Studies
17
groups. The survival rates, liver related complications, and deaths in HBsAg positive allograft recipients and 28 HBsAg positive uremic patients under dialysis were similar. The authors conclude that HBV infection is not a contraindication to kidney transplantation. However, pretransplant candidates should be warned of potentially serious liver related complications. 3 figures. 4 tables. 28 references. •
Detection of Hepatitis B Virus (HBV) in HBsAG Negative Individuals with Primary Liver Cancer Source: Digestive Diseases and Sciences. 36(8): 1122-1129. August 1991. Summary: The importance of chronic hepatitis B virus (HBV) infection in the development of primary liver cancer has been established by epidemiological studies. This article discusses the detection of HBV in HBsAG negative individuals with primary liver cancer. The authors report the use of the polymerase chain reaction to detect HBV DNA in the serum and liver of these patients. This technique allows both for the detection and cloning of HBV variants. The authors contend that the laboratory values obtained with this technique reinforce the role of HBV in the pathogenesis of this tumor. 5 figures. 39 references. (AA-M).
•
Benefit-Cost Analysis of Hepatitis B Vaccine Programs for Occupationally Exposed Workers Source: Journal of Occupational Medicine. 33(6): 691-698. June 1991. Summary: The Occupational Safety and Health Administration proposed a vaccination program for workers exposed to the hepatitis B virus 12 or more times per year. This article reports on a benefit-cost analysis of the proposed regulation and an expanded rule that covers all at-risk workers, regardless of the number of exposures. The authors estimated the dollar benefit of the program using two methods. The first estimates the avoided cost of medical care, prophylaxis, and lost productivity at $124 million annually. The second approach includes the value of avoided pain and suffering from hepatitis B, thus increasing the total dollar benefit to $679 million. Although both methods indicate benefits are greater than program costs, the valuation of avoided pain and suffering substantially increases net benefits. Furthermore, providing the vaccine to all exposed workers is cost-effective if one or more cases of hepatitis B are avoided per 6500 workers annually. 1 figure. 7 tables. 12 references. (AA).
•
Chronic Hepatitis B Infection in Eastern Europe and the Middle East Source: Viral Hepatitis Review. 6(1-4): 111-128. 2000. Contact: Available from Harcourt Brace and Company Ltd. Journals Subscriptions Department, High Street, Foots Cray, Sidcup, Kent DA14 5HP UK. Telephone +181 300 3322. Summary: The World Health Organization estimates that about 350 million chronic carriers of hepatitis B exist worldwide; many carriers develop cirrhosis (liver scarring) or hepatocellular carcinoma (HCC, liver cancer) over the course of their lives. Although infection poses a substantial public health burden in many parts of the world, the magnitude of this burden is often unclear (because available information is not readily accessible). This report summarizes the available information from multiple sources for two geographic regions: Eastern Europe and the Middle East. To estimate the hepatitis B burden in the two regions, the authors collated existing information from published literature, organizations with health care data, the Internet, and the Global Burden of
18
Hepatitis B
Disease and Injury Series. Published literature provided the most extensive information about the occurrence of hepatitis B infection and was more available for Middle Eastern countries than for Eastern European countries. In both regions, most countries with prevalence data had an intermediate or high prevalence of carriers, but there was considerable heterogeneity within regions. Population subgroups within countries had different prevalences. Compared with the Middle East, relatively few Eastern European countries had infant immunization programs. The availability of information varies from country to country across the regions, and data comparisons are problematic. The low frequency of infant immunization programs in Eastern Europe constitutes an important missed opportunity for an effective public health intervention. Information about hepatitis B prevalence in population subgroups could be especially useful for identifying people who have the greatest need for intervention. 1 appendix. 2 figures. 4 tables. 69 references. •
Public Health Service Inter-Agency Guidelines for Screening Donors of Blood, Plasma, Organs, Tissues, and Semen for Evidence of Hepatitis B and Hepatitis C Source: MMWR. Morbidity and Mortality Weekly Report. 40(RR-4): 1-17. April 19, 1991. Summary: These guidelines address the use of tests for the hepatitis B and C viruses to screen donations of blood and plasma collected for transfusion or further manufacture into injectable products, as well as to screen donors of organs, tissues, and semen. These guidelines are intended to serve as a resource to individuals and organizations involved in testing, counseling, and evaluating donors tested for these viruses, and are based on currently available knowledge. 76 references. (AA).
•
HIV and Hepatitis B Infection and Risk Behavior in Young Gay and Bisexual Men Source: Public Health Reports; Vol. 112, March/April 1997. Contact: Boston University School of Public Health, Department of Epidemiology and Biostatistics, 80 East Concord St, Boston, MA, 02118, (617) 638-7718. Summary: This article describes a study conducted to estimate the prevalence of, and identify risks for, HIV type I (HIV-I) and hepatitis B virus (HBV) infections and unprotected anal intercourse among young homosexual and bisexual men. The authors performed a cross-sectional analysis of data from a prospective cohort of 508 gay and bisexual men aged 18-24. HIV-I seroprevalence was 2.4 percent with five of 390 college students and seven of 117 non-students infected. HIV-I infection was associated with having a history of a sexually transmitted disease (STD) other than HIV-I or hepatitis B. The prevalence of hepatitis B markers in unvaccinated men was 12.9 percent. This was significantly associated with Asian ethnicity, off-campus residence, and a history of an STD other than HIV-I or HBV. It was inversely associated with recent non-intravenous drug use. Eighteen percent of the participants reported having had sex with women during the previous 12 months, and 26.4 percent reported a history of unprotected anal intercourse during the previous 6 months. Men who reported unprotected anal intercourse were more likely to have a steady partner, to have met their partners in anonymous settings, and to be identified as probably alcohol-dependent. Although prevalence of HIV-I infection among young homosexual and bisexual men in Boston was relatively low, the high rates of unprotected anal intercourse suggest a potential for future HIV-I and HBV transmission. Interventions should focus on young men with histories of sexually transmitted diseases, alcohol abuse, and depression.
Studies
•
19
Family Physician Acceptance of Universal Hepatitis B Immunization of Infants Source: Journal of Family Practice. 36(2): 153-157. February 1993. Summary: This article describes a study that assessed the effectiveness of the Centers for Disease Control's (CDC) dissemination of a new immunization recommendation to family physicians; the effect of the new recommendation on clinical practice; and the degree to which noneconomic barriers may affect adoption of universal hepatitis B immunization. A random sample of 300 family physicians in North Carolina was surveyed by mail; a response rate of 78 percent was obtained. Overall, 48 percent of family physicians were aware of the new hepatitis B vaccine recommendation; however, only 17 percent agreed that it was warranted for all newborns in their practice. The authors conclude that the CDC does not have an effective mechanism for disseminating information to all physicians who care for children. Additionally, practical concerns of physicians and their patients regarding multiple injections and other practice-relevant issues must be considered when formulating new immunization recommendations. 4 tables. 6 references. (AA-M).
•
Hepatitis B Infection and Liver Transplantation Source: Canadian Journal of Gastroenterology. 11(5): 462-468. July-August 1997. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Summary: This article discusses liver transplantation in patients with hepatitis B. Patients with chronic hepatitis B virus (HBV) infection have historically high rates of allograft reinfection from extrahepatic (outside the liver) reservoirs of HBV, with worse long term outcome compared with that of transplant recipients without HBV infection. As a result, chronic HBV infection has been considered a contraindication for transplantation. However, prophylaxis against HBV recurrence, in the form of passive immunization with high dose hepatitis B hyperimmunoglobulin and the antiviral agent lamivudine, has recently been demonstrated to decrease the risk of reinfection. The author summarizes past experience and current status of HBV infection and transplantation, with emphasis on the issues surrounding prophylaxis. The author concludes that with appropriate prophylaxis, liver transplantation can be a viable proposition for patients with HBV infection. The main obstacles to high dose HBIG prophylaxis are the continued availability of the product, practicality of administration, and the cost and long term duration of treatment. 2 tables. 60 references. (AA-M).
•
Hepatitis B Virus Source: Scientific American. 264(4): 116-123. April 1991. Summary: This article discusses the hepatitis B virus (HBV) which causes liver diseases and a common form of cancer. During the past decade, evolving understanding of the molecular biology of HBV has found medical applications, particularly for preventing the infection. Mass vaccinations with the recombinant vaccine, the first vaccine for human use ever developed by recombinant DNA technology, will go far in controlling hepatitis B. The authors stress that such a campaign of vaccination would prevent not only the acute liver illness but also the associated cancer. This article emphasizes the epidemiology of hepatitis, the genetic structure and activity of HBV, and genetic engineering techniques used to develop a medical response to HBV. 6 figures. 5 references.
20
Hepatitis B
•
Treatment of Chronic Hepatitis B and Hepatitis C with Interferon Alfa-2b Source: American Family Physician. 54(5): 1598-1602. October 1996. Summary: This article discusses the treatment of chronic hepatitis B and hepatitis C with interferon alfa-2b. Interferon alfa-2b is the only agent currently approved by the U.S. Food and Drug Administration for the treatment of chronic hepatitis B and C. The authors note that initial enthusiasm for this therapy has waned with the realization that response rates are low and relapses are common. Recent studies, however, provide evidence of improved response rates with higher doses of interferon alfa-2b. Improved response is also being obtained with the use of interferon alfa-2b in combination with iron reduction therapy consisting of repeated phlebotomies. The research has enabled the identification of predictors of an increased likelihood of response to interferon alfa2b therapy. The application of these predictors to patient selection may improve the cost-benefit ratio for this treatment. Research data have documented a significant reduction in the cost of health care and an increased life expectancy with interferon alfa2b therapy in patients who have chronic hepatitis C, particularly young patients without fibrosis. A patient care algorithm for the management of chronic hepatitis C with interferon alfa-2b is provided. 1 figure. 22 references. (AA-M).
•
Hepatitis B Vaccination: Dosing Alternatives, Current Guidelines Source: Modern Medicine. 59(Supplement A): 6-10. 1991. Summary: This article explores the current guidelines for hepatitis B vaccination and offers suggestions for alternative dosing schedules. The author stresses that a national vaccination program will be necessary to prevent HBV infection in the general population and in specific high-risk groups. The use of an accelerated dosing schedule offers an alternative for patients who must develop immunity quickly, or who may be unable to comply with the longer conventional schedule. Other topics include booster doses, managing poor responses to the vaccine, safety issues, and routes of administration. 2 tables. 4 references.
•
Hepatitis B: Immunising Health Workers and Patients Source: Nursing Times. 91(36): 29-31. September 6, 1995. Summary: This article familiarizes readers with current recommendations regarding hepatitis B immunizations for health care workers and patients. The author describes the disease process and the implications for people working in at-risk occupations in the hope of increasing the awareness of the need for, and subsequent use of, vaccination programs. Topics include the consequences of hepatitis B infection; the incidence and prevalence of hepatitis B; the main routes of transmission of hepatitis B virus (HBV); groups at higher risk of HBV infection; and signs and symptoms. The article also includes a brief glossary of related terms. 1 figure. 4 tables. 10 references. (AA-M).
•
Towards Control of Hepatitis B in the Asia-Pacific Region: Natural History of Chronic Hepatitis B Virus Infection Source: Journal of Gastroenterology and Hepatology. 15(Supplement): E20-E24. May 2000. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com.
Studies
21
Summary: This article highlights four aspects of the natural history of chronic hepatitis B virus (HBV) infection that require clarification: the differences between Caucasians and Asians with chronic HBV infection; the relationship between HBeAg seroconversion and the onset of cirrhosis (liver scarring), the role of precore and core promoter mutations, and when patients develop hepatocellular carcinoma (HCC, or liver cancer) and other complications of cirrhosis. In chronic HBV infection acquired during adulthood, which is the type mostly seen in the Caucasian population, there is biochemical and histologic regression after HBeAg seroconversion, and the risk of death from hepatitis B related causes is low. In chronic HBV infection acquired during birth or early childhood, which is the type most commonly seen in the Asian population, there is a prolonged phases of immunotolerance. The immune clearance phase is characterized by multiple acute exacerbations preceded by elevations in serum HBV DNA levels, HBeAg concentration and HBeAg/anti HBe immune complexes. Of these patients, 2.4 percent may develop hepatic (liver) decompensation during the stage of HBeAg seroconversion. The development of cirrhosis occurs more frequently in patients with episodes of decompensation and with repeated severe acute exacerbations. However, progression to cirrhosis can be relatively silent and can occur even in children. After HBeAg seroconversion, precore and core promotor mutations occur frequently in the Asian population. However, there is little correlation between the occurrence of these mutations and alanine aminotransferase elevation in patients who are positive for anti HBe. Although cirrhosis develops during the process of HBeAg seroconversion, 68 percent of the complications of cirrhosis and of hepatocellular carcinoma occur after HBeAg seroconversion. These complications may still occur even after HBsAg seroclearance. 21 references. •
Nonresponders to Hepatitis B Vaccine Source: Postgraduate Medicine. 107(3): 97-98. March 2000. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: This article is one in a series of professional consultation clinical questions to which the author responds. In this article, the questioner notes that routine testing showed a health care worker in the clinic who was nonreactive for HbsAb (antibody to the hepatitis B surface antigen) after receiving the triple dose vaccine. The questioner asks for recommendations in handling this situation, both in regular daily settings and after a high risk exposure. The author replies by stating that treatment of health care workers who do not respond to hepatitis B vaccine is an important issue, because hepatitis B is the major infectious hazard among these personnel. Between 5 and 32 percent of people receiving the vaccine are nonresponders. The Centers for Disease Control (CDC) recommends that persons who do not respond to the initial vaccine series complete a second three dose series and get tested again. Current hepatitis B vaccines contain only recombinant HBsAg. However, a third generation hepatitis B vaccine is being reviewed for licensure that also contains proteins derived from the virus envelope. The author notes that this vaccine may offer an alternative for persons who do not respond to current vaccines. Some persons remain nonresponders, even to this new vaccine, suggesting that hepatitis B vaccine response may have a genetic basis. 1 reference.
•
Antiviral Therapy for Chronic Hepatitis B and C: Which Patients are Likely to Benefit from Which Agents? Source: Postgraduate Medicine. 107(2): 135-138, 141-142, 144. February 2000.
22
Hepatitis B
Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Summary: This article is the third in a four article symposium that provides a practical approach to the diagnosis and management of common hepatic disorders encountered by primary care physicians. In this article, the author discusses current therapies for chronic hepatitis B and C and provides insight into future medications. Antiviral therapy in chronic hepatitis can completely eradicate the virus and induce remission of liver disease. To achieve such benefits, however, therapy should be initiated before decompensated liver disease ensues; at that point, liver transplantation is the only available option. The author describes indications for and contraindications to antiviral therapy in chronic hepatitis. For chronic HBV infection, interferon alfa2b requires only a 4 month course. However, it has adverse effects and contraindications and does not produce a universal response. Another option for HBV infection is lamivudine, which is administered orally and causes few side effects. However, relapse may occur when treatment is discontinued, and mutant virus may emerge. For chronic HCV infection, interferon alfa2a, interferon alfa2b, consensus interferon, and interferon combined with ribavirin have been used. The combination alternative is emerging as the method of choice in patients who do not have contraindications to oral ribavirin. Adverse effects are common and durability of response varies according to HCV RNA level and genotype. 5 tables. 21 references. •
Hepatitis B: Virology, Epidemiology, Disease, and Prevention, and an Overview of Viral Hepatitis Source: American Journal of Preventive Medicine (Immunization in Medical Education Supplement). 10(supplement): 45-55. 1994. Contact: Available from Oxford University Press. 2001 Evans Road, Cary, NC 27513. Summary: This article presents an overview of viral hepatitis, with a focus on the virology, epidemiology, disease, and prevention of hepatitis B. The article also covers hepatitis A, delta hepatitis, hepatitis C, and hepatitis E. Other topics include the incidence and prevalence of hepatitis B virus (HBV) worldwide; the history of HBV isolation; HBV structure and infection nomenclature; the disease burden of HBV in the United States; modes of transmission; the clinical features of HBV infection; the outcome of HBV infection; diagnostic tests used to confirm the disease; the management of acute and chronic HBV infection; the prevention of HBV infection, notably the HBV vaccine, its safety and efficacy; and current recommendations for vaccination. 1 appendix. 9 figures. 1 table. 72 references.
•
Hepatitis B Vaccination in Hospital Personnel and Medical Students Source: Journal of Clinical Gastroenterology. 28(4): 317-322. June 1999. Contact: Available from Lippincott-Raven Publishers. P.O. Box 1550, Hagerstown, MD 21741. (800) 638-3030 or (301) 714-2300. Summary: This article reports on a project undertaken to determine the prevalence of hepatitis B markers and the compliance to hepatitis B vaccination at University Hospital of Santa Maria, Lisbon. The program was begun in 1989 for all hospital personnel and students of the medical school. The screening included 2,360 health care workers and 1,153 students: 57 percent of hospital personnel and 41 percent of medical students appeared for vaccination. The prevalence of hepatitis B markers was 16.8 percent for hospital personnel and 5.5 percent for students; 0.95 percent of the hospital personnel
Studies
23
and 0.3 percent of students were chronic carriers. The departments with the highest prevalence were the Biochemical Laboratory (7 out of 11 people, or 64 percent), Surgery (13 out of 31 people, 42 percent), Pulmonary (9 out of 23 people, 39 percent), Emergency (7 out of 24 people, 29 percent), Hematology Laboratory (7 out of 24 people, 29 percent), and Orthopedics (10 out of 35 people, 29 percent). The prevalence was higher in students in the last 3 years of medical school than those in the first 3 years (12.2 percent versus 7.2 percent, respectively). Adverse affects from vaccination occurred in 14.5 percent, with local pain the most frequent in 8.6 percent. The serologic efficacy was 95 percent. A nonresponse was observed in male workers: 13 percent compared with 5 percent for women. Older employees also showed higher nonresponse. The authors conclude that hepatitis B vaccination is safe and effective. This study shows the need for a more aggressive approach to the vaccination of health care workers because a significant percentage of them are not protected. 5 figures. 1 table. 32 references. (AAM). •
Prevalence of HIV, Hepatitis B, and Hepatitis C in People with Severe Mental Illness Source: American Journal of Public Health. 91(1): 31-37. January 2001. Contact: American Public Health Association. 800 I Street, NW, Washington, DC 200013710. (202) 777-2742. Fax (202) 777-2534. E-mail:
[email protected]. Website: www.ajph.org. Summary: This article reports on a study that assessed seroprevalence (as determined by blood test) of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among individuals with severe mental illness. Participants in the study (n = 913) were patients undergoing inpatient or outpatient treatment in Connecticut, Maryland, New Hampshire, or North Carolina. The prevalence of HIV infection in this sample (3.1 percent) was approximately 8 times that estimated in the United States population, but lower than rates reported in previous studies of people with severe mental illness. Prevalence rates of HBV (23.4 percent) and HCV (19.6 percent) were approximately 5 and 11 times the overall estimated population rates for these infections, respectively. Although routes of transmission were not ascertained in this study, the high rates of substance use disorder, particularly injection drug use among women, are likely to contribute to increased risk. The authors conclude that elevated rates of all three infections were found in this population. Of particular concern are the high rates of HCV infection, which are frequently undetected. Individuals with HCV infection commonly fail to receive appropriate treatment to limit liver damage and unknowingly may be a source of infection to others. Greater efforts at prevention, screening, and treatment for HIV, HBV, and HCV are important. There is a lack of information and concern about HCV on the part of both providers and patients with severe mental illness. For example, a great majority of clients in this study who were infected with HIV were aware of their condition, but most of those with HCV were not. Previous experience with this population suggests that a cornerstone of successful intervention will be integrated dual diagnosis in the context of intensive case management. 3 tables. 35 references.
•
Attitudes and Educational Practices of Obstetric Providers Regarding Infant Hepatitis B Vaccination Source: Obstetrics and Gynecology. 89(1): 61-64. January 1997. Summary: This article reports on a study to survey the current knowledge, attitudes, and practices of obstetric providers regarding the education of pregnant women about
24
Hepatitis B
infant hepatitis B vaccination. A questionnaire was mailed to 264 physicians providing obstetric services in San Francisco; of these, 113 were confirmed to be providing prenatal care and 76 obstetric providers returned completed questionnaires. Among these respondents, 79 percent believed that hepatitis B vaccine should be administered to all infants at birth, and 92 percent believed that it is feasible to educate all expectant mothers about infant hepatitis B vaccination. However, only 53 percent of respondents provided such education to all their pregnant patients. Only 23 percent provided education about other routine childhood immunizations. The authors conclude that obstetric providers in San Francisco are willing to educate pregnant patients about hepatitis B vaccination but are not always doing so. Providing education in a consistent manner may improve infant hepatitis B vaccination rates and may increase coverage with other childhood vaccines. 3 tables. 18 references. (AA-M). •
Hepatitis B Carriage Explains the Excess Rate of Hepatocellular Carcinoma for Maori, Pacific Island and Asian People Compared to Europeans in New Zealand Source: International Journal of Epidemiology. 28(2): 204-210. April 1999. Contact: Available from Oxford University Press. Journals Subscription Department, Great Clarendon Street, Oxford OX2 6DP, UK. 44 (0)1865 267907. Fax 44 (0)1865 267485. Summary: This article reports on a study undertaken to determine the prevalence of hepatitis B surface antigen (HBsAg) carriers among cases of hepatocellular carcinoma (HCC), and the population attributable risk of HBsAg carriage for HCC, by ethnicity in New Zealand. The authors reviewed the hospital notes of HCC cases registered with the New Zealand Cancer Registry for the years 1987 to 1994. The HBsAg status was determined for 193 cases of HCC. The HBsAg carrier prevalence for non Europeans with HCC was markedly higher than that for Europeans (76.7 percent for Maori, 80.0 percent for Pacific Island people, and 88.5 percent for Asians, compared to 6.0 percent for Europeans). In addition to the effect of ethnicity, HCC cases younger than 60 years were more likely to be HBsAg carriers than those older than 60. The estimated population attributable risk of HBsAg for HCC, within each ethnic group, was only marginally less than the HBsAg prevalence due to the high relative risk of HBsAg carriage for HCC. The standardized incidence rate ratios of HCC for Maori, Pacific Island people, and Asians compared to Europeans were 9.6, 20.4, and 22.3, respectively. HCC attributable to HBsAg carriage explained 79 percent, 83 percent, and 92 percent of the excess standardized rate for Maori, Pacific Islanders, and Asians, respectively. The authors conclude that their data predict that 75 to 90 percent of the cases of HCC that will occur in the target population (subpopulations of New Zealand) will occur among HBsAg carriers and are therefore potentially detectable by ongoing screening. 5 tables. 28 references. (AA-M).
•
Worldwide Immunization Program Targets Hepatitis B and Liver Cancer Source: Journal of the National Cancer Institute. 83(10): 666-668. May 15, 1991. Summary: This article reports on the worldwide immunization program that targets hepatitis B and liver cancer. Three doses of hepatitis B vaccine have been shown to be 95 percent effective in preventing chronic hepatitis B virus (HBV) infection, the cause of over four-fifths of the world's primary liver cancers. The article details the work of the International Task Force on Hepatitis B Immunization, an independent body of health professionals from eight countries that was created in 1986. A major accomplishment of the Task Force has been to foster more international acceptance of the hepatitis B vaccine
Studies
25
and the concept of universal childhood immunization, even in areas with a relatively low prevalence for HBV, such as the United States. 1 figure. •
Prevalence of Syphilis, Hepatitis B Virus (HBV), and Human Immunodeficiency Virus (HIV) Infection in New Arrestees at the Lake County Jail, Crown Point, Indiana Source: Journal of Prison & Jail Health; Vol. 12, no. 2, Winter 1993. Contact: Eli Lilly and Company, Eli Lilly Corporate Center, Indianapolis, IN, 46285, (317) 276-2000, http://www.lilly.com. Summary: This article reviews a study conducted to determine the prevalence in arrestees of syphilis, hepatitis B virus (HBV), and HIV infection by demographic and behavioral characteristics, and to evaluate the costs associated with universal screening for these sexually transmitted diseases compared with a theoretical targeted screening program. Three hundred and nineteen arrestees were screened for syphilis, HBV, and anonymously for HIV infection. The prevalence of syphilis was 2.5 percent; hepatitis B surface antigen prevalence was 1.6 percent; the prevalence of past or present HBV infection was 21.9 percent; and the prevalence of HIV infection was 1.6 percent. Targeted screening for sexually transmitted diseases was found to be more costeffective.
•
Treatment of Hepatitis B: Current Practice Source: Comprehensive Therapy. 20(4): 239-243. 1994. Contact: Available from American Society of Contemporary Medicine and Surgery. 233 East Erie Street, Suite 710, Chicago, IL 60611. (800) 621-4002 or (312) 951-1400. Summary: This article reviews current practice for treatment of hepatitis B. Topics include the use of interferon A, an immune modulator; typical chronic hepatitis; acute hepatitis B; mild chronic hepatitis B; decompensated cirrhosis due to hepatitis B; atypical serology in hepatitis B; immunosuppressed hosts with hepatitis B; thymosins; other immune modulators; antivirals, including ara-A and ara-AMP; and other antiviral agents. The author stresses the great strides made in the treatment of chronic hepatitis B. Interferon A is now widely employed and, although far from a perfect treatment, a significant number of patients are benefiting from its availability. 24 references.
•
Current Treatment Strategies for Chronic Hepatitis B and C Source: in Coggins, C.H.; Hancock, E.W., Eds. Annual Review of Medicine: Selected Topics in the Clinical Sciences, Volume 52. Palo Alto, CA: Annual Reviews Inc. 2001. p. 29-49. Contact: Available from Annual Reviews Inc. 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139. (800) 523-8635. Fax: (415) 855-9815. PRICE: $47. ISBN: 0824305450. Summary: This article reviews current treatment strategies for chronic hepatitis B and hepatitis C, two types of liver inflammation caused by the hepatitis virus. For chronic hepatitis B, treatment with a 4 month course of interferon alfa-2b can achieve hepatitis B e antigen seroconversion, normalization of aminotransferase levels, reduced hepatic inflammation, and possibly reduced progression to cirrhosis (liver scarring), and improvement in survival in 20 to 30 percent of patients. Similar results can be achieved with a 12 month course of lamivudine, with response rates increasing to 40 to 65 percent after 3 years of therapy. Interferon can also be used in early cirrhotic patients, and lamivudine can be used in people with advanced cirrhosis and in immunosuppressed
26
Hepatitis B
patients. Combination interferon and lamivudine therapy does not confer additional benefits. For chronic hepatitis C, the combination of interferon alfa-2b and ribavirin in the treatment of choice, offering superior sustained response rates (40 percent) compared with interferon alone (15 percent). Therapy should be administered for 12 months to patients with genotype 1 virus but for only 6 months to patients with genotypes 2 and 3. Patients experiencing relapse after 6 months of interferon monotherapy can be re-treated with interferon and ribavirin or high-dose interferon, with 45 to 56 percent sustained response rates. However, relatively few patients who are prior nonresponders to interferon monotherapy will have sustained response to further interferon-based treatments, including combination therapy with ribavirin. Successful therapy not only leads to the eradication of viral RNA but also may delay progression to cirrhosis and hepatocellular carcinoma (HCC, liver cancer). Interferon combined with polyethylene glycol (PEG) shows promise as an improved formulation of interferon with yet higher sustained response rates. 1 figure. 6 tables. 99 references. •
Hepatitis B: Diagnosis and Treatment Source: Southern Medical Journal. 90(9): 866-870. September 1997. Contact: Available from Southern Medical Association. 35 Lakeshore Drive, Birmingham, AL 35209. (205) 945-1840. Summary: This article reviews the current methods of diagnosis and treatment of hepatitis B virus (HBV) infection. Physicians are now able to accurately diagnose acute and chronic hepatitis infection, though the understanding of viral quantitation and its impact on disease course and treatment response is evolving. The author notes that hepatitis B must now be considered a preventable disease, since acute infection can be effectively prevented by either passive or active immunization. However, when acute infection does occur, it evolves into chronic hepatitis or a chronic infectious carrier state in a variable proportion of cases, depending on the age and underlying immune competence of the patient. Chronic infection can be treated, though the effectiveness of available antiviral and immunomodulatory agents is less than complete. Finally, the author notes that variants of the HBV are being recognized and coinfection with the defective viroid known as hepatitis D has been described. 5 figures. 15 references. (AAM).
•
Vaccination Against Hepatitis B: Current Challenges for Asian Countries and Future Directions Source: Journal of Gastroenterology and Hepatology. 15(4): 396-401. April 2000. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: This article reviews the current status of hepatitis B immunization programs as well as future issues concerning hepatitis B immunization in Asian countries. The literature was identified via in house and MEDLINE (1980 to 1999) searches and references cited in published articles. Results showed that chronic hepatitis B infection is responsible for 75 to 90 percent of primary hepatocellular carcinoma (liver cancer), one of the 10 most common cancers worldwide. Hepatitis B and its chronic sequelae can potentially be eradicated through vaccines that have been shown to be 95 to 99 percent effective in preventing development of the disease or the carrier state in immunized infants. Approximately 75 percent of the world's hepatitis B carriers live in Asian countries wherein wide variations in immunization strategies exist. Vaccination
Studies
27
programs in hyperendemic Asian countries have elicited decreases in the incidence of acute and chronic infections as well as a decrease in chronic carriers in the unvaccinated population. Decreases in the incidence of hepatocellular carcinoma have been recorded in Taiwan and Singapore after at least 10 years of universal hepatitis B immunization programs. The authors conclude that, in Asian countries currently without nationwide hepatitis B programs, utilization of the existing vaccination infrastructure (for administration of other World Health Organization vaccines) will provide the most economical and efficient means of administration of the hepatitis B vaccine. 3 tables. 40 references. •
Chronic Hepatitis B: What You Need to Know Source: IM. Internal Medicine. 20(9): 32-34, 44-46. September 1999. Contact: Available from Medical Economics. 5 Paragon Drive, Montvale, NJ 07645. (800) 432-4570. Summary: This article reviews the current thinking regarding the transmission, pathogenesis, diagnosis, prevention, and treatment of hepatitis B virus (HBV). In geographic areas such as the United States, with a low prevalence of HBV infection, sexual contact is the most common mode of transmission of the virus. The illegal use of injection drugs, particularly among those who share unsterilized needles, accounts for 23 percent of cases of HBV transmission in the United States. Health care workers are a recognized HBV risk group because of their exposure to needles, syringes, and other objects contaminated with blood, bodily fluids, or other secretions from infected individuals. The host immune response appears to be more important than viral factors in the pathogenesis of HBV infection. The serologic hallmark of chronic HBV infection is the presence of hepatitis B surface antigen (HBsAg) for a period of more than 6 months. Immunocompromised adults and those who are infected with HBV in early childhood are at 50 percent risk of developing chronic infection. Measures that reduce the risk of exposure to HBV include sexual behavior changes and need exchange programs for injection drug users. Vaccination is now recommended for high risk groups and for all children. The authors discuss treatment options, including postexposure prophylaxis, lamivudine therapy, and other strategies, notably immunomodulator and antiviral drugs. One sidebar briefly reviews the epidemiology of HBV worldwide. 1 figure. 4 tables. 13 references.
•
High-Risk Groups for Hepatitis B and Interpretation of the Hepatitis B Profile Source: Hepatitis B Coalition News. 2(3): 5. April 1992. Contact: Available from Hepatitis B Coalition. 1573 Selby Avenue, Suite 229, St. Paul, MN 55104. (612) 647-9009. Summary: This brief article presents a listing of groups at high risk for hepatitis B, noting that most people in these groups should be vaccinated with or without prior testing, depending on individual risk factors. The latter half of the article consists of a chart designed to help the reader understand the hepatitis B profile of diagnostic tests, including HBsAg, anti-HBc, anti-HBs, and HBeAg. For various results of each of these tests, the chart indicates the interpretation and recommendation as per vaccination.
•
Brief Introduction to Hepatitis B for Parents of Adopted Children Source: Hepatitis B Coalition News. p. 6. September 1994.
28
Hepatitis B
Contact: Available from Hepatitis B Coalition. 1573 Selby Avenue, Suite 229, St. Paul, MN 55104. (612) 647-9009. Summary: This brief article provides an overview of hepatitis B. Written to encourage parents of adopted children to have the children tested for hepatitis B, the article addresses hepatitis B infection in general; what tests should be done for children adopted from areas where hepatitis B is common; and what to do if the child is infected with hepatitis B. The article concludes with a list of resource organizations through which parents can obtain additional information. •
Characteristics of and Current Treatment Options for Hepatitis B and Hepatitis C Source: Journal of the Canadian Dental Association. 66(10): 537. November 2000. Contact: Available from Canadian Dental Association. 1815 Alta Vista Drive, Ottowa, ON K1G 3Y6. (613) 523-1770. E-mail:
[email protected]. Website: www.cda-adc.ca. Summary: This brief article reviews the characteristics of and current treatment options for hepatitis B and hepatitis C, focusing on the risks to health care workers, including dental professionals. The author provides information about the natural history, therapeutic choices, and future directions of therapy for these two forms of hepatitis. Not all patients who test positive for hepatitis B surface antigen (HbsAg) require antiviral therapy; many people have circulating HBsAg without evidence of significant hepatitis. These people are chronic carriers and account for the majority of hepatitis B cases. Treatment options include alpha interferon or oral lamivudine; however, conversion to negative status is achieved in only approximately 20 percent of cases with either therapy. Hepatitis C is a common condition affecting approximately 2 percent of Canadians; of patients with chronic hepatitis C, approximately 20 percent experience serious liver complications. These complications can include cirrhosis, need for liver transplantation, hepatocellular carcinoma (liver cancer), or death. Standard treatment for hepatitis C is alpha interferon and ribavirin; sustained remission occurs in approximately 40 percent of cases. The article concludes with the website for the Canadian Association for the Study of the Liver (www.lhsc.on.ca/casl/summ.htm ).
•
Hepatitis B e Antigen: The Dangerous Endgame of Hepatitis B. (editorial) Source: New England Journal of Medicine. NEJM. 347(3): 208-210. July 18, 2002. Summary: This editorial familiarizes readers with the complication of hepatitis B that results in the hepatitis B e antigen (HBeAg). Shortly after the discovery of hepatitis B virus (HBV), the striking epidemiological association between HBV infection and liver cancer (hepatocellular carcinoma) was noted. Subsequent research demonstrated that the risk of liver cancer was increased by a factor of 10 among men who were positive for HBsAg (hepatitis B surface antigen) alone and by a factor of 60 among those who were positive for both HBsAg and HBeAg. Older age, the presence of antibodies against hepatitis C virus, cigarette smoking, and use of alcohol were also identified as independent risk factors for the development of liver cancer. The author explores the evidence for the role of HBeAg and notes that although this proposed role of HBeAg may contribute to the development of liver cancer, it is most likely that its role as a marker of active virus replication is associated with the increased risk in cancer. The author also briefly considers the pathogenesis of HBV-associated liver cancer, the role of environmental hepatotoxins (liver toxins), and the strategies used to fight HBV (vaccination and drug therapy). 1 figure. 16 references.
Studies
•
29
Public's Health Unprotected: Reversing a Decade of Underutilization of Hepatitis B Vaccine (editorial) Source: JAMA. Journal of the American Medical Association. 274(15): 1242-1243. October 18, 1995. Summary: This editorial highlights and praises the progress that has been made in hepatitis B vaccination in the United States, while examining why it takes so long to apply safe, effective, and low-cost preventive modalities to improve public health. The author first reviews a success story in which, in an extremely high incidence area, HBV transmission has all but been eliminated. The author then discusses the findings of two other articles from this issue of the journal that also document advances in this area. The remainder of the editorial focuses on the length of time required to institute an aggressive vaccination program and how leaders in the biomedical, public health, and political arenas must become more cognizant of the need for vaccination programs. The author concludes with a challenge to physicians to help eliminate hepatitis B. 15 references.
•
Variants of Hepatitis B Virus Associated with Fulminant Liver Disease Source: New England Journal of Medicine. 324(24): 1737-1739. June 13, 1991. Summary: This editorial, which serves as an introduction for two other articles, considers variants of hepatitis B virus (HBV) that are associated with fulminant liver disease. The author reviews the current literature in this area, with an emphasis on examining the role of host immune responses in the activity and severity of liver disease. The author concludes that the current findings represent a major advance in the understanding of the pathogenesis of fulminant HBV infection and may ultimately lead to new therapeutic strategies to prevent its consequences. 22 references.
•
Spring-Loaded Finger-Stick Device Transmits Hepatitis B Source: Hepatitis B Coalition of Minnesota News. 2(3): 3. April 1992. Contact: Available from Hepatitis B Coalition. 1573 Selby Avenue, Suite 229, St. Paul, MN 55104. (612) 647-9009. Summary: This newsletter article summarizes two reports regarding the transmission of hepatitis B with a spring-loaded finger-stick device of the type used by people with diabetes. This article briefly reports on articles in the Morbidity and Mortality Weekly Report and the New England Journal of Medicine, and notes that the Food and Drug Administration is issuing a safety alert concerning the use of all spring-loaded fingerstick devices. The editor notes that many medical offices continue to use these devices when checking hemoglobin and blood glucose levels, and they do not change or sterilize the platforms between patients.
•
Is Hepatitis A More Severe in Patients with Chronic Hepatitis B and Other Chronic Liver Diseases? Source: American Journal of Gastroenterology. 90(2): 201-205. February 1995. Summary: This review article analyzes published literature on the clinical course and outcome of acute hepatitis A in patients with chronic hepatitis B virus (HBV) infection and other chronic liver diseases, to determine if hepatitis A is more severe in these patients. The author reviews epidemics and large case series; small case series and case reports; and hepatitis A in other chronic liver diseases. The author concludes that the
30
Hepatitis B
data seem to suggest that acute hepatitis A superimposed on chronic HBV infection is associated with higher peak laboratory abnormalities, more severe disease, including fulminant hepatic failure, and a higher case fatality rate. These conclusions, however, are not supported by all case series or case reports. 1 table. 17 references. (AA-M). •
Management of Viral Hepatitis B Source: Journal of Gastroenterology and Hepatology. 17 (Supplement): S125-S145. February 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: This review article discusses hepatitis B virus (HBV) infection, a major global health concern and the most common cause of chronic liver disease worldwide. The natural history and clinical outcomes of chronic HBV infection are determined by the viral replication cycle and the host immune responses. Treatment of chronic hepatitis B is directed at interrupting the natural history of suppressing HBV replication before development of any significant irreversible liver cell damage. Two major classes of antiviral therapeutic agents that have been approved for treatment of chronic hepatitis B are immunomodulating agents (i.e., interferon) and the nucleoside analogs (i.e., lamivudine). A major problem of antiviral treatment is the emergence of drug resistance. Many new immunomodulatory therapies and antiviral agents are in various stages of clinical development and have shown some promise. Among newer HBV antivirals, adefovir dipivoxil, entecavir, emtricitabine, DAPD, and clevudine appear to be at least as potent as lamivudine in suppressing HBV replication. The author hypothesizes that combinations of an immunomodulatory agent and nucleoside analog may improve the therapeutic efficacy and reduce the emergence of drug resistance. Nevertheless, combinations of interferon and lamivudine therapies do not confer such additional benefits. The next challenge for HBV treatment is to use antivirals in combination or cyclical therapy to minimize the emergence of drug resistance and increase efficacy, particularly to achieve sustainable post treatment suppression of HBV. 4 tables. 147 references.
•
Interferon in the Management of Chronic Hepatitis B Source: Digestive Diseases and Sciences. 38(4): 577-593. April 1993. Contact: Available from Plenum Publishing Corporation. 233 Spring Street, New York, NY 10013. (800) 221-9369 or (212) 620-8000. Summary: This review article discusses the use of interferon in the management of chronic hepatitis B. The author reviews the importance of chronic hepatitis B as a health problem, as well as the mechanisms of action, benefits, and adverse effects associated with interferon. Particular emphasis is given to the safety and efficacy data for recombinant interferon alfa-2b. The article reviews the magnitude and medical significance of hepatitis B; populations at risk; potential populations for treatment; the immunopathogenesis of chronic hepatitis B and the potential role for interferon; predictors of response and selection of patients; interferon trials; the combination of recombinant interferon alfa-2b with prednisone pretreatment; the adverse affects of interferon; guidelines for monitoring and dose modification; short-term and long-term benefits of therapy; and patient groups for further study. 5 tables. 116 references. (AAM).
Studies
•
31
Hepatitis B Viral Genotypes: Clinical Relevance and Molecular Characteristics Source: Journal of Gastroenterology and Hepatology. 17 (6): 643-650. June 2002. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E- mail:
[email protected]. Website: www.blackwell-science.com. Summary: This review article focuses on hepatitis B virus (HBV) infection, a global health problem. The clinical outcome of chronic HBV infection depends on the frequency and severity of hepatitis flares in the immune clearance phase. Currently, four subtypes and seven genotypes of HBV are identified and most have specific geographic distributions. The impact of HBV genotypes on the clinical outcome of chronic HBV infection has been partially clarified. The author provides numerous examples from Taiwan, Japan and China. The author concludes that pathogenic (how the disease develops) and therapeutic differences do exist among HBV genotypes, and determining the genotype in patients with chronic HBV infection would help gain further information for etiologic (causative), clinical, virologic, and anthropologic investigations. 1 figure. 2 tables. 61 references.
•
Hepatitis B Virus Infection in Asian Americans Source: Gastroenterology Clinics of North America. 23(3): 523-536. September 1994. Contact: Available from W.B. Saunders Company, Periodicals Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 654-2452. Summary: This review article summarizes studies on hepatitis B in the Asian American population. The authors include prevalence rates among different Asian subgroups, routes of transmission, and sequelae of both perinatal and childhood-acquired hepatitis B virus infection. The article also covers the rationale for the use of hepatitis B immune globulin and hepatitis B vaccine for Asian infants, and vaccine for children and seronegative adults. The authors review chronic hepatitis B, cirrhosis, and primary hepatocellular carcinoma in adults and screening for early detection of liver cancer. 4 tables. 48 references. (AA-M).
•
Treatment of Chronic Hepatitis B Virus Infection in Special Groups of Patients: Decompensated Cirrhosis, Immunosuppressed and Paediatric Patients Source: Journal of Gastroenterology and Hepatology. 15(Supplement): E71-E78. May 2000. Contact: Available from Blackwell Science. 54 University Street, Carlton South 3053, Victoria, Australia. +61393470300. Fax +61393475001. E-mail:
[email protected]. Website: www.blackwell-science.com. Summary: Treatment of special groups of patients (i.e., patients with decompensated cirrhosis, immunocompromised patients, and children) is challenging and requires different treatment strategies. This article explores the management of chronic hepatitis B in these special populations. Patients with decompensated liver disease have a poor prognosis and are difficult to treat. Chances of survival for this group are limited without liver transplantation. Interferon alpha (IFN alpha) is presently the recommended treatment for patients with clinically stable chronic hepatitis B. The aim of treatment is to permanently suppress or eliminate HBV infection and thereby induce remission of liver disease. The author notes that there is increasing interest in the use of nucleoside analogues in the treatment of decompensated liver disease and those going
32
Hepatitis B
for liver transplantation. The author discusses the use of thymosin alpha 1 and lamivudine as treatment options. Chronic hepatitis B is common in immunosuppressed patients, including antiHIV positive patients, patients with chronic renal failure, and patients undergoing organ transplantation. Unfortunately, their response to IFN therapy is poor, mostly because of high level viraemia (levels of virus in the blood) and depressed cell mediated immunity. The prevalence of hepatitis B in Asian children is probably similar to that in adults. Infection acquired early in life may not progress to liver disease until later in childhood or early adulthood. However, both cirrhosis and liver cancer (hepatocellular carcinoma, or HCC) have been documented in children. It is therefore important to consider effective therapy for children with chronic HBV infection and to monitor these children closely for HCC. 64 references.
Federally Funded Research on Hepatitis B The U.S. Government supports a variety of research studies relating to hepatitis B. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to hepatitis B. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore hepatitis B. The following is typical of the type of information found when searching the CRISP database for hepatitis B: •
Project Title: A RANDOMIZED TRIAL OF VACCINE ADHERENCE IN YOUNG IDU Principal Investigator & Institution: Lum, Paula J.; Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2007 Summary: (provided by applicant): We propose a study to examine strategies to deliver a promising preventive HIV vaccine candidate-employing a surrogate hepatitis B vaccine-to a cohort of high-risk young injection drug users (IDU) and young male IDU that have sex with men (MSM-IDU). We will screen 750 IDU aged 29 or less in San Francisco and over sample MSM-IDU, who have very high rates of HIV seroconversion. We expect that about 50% of those screened will meet eligibility criteria for prospective study and of those, that 80% will enroll. We will follow this cohort of 300 individuals for one year, administering a combined hepatitis A virus (HAV) inactivated and hepatitis B virus (HBV) recombinant vaccine (Twinrix() to study medical management and implementation issues, including: (1) adherence to multi-dose immunization schedules, (2) novel methods to minimize losses to follow-up, and (3) physiologic and behavioral
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
33
factors that may alter vaccine effectiveness. The primary purpose of the study is to efficiently compare interventions to improve vaccine series adherence. In particular, we propose a randomized trial using a factorial design to compare the effects of clinical setting (syringe exchange program vs. immunization clinic) and outreach worker support (outreach vs. none) in enhancing adherence to a multiple dose immunization schedule. We have three secondary objectives. The first focuses on transience, one of the major causes of attrition in cohort studies of often-homeless IDU and other disenfranchised populations. For subjects who leave San Francisco during the study period, we will use novel technology to map their travel and achieve immunizations remotely. Secondly, we will compare vaccine effectiveness between HCV-infected and uninfected young IDU. We will measure protective antibody levels after immunizations. Finally, given the potential for reduced vaccine effectiveness in the setting of continued high-risk behavior, we will measure changes in behavior and vaccine attitudes. By testing strategies for delivering a multi-dose schedule of hepatitis vaccine and developing models for improving future HIV vaccine adherence and effectiveness, we can advance HIV vaccine development for young adult high-risk injection drug users. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADJUVANTED DNA VACCINE FOR IMMUNOTHERAPY HIV INFECTION Principal Investigator & Institution: Haynes, Joel R.; Powderject Vaccines, Inc. 585 Science Dr Madison, Wi 53711 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-MAR-2004 Summary: The goal of this program is the optimization and evaluation of an adjuvanted therapeutic DNA vaccine strategy for AIDS using the rhesus monkey/SIV model system. In addition, a graduated clinical evaluation approach is planned to introduce this technology into the clinic in a stepwise manner. The DNA vaccine to be employed will encode the full length gag, pol, and env products of SIV as well as a series of defined CTL epitopes fused to an immunogenic carrier protein. The novelty of our approach centers on the inclusion of an adjuvant vector encoding the A and B subunits of cholera toxin (CT) or the E. coli heat labile enterotoxin (LT) to augment antigenspecific Th1 immunity and systemic and mucosal CTL responses. The adjuvanted DNA vaccine will be formulated onto microscopic gold particles and delivered to the skin as a therapeutic vaccine using a clinical "gene gun" device. Elucidation of the mechanism of adjuvant action will be assisted by the analysis of chemokine involvement and the activation and trafficking of dendritic cells. Justification of the proposed approach is based on three important findings from our laboratories: 1, Human clinical evaluation of a "gene gun"-based DNA vaccine for hepatitis B resulted in the induction of vigorous antigen-specific, Th1 and cytotoxic cellular immune responses in humans, confirming the clinical effectiveness of this means of DNA vaccine delivery. 2, The induction of SIVspecific CTL responses via gene gun-based DNA vaccination in the rhesus/SIV model provides measurable protection from challenge with pathogenic SIVdeltaB670. 3, The formulation of DNA vaccines with vectors encoding eith4r CT or LT results in marked and surprising enhancements of Th1 and CTL responses without any evidence of local or systemic toxicity in small and large animals. Clinical development of the adjuvanted DNA vaccine approach will take place in a graduated manner involving initial evaluation of a single HIV therapeutic DNA vaccine vector in a small phase I/II trial. A second clinical trial attempting to establish clinical proof of concept of the adjuvanted DNA vaccine approach will follow. The later trial will include the addition of a vector encoding CT or LT.
34
Hepatitis B
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Goldman, Mitchell; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (adapted from application's abstract): The Indiana University proposes to build upon the following in the renewal application: (1) scientific and administrative contributions. The Indiana ACTU ranks among the top 20 percent of ACTUs scientifically; (2) cost efficient accrual into AACTG trials. Indiana ranked third in cost weighed accrual; and (3) recruitment of women and minorities. The ACTU ranked second in recruitment of African- Americans and third in women. The long-term objectives of this site are to: expand scientific and administrative contributions through recruitment of additional investigators; increase accrual potential for women and minorities by expansion of the Wishard Hospital subunit; and increase the patient base by establishing a subunit at Community Hospital of Indianapolis. The first specific aim of the Indiana University ACTU is to contribute scientifically through submission of concept proposals and memberships on AACTG protocol teams and committees. Currently, Indiana investigators hold 32 positions on protocol teams. Concepts are proposed for: (a) salvage therapy for efavirenz failures; (b) evolution of anal dysplasia and the role of HPV in patients on HAART; (c) the role of gp 120 in HIV induced apoptosis of neurological cells in pathogenesis of dementia; (d) the role of GM-CSF and CD4 ligand on immunity to H. Capsulatum and HIV-1; (e) use of in vitro assays for drug interactions with protease inhibitors; and (f) the role of intestinal metabolism and bioavailability of antiretroviral drugs. The second specific aim is to expand the patient base, including women and minorities, though increased support for subunits at Wishard Hospital and Community Hospital. The work proposed in this application will be implemented through conduct of clinical trials as a member the AACTG, using an infrastructure that has been refined during 12 years as an ACTU. Specialized immunology, virology, and pharmacology laboratories will support this work. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: AFB1 AND P53 CARCINOGENESIS IN HBSAG TRANSGENIC MICE Principal Investigator & Institution: Sell, Stewart; Professor; Pathology and Lab Medicine; Albany Medical College of Union Univ Union University Albany, Ny 12208 Timing: Fiscal Year 2001; Project Start 15-DEC-1998; Project End 30-NOV-2002 Summary: The interaction and mechanisms of the major risk factors for human hepatocellular carcinoma (HCC) will be analyzed in an animal model. World- wide HCC is arguable the tumor that causes the highest cancer mortality. HCCs occurring in high-risk areas of the world are associated with hepatitis B(HBV) infection and aflatoxin (AFB1) exposure, and these tumors have a high frequency of mutations in the tumor suppressor gene p53 at codon 249 (p53ser249). In specific Aim 1, the effect of expression of p53, HBV injury and AFB1 exposure on development of pre-neoplastic lesions and HCC development will be studied using F1s of p53 null mice X HBsAg transgenic lineage 50-4 mice. In specific aim 2, the effect of p53 mutation will be determined using a newly established mutant p53ser246 (equivalent to human p53ser249) mouse lineage. In specific aim 3 the mechanisms for effects of loss on p53, p53 mutation and AFB1 exposure on hepatocyte proliferation during carcinogenesis will be examined by analysis of specific cell cycle events and expression or reactivity to liver growth factors.
Studies
35
In specific aim 4 HCCs arising in this model will be tested for chromosomal changes and cell cycle alterations and related to those in pre-neoplastic livers. These studies should lead to an understanding of how each of these risk factors affect hepatocyte proliferation and how these effects contribute to AFB1 hepatocarcinogenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIGEN SPECIFIC MODULATION OF T CELL RESPONSES Principal Investigator & Institution: Schneck, Jonathan P.; Associate Professor; Pathology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-MAY-2004 Summary: Using Ig as a molecular scaffold, we have developed a general approach to making soluble divalent analogs of MHC class I and II molecules (MHC-I/Ig and MHCII/Ig). The divalent nature of these molecules effectively increased the affinity of these analogs for their cognate ligands, antigen specific T cells. Peptide loaded divalent high affinity MHC analogs (pepMHC/Ig) can be used to directly visualize antigen specific T cells by flow cytometry. The goals of the current application are to selectively modulate and monitor antigen-specific T cell responses in murine models using pepMHC/Ig complexes. Our first specific aim will focus on defining the mechanism of in vitro CTL modulation by pepMHC-I/Ig complexes. We will determine if pepMHC/Ig complexes inhibit 2C CTL by competitive inhibition, induction of anergy, or induction of apoptosis. The second specific aim will analyze the effects of pepMHC-I/Ig complexes on T cells in vivo using two model systems: peptide- specific 2C CTL and a Hepatitis B specific CTL, 6C2. The influence of pepMHC-I/Ig on both trafficking and modulation of CTL responses in vivo will be defined. Initial experiments will be aimed at optimizing platform development for homogeneously loading MHC-I/Ig complexes with the peptides of interest. Trafficking studies on 2C CTL will be studied using B6 animals injected with P815 tumor cells and suppression will be studied in a 2C-mediated model of diabetes. We will analyze the effects of HepBLd/Ig on Hepatitis B specific CTL by characterizing the ability of HepBLd/Ig complexes to: bind to HepB specific CTL, inhibit HepB specific CTL mediated lysis of target cells in vitro, and modulate hepatocellular necrosis in HBsAg transgenic mice injected with 6C2, HepB specific CTL in vivo. Should the direct modulation of specific CTL in vivo prove ineffective, the ability of pepMHC-I/Ig coupled to a fungal toxin, ricin, to specifically kill T cells in vitro and in vivo will be analyzed. To analyze the ability of pepMHC/Ig complexes to selectively regulate class II-restricted immune responses, we will study the ability of pepMHC-II/Ig compounds to modulate class II-restricted, immune responses. The model system to be analyzed will be the effects of MCCI-Ek/Ig on cytochrome-specific immune responses. Analysis of the effects of soluble divalent class II MHC molecules will reveal several interesting and unique features about regulation of class II-restricted immune responses. The first part of this specific aim we will analayze modulation of in vitro immune responses by MHC-II/Ig complexes and also address the ability of soluble divalent analogs of peptide antagonists complexed to the I-Ek/Ig molecule to modulate in vitro immune responses. In the second part of this specific aim we will study the ability of MHC-II/Ig complexes to modulate in vivo immune responses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIVIRALS AGAINST HBV Principal Investigator & Institution: Otto, Michael J.; Pharmasset, Inc. 1860 Montreal Rd Tucker, Ga 30084
36
Hepatitis B
Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2003 Summary: (provided by applicant): The global magnitude of hepatitis B viral (HBV) infection warrants development of efficient treatment strategies to combat the virus. These treatment protocols will also aid in minimizing the protracted long-term effects of HBV infection namely cirrhosis and hepatocellular carcinoma. The short-term benefits of the currently available treatment protocols are greatly offset by the emergence of the resistant phenotype in the case of Lamivudine therapy and adverse side effects in the case of alpha-interferon. As a consequence of this, the goal of maintaining low viral loads cannot be achieved. The generation of a panel of potent antivirals against HBV would be a valuable addition to existing treatments. Novel combinations of anti-HBV drugs would greatly minimize the chances of development of resistance and provide sustained reduction in viral loads. A number of 2'-fluoro-2',3'-unsaturated D- and Lnucleosides (2'-F-D4N) showed potent anti-HBV activity with no appreciable toxicity in a number of cell lines. These compounds also demonstrated anti-HIV activity in vitro. In the proposed Phase I study, these compounds will be further characterized with respect to their anti-HBV activity in combination treatments, mechanisms of action, mitochondrial toxicity, and efficacy of inhibition of HBV viral polymerase. Crossresistance of these active nucleosides against the Lamivudine-resistant mutants will be determined. Pharmacokinetics of molecules with antiviral activity and no appreciable cellular and mitochondrial toxicity will be conducted. At the conclusion of the Phase I study, it should be possible to identify one or two best candidate molecules for detailed studies in animal models, preclinical studies and further development. Detailed studies for phase II studies which will include in vivo efficacy and sub chronic toxicology of the compounds. PROPOSED COMMERCIAL APPLICATION: There is an urgent need for therapies for the treatment and management of HBV worldwide. Limited success of the Lamivudine monotherapy and development of clinical resistance to Lamivudine have made the researchers as well as clinicians aware of the fact that alternate modalities of treatment have to be in place to tackle HBV infections successfully. Novel anti-HBV agents, hence, would have a much broader market as new combinations of drugs can be formulated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLIN. & HISTOLOGIC SPECTRUM OF HCV LIVER DISEASE IN IDU Principal Investigator & Institution: Edlin, Brian R.; Associate Professor of Medicine and Publ; Family and Community Medicine; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2002 Summary: Injection drug users (IDUs) have the highest hepatitis C (HCV) infection rates of any risk group in the United States; fully 70-96 percent of IDUs have been infected. Natural history studies of transfusion recipients have suggested that HCV infection represents a slowly progressive disease culminating in cirrhosis and liver cancer after decades. But while active IDUs represent the largest single group of persons infected with HCV, there are no studies to date describing the prevalence and severity of HCVrelated liver disease among street-recruited, actively injecting IDUs. Because most IDUs acquired HCV when they began injecting decades ago, many are at imminent risk for life-threatening complications. We propose a cross-sectional study of 1000 active, streetrecruited IDUs who test positive for HCV antibody in the Urban Health Study's ongoing program of HIV and hepatitis testing in inner-city neighborhoods in San Francisco. Indepth epidemiological, clinical and laboratory evaluations of HCV-positive participants will be conducted to assess signs, symptoms, and correlates of liver disease. A subset of
Studies
37
200 HCV-positive participants will undergo liver biopsies. Specifically, this study aims to: 1) to describe the clinical and laboratory spectrum of HCV-related liver disease among 1000 active, street-recruited IDUs in San Francisco, 2) to determine the correlates of advanced liver disease among active IDUs, including demographic factors, injection and other behaviors, comorbidities, and viral markers. Advanced liver disease will be defined as Child-Pugh score B or greater, 3) to describe the histologic spectrum of HCVrelated liver disease in a subset of 200 active IDUs who will undergo liver biopsy, and 4) to determine the correlates of progressive liver disease among the 200 IDUs who undergo biopsy. Progressive liver disease will be defined as fibrosis stage 3 or 4 on liver biopsy. In addition, contact information will be collected so that this cross-sectional study can serve as a baseline for future cohorts to examine the incidence of clinical and histological disease in this cohort. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL AND CELLULAR EFFECTS OF INTERFERON ALFA 1 Principal Investigator & Institution: Borden, Ernest C.; Director; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, Oh 44195 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: Using a preparation that was in limited supply, we previously assessed Interferon-alpha 1 (IFN-alpha 1) clinically in a randomized, double blind comparison to IFN-alpha 2. The frequency of side effects was much less with IFN-alpha1 (p less than 0,01). Yet effects of IFN-alpha 1 on granulocyte counts, NK cell cytotoxicity, and an ISG were comparable to IFN-alpha2. These findings suggest that IFN-alpha 1 might be given with better tolerance and or higher doses than IFN-alpha 2. Recombinant DNA produced IFN-alpha 1 has now come available in adequate supply through a collaboration with the Ministry of Public Health in Shanghai. In randomized, multicenter clinical trials in China, IFN-alpha 1 has proven effective for chronic hepatitis B and C. Data from China also suggests IFN-alpha 1 is better tolerated than IFN-alpha 2. IFN-alpha 1, together with IFN-alpha 2, is a predominant IFN-alpha species generally characteristic of an IFN. However, IFN-alpha 1 has differing receptor binding affinities and differing cross species antiviral activity differences in the transcription factor complexes activated in response to IFN-alpha 1 as compared to IFN-alpha 2. In addition to expected IFN antiproliferative and gene stimulatory (ISG) effects, we have also identified an increase in STAT1 protein expression and induction of apoptosis in myeloma cells by IFN-alpha 1. Studies of IFN-alpha have been designed with the following goals: a) confirm good clinical tolerance and define the dose response characteristics of ISG induction in patients, b) compare the signal transducing and gene modulatory activity to those of IFN-alpha 2 by oligonucleotide gene array and assessment of transcription activating factors, c) study apoptosis and gene induction in myeloma and renal carcinoma to confirm clinical antitumor activity. Since expanded clinical use of IFN- alpha 2 has increasingly been limited by side effects, IFN-alpha 1 may be particularly important in extending clinical leads provided by LFN-alpha 2. Finally, results will further confirm the postulate that antiviral specific activity in vitro does not predict for other biological and clinical effects of IFN. In addition, if the pattern of novel gene induction and cellular effects are expanded, IFN-alpha 1 could have a broader spectrum of responsive clinical tumor types. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
38
Hepatitis B
•
Project Title: CLINICAL TRIAL OF SHORT COURSE VS. INH FOR LTBI IN JAIL Principal Investigator & Institution: White, Mary C.; Community Health Systems; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Tuberculosis (TB) in incarcerated populations is a serious problem, due to the large proportion of inmates who are at high risk of having latent tuberculosis infection (LTBI) and developing active disease. Completion of treatment of LTBI has not been successful in jails, mainly because inmates are frequently released before finishing a 6-9 month course of standard therapy with daily isoniazid (INH), and because they have low rates of completing therapy in the community. Effective treatment of LTBI is complicated by length of therapy and toxicity of the drugs used against L TBI. Short-course therapies for LTBI may address this problem but they have not been studied adequately to answer questions about side effects, completion rates, and overall cost. We propose a two arm, open label randomized trial to test the effects of a short-course therapy for LTBI in jailed inmates; rifampin given daily for 4 months as compared to INH given twice weekly for 9 months. A sample of 972 consented and enrolled participants will be administered directly observed therapy (DOT) in jail. The study protocol includes links to the TB Clinic for post-release DOT, and close clinical and laboratory monitoring throughout the course of therapy. Participants will be followed, in jail and after release, for one year after enrollment, to measure three outcomes: toxicity, adherence, and cost-effectiveness. Toxicity leading to stopping drug will be analyzed by study group, and other predictors will be examined, such as age, alcohol use and hepatitis B and C. Adherence, measured by completion of therapy, will be compared by study group, and other predictors will be examined, including sociodemographic variables, intent to adhere, and stability of housing. Costeffectiveness will be compared by study group and will be calculated using direct costs of administering and monitoring care and costs of re-starting care in this population with a high rate of re-arrest, measured against the cost of prevented cases of TB. Short course regimens are promising in the inmate population to treat LTBI and eliminate risk of progression to active disease. This study will answer questions about the safety of rifampin compared directly to INH. Analysis of completion of therapy and costeffectiveness of this regimen will provide important information for policy change in the way L TBI is managed in jail. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COST-EFFECTIVE SCREENING IN INTERNATIONAL ADOPTEES Principal Investigator & Institution: Mandalakas, Anna M.; Pediatrics; Case Western Reserve University 10900 Euclid Ave Cleveland, Oh 44106 Timing: Fiscal Year 2001; Project Start 04-SEP-2001; Project End 30-JUN-2006 Summary: (provided by applicant): The candidate is a junior academic clinician, trained in pediatrics and epidemiology, whose long-term career goals are to conduct patient oriented research that will improve health care delivery to vulnerable children in the US and in the developing world. The proposed training program was designed to enable the candidate to transition from novice to independent researcher in epidemiology with expertise in international child heath. The specific objectives are to obtain maundered practical experience in patient oriented research and rigorous methodological training in decision analytic methods with an experienced team of mentors and national experts. The training plan describes activities (advanced degree coursework, independent study and patient oriented research) focused on further developing skills in epidemiology
Studies
39
with immediate applications to cost- effective screening in internationally adopted (IA) children. Two complementary studies are proposed that address the clinical and costeffectiveness of hepatitis B virus (HBV) and tuberculosis (TB) screening in IA children. These studies are based on the hypothesis that focused, rational screening can provide a cost-effective means for improving the long-term health outcomes of immigrant children and is consonant with public health imperatives. Each study involves primary collection of new data that address important gaps regarding the prevalence and risk factors for infectious diseases in IA children, and the utility of markers (skin tests and immunization history) to predict infection, disease or protective immunity. This will provide new information regarding the infectious disease burden, and its expression, in the growing group of IA children in the US. These new data also will provide estimates necessary for cost-effectiveness analyses that will be developed to assess the utility of alternative approaches for immunization and TB screening. The proposal addresses important knowledge gaps about the health of children immigrating to the US from resource-poor environments and may provide important new data for rational and costeffective screening in IA children. The cohort of children developed in this proposal may be followed in future research designed to answer challenging questions with respect to the long-term impact of early screening and preventive TB therapy. Finally, the proposal will provide a key training opportunity to foster the candidate s career development as an epidemiologist with a commitment to patient oriented research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COUPLES HIV INTERVENTION RANDOMIZED CONTROLLED TRIAL Principal Investigator & Institution: Mcmahon, James M.; National Development & Res Institutes Research Institutes, Inc. New York, Ny 10010 Timing: Fiscal Year 2003; Project Start 26-SEP-2003; Project End 30-JUN-2007 Summary: The broad, long-term objective of the proposed research is to establish primary preventive interventions to reduce human immunodeficiency virus (HIV) risk behavior among drug-using minority women. Recent studies indicate that high rates of sexual risk behavior occur within drug-using minority women's primary heterosexual relationships. Based on an integrated theory of HIV risk behavior, it is predicted that a) interventions administered to couples rather than to women only, and b) interventions that focus on relationship dynamics in the context of HIV risk, will result in a reduction of sexual risk behavior among drug-using women and their primary partners. This fouryear study will employ a randomized controlled trial (RCT) 3-group design to test the efficacy of HIV intervention modality (couples versus women-only) and intervention content (relationship-focused versus standard HIV counseling and testing) on crack, cocaine and heroine (injected and noninjected) using women's sexual risk with primary partners. A total of 390 women drug-users and their partners will be recruited from the streets of East Harlem, New York City. Participants will be randomly assigned to one of three HIV intervention conditions: a) couples, relationship-focused; b) women-only, relationship-focused; or, c) women-only standard HIV-CT (control). All subjects will be administered baseline, 3-month, and 9-month follow-up assessments using a combination of computerassisted personal interview (CAPI) and computer-assisted self interview (CASI) techniques. In addition to sociodemographic characteristics, the interview will measure drug-use patterns, HIV risk behavior, and dyadic- and individual-level variables operationalized to test specific hypotheses of women's HIV risk behavior and behavior change. In addition to testing the effectiveness of the experimental interventions, data analyses will determine the theory-driven psychosocial
40
Hepatitis B
mechanisms that act to mediate and moderate any observed association between intervention treatment and subsequent risk reduction. Incremental cost-effectiveness analyses will also be performed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIETARY FACTORS IN THE ETIOLOGY OF CANCER IN SHANGHAI Principal Investigator & Institution: Ross, Ronald K.; Professor; Preventive Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 01-APR-1987; Project End 30-JUN-2002 Summary: (Adapted from the Applicant's Abstract): We are requesting continued support for an ongoing cohort study of 18,244 men, ages 45-64, living in a geographically defined area of metropolitan Shanghai, Peoples Republic of China. All cohort members have completed detailed diet and medical histories and have blood and urine samples. Questionnaires have been edited and computerized and blood and urine samples have been processed, aliquoted, and continuously stored at both -20_C and 70_C. The cohort was fully established in 1989. Follow-up of the cohort is proceeding through cancer registration by the population-based Shanghai Cancer Registry, by routine ascertainment of death certificates, and by annual recontact of all cohort members. As of March 1994, 606 have developed cancer and 989 have died. The leading cancers include lung, stomach, liver, and colorectal cancers, while stroke is the number one cause of death. Major accomplishments achieved through this cohort to date include: (1) the first direct evidence linking aflatoxin ingestion to human hepatocellular carcinoma (HCC); (2) strong evidence of synergy between aflatoxin biomarkers and chronic infection with hepatitis B virus in establishing risk of HCC; (3) failure to find an association between H. pylori serology and stomach cancer risk; (4) the absence of an inverse association between antioxidants and fatal stroke; and (5) the first comprehensive and systematic evaluations of smoking-related cancer incidence and mortality in China. We propose to continue to follow this cohort for an additional five years. We will continue to evaluate risk factors for major health outcomes in the cohort, building on previous observations and continuing to exploit the serum and urine banks available for biomarker studies. Although we did not collect buffy coats for genetic studies on cohort members, we have demonstrated that the stored serum samples contain sufficient cells for conducting selected PCR-based genetic studies. Among the scientific goals for the next five years are: (1) to continue to evaluate the aflatoxin/HCC association and to assess the impact of sequence variations in genes involved in aflatoxin metabolism (GSTM1 and EPHX) in modifying risk; (2) to continue to assess the role of H. pylori in gastric cancer etiology in Shanghai, and to assess the possible protective effect of tea polyphenols on risk; and (3) to better understand the complex interrelationships among carotenoids, smoking, and lung cancer and to assess the possible risk modifying impact of genes involved in metabolism of smoking-related carcinogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ELECTROCHEMICAL ENZYME IMMUNOASSAY TO TEST BLOOD HBV Principal Investigator & Institution: Henkens, Robert W.; Alderon Biosciences, Inc. 2810 Meridian Pky, Ste 152 Durham, Nc 27713 Timing: Fiscal Year 2001; Project Start 15-APR-2000; Project End 30-JUN-2003
Studies
41
Summary: (provided by applicant):Millions of Americans are infected by the hepatitis B virus (HBV)-many of whom have no reason to believe they are infected. There is a need to track down America's millions of HBV victims-as well as a corresponding need for innovative technology to test blood for HBV. HBV is clearly a national medical priority. The overall goal of this project is to further develop and then integrate core sensor and enzyme immunoassay technologies into a novel technique for the rapid and accurate measurement of HBV levels in blood. We are targeting diagnostic (detection) applications as well as quantitative measurement needs (to monitor viral levels and treatment efficacy). The feasibility of our approach was clearly demonstrated during Phase I. The Phase II goal is to demonstrate/validate/optimize the integration of a unique electrochemical measurement method with proprietary electrochemical enzyme immunoassay architecture to produce a new diagnostic/monitoring capability for "real time," cost-effective HBV assessment in an outpatient setting. The product we envision is a disposable HBV test strip that can be read by an inexpensive, small (hand-held) instrument. It would represent a key development in medical diagnostics that would address major domestic and international market needs for low-cost HBV screening and monitoring. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENHANCED T AND B CELL RESPONSES VIA RECOMBINANT PROTEINS Principal Investigator & Institution: Gosselin, Edmund; Assistant Member; Alld Health Education Programs; Albany Medical College of Union Univ Union University Albany, Ny 12208 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JUL-2004 Summary: (Adapted from Applicant's Abstract) A safe and successful vaccine against HIV will likely require the simultaneous priming of both cellular and humoral immune responses, and will preferentially involve the use of recombinant proteins. Targeting immunogens to Fc gamma receptor type I (FcgRI) on antigen presenting cells (APC) significantly enhances T cell activation in vitro, and antibody production in vivo. In addition, it can also lead to simultaneous priming of both cytotoxic and helper T cell responses. Furthermore, by combining the administration of antigen with cytokines, T cell activation can be further enhanced, and T cell subset development modulated. It has also been demonstrated that targeting antigen (Ag) to FcgRI on APC can eliminate the need for traditional adjuvant, easing difficulties associated with vaccine preparation and distribution. Therefore, developing a strategy which facilitates antigen targeting to APC, and the use of cytokines in vaccines, is likely to have a significant impact on current vaccine technology, in particular as it applies to HIV. We propose to utilize molecular techniques, and FcgRI-specific constructs, to create and test the ability of a prototype two component (modular) immune targeting system to stimulate enhanced humoral, CD4 helper T cell, and CD8 cytotoxic T cell responses in vitro and in vivo. Components will consist of a humanized divalent FcgRI-specific biotin-binding targeting element, and biotinylated functional elements including Hepatitis B Ag, gp120 Ag, and IL-2. The ability of the two component immunogens to modulate human CD4 and CD8 T cell responses in vitro, and murine B cell, CD4 T cell, and CD8 T cell responses in vivo, will be examined. In the latter instance, transgenic mice that express human FcgRI will be immunized with two component immunogens. Following immunization, CD4 and CD8 T cell responses, as well as the generation of Ag-specific antibody will be measured. These studies will provide a novel and safe approach for simultaneously priming humoral and cellular responses in vivo using recombinant proteins. This approach will
42
Hepatitis B
not only provide an effective means for controlling the spread of HIV, but many other infectious organisms as well. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ETIOLOGY AND PREVENTION OF BLOOD BORNE VIRUSES IN IDUS Principal Investigator & Institution: Hagan, Holly C.; Deputy Director; National Development & Res Institutes Research Institutes, Inc. New York, Ny 10010 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-MAR-2007 Summary: (provided by applicant): The etiology and prevention of blood-borne viral infections in injection drug users (IDUs) have not been fully characterized, and many questions remain regarding which injection practices may result in I infection. Viral hepatitis infections in IDUs are among the most frequently occurring 81ood-bornel l infections in humans; in low HIV-prevalence settings, morbidity and mortality in IDUs attributable to l hepatitis virus infections may exceed that for HIV. Hepatitis C virus (HCV) is highly prevalent in IDU- populations, and is more efficiently transmitted l abouty injection than HIV. Because sexual HCV transmission is relatively rare, it may serve as a highly sensitive biologic marker of direct percutaneous exposure to these infections in drug injectors, and may contribute to understanding the mechanism of transmission of other infections via injection practices. The long-term goal of our research is to advance knowledge of the epidemiology, etiology and-prevention of HIV and hepatitis infections in IDUs. We propose studies that will make new contributions toward our long-term goal: Aim 1. Examine the extent to which HCV prevention education at the Seattle needle exchange program has reduced the risk of HCV infection. Aim 2. Measure the risk of HCV seroconversion associated with specific injection risk behaviors, and calculate the risk of HCV attributable to these practices in the IDUpopulation. Aim 3. Compare reporting of socially-undesirable or stigmatized injection and sexual risk behavior collected by A-CASI to interviewer-administered data collection methods. Aim 4. Assess the feasibility and disease control benefits of HBV and HCV partner notification for IDUs. Aim 5. Study whether changes in hepatitis C reporting laws are associated with increased reporting in IDUs. The significance of this research is its potential contribution to our understanding of the etiology of these l infections, and examines many practical questions related to the effectiveness of public health surveillance and prevention programs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GROWTH HEPATOCYTES
CONTROL
OF
NORMAL
AND
CIRRHOTIC
Principal Investigator & Institution: Behrns, Kevin E.; Associate Professor of Surgery; Surgery; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, Nc 27599 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Hepatocytes are unique parenchymal cells that divide and regenerate the liver in response to major injury. This regenerative capacity, however, leads to disordered hepatocyte growth in the chronically injured, cirrhotic liver. Hepatocytes in the cirrhotic liver respond differently to growth control signals. Most hepatocellular carcinomas arise in a cirrhotic liver, providing evidence that cirrhotic hepatocytes have altered growth control behavior. Cirrhosis is a major worldwide health problem that is expected to increase in prevalence because of
Studies
43
increasing alcohol abuse and dissemination of the hepatitis B and C viruses, all major causes of cirrhosis. In an earlier proposal (K08), we hypothesized that cirrhotic hepatocytes would be less sensitive to apoptosis. Indeed, studies confirmed that cirrhotic hepatocytes are less responsive to multiple apoptotic agents including tumor necrosis factor a (TNFalpha), transforming growth factor beta (TGFbeta), and ultraviolet-C irradiation (UV-C). The resistance to TGFbeta-induced apoptosis is of special interest because this cytokine is a known inhibitor of hepatocyte growth, and it is present in high concentrations in the cirrhotic liver. The mechanisms by which TGFR induces hepatocyte apoptosis are not well known, but our studies in primary normal mouse hepatocytes suggest that this occurs through a caspase-8 dependent mechanism that requires the generation of reactive oxygen species, depolarization of the mitochondria with cytochrome c release, and caspase-3 activation. This is the first demonstration of caspase-8 dependence. The mechanisms that inhibit this pathway in cirrhotic hepatocytes are unknown, but may involve other TGFR-activated pathways such as the Smad signaling pathway. We hypothesize that the Smad signaling pathway is necessary for hepatocyte apoptosis, and that defects in this pathway are present in cirrhotic hepatocytes. Alterations in the Smad signaling pathway may alter pro- or antiapoptotic factors that govern the cellular balance between survival and death. In this proposal, we aim to determine if the Smad signal transduction pathway is necessary for TGFbeta-induced hepatocyte apoptosis. In addition, because cirrhotic hepatocytes exhibit resistance to apoptosis that may be due to changes in expression of pro-and antiapoptotic factors, we hypothesize that normal and cirrhotic hepatocytes differ in their gene expression profiles. We propose to identify and characterize differences in gene expression profiles between normal and cirrhotic hepatocytes in response to apoptotic stimuli. Examination of these hypotheses will allow our laboratory to growth both in depth and in breadth, because we will use new microarray technology provided within the UNC Genomics Core and Microarray Facility. We will continue to seek counsel from our K08 mentors (Drs. David Brenner and Lola Reid) and use liberally the UNC Center for Gastrointestinal Biology and Disease for core facilities such as the Molecular Imaging Core. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HAWAII ACTU - ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM Principal Investigator & Institution: Shikuma, Cecilia M.; Associate Professor of Medicine; Family Practice & Cmty Health; University of Hawaii at Manoa Honolulu, Hi 96822 Timing: Fiscal Year 2001; Project Start 01-JAN-1996; Project End 31-DEC-2004 Summary: (adapted from the application's abstract): The HACTU is part of the HIV clinical research arm of the University of Hawaii's program in Retrovirology. The HACTU has been a formal unit of the AACTG since 1990 with funding received under a minority institution initiative. The site brings to the AACTG: (1) an established clinical trials unit within the AACTG with a record in clinical trial management, currently meeting all ACTG standards for site operations; (2) access to Hawaii's ethnically diverse population, having previously contributed 41 percent of all ACTG's enrollees of Asian/Pacific Islander descent; (3) a unit with wide community, state governmental and university support for its operations as the only HIV/AIDS clinical research program in Hawaii; (4) a continued commitment to participate as broadly as feasible not only in AACTG's main antiretroviral trials but also in specialized areas of HIV immunology and complication research targeted at areas of special importance by the AACTG leadership;
44
Hepatitis B
and (5) a minority unit with a record of increasing scientific contributions to the ACTG over the past five years and a commitment to contribute to the AACTG's scientific agenda in the next five years. The areas of pathogenesis/treatment of HIV/Hepatitis B and C co-infection; HIV-associated interest include metabolic complications; role of insertional mutagenesis and macrophages in the pathogenesis of HIV- associated malignancies; central nervous system (CNS) disease; and the impact of menopause and female replacement hormonal therapy on HIV-1 activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HBV DIPSTICK FOR RESOURCE-LIMITED BLOOD BANKS Principal Investigator & Institution: Lee, Helen H.; Diagnostics for the Real World, Ltd 50 Mounds Rd, Unit 512 San Mateo, Ca 94402 Timing: Fiscal Year 2002; Project Start 16-SEP-2002; Project End 31-AUG-2003 Summary: (provided by applicant): According to WHO statistics on blood safety, 80 percent of the world's population has access to 20 percent of the world's safe blood supply. However, more than 20 percent (13,000,000 units) of the world blood supply is not tested for the three major transfusion-transmissible infections: HIV, HBV and HCV. Transfusion of unsafe blood accounts for 8-16 million hepatitis B virus infections. If inexpensive, rapid, improved dipsticks with sensitivity comparable to EIA were developed for blood screening, it would greatly improve the safety of the blood supply in developing countries.The overall aim of the project is to develop a HBsAg dipstick assay with high sensitivity, designated as the reflex diagnostic. The test can be used in developed countries under circumstances where an immediate result is required. For the developing countries, we propose that this test be integrated into a triplex test (HBV, HIV & HCV) and used as the initial step of pre-donation screening in high prevalence countries. The associated second step is to use the HBsAg reflex diagnostic test in order to identify the agent responsible for the positive Triplex test result.The specific aims of Phase I are to optimize the reagents in order to produce a prototype with sub-nanogram sensitivity and to evaluate the assay in 50 HBV-positive samples. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HBV INDUCED LIVER PATHOGENESIS Principal Investigator & Institution: Siddiqui, Aleem A.; Professor; Microbiology; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2001; Project Start 01-APR-1996; Project End 31-MAR-2006 Summary: (provided by applicant): Hepatitis B virus infections are one of the leading causes of chronic hepatitis. Infection results in a broad range of clinical symptoms from mild, nonapparent disease to fulminant hepatitis to hepatocellular carcinoma. Due to lack of in vitro infection system for HBV, the events of infectious processes are poorly understood. HBV encodes a regulatory protein termed HBx. While many functions have been attributed to HBx, a clear picture of how this protein participates in establishing infectious process has not emerged. In this competing renewal grant application, the focus of our study will be on the detailed characterization of HBx s association with mitochondria and exploring the functional consequences of that association. First, we propose to identify the mitochondrial targeting domain within HBx protein. Using those mutants, which fail to associate with mitochondria, further characterization of various possible functions of HBx within mitochondria will be investigated. These include, the ability of HBx via its interaction with the outer membrane channel VDAC to alter
Studies
45
mitochondrial membrane potential (delta-psim), generation of reactive oxygen species (ROS). Ca+2 homeostasis. and permeability transition among others. Alteration of these functions will be correlated with induction of gene expression via NF-kB, AP-1, NF-AT and STAT-3 transcription factors. The results of these studies will delineate the molecular mechanisms in the induction of HBV-induced liver disease pathogenesis including hepatocellular carcinoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HBV PREVENTION FOR HOMELESS AT-RISK FOR HBV/HCV/HIV Principal Investigator & Institution: Nyamathi, Adeline M.; Professor and Associate Dean; None; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 30-JUN-2008 Summary: (provided by applicant): Nationwide, homeless populations are at risk for HIV infection due to disproportionate use of injection drugs, unprotected sexual activity, prostitution and victimization. Infection with the Hepatitis B Virus (HBV) and the Hepatitis C Virus (HCV) is high among homeless adults as they share risk factors with HIV. Hepatitis A Virus (HAV) is also high among populations vulnerable to HBV, HCV, and HIV as modes of transmission for HAV overlap with those of HBV, HCV, and HIV. Thus, education and screening programs for HAV, HBV, HCV, and HW, combined with vaccination programs for HAV and HBV, can significantly decrease Hepatitisrelated morbidity and mortality. However, homeless persons, many of whom may be contending with drug and alcohol abuse and unemployment, and live in a disorganized world with little access to health and social services, are often non-compliant. In this prospective two group quasi-experimental design, we will evaluate with approximately 1000 sheltered men and women in the Skid Row area of Los Angeles, the effectiveness of a theoretically-based HAV/HBV vaccination intervention focused primarily on completion of the combined Twinrix HAV/HBV vaccination series and secondarily on risk reduction of HAV, HBV, HCV, and HIV. We will also collect data on the relative cost of each of these programs in terms of completion of HAV/HBV vaccination, the cost effectiveness of improving vaccination completion, the cost per sero-protected case, and the cost per infection prevented. Once determined eligible, participants will be randomized by shelter into one of two programs: a Nurse Case Managed Plus Incentive and Tracking (NCMIT) program and a Standard Plus Incentive and Tracking (SIT) program. The proposed study is innovative in that the comparison of the SIT and NCMIT programs will allow us to look at the effect of a standard intervention combining brief education, incentives and tracking with that of a similar intervention that also includes nurse case management on completion of the HAV/HBV vaccination. Participants in the two programs will receive the 3-series vaccination by trained research nurses at the study clinic over six months, along with either the NCMIT, or the SIT program. All participants will be assessed at baseline and six- and twelve-month followup using a battery of psychosocial, behavioral, health and physical status, as well as HAV, HBV, HCV, and HIV sero-status measurements. This proposed study supports the National Drug Abuse Research Initiative as it is focused on assessing the effectiveness of intervention programs promoting the prevention of medical consequences of HAB, HBV, HCV, and HIV in homeless and drug abusing populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
46
Hepatitis B
•
Project Title: HBV, HCV, CMV & HHV-8 IN HIV POSITIVE WOMEN IN THAILAND Principal Investigator & Institution: Lallemant, Marc J.; Immunology/Infections Diseases; Harvard University (Sch of Public Hlth) Public Health Campus Boston, Ma 02460 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-JUL-2003 Summary: (adapted from abstract) The Harvard School of Public Health's Perinatal HIV Prevention Trial, Thailand study (PHPT) and Thailand's recently established National Data Center for AIDS Vaccine Development (NDCAVD) at Mahidol University's Institute for Population and Social Research have combined efforts to strengthen Thailand's research capacity in the areas of data management and statistics within the context of clinical trials. The specific aims of this proposal are to investigate the epidemiology of four viral infections -- Hepatitis B (HBV), Hepatitis C (HCV), Cytomegalovirus (CMV), and Human Herpes Virus-8 (HHV-8) -- in relation to HIV among a large representative sample of pregnant Thai women. These viruses were chosen for their public health importance or their theoretical/known associations with HIV. This study plans to: 1) determine the seroprevalence of each infection and associated risk factors in HIV+ and HIV- pregnant women; 2) determine the rates of transmission of these viruses and risk factors for transmission in HIV+ women who are not breast feeding; 3) explore the relationship of perinatal HIV transmission to these other viruses; and 4) determine whether co-infection by these viruses are prognostic risk factors for progression of HIV disease in mothers and children. The sera from 35,000 women screened for HIV within the PHPT are available for testing. All HIV-positive women, as well as a randomly selected group of HIV-negative (stratified by urban/rural residence and age), will be screened for these four viruses. All infants born to coinfected (HIV and another virus) mothers will also be tested for the corresponding virus. Sociodemographic and behavioral data from all women, the HIV status of the infants and progression data from HIV-infected children are available from the PHPT. NDCAVD will perform all necessary data management and collaborate in the analysis and interpretation. As a retrospective substudy, this project will provide appropriate training for NDCAVD researchers in the data management of clinical trials, as well as answer some important questions regarding the association of these viruses with HIV and perinatal transmission. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HCV GENOMIC VARIABILITY IN HIV INFECTED HEMOPHILIACS Principal Investigator & Institution: Sherman, Kenneth E.; Associate Professor; Internal Medicine; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2005 Summary: Hemophiliacs with symptomatic disease are multiply exposed to blood products including factor concentrates to correct the Internet clotting factor deficiencies. Prior to routine use of heat inactivation and screening of donor blood for specific viral pathogens, hemophilia patients were routinely exposed to, and infected with, viruses such as hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency virus (HIV). Cohort studies in hemophiliacs suggest several clinically and scientifically important findings that warrant further detailed investigation including; a) Liver disease progression may be altered in hemophiliacs infected with HCV with more rapid progression to liver failure and death; b) The source of infection from large pools of concentrate that were potentially infected by multiple discreet donors leads to a high
Studies
47
risks of mixed infection represented by both genotype and quasi species heterogeneity; c) The HIV coinfected hemophiliacs may have different clinical outcomes and an altered immune response may facilitate our understanding of the underlying process of mutant virus selection, and the associated clinical outcomes. The overall goals of this proposal include the study and characterization of the genomic RNA of HCV in infected hemophilic patients with and without confection with HIV. In the retrospective Phase 1, we utilize the NCI Multi center Hemophiliac Cohort Study serum bank database to study the relationship between progression to decompensated liver disease and quasi species variability in the viral envelope hyper variable and core domain. Heteroduplex analysis will be used to rapidly screen samples from index patients and matched controls using samples longitudinally collected over a 10 year or longer period of time. Peptides will be produced from unique quasi species and these peptides will be evaluated for their function as CTL epitomes. Phase 2 involves the initiation and performance of a clinical intervention trial designed to determine variable kinetic response rates to PEG-interferon+ribavirin between hemophiliacs with HCV alone vs HCV/HIV coinfected subjects. Quasi species populations will be modified/cloned, sequencing will be performed to generate families of closely related core peptides that will be studied for their ability to bind and stimulate an immune response. Treatment nonresponders will be followed in a prospective cohort study for up to 3 additional years so that the evolution of the virus, and its associated immune response in this group can be evaluated. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HCV IN ALCOHOLICS Principal Investigator & Institution: Wands, Jack R.; Professor of Medicine; Rhode Island Hospital (Providence, Ri) Providence, Ri 02903 Timing: Fiscal Year 2003; Project Start 01-DEC-1993; Project End 30-JUN-2007 Summary: (provided by applicant): Chronic hepatitis C (HCV) infections are common in alcoholics with or without liver disease contributing to significant morbidity and mortality. The reasons for high rates of persistent viral hepatitis infection are unknown but may partially relate to the effects of alcohol on the humoral and cellular immune response to viral structural and nonstructural proteins. We established an animal model system of HCV specific antibody stimulation, CD4+ proliferative response, and CD8+ CTL activity in the context of genetic immunization to test this hypothesis. We plan to do the following: Specific Aim #1 - Further establish the differential effects of ethanol on the immune response(s) to HCV structural and nonstructural proteins in the context of genetic immunization with respect to: a. Assess variations in CD4+ T cell proliferative activity particularly against HCV core, NS3, NS3 helicase, NS4, NS5A and NS5B proteins. b. Evaluate Th1 and Th2 responses to determine if ethanol consumption shifts the immune response from the Th1 to Th2 phenotype. c. Characterize CD8+ CTL precursor frequency and function including possible differential effects of ethanol at the epitope level. d. Examine CTL activity in vivo against HCV derived peptides using an animal model of tumor growth. e. Determine the duration and reversibility of ethanol effects on CD4+ and CD8+ T-cell responses by crossover feeding studies with an isocaloric control diet. Specific Aim #2 - Develop approaches to augment and/or amplify humoral and cellular immune responses generated by DNA immunization in the setting of chronic ethanol administration, a. Explore whether systemic administration (murine and human IFN-a2, or pegylated IFN- a2) is more effective than local administration of cytokine expression construct (IL-2, GM-CSF, IL-12) at the site of gene delivery with respect to augmentation of the humoral and cellular immune
48
Hepatitis B
response(s) to HCV structural/nonstructural proteins. b. Determine the value of coimmunization with CpG motifs as an enhancer of the host B and T cell immune responses. c. Employ chimeric constructs to assess their possible role as a stimulant of virus specific B and T cell activities. Thus, principle long term goals of this application are to develop: a clinical DNA vaccine approach, effective alone or in combination with other antiviral agents (IFN-2a, etc.), to enhance the host immune response in an attempt to eradicate persistent viral infection from the liver in alcoholics; and obtain a clearer understanding of ethanol's effects on the immune response to HCV structural and nonstructural proteins in an experimental animal model system thereby generating principles applicable to chronic alcoholics Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATITIS B AND C AMONG HOMELESS ADULTS Principal Investigator & Institution: Gelberg, Lillian; Family Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 31-MAY-2004 Summary: Applicant's Abstract Persons infected with the hepatitis B virus (HBV) or hepatitis C virus (HCV) are at high risk for serious long-term health problems, and they are potentially infectious to others. Because of the seriousness of these infections, the NIH has developed a national agenda for preventing the spread and consequences of HBV and HCV. This agenda includes early detection, treatment, and prevention efforts for high-risk and infected persons. Homelessness has reached crisis proportions in the US today. Recent research by our team and others suggests that homeless adults in urban areas are a group at particularly high risk for HBV and HCV infections due to high rates of risky drug use and risky sexual behaviors. Despite the apparent high risk, however, there is only limited research on viral hepatitis in this group. We propose to conduct epidemiologic and health services research regarding HBV and HCV in a population-based sample of 500 homeless adults. We will recruit a probability sample of homeless adults with oversampling of injection drug users from 30 shelters and meal programs in the Skid Row area of Los Angeles. Respondents will undergo a two-hour interview (including the Diagnostic Interview Schedule-DIS-IV) and blood draw for hepatitis serology. We will estimate the prevalence of HBV and HCV and identify risk factors for each. We will evaluate whether homeless adults with histories of injection and non-injection drug use, risky sex, serious alcohol or mental disorders, or chronic homelessness have an elevated risk for these infections. We will also conduct health services research in which we will describe the respondents' past history of HBV/HCV testing, awareness of infection status, medical care for HBV and HCV, and willingness to return for HBV/HCV test results. Further, we will identify utilization of medical and non-medical settings to identify sites for future screening, treatment, and prevention efforts. We will provide hepatitis B immunization to those that test negative for hepatitis B. We will bridge the gap between research and prevention by using the Theory of Planned Behavior to understand protective behaviors used by homeless adults to avoid exposure to infectious diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEPATITIS B SUBUNIT ORAL VACCINE IN TRANSGENIC PLANTS Principal Investigator & Institution: Thanavala, Yasmin; Professor; Roswell Park Cancer Institute Corp Buffalo, Ny 14263 Timing: Fiscal Year 2003; Project Start 30-SEP-1998; Project End 30-NOV-2007
Studies
49
Summary: (provided by applicant): The proposal describes a series of experiments designed to target and track antigen following oral delivery via edible transgenic plants. The overall objective is to enhance both systemic and mucosal immune responses to orally delivered antigen. During the previous grant period we have demonstrated that mice fed potatoes expressing HBsAg make both primary and secondary antibodies responses in serum and anti-HBs IgA responses in mucosal secretions. We have provided transmission electron microscopic evidence that the transgenic potato cells harbored unusual membrane-bound bodies that contained circular structures that are approximately 17 nm in diameter. These structures are very similar to the virus-like particles (VLP) found in the serum samples of HBV infected patients and the distended ER vesicles are similar to those produced in yeast expressing HBsAg. These images provide the first ever evidence that in transgenic plants antigen is refined within vesicular structures. We also performed a successful double-blind placebo controlled Phase 1 trial to evaluate the safety and immunogenicity of the edible plant vaccine. None of the volunteers who ate nontransgenic potatoes showed changes in anti-HBs antibody titer. However, after volunteers ate transgenic potatoes, serum antibody titers increased in 62% who ate three doses and 53% who ate two doses of transgenic potatoes. Buffering of the stomach pH was not performed nor was any mucosal adjuvant used. This trial firmly establishes that oral vaccination via edible plant vaccines is possible for a non-enteric antigen such as HBsAg. Taken together, these data form a very solid foundation for the studies proposed in this application. In the current application we propose four specific aims designed (1) to improve the expression of HBsAg in transgenic plants, (2) target antigen to M cells in the gut, (3) to track the immune response elicited and (4) to potentiate the immune response to orally administered antigen by use of nontoxic mucosal adjuvants. We have provided significant new preliminary data and we believe that these provide strong documentation of the likelihood of continued success. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATITIS B VIRUS E ANTIGEN EXPRESSION Principal Investigator & Institution: Tong, Shuping; Rhode Island Hospital (Providence, Ri) Providence, Ri 02903 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Hepatitis B virus (HBV) infects nearly 1/10th of the world population and causes severe liver diseases including cancer. The e antigen (HBeAg) is a secreted soluble protein that promotes immune tolerance during perinatal infection and buffers immunity against HBcAg. The corresponding anti-HBe immune response plays a critical role in the clearance of HBV infection. Therefore, following seroconversion from HBeAg antigenemia to anti-HBe, HBV escape mutants with reduced or no HBeAg production often replace wild-type HBV genomes. The core promoter mutants have various nucleotide changes around positions 1750 -1770 of the HBV genome, and the most common mutations at 1762 and 1764 are known to reduce HBeAg expression at the transcriptional level. The precore mutants have nonsense or frameshift mutations in the HBeAg coding sequence and terminate HBeAg expression at the translational level. Considering the critical importance of HBeAg and anti-HBe in shaping the outcome of HBV infection, we wish to uncover novel regulatory mechanisms for HBeAg expression. In this regard, perinatally infected South African patients seroconvert from HBeAg to anti-HBe at a much accelerated pace than similarly infected Asian patients. Interestingly, the South African HBV variants often harbor two or three point mutations near the precore initiation codon. We plan to verify whether
50
Hepatitis B
the mutations cause leaky scanning to reduce HbeAg translation. Second, HBeAg maturation requires double proteolytic cleavage events in the secretory pathway. The first cleavage occurs in endoplasmic reticulum to remove the N-terminal signal peptide of 19 residues. A Val to Phe missense mutation at residue 17 is frequently detected in HBV genomes isolated from seroconverted patients. Since an aromatic residue at the -3 position of cleavage site is forbidden, we will test whether this mutation impairs HBeAg cleavage and secretion. Third, we recently identified several naturally occurring core promoter mutants with wild-type level of HBeAg production. Based on the results of preliminary mapping experiments, we will determine whether the number and position of core promoter mutations influence the level of HBeAg expression, and whether missense mutations in the HBeAg coding sequence also regulate HBeAg level. This study promises to verify and identify novel mechanisms regulating HBeAg expression, which has a major impact on the outcome of HBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HEPATITIS DELTA VIRUS REPLICATION AND PATHOGENESIS Principal Investigator & Institution: Lazinski, David W.; Assistant Professor; Molecular Biol & Microbiology; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2001; Project Start 01-JAN-1997; Project End 31-DEC-2002 Summary: The principal investigator is interested in the mechanisms by which human pathogenic viruses replicate and establish chronic infections. For the past five years, such interests have been directed toward studies of the replication of hepatitis delta virus (HDV). This subviral human pathogen establishes acute and chronic infections of the liver and uses a helper, hepatitis B virus (HBV), to provide envelope proteins needed for virus assembly. The 25 million carriers worldwide who are chronically infected with HDV suffer a greater incidence of active hepatitis, liver cirrhosis and hepatocellular carcinoma than do those infected with the helper virus alone. The mechanisms responsible for such HDV-associated pathogenicity remain poorly understood and there are currently no effective treatments for HDV-infected individuals. A more detailed understanding of the molecular details involved in HDV replication will be essential if such antiviral therapies are to be developed. In addition to its clinical importance, HDV is also of scientific significance. Unlike all other infectious agents of animals, HDV contains a circular, single-stranded RNA genome that encodes ribozymes. These ribozymes self-cleave multimeric replication intermediates into unitlength species and the resulting termini are joined in a ligation reaction to generate the monomeric circular species. HDV also expresses a protein, the delta antigen, that binds viral RNA to form a ribonucleoprotein (RNP) complex. Like the RNA processing reactions, both the assembly of this RNP and its subsequent incorporation into HBV envelope particles represent essential steps in the viral life cycle that are logical targets for antiviral intervention. Both biochemical and genetic methods will be used in an effort to otter understand the process by which the delta antigen specifically identifies and assembles on its target RNA. Additional experiments are proposed to determine the domain within the helper virus envelope protein responsible for RNP packaging. This will be accomplished by making hybrids with a relative of HBV, duck hepatitis B virus, which is unable to package the HDV RNP. Such experiments may also enable the development of a new animal model useful for the study of HDV pathogenesis. Finally, the principal investigator has previously established a role for host-specific factors in the processing of HDV RNA. To better understand their role in both HDV and host RNA maturation, these factors will be cloned and biochemically characterized. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
51
Project Title: HEPATITIS VIRUS, ALCOHOL EXPOSURE AND OXIDATIVE STRESS Principal Investigator & Institution: Hassan, Manal M.; Gastrointestinal Med Oncology; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2003 Summary: (provided by applicant) Hepatitis C virus (HCV) infection and alcohol abuse are the 2 major risk factors for hepatocellular carcinoma (HCC) in this country. The higher prevalence of HCV infection in the general population has resulted in a significant increase of the incidence of HCC in the United States. Although both HCV and alcohol can independently induce liver disease, exposure to both agents may accelerate the course of liver pathology and/or lead to more severe injury. The mechanism underlying the synergistic effect of HCV and alcohol intake is not well understood. One hypothesis is that both HCV and alcohol intake may contribute to chronic hepatitis, cirrhosis and subsequent liver cancer through enhanced oxidative stress. It is known that alcohol could induce oxidative stress and lipid peroxidation. Interestingly, a recent study has reported that HCV encodes a selenium (Se)-dependent antioxidant enzyme, glutathione peroxidase, GPx, and GPx may have a regulatory role in HCV replication. The virus-induced overexpression of GPx may lead to a decreased level of Se in the host due to the competition of HCV for Se. In fact, patients with HCV have been shown to have a significant decline in their serum Se. On the other hand, the hepatotoxicity of ethanol and its associated malnutrition will further reduce the cellular Se level. This additive decline in the Se level will make the cell more susceptible to reactive oxygen species (ROS). Previous studies have shown an association between oxidative DNA damage and either alcohol exposure or chronic viral infection. It seems that chronic HCV infection may lead to an increased ROS, overexpression of GPx and reduced serum level of Se. When the Se-GPx level is low, the virus will be more provoked for replication, leading to a higher viral load in the infected cell. Eighty newlydiagnosed HCC patients will be recruited from University of Texas MD Anderson Cancer Center (UTMDACC). The current project will explore the effect of dietary selenium intake and its interaction with HCV and alcohol intake in HCC in a casecontrol study. Eighty healthy individuals (first control group), matched with cases by age, sex and ethnicity, will be recruited from the patients non-blood relatives and friends from UTMDACC. To have a control group with comparable prevalence of HCV infection, 80 patients with liver cirrhosis, who have no evidence of HCC (second control group), will be recruited from Baylor College of Medicine. Information on alcohol intake, dietary Se intake and other risk factors will be collected by a questionnaire. The frequency and profile of hepatitis B virus (HBV) and HCV infection will be determined by measuring serum HBsAg, anti-HBC, anti-HCV, and HCV-RNA. Oxidative stress will be evaluated by measuring the levels of serum Se, GPx activity, lipid peroxides, and 8hydroxy-deoxyguanosine (8-OH-dG), a marker of oxidative DNA damage. The expression of GPx and the level of 8-OH-dG will also be measured in tissue samples from cirrhotic and HCC patients. Serum Se, GPx activity, lipid peroxides and oxidative DNA damage will be measured in relation to HCV and alcohol intake history. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HIV AND HEPATITIS IN YOUNG INJECTORS: A COMMUNITY STUDY Principal Investigator & Institution: Moss, Andrew R.; Adjunct Associate Professor; Epidemiology and Biostatistics; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122
52
Hepatitis B
Timing: Fiscal Year 2001; Project Start 25-SEP-1999; Project End 31-AUG-2003 Summary: Hepatitis C virus (HCV) infection is common in young injection drug users in San Francisco even though most use sterile syringes. HIV infection is relatively uncommon, and may be contained by the use of sterile equipment. We propose an epidemiological and ethnographic study to investigate this anomaly, and to study HIV and hepatitis infections in young injectors. First, we will examine HIV infection crosssectionally in 1200 injectors aged 29 and under. We will explore risk factors for prevalent HIV infection in this needle exchange-using population. Second, we will carry out a prospective cohort study of HCV seroconversion. The principal aim of the proposed research is to estimate the seroconversion rate for HCV in the young injector population and to determine the reasons for seroconversion. In particular, we will examine the sharing of drug doses and of injection equipment other than syringes as the main reason for ongoing HCV transmission. We will accrue a cohort of 300 HCV seronegative injectors from among the 1200 persons screened and will follow them for one year. We will record HCV seroconversion prospectively. We will also identify individuals with early HCV infection, using a viral RNA amplification technology. Third, we will carry out a randomized controlled trial of a method to improve vaccination against hepatitis B virus (HBV) in young injectors. We will randomize eligible cohort members to either an accelerated vaccine schedule, which may be effective in achieving rapid immunity in young IDUs, or the standard schedule, and will study the development of immunity. Fourth, because little is known about detailed injection and sharing practices among young injectors, we will complement the epidemiological studies with an ethnographic investigation of the injecting practices of street-based youth in their natural context. We will examine how the moral economy of mutual dependency in a street-based youth culture promotes frequent paraphernalia sharing among network members, but direct needle sharing between running partners. We will explore aspects of the cultural, economic and social-status determinants of risktaking that may explain the differential HCV and HIV infection rates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV DISEASE OUTCOMES IN DRUG USERS IN CLINICAL PRACTICE Principal Investigator & Institution: Moore, Richard D.; Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): In 1998, we were awarded an RO-1 (DA11602) from NIDA to conduct a longitudinal study in HIV-infected persons who have a history of illicit drug use (DU). The major aims of that study were to develop a longitudinal cohort of HIV-infected patients in medical care in order to characterize utilization of the new highly active antiretroviral drug therapies (HAART), and assess the effect of these therapies on HIV disease progression in DUs. We established a comprehensive longitudinal clinic-based cohort of over 4600 HIV infected persons; half of who have a history of DU. Our research suggests that DUs have not received the same level of benefit from HAART as non-DUs. Prior to HAART, there was little difference between DUs and non-DUs in HIV progression. Our research has shown that active DU is a barrier to receiving and adhering to HAART, and achieving effective viral and immunologic improvement on HAART. We hypothesize that the early differences that have emerged between DUs and non-DUs will substantially widen over the next 5 years as HIV resistance to current drugs increases, toxicity limits the use of therapy, and viral hepatitis along with other medical consequences of DU further increase the burden of
Studies
53
morbidity. Because of HAART, HIV is now a chronic illness, and DUs have numerous barriers to stable, chronic disease management. We are optimally situated to assess the core factors that impede successful HIV management as the HAART era matures over the next 5 years, and are submitting a new proposal for a competitive continuing RO-I. We propose the following aims, consistent with our overarching goal of improving the outcomes of HIV infection in DUs: 1) Evaluate virologic, immunologic and clinical HIV disease progression for up to 10 years, 2) Assess the impact of viral hepatitis coinfection, 3) Assess other medical consequences of DU including bacterial infection and STDs, 4) Assess adverse effects of HIV therapy. We offer a productive resource to address our aims that is unique in scope and size, cost-efficient in conducting research, highly relevant to the HIV epidemic as it effects DUs, and fully operational from our prior R01. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV RISK BEHAVIORS AMONG URBAN NOMAD DRUG INJECTORS Principal Investigator & Institution: Des Jarlais, Don; Director of Research; National Development & Res Institutes Research Institutes, Inc. New York, Ny 10010 Timing: Fiscal Year 2001; Project Start 05-SEP-2000; Project End 31-JUL-2004 Summary: The global diffusion of HIV, hepatitis B and hepatitis C among injecting drug users (IDUs) shows both that they engage in substantial travel and that research is needed on their travel patterns. Previous research makes it clear that IDUs travel regionally, nationally, and internationally, but has not adequately described travel patterns nor the factors that influence IDUs' HIV risk behavior when they travel. Through our street-based research with IDUs in New York City, we have developed considerable familiarity with a large group of highly mobile, young IDUs, self-defined as "urban nomads", who travel frequently and widely throughout the U.S. These urban nomads are often homeless, but are conceptually and behaviorally distinct from "locally homeless" drug injectors who are not geographically mobile. The specific aims include both methodological and substantive objectives: (Aim 1) Analytically describe a large sample (n = 800) of "urban nomad" young IDUs, including their demographics, drug use histories, travel histories, HIV risk behaviors and serostatus. Identify factors associated with (a) HIV risk behaviors and (b) frequency of intercity travel. (Aim 2) Identify patterns of drug use and HIV risk behavior during travel by urban nomad IDUs, including numbers of "person-trips" (a trip by a person to another metropolitan area), the geographic distribution of person- trips where HIV risk behaviors do and do not occur, and factors that differentiate person-trips with and without HIV risk behavior. Aims 1 and 2 will be achieved through interviews with 600 urban nomad IDUs recruited in New York City and 200 urban nomad IDUs recruited at collaborating research sites across the country. (Aim 3) Implement and assess a long-distance telephone follow-up interview system for collecting data from urban nomad IDUs in their travels. Subjects will be intensively prepared to maintain telephone contact with researchers. Longdistance telephone interviewing will be supplemented by referrals to local research studies for HIV counseling and testing, by referrals to syringe exchange programs, and by e-mail and web site communication. (Aim 4) Determine potential biases in loss to follow-up in using these techniques. Estimated biases can then be used to adjust estimates of continuing drug use and risk behaviors. Aims 3 and 4 will be achieved through a cohort study of 300 subjects recruited in New York. Drug use and HIV risk behavior among IDUs are often viewed as local phenomena, with drug practices, risk behaviors and HIV epidemics occurring within defined geographic areas. The proposed research will provide data and research technologies for a complementary perspective
54
Hepatitis B
that sees drug use practices and blood-borne pathogens diffusing within a loosely integrated nation-wide "system" of illicit drug use. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV/INFECTIOUS DISEASE TEST/TREATMENT IN SUBSTANCE ABUSE Principal Investigator & Institution: Lally, Michelle A.; Miriam Hospital Providence, Ri 02906 Timing: Fiscal Year 2001; Project Start 25-SEP-2000; Project End 31-AUG-2005 Summary: (Applicant's Abstract) Phase I of the proposed project will examine barriers to comprehensive HIV and other infectious disease testing and follow-up care among substance abusers at a short term (detox) substance abuse treatment center. In Phase II an intervention that includes comprehensive testing, counseling, medical deferral, and practical strategies to overcome barriers to follow up care will be designed and pilot tested. During Phase III, the intervention will be evaluated against the standard of care of offering HIV testing done through a randomized controlled trial. Three hundred and forty-four participants will be randomized to receive either the comprehensive testing and facilitated referral intervention which will offer testing for HIV, hepatitis B and C, and the STDs gonorrhea and chlamydia (and trichomonas for women only) or standard of care HIV testing alone and referral for further hepatitis and STD testing. Primary endpoints will be the number of tests performed, the number of test results received, and the degree of follow up medical care obtained for the two groups. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HOMELESS YOUTH: STREET CULTURE/SOCIAL NETWORKS/HIVRISK Principal Investigator & Institution: Auerswald, Colette L.; Pediatrics; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 11-JUN-2001; Project End 31-DEC-2005 Summary: (Adapted from applicant's description): Rates of risky behaviors in homeless youths are persistently high, resulting in high rates of morbidity, including seropositivity for HIV and Hepatitis B and C. Interventions based on risk-reduction in this population have had limited effectiveness. Recent research emphasizes that removal from the street should be a primary focus of HIV risk-reduction for homeless youths. Studies of risky behaviors in non-homeless youths and in at-risk adults strongly suggest that a better understanding of the relationships within which risk behaviors take place and of the meaning of the risky behaviors to the actors will lead to more effective interventions. The applicant is a pediatrician and specialist in adolescent medicine who has expertise in the ethnographic study of marginalized youths and experience in quantitative behavioral studies of risky behavior in adolescents. The candidate's career objective is to improve the health of marginalized youths, including homeless youths, through multidisciplinary research on the behavioral determinants of the health- related behaviors and barriers to care in this population. In the training phase of the award the applicant will have four primary development objectives: a) to develop further skills in patient-oriented qualitative research, b) to learn to follow longitudinal cohorts of hardto-reach populations, c) to gain additional expertise in the integration of qualitative and quantitative methodologies in the study of adolescent health-related behavior, and d) to learn to analyze social network data in the study of risky behavior. She will pursue her objectives through mentored research experiences. These will be complemented by
Studies
55
focused course work offered by the K-30 funded Advanced Training in Clinical Research program at the University of California, San Francisco. The objective of the research phase of the award will be to conduct a joint ethnographic-epidemiologicalsocial network study to test the findings of her preliminary research. These findings, based on a street-based ethnographic study of youths, suggest that youths pass through stages of a life cycle of homelessness, each of which is characterized by different levels of acculturation to the street and different compositions of their social networks. By demonstrating in a large street-based longitudinal sample that youths in each stage differ according to acculturation and social networks and that these differences are correlated with rates of risky behaviors, we may have a powerful tool for designing interventions. An approach to intervention based on an understanding of these stages has practical implications, including new screening tools, the designing of stage- based services, and the development of intensive programs for the youths who are most susceptible to removal from the street. An understanding of how social network connections promote and prevent risky behaviors would also have significant implications for the designing of interventions with this population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST AND VIRAL GENETIC VARIABILITY IN HBV CARRIERS Principal Investigator & Institution: Evans, Alison A.; Assistant Member; Fox Chase Cancer Center Philadelphia, Pa 19111 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2006 Summary: Chronic carriers of hepatitis B virus (HBV) are at increased risk for hepatocellular carcinoma (HCC). Worldwide, however, the risk of HCC and other adverse outcomes varies substantially both between and within populations of HBV carriers. The reasons for these differences in the natural history of infection are not known. Our analysis of cohort studies in three endemic populations have suggested that the long term maintenance of high-titer viremia (i.e., equal to or > 1 pg/ml) is an important predictor of HCC. The mechanism behind the maintenance of viremia is, however, not well understood although it is clear that the host immune response plays a key role. In this application, we focus on molecular variants of the virus itself and polymorphisms of human immunoregulatory genes as potential predictive or explanatory factors in maintenance of viremia. We will draw upon established prospective cohorts of chronic HBV carriers in China, West Africa, and AsianAmericans. Our preliminary data support a relationship between deletions in the C ORF of HBV and clearance of active viral replication. In the proposed project we will test this hypothesis and extend our studies of molecular variation of HBV by application of novel statistical methods to sequence data. We will also test the hypothesis that maintenance of HBV viremia is associated with polymorphisms of the vitamin D receptor (VDR) and tumor necrosis factor alpha (TNFalpha) promoter. Allele frequencies for polymorphisms of lesser-studied immunomodulatory genes in our cohorts will be estimated in order to develop hypotheses about their relationship to maintenance of viremia in HBV carriers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: 'IMMATURE SECRETION' VARIANTS OF HUMAN HEPATITIS B VIRUS Principal Investigator & Institution: Shih, Chiaho; Professor; Pathology; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555
56
Hepatitis B
Timing: Fiscal Year 2001; Project Start 04-FEB-2000; Project End 31-JAN-2005 Summary: Our long-term goal is to understand the pathobiology of viral hepatitis. Hepatitis B virus (HBV) is the 4th most common infectious agent in humans worldwide. Chronic infection with HBV is tightly associated with the development of liver cancer. The mechanism of how HBV chronic infection is established and its pathogenesis remains to be fully explored. Recently, there has been increasing evidence that HBV chronicity may be influenced by the presence of genetic variants that evolve in patients as liver disease progresses. Since the invention of polymerase chain reaction technology, many HBV sequence variants have been reported. However, a common frustration in the research of HBV variants is that the majority of these reported sequence variants has no known functional significance and does not exhibit a strong phenotype distinctively different from the wild type virus. The most frequent missense mutation found in the HBV core antigen occurs at codon 97 in chronic carriers worldwide (in 83 percent hepatoma patients). Our recent functional characterization of this mutant uncovered a novel and strong phenotype, dubbed an "immature secretion" phenotype. Unlike wild type HBV, the secreted Dane particles of codon 97 mutants contain predominantly the immature form (lower molecular weight) of the HBV DNA genome. In this application, we propose 1) to extend our observation of the "immature secretion" phenomenon from tissue culture to patients and animal models. We also attempt to extend the "immature secretion" phenotype to other viral subtypes prevalent in different geographic locations. 2) to investigate the mechanism of "immature secretion" by both genetic and biochemical approaches. One of the several hypotheses to be tested is that "immature secretion" could be caused by hyper-efficient interactions between wild type envelope and mutant core proteins. 3) Finally, we will compare the infectivity of the highly frequent codon 97 mutants and wild type HBV via in vitro infection assays. Successful completion of this work will help understand the fundamental rules governing HBV morphogenesis and virion secretion, in addition to the important implications for chronic viral hepatitis as well as many other chronic progressive viral diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNE REGULATION OF CNS VIRAL RECRUDESCENCE Principal Investigator & Institution: Bergmann, Cornelia C.; Associate Professor; Neurology; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2002; Project Start 15-MAY-2001; Project End 31-MAR-2006 Summary: (provided by applicant): A variety of human viruses, including herpes viruses, hepatitis B virus and HIV, produce acute infections followed by persistence or recrudescence. However, the mechanism(s) regulating persistence and recrudescence depend on a balance between viral replication and the host immune response. Viral tropism and antigenic load provide additional determinants in this complex scheme. This proposal examines the contribution of cell mediated and humoral immunity in controlling recrudescence of a neurotropic virus following initial clearance. Infection of immunocompetent mice induces an acute encephalomyelitis, followed by persistence without infectious virus. During acute infection cell mediated immunity, predominantly the CD8+ T cells, are crucial in controlling virus replication within the central nervous system (CNS). However, in the absence of B cells, these effector functions do not suffice to suppress virus to undetectable levels, thereby allowing virus reactivation. Importantly, transfer of anti-viral antibody (Ab) prevents virus reactivation, implicating a crucial role for Ab and/or B cells in controlling persistence. However, analysis of virus specific T cells using class I tetramet technology revealed that the percentage of virus
Studies
57
specific CD8+ T cells in the CNS is reduced compared to immunocompetent mice. In addition, there is no increase in virus specific T cells during reactivation. These data suggested that CD8+ T cells may be functionally impaired or exhausted due to increased antigen load. This proposal distinguishes between the requirement(s) for potent CD8+ T cell function vs Ab in controlling virus reactivation in a persistently infected host. The contribution of both neutralizing and non neutralizing Ab, Fc receptor (FcR) activity and complement are examined by Ab transfers and using mice deficient in FeR. These experiments will determine the mechanism of Ab mediated prevention of virus reactivation in an Ab deficient milieu. The possibility that the absence of Ab and/or B cells results in defective CD8+ T cell priming, ultimately leading to exhaustion during recrudescence is tested by functional and phenotypic analysis of CD8+ T cells during priming and recrudescence. Intervention via transfer of protective Ab or CD8+ T cells activated in vitro will determine if functionally impaired CD8+ T cells can be overcome. These experiments may have direct implications for therapeutic interventions during persistent viral infections. Finally, virus reactivation will be tested in an Ab deficient mouse with a normal B cell compartment. These experiments will distinguish between the possibilities of an Ab independent effect of B cells and a CD8+ T cell defect related to the absence of B cells. This proposal will provide insight into the immunological regulation of both virus recrudescence and the CNS as a target organ. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INITIATION OF HEPATITIS B VIRUS REPLICATION Principal Investigator & Institution: Mclachlan, Alan; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 30-JUN-2005 Summary: (provided by applicant): Hepatitis B virus (HBV) infection is a worldwide health problem. It is estimated that there are 200 to 500 million HBV chronic carriers in the world for whom, to date, there is no reliable treatment. HBV causes both acute and chronic liver disease and the estimated relative risk of primary hepatocellular carcinoma (PHC) in chronic HBV carriers is approximately 100 times greater than in uninfected individuals. Therefore, effective treatments for chronic HBV infection are required. In these studies, the mechanism(s) regulating the initial steps in the synthesis of hepatitis B virus (HBV) DNA will be investigated. HBV DNA synthesis is initiated by binding of the viral polymerase to a stem-loop structure, epsilon, located at the 5'-end of the HBV pregenomic RNA. Initially, the first three nucleotides of HBV minus-strand DNA are synthesized utilizing the amino-terminal domain of the polymerase as a primer and the bulge region of epsilon as a template. The HBV polymerase with the covalently attached trinucleotide sequence is subsequently translocated to the DR1 sequence at the 3'-end of the pregenomic RNA. HBV minus-strand DNA synthesis then proceeds by the reverse transcription of the pregenomic RNA. The mechanism(s) regulating the translocation step are unknown. Recently, a regulatory sequence element, phi, located immediately upstream of the DR1 sequence at the 3'-end of the pregnomic RNA that is important for efficient viral replication and is complementary to the 5'-half of epsilon was identified. This finding suggests that the translocation of the minus-strand primer from epsilon to DR1 might be mediated by a conformational change in the pregenomic RNA that brings the primer into proximity with the DR1 sequence at the 3'-end of the pregenomic RNA. The conservation of the complementarity between epsilon and phi in the woodchuck hepatitis virus (WHV) and the duck hepatitis B virus (DHBV) genomes also supports this contention. Therefore, the role of the complementarity between epsilon and phi in regulating HBV replication will be examined directly by mutational analysis of these
58
Hepatitis B
sequence elements. This approach is aimed at identifying possible targets for therapeutic intervention in chronic HBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INNOVATIVE FORMULATION
SINGLE-DOSE
HEPATITIS
B
VACCINE
Principal Investigator & Institution: Kitchell, J P.; Director, Biodegradable Implants; Biotek, Inc. 21-C Olympia Ave Woburn, Ma 01801 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JAN-2004 Summary: (provided by applicant): Hepatitis B (HBV) is a serious viral disease that can result in acute massive hepatic necrosis, chronic active hepatitis, and cirrhosis of the liver. HBV vaccines are commercially available and HBV vaccination is now recommended for all infants, adolescents, health workers and others who may be exposed to the virus through their work. Three HBV vaccine injections are required to generate protective immunity. Compliance depends on completing three visits to the healthcare provider. Incomplete vaccination is common and often attributed to scheduling difficulties. The vaccination success rate could be improved if only one dose were needed for full protection. There have been many attempts to address the need for single dose formulations for vaccines. Kitchell and Crooker (1997) studied the physicochemical properties of alum, the adjuvant used in the approved HBV vaccine, and they made an important observation about the hydration behavior of this material. Their discovery led to a simple and elegant method of formulating alum-adjuvanted hepatitis A vaccine as a single-dose injection giving multiple delayed pulses. This innovative approach to reformulation is also appropriate for the HBV vaccine. BIOTEK believes that it has gained further insight into the techniques needed to prepare a single dose HBV vaccine which provides three discrete pulses of vaccine exposure. The formulation will utilize the established HBV vaccine antigen and adjuvant, and a FDA approved biodegradable polymeric excipient. The specific aims of the Phase I project are to prepare and test in vivo both one month and four month delayed pulse formulations. PROPOSED COMMERCIAL APPLICATIONS: The technology, first directed at an improved hepatitis B vaccine formulation, could be transferred to hepatitis A vaccine and to the childhood DPT vaccination series. One important application in the future may be with an AIDS vaccine, where relaible single-dose protection for high risk populations may be especially important. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT
INTEGRATED
DUAL
DIAGNOSIS/INFECTIOUS
DISEASE
Principal Investigator & Institution: Rosenberg, Stanley D.; Professor; Psychiatry; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, Nh 03755 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2003 Summary: (adapted from the applicant's abstract): People with severe mental illness (SMI), and particularly those dually diagnosed with comorbid substance use disorder (SUD), are at extremely elevated risk for several serious blood-borne infections, including HIV, Hepatitis B and Hepatitis C. One third of dually diagnosed clients in many mental health service settings are likely to have one of these infections, and the rate of co-infection is very high. However, the field lacks effective and feasible models for responding to this problem, and neither infected nor high-risk clients receive services that meet authoritative standards. Indeed, infected clients may be the least
Studies
59
likely of all people with SMI to receive adequate medical care. By and large, mental health providers are not well informed regarding these issues, and do not systematically provide the necessary interventions to help clients understand and cope with these risks and diseases. Providers do, however, express interest and willingness to respond by increasing staff education and by adding services for their high-risk clients. To date, no such innovation has been reported in any state mental health system, even in those states with known high rates of seroprevalence. Barriers to dissemination and provision of best practices have been identified, and include providers' underestimation of the problem in clients they serve, and confusion about how to best respond to information about clients' risk and infection status. To implement and sustain best practices interventions for this vulnerable group of clients, integrated procedures to change the knowledge, attitudes, training resources and practices of community mental health providers are required. Procedures for dealing with blood-borne pathogens should be structured to be a standard part of multidisciplinary team treatment. They should include a very basic set of evidence based practices for HIV, Hepatitis B and Hepatitis C, including screening, diagnosis, counseling, risk reduction, immunization, linkage with appropriate medical providers, and support for clients through treatment. We propose, in this Exploratory/ Developmental Grant application (R21), to develop an easily disseminated intervention, packaged as a "toolkit" and supported by implementation assistance, to enhance the knowledge, attitudes and practices of typical community mental health providers so that they will achieve sustainable, best practices standards for their infected and at-risk clients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERNATIONAL CONFERENCE ON HEPATITIS B VIRUSES Principal Investigator & Institution: Slagle, Betty L.; Assistant Professor; Molecular Virology & Microbiol; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2002 Summary: (provided by applicant): Infection with Hepatitis B virus (HBV) is still a serious public health problem, with an estimated 300 million chronic carriers worldwide. In recent years, substantial progress has been made in establishing the molecular basis of individual steps in the replication of the virus, revealing its unique status among retroelements. However, immense experimental difficulties, including the lack of appropriate in vivo and experimental, infection systems, have hampered a similarly detailed analysis of the early steps of infection. The limitations have further hindered the fundamental understanding the complex interplay between virus and host and its effects on pathogenicity. This conference is distinct from clinically oriented meetings, and is intended to gather scientists studying different aspects of HBV and related animal model viruses, for joint discussion of the latest conceptual and technical advances. The meeting is organized by Drs. Betty Slagle and Michael Roggendorf, who are assisted by a panel of expert HBV scientists acting as chairpersons for 12 lecture and 2 poster sessions. In addition, it is planned to have a workshop on controversial issues. Session topics will include: transcription; replication; structural proteins and receptors; regulatory proteins; hepatocellular carcinoma; HBV variants and hepatitis delta virus; and persistence, pathogenesis, and immunology. Each session will comprise 4-8 talks, selected from submitted abstracts that are peer-reviewed by the session chairpersons. In the tradition of previous meetings of this series, in addition to the attendance and presentations by senior investigators, graduate students and postdoctoral fellows will be particularly encouraged to participate in the lecture and poster sessions. HBV research is
60
Hepatitis B
a major topic in the research mission of NIAID, and this is the only annual HBV meeting of its kind. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERNATIONAL CONFERENCE ON THE HEPATITIS B VIRUSES Principal Investigator & Institution: Tavis, John E.; Molecular Microbiol and Immun; St. Louis University St. Louis, Mo 63110 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2004 Summary: (provided by applicant): The 350 million chronic carriers of Hepati tis B Virus (HBV) worldwide are at risk of hepatitis, cirrhosis, and hepatocellular carcinoma. A recombinant subunit vaccine is available, but it has a 5-10% failure rate, and there is no widely effective therapy for HBV infection. The development of effective therapies could be advanced more rapidly by a better understanding of the mechanisms of pathogenesis, the immune response, and function of the proteins involved in HBV replication. This conference will gather about 200 scientists who study different aspects of HBV, animal hepadnaviruses, and Hepatitis Delta Virus for discussions of the latest conceptual and technical advances. This meeting has been held annually since 1985, and is the only basic science HBV and HDV meeting of its kind. The primary goal of this application is to raise funds to support travel grants for junior scientists. The 2003 HBV Meeting will be organized by Drs. Antonio Bertoletti and John Tavis. The meeting will be modeled on the successful traditions of this series: intimate interactions through small size, presentation of work-in-progress, and a focus on training younger scientists. The meeting will have 9 oral sessions, two poster sessions, a keynote speaker, and one workshop. The oral session will be: New Models & Viral Entry, RNA & DNA Synthesis, Assembly, Morphogenesis & Trafficking, Regulatory Proteins and Variants, Immune Responses, Pathogenesis, Hepatitis Delta Virus, Hepatocellular Carcinoma & Oncogenesis, and Antivirals & Immunomodulation. Involvement of women and minorities in leadership positions will be emphasized. Each session will have approximately 7 talks selected through peer-review by the organizers of submitted abstracts. Posters for each topic will be presented in the poster sessions. A theme of the meeting will be to compare and contrast HBV with Hepatitis C Virus (HCV), the other most medically important hepatitis virus. The keynote speaker, Dr. Raft Bartenschlager, will contrast the molecular biology of HCB with that of HBV. The workshop will compare HBV and HCV immunology and pathogenesis. This conference will advance HBV research by introducing ideas from the HCV field, promoting constructive interactions between researchers, encouraging exchange of unpublished data and key reagents, and educating graduate students and post-doctoral trainees. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INTERVENTIONS TO INCREASE HBV VACCINATION IN STD CLINICS Principal Investigator & Institution: Zimet, Gregory D.; Associate Professor; Pediatrics; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, in 462025167 Timing: Fiscal Year 2002; Project Start 05-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): The objective of this study is to evaluate interventions to increase acceptance of, and follow through with, hepatitis B virus (HBV) immunization among patients attending sexually transmitted disease (STD) clinics in Chicago, IL and Indianapolis, IN. This research will have implications for the
Studies
61
design of interventions that may increase HBV vaccine uptake in at-risk groups. The interventions may also be applicable to other STD vaccines as they become available. The first specific aim is to assess the effect of message framing on vaccine acceptance. Prospect theory will be used to guide the development of the message-framing interventions. This theory suggests that positively framed messages (i.e., benefits of getting vaccine) are more effective than negatively framed messages (i.e., dangers of not getting vaccine) in stimulating preventive health behaviors. Research on Prospect Theory and engagement in health behaviors suggests also that the effects may be moderated by other attitudinal factors, including perceived risk of the behavior and degree of involvement in the message. The second aim is to evaluate the effect of provider-based interventions. Prior research suggests that recommendations by health providers are very important in patients' decisions regarding acceptance of healthcare procedures. The third aim is to examine the effect of the interventions on follow-through with the second and third recommended vaccination. During Year 1 of the proposed plan, the message framing interventions will be developed and pilot tested and healthcare providers in Chicago and Indianapolis will be trained in the provider-based interventions. During Years 1-5, 3,344 patients (18 years and older) will be recruited and followed from Chicago and Indianapolis STD clinics during routine medical visits. An audio computer-assisted self-interview (A-CASI) will cover demographics, risk behaviors, and perceived risk associated with vaccination. Subjects then will be randomized to receive a gain-framed, loss-framed, or information only message regarding HBV immunization (also delivered by A-CASI). Upon completion of the message-framing intervention, subjects will be complete additional attitude questions via A-CASI, then will be randomly assigned to one of two provider intervention conditions: 1. vaccine-offered or 2. vaccine-recommended. For both conditions free HBV immunization will be provided by a nurse practitioner. Debriefing interviews will be carried out. Subsequently, postcard reminders will be sent and phone call reminders made for follow-up appointments for those receiving the first and second doses of vaccine. Outcome measures of interest include: (1) acceptance vs. rejection; (2) compliance with two doses vs. one dose only; and (3) completion of immunization vs. two doses only. The relationships of the interventions, socio-demographics, attitudes and behaviors to the outcome measures will be assessed with multiple logistic regression (MLR) and path analysis via structural equation modeling. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: JOHNS HOPKINS ADULT AIDS CLINICAL TRIALS UNIT Principal Investigator & Institution: Flexner, Charles W.; Associate Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: (adapted from applicant's abstract): Johns Hopkins University has had an ACTU since its inception in 1986. The Unit is administratively within the Division of Infectious Diseases as a component of the Johns Hopkins HIV Care Program, but it is configured to make maximum use of relevant institutional resources with investigators from multiple departments and divisions including Pharmacology, Neurology, Ophthalmology, Gynecology, Pathology and Internal Medicine. The Hopkins ACTU has provided leadership to the ACTG scientific agenda and has provided HIV clinical trials to Baltimore, a city that ranks ninth among metropolitan areas in AIDS rates. The performance record for the last grant cycle shows average enrollment, data performance and a rank of No. 3 in scientific contributions. Assets of this ACTU include leadership and scientific expertise in virology (B. Jackson), immunology (H. Lederman, T. Quinn, R.
62
Hepatitis B
Bollinger), quality of life assessment (A. Wu), neurology (J. McArthur), pharmacology (C. Flexner), CMV retinitis (D. Jabs), and mycobacteriology (R. Chaisson). This unit has a subunit in the prison system, has developed an ACTG study of tuberculosis in Haiti and has high enrollment of injection drug users and African-Americans. This application proposes to continue a scientific portfolio that has depth and diversity to support the ACTG scientific agenda and a clinical trials program that includes good data performance and the enrollment of high priority participants. All current investigators will continue in their present roles as will the three advanced technology laboratories. Three new investigators, Dr. R. Siliciano (latent reservoirs of HIV), Dr. Richard Moore (HIV outcomes, cost and cost effectiveness), and Dr. David Thomas (hepatitis C coinfection) will be added. Preference will be given to protocols that reflect emphasis areas of the Hopkins ACTU, especially pharmacology, neurology, immunology, mycobacteriology, hepatitis C, long-term outcomes (quality of life and cost analyses) and simplified ART regimens (to better serve the patients). There will be emphasis on enhanced enrollment with a new peer recruiter and a new subunit to increase the catchment area. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LIVER CANCER CONTROL AMONG NORTH AMERICAN CHINESE Principal Investigator & Institution: Taylor, Victoria C.; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2003; Project Start 25-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Little is known about the disease prevention behavior of Chinese in North America, and few studies have addressed cancer control in this group. However, Chinese American men and women are four times more likely to be diagnosed with liver cancer than their non-Latino White counterparts. This excess risk is attributable to high rates of hepatitis B virus (HBV) infection combined with low levels of hepatitis B vaccination coverage. The goal of this research is to increase the proportion of less acculturated Chinese adults who have been tested for HBV (and, therefore, either have been vaccinated, are screened for liver cancer, or know they are immune to the disease). Objectives are to: obtain qualitative and quantitative information about the liver cancer prevention behavior of Chinese Americans and Canadians; develop a culturally and linguistically appropriate outreach intervention targeting hepatitis B and liver cancer among Chinese; and conduct a randomized controlled trial to evaluate the effectiveness, feasibility, and acceptability of the intervention program. To increase the generalizability of our findings, the research will be conducted in two cities: Seattle, Washington and Vancouver, British Columbia. The project will emphasize community involvement. PRECEDE and qualitative methods (i.e., forty in-depth interviews and eight focus groups) will be used to develop a quantitative survey instrument as well as intervention components. Six hundred Chinese men and women aged 18-64 who have not been serologically tested for HBV will be identified from a community-based survey of 1,200 individuals, and randomized to intervention or control status. Individuals in the experimental group will receive an outreach worker intervention (which will include a home visit and follow-up telephone call, tailored counseling and logistic assistance, and the use of audiovisual and print materials). Outcome evaluation will be based on data from a follow-up survey as well as medical record verification. If effective, our outreach intervention could be used by health care facilities and community organizations serving less acculturated Chinese in North America. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
63
Project Title: LIVER-TARGETED PRODRUGS FOR THE TREATMENT OF HEPATITIS B Principal Investigator & Institution: Van Poelje, Paul D.; Metabasis Therapeutics, Inc. 9390 Towne Centre Dr, Ste 200 San Diego, Ca 921213026 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 31-JUL-2002 Summary: (provided by applicant): The synthesis and characterization of novel prodrugs of the antiviral nucleosides acyclovir, penciclovir, and lamivudine are proposed with the purpose of identifying an agent with improved efficacy in the treatment of hepatitis B. The proposed prodrugs are designed to target the nucleosides selectively to the liver in their monophosphate form, and to enhance significantly the formation of the corresponding nucleoside triphosphates (NTP's), which are potent inhibitors of hepatitis B virus (HBV) polymerase. Enhanced hepatic NTP formation is likely to confer more rapid and complete suppression of HBV replication, and consequently to prevent the emergence of drug resistance, a major problem with current therapies. Studies are planned that will address (a) prodrug activation by a liver-specific enzyme (b) prodrug activation and phosphorylation in isolated hepatocytes and (c) prodrug pharmacokinetics and hepatic NTP generation in the rat. A key indicator for the success of the prodrug approach and its therapeutic potential is the temporal profile of hepatic NTP levels in vivo relative to parent nucleoside. A favorable profile will provide the impetus for additional studies envisaged for phase II of the proposal: the assessment of efficacy in animal models of HBV and the toxicological evaluations necessary to support clinical development. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MEASLES VIRUSES WITH ADDED VACCINE SPECIFICITIES Principal Investigator & Institution: Cattaneo, Roberto; Professor of Biochemistry & Molecular Bi; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2004; Project Start 01-DEC-2003; Project End 30-NOV-2007 Summary: (provided by applicant): The live attenuated measles vaccine has an outstanding efficiency and safety record and induces enduring immunity. We hypothesize that a currently used measles virus (MV) vaccine strain is an ideal platform for the development of pediatric vaccines eliciting immunity against other pathogens. We will test two propositions of this hypothesis: first that vectored MVs can protect against infection with another pathogen. Second, that they can elicit a strong immune response against other human pathogens whilst maintaining vaccine function against measles. To test the first proposition we will complete the production of a panel of vectored MV with the potential of inducing strong humoral and/or cellular immune responses to a mouse pathogen. We will take advantage of the detailed knowledge of the determinants of the immune response against the Daniels strain of the picornavirus Theiler. Proteins or peptides of this virus will be expressed in MV vectors with different scopes: induction of high neutralizing antibody titers, of specific cytotoxic T lymphocytes, or of both. The quality and strength of the immune response and the efficiency of protection against challenge with Theiler virus will then be measured in genetically modified mice permissive for MV infection. The correlates of vaccine efficiency will be established. To test the second proposition we will produce recombinant MVs with the potential of eliciting strong and sustained immune responses against two human pathogens for which an inexpensive vaccine requiring a single immunization is highly desirable. Recombinant MV expressing the surface antigen of
64
Hepatitis B
the hepatitis B virus at different levels will be used to define the expression strategy most effective in inducing a strong humoral immune response. Recombinant MV expressing different proteins and CTL-inducing peptides of the hepatitis C virus will also be produced, and the strength of the induced humoral and cellular immune responses measured. Those viruses inducing the strongest immune response against hepatitis B and hepatitis C virus components in genetically modified mice will be inoculated into juvenile macaques. Their efficacy in protecting these primates against wild type measles infection and in inducing an immune response against the additional pathogen will be measured. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF CHRONIC HEPATITIS B INFECTION Principal Investigator & Institution: Milich, David R.; President; Vaccine Research Institute of San Diego San Diego, Ca 92109 Timing: Fiscal Year 2001; Project Start 01-MAY-1984; Project End 31-MAR-2006 Summary: (Adapted from applicant's abstract): The hepatitis B virus (HBV) is a major cause of infectious liver disease throughout the world. There are 1.2 million carriers of HBV in the U.S. and approximately 300 million worldwide. Neonatal HBV infection is rarely cleared and as many as 90 percent of perinatally infected children become chronically infected. Therefore, in addition to worldwide vaccine programs to prevent new infections, methods for treating HBV chronic carriers will be necessary to eradicate this disease. This application is focused on understanding the mechanisms responsible for inducing and maintaining chronic HBV infection, and specifically the role of HBV nucleoprotein antigens, the nucleocapsid (HBcAg) and the secreted non-particulate HBeAg. The specific aims are addressed through the use of HBc/HBeAg-expressing and HBV replicating transgenic (Tg) mice, the eight recently developed HBc/HBeAg-specific T cell receptor (TCR)-Tg lineages and various combinations of "double and triple-Tg" hybrids. The specific aims are: (1) production and characterization of TCR-Tg lineages; (2) development of models to explore the relationship between chronicity and perinatal infection; (3) examine the potential of the secreted HBeAg to elicit and maintain immune tolerance and promote chronicity; (4) explore mechanisms that allow HBc/HBeAgspecific CD4+ T cells to escape tolerance induction and co-exist with viral antigens; (5) examine mechanisms by which residual (i.e., non-tolerized) HBc/HBeAg-specific CD4+ T cells cause liver injury; and (6) use the models of liver injury to screen HBc/HbeAgspecific immunotherapies potentially useful in the treatment of chronic infection. It is anticipated that the results of these studies will have diagnostic, therapeutic, and vaccine applications and will provide a better understanding of basic immune mechanisms responsible for viral persistence and clearance in chronic HBV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REPLICATION
MECHANISMS
OF
HEPADNAVIRUS
ASSEMBLY
AND
Principal Investigator & Institution: Hu, Jianming; Assistant Professor; Microbiology; Boston University Medical Campus 715 Albany St, 560 Boston, Ma 02118 Timing: Fiscal Year 2001; Project Start 15-FEB-1999; Project End 31-JAN-2004 Summary: Hepadnaviruses, or hepatitis B viruses, are small, hepatotropic DNA viruses that replicate through an RNA intermediate (the pregenomic RNA or pgRNA) by reverse transcription. A critical early step in viral replication is the assembly of a ribonucleoprotein (RNP) complex comprised of the viral reverse transcriptase (RT) and
Studies
65
pgRNA, which triggers both the assembly of nucleocapsids, the site of viral DNA synthesis, and the initiation of reverse transcription, which is primed by RT itself (the protein priming reaction). Through a complex multi- step reverse transcription pathway, the pgRNA is subsequently converted, within the context of the nucleocapsids, into the characteristic, relaxed circular DNA genome which can then exit the cell. The broad, long term objective of this proposal is to elucidate the molecular mechanisms of hepadnavirus replication, focusing on the virus-cell interactions critical for viral assembly and replication. The first specific aim is to identify host factors required for the interaction between RT and pgRNA and for protein priming. A combined approach based on physical association with RT, pgRNA and viral particles and biochemical fractionation and reconstitution will be used for this purpose, taking advantage of an established cell-free system that can recapitulate these early events in viral replication. The second aim is to elucidate the determinants on both RT and pgRNA responsible for specific RNA-protein interaction. Optimal conditions for RTbinding and crosslinking will be sought. The RT and contact sites in the RNP complex will then be identified through protein and RNA sequence analyses. This will, in turn, guide further mutagenesis studies to elucidate the specific requirements of RT and pgRNA for RNP formation. The third aim is to determine the requirements for individual steps of the viral reverse transcription pathway, using a recently developed synchronized viral replication system. Nucleocapsids from every stage of reverse transcription will be isolated to determine their structural changes, which accompany, and may be required for, the progression of viral DNA synthesis. Furthermore, specific host factors required for the different steps of reverse transcription will be identified by (1) carrying out viral DNA synthesis with the isolated nucleocapsids under cell-free reconstitution conditions and (2) treating virus-producing cells, at different stages of reverse transcription, with agents that target candidate host factors. The accomplishment of these goals should reveal novel cellular, as well as viral, targets for developing effective antivirals which is urgently needed for the treatment of over 300 million patients worldwide infected with the hepatitis B virus, who are at great risk of developing hepatic failure and hepatocellular carcinoma. In addition, studies on how host factors facilitate viral replication will also provide important insights into the normal cellular functions of these factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG Principal Investigator & Institution: Fischl, Margaret A.; Associate Professor; Medicine; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2001; Project Start 01-APR-1992; Project End 31-DEC-2004 Summary: (adapted from application's abstract): The Miami ACTU has been a member of the AACTG since its inception and has contributed to a number of AACTG studies that led to the approval of seven antiretroviral drugs and numerous HIV treatment strategies including lower and alternative dosing schedules for all three classes of antiretroviral agents, early treatment intervention, combination therapies with dual NRTIs and triple-drug therapy. The Miami ACTU has also actively participated in the Virology Laboratory Subcommittee working groups with an active role in the standardization of a PBMC culture assay for determining drug susceptibility, the assessment of interlaboratory concordance of DNA sequencing analysis of HIV RT, and the development of a consensus sequencing protocol to detect drug resistant mutations. This unit has also been involved with the Surrogate Markers Subcommittee with an active role in the assessment of plasma cytokines and soluble markers, cytotoxic T-
66
Hepatitis B
lymphocyte activity, lymphocyte proliferation and advanced flow cytometry, and defining and validating immunologic markers as surrogate markers independent of CD4 and HIV RNA. Finally, this unit has contributed to the Pharmacology Committee with the evaluation of targeted- concentration control studies and the correlation of drug exposure with treatment response and failure parameters. The Miami ACTU will actively participate in HIV Disease RAC efforts and provide expertise to address study treatment strategies for initial therapy, treatment options for virologic failure and utilization of phenotypic and genotypic assessments to direct subsequent therapy and treatment intensification. The Miami ACTU will also bring expertise in the areas of hepatitis B and C pathogenesis and treatment, metabolic complications of HIV-1 protease inhibitor pathogenesis and treatment, HIV dementia pathogenesis and treatment and peripheral neuropathy pain assessment, Kaposi sarcoma (KS) pathogenesis, intensive immunologic monitoring and definition, and validation of immunologic determinants of treatment response. The Miami ACTU plans to enroll 100 subjects per year across AACTG studies and 70 patients into AACTG substudies, including but limited to Compartmental, Virology, Viral Dynamics, Pharmaceuticals, Metabolic, Neurologic, Women's Health and Adherence and Outcomes substudies. With a support system in place for the long-term follow-up of patients, the Miami ACTU anticipates to enroll approximately 80 patients into the ALLRT study (ACTG 5001) over a 2-year period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODELING VIRAL AND T LYMPHOCYTE DYNAMICS Principal Investigator & Institution: Perelson, Alan S.; Staff Member; None; University of Calif-Los Alamos Nat Lab Ms G758 Los Alamos, Nm 87545 Timing: Fiscal Year 2001; Project Start 19-APR-1991; Project End 31-MAR-2005 Summary: Mathematical modeling combined with experiment has led to increased understanding of the processes that underlie HIV-1 infection in humans and the development of improved therapies. Nevertheless HIV has not been eradicated from infected individuals and various reservoirs including latently-infected cells, virus trapped on folliculary dendritic cells (FDC), and virus in semen have been identified. This application proposes to continue the development of more realistic models of HIV infection with particular emphasis on events that occur in lymphoid tissue. The applicants propose to develop models that explicitly take into consideration infection in blood and tissue, the role of FDC, and possible incomplete penetrance of drugs into various cell populations and tissues. The primary health-related effects of HIV infection are consequences of CD4+ T cell depletion. Nevertheless, the population dynamics of T cells in vivo are poorly characterized. It is proposed to develop theory and analyze data from in vivo labeling studies that will help characterize the rates of proliferation and death of T cells in uninfected, HIV-infected, and HIV-infected individuals under potent antiretroviral treatment. Infection by hepatitis C virus (HCV) and hepatitis B virus (HBV) continue to cause liver failure and hepatocellular carcinoma in many infected individuals. Antiviral therapy for these agents lags behind developments in HIV. The applicants propose to use the modeling and analysis tools that they have developed for HIV to increase understanding of the in vivo kinetics of HCV and HBV infection and the effects of antiviral therapy. In addition to gaining basic understanding, this approach aims to put information into a practical setting, and the applicants hope to interact with clinical groups in the design and evaluation of new treatment protocols. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
67
Project Title: MODULATION OF OXIDATIVE DAMAGE BY TEA POLYPHENOLS Principal Investigator & Institution: Wang, Jia-Sheng; None; Texas Tech University Health Scis Center Health Sciences Center Lubbock, Tx 79430 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-AUG-2003 Summary: (provided by applicant) The primary objective of this research project is to study the modulating effects of green tea polyphenols on reducing hepatocarcinogeninduced oxidative damages in high-risk human populations. Oxidative damage induced by reactive oxygen species in vivo plays important roles in human hepatocarcinogenesis primarily caused by chronic infection of hepatitis B/C viruses and exposure to dietary aflatoxins. The level of 8-hydroxy-2'- deoxyguanosine, a biomarker for oxidative DNA damage, increases in hepatitis B virus surface antigen positive and aflatoxin-exposed humans and in aflatoxin- treated animals. Dietary antioxidants are important components of cancer modulating agents, which have been proven to effectively target carcinogen biomarkers, including oxidative damages, in high-risk human populations. Among various identified dietary associated antioxidants, green tea and its polyphenols have been shown to be safe and highly effective in inhibition of a variety of carcinogeninduced oxidative damages, mutagenesis, and tumorigenesis in in vitro bioassays and in vivo animal models. The general hypothesis underlying this proposal is that green tea polyphenols have a protective effect against oxidative stress or damage induced by aflatoxin and hepatitis B/C viruses through the mechanisms of modulating aflatoxin metabolism and oxidated DNA damage. The specific aims include: (1) to determine antioxidative role of green tea polyphenols in inhibition of the level of 8-hydroxy-2'deoxyguanosine in urine samples collected from an intervention study of 120 participants who are double positive for hepatitis B virus surface antigen and aflatoxinalbumin adducts, and (2) to determine the modulating effect of green tea polyphenols on excretion of carcinogen detoxifying product, aflatoxin Bl-mercapturic acid in urine samples collected from the study participants. The results of this proposed study will help to understand the mechanisms of antioxidative role of tea polyphenols in modulating human hepatocarcinogenesis caused by hepatitis B/C viruses and aflatoxins. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR BIOLOGY OF THE HEPATITIS B TYPE VIRUSES Principal Investigator & Institution: Ganem, Don E.; Professor & Howard Hughes Investigator; Microbiology and Immunology; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2001; Project Start 01-SEP-1982; Project End 31-MAR-2003 Summary: Hepatitis B virus (HBV) and hepatitis D virus (HDV) are important causes of acute and chronic hepatitis in humans. Although much is known about the replication of these viruses, less is known about how replication causes disease. Evidence suggests that, in HBV infection, host immune responses trigger liver injury and affect viral replication. This application proposes studies to further examine the nature of these immune responses and to determine if similar responses can occur in HDV infection; the ability of such responses to affect HDV RNA replication will also be examined. In addition, detailed studies of the mechanisms of HDV RNA replication will be conducted, with emphasis on the involvement of host factors in this important reaction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
68
Hepatitis B
•
Project Title: CARCINOMA
MOLECULAR
EPIDEMIOLOGY
OF
HEPATOCELLULAR
Principal Investigator & Institution: London, W. Thomas.; Senior Member; Fox Chase Cancer Center Philadelphia, Pa 19111 Timing: Fiscal Year 2001; Project Start 15-DEC-1988; Project End 31-JAN-2004 Summary: Worldwide, hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths in men and the seventh most common in women. About 80% of the cases of HCC are associated with chronic infection with hepatitis B virus (HBV), but chronic carriers of HBV differ widely in their risk of HCC. Prospective studies of 60,984 men in Haimen City, China and 19,469 men in Senegal, west Africa, undertaken during the current funding period, revealed a 14-fold greater death rate from HCC among the Haimen than the Senegalese cohort. The age-adjusted prevalence of chronic HBV infection is about 20% in both cohorts. Exposure to aflatoxin, a postulated major risk factor for HCC, does not distinguish these two populations; Senegalese men were universally and heavily exposed. The prevalence of viremia (HBV DNA in serum) among HBV carriers throughout adult life is much higher among the Chinese than the Senegalese population and may be related to the mechanism by which chronic HV infection induces HCC. The mechanism, however, is still unknown. Therefore, the purpose of this program project is to understand the inter- relationships of HBV and other viral infections, environmental factors, genetic events and gene-environment interactions to the etiology and pathogenesis of (HCC). The Specific Aims are: 1) To compare variations in viral, genetic, and environmental factors associated with development of HCC to variations in risk of HCC observed in 3 cohort studies in China, Senegal, and Philadelphia. 2) To understand the cellular and molecular changes in the liver induced by chronic molecular genetic changes in tumor cells associated with HCC. 4) To identify genetic factors and gene- environment interactions associated with susceptibility to HCC. A multi- disciplinary team of scientists from China, Senegal, and the Fox Chase Cancer Center will address these Aims in three Projects (Molecular Epidemiology of HBV and HCC in Three Populations, Genetic Epidemiology of HCC, and Pathobiology of Acute and Chronic Hepadnavirus Infections) supported by three Core facilities (Population Resources, Laboratory Services, Administration). The ultimate goal of this research is to develop strategies for reducing the global burden of HCC. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR DITHIOLETHIONES
MECHANISMS
OF
CHEMOPREVENTION--
Principal Investigator & Institution: Kensler, Thomas W.; Professor; Environmental Health Sciences; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2001; Project Start 01-SEP-1985; Project End 31-JAN-2004 Summary: Cancer prevention involving reduction or elimination of human exposure to environmental carcinogens may not always be possible. Inhibition of the development of cancer by the administration of anticarcinogenic age may offer a practical alternative for reducing human cancer burden. However, the successful utilization of chemopreventive interventions will require solid mechanistic understanding of the action(s) of these agents. The proposed studies will continue to investigate the modes of protection afforded by oltipraz and other 1,2-dithiole-3-thiones on aflatoxin (AFB1) hepatocarcinogenesis in the rat. Oltipraz is an effective and potent inhibitor of experimental carcinogenesis induced by many agents in many tissues. Oltipraz is
Studies
69
currently being evaluated in Phase I and II clinical chemoprevention trials. This project will continue the development and evaluation of dithiolethiones more active than oltipraz on a) inhibition of AFB1-induced tumorigenesis in rats; b) altered AFB- DNA adduct formation; and c) induction of carcinogen detoxication ("phase 2") enzymes. Using a large series of analogs synthesized previously, the structure-activity relationships for inhibition of cytochrome P450 activation of AFB1 metabolism will also be determined. Using molecular genetic approaches, the identification and characterization of genes induced by dithiolethiones in rat liver will be continued together with elucidation of the role(s) of these gene products in protection against aflatoxin toxicity and carcinogenicity. Several novel inducible genes recently identified may protect against inflammation and oxidative stress. Finally, the chemopreventive actions and efficacy of oltipraz will be evaluated in a unique experimental model, the tree shrew, in which infection with human hepatitis B virus and exposure to AFB1 synergistically enhance the incidence of liver cancer, as occurs in humans. Collectively, these multifaceted, integrated studies will more fully define the chemical, molecular, biochemical and biological mechanisms of action of this versatile class of chemoprotective agents. The long-term goal of this project is to facilitate the most efficient and effective use dithiolethiones as protective agents in human populations exposed to environmental toxicants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENOTYPING
STANDARDS
FOR
HEPATITIS
B
AND
C
Principal Investigator & Institution: Neuwald, Paul D.; Acrometrix Corporation 1440 4Th St Berkeley, Ca 94710 Timing: Fiscal Year 2001; Project Start 15-JUN-2001; Project End 30-NOV-2001 Summary: (Applicant's Abstract): Nucleic acid testing procedures for genotyping of viral pathogens provide results that are utilized in the diagnosis and treatment of diseases such as hepatitis and AIDS. Medical products that directly measure these genetic variants currently utilize internal standards developed by the test manufacturers. The need exists for third party genotyping standards that offer common units of measure and provide testing laboratories with independent methods for ensuring accuracy, reproducibility and consistency in their test procedures. During Phase I, clinical specimens representing the major genotypes of hepatitis B virus (HBV genotypes A - F) and hepatitis C virus (HCV genotypes 1 - 6) will be obtained for calibration against World Health Organization International Standards for these virus nucleic acids, and evaluated for use as potential genotype standards using a variety of commercially available genotyping systems. During Phase II of this project, these materials will be further developed into viral and molecular (cloned DNA or RNA transcripts) standards for HBV and HCV genotyping. The HBV product will be further expanded to include standards for antiviral drug resistance mutations in this virus. All viral and molecular standards will be made commercially available during Phase Ill. PROPOSED COMMERCIAL APPLICATION: This research will lead to the development and commercialization of viral and molecular standards for HBV and HCV genotyping, including HBV drug resistance mutations. Such standardization, currently being implemented for viral load testing, is sorely needed for genotype testing, will facilitate the acceptance of common units of measure for assessing viral genotypes, and will help ensure that genotyping results obtained from multiple laboratories using a variety of test systems throughout the world are accurate,
70
Hepatitis B
reproducible, consistent and high quality. Commercial manufacturers of genotype assays have expressed a need for independent genotype standards. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MUTATIONS IN HUMAN P53 SEQUENCES OF A P53 KNOCK-IN MOUSE Principal Investigator & Institution: Hollstein, Monica C.; German Cancer Research Center Im Neuenheimer Feld 280 Heidelberg, Timing: Fiscal Year 2001; Project Start 15-JUL-1999; Project End 30-JUN-2002 Summary: The long-term objectives of this proposal are to test a humanized genetargeted p53 tumor suppressor gene knock-in mouse as an experimental tool for molecular epidemiology, chemoprevention, and cancer therapy studies. This new model is designed to reflect and predict more faithfully than the currently used mouse models, human in vivo mutagenesis, carcinogenesis and responses to therapeutic drugs that target p53 protein. The specific aims are 1) to induce tumor mutations in human p53 sequences of knock-in mice exposed to human carcinogens, and compare them to human tumor p53 mutation spectra; 2) to test whether a p53 hotspot mutation common in aflatoxin-associated human liver cancers occurs in liver tumors of aflatoxin B1exposed, hepatitis B virus-transgenic/human p53 knock-in mice; 3) to generate mouse strains that harbor a mutant human p53 sequence identical to one of the inherited p53 mutations of cancer-prone Li-Fraumeni families. These p53 mutant mouse strains provide a new animal model, with an allelic configuration that parallels the human situation, for testing chemotherapeutic agents and chemopreventive dietary factors; 4) to replace mouse regulatory sequences with human elements, and determine how this alters p53 expression; these data may be useful in developing next generation p53 knock-in mouse strains. The research plan involves: 1) Construction of gene-targeting plasmids; 2) Generation of gene-targeted mouse strains in which exons 5-9 of the endogenous mouse p53 gene have been replaced by the corresponding human segment; 3) Treatment of p53 knock-in strains with human carcinogens; 4) Analysis of tumors and normal tissues for p53 mutations, and alterations in p53 message and protein. The methods to be used are: (a) Standard cloning procedures for plasmid construction; (b) gene-targeted technology with ES cells, and knock-in/knock-out strategies; (c) mouse breeding and treatment with carcinogens; (d) DNA sequencing, PCR and RT-PCR amplification; (e) immunohistochemistry; (f) mutation analysis by DGGE and allelespecific PCR. New pharmaceuticals designed to regenerate tumor suppressor functions of a mutated p53 in humans can be tested in vivo in these humanized" mice because they have a core domain identical to the human p53 protein rather than the mouse p53 protein. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEW HEPATITIS B SMALL MOLECULE INHIBITORS Principal Investigator & Institution: Mehta, Anand S.; Associate Professor; Synergy Pharmaceuticals, Inc. 2 Executive Dr, Ste 450 Somerset, Nj 08873 Timing: Fiscal Year 2001; Project Start 01-SEP-2001; Project End 31-AUG-2003 Summary: (provided by applicant): The over-all goal of this "fast track" proposal is to develop a new class of orally available compounds for the treatment of chronic human hepatitis B virus (HBV) infection through a "proof of principle" Phase I/IIa Human clinical trial. With our colleagues, we have shown that alkylated imino sugars, called "alkovirs," are novel and effective in preventing HBV replication in tissue culture
Studies
71
systems under conditions where there is no detectable cyto-toxicity. The alkovirs are previously undescribed synthetic (hence completely characterized) small molecules. Unlike the glucosidase inhibitors, (another class of imino sugars that we have been studying) alkovirs do not inhibit glucosidases, making them distinct and conferring certain advantages. Moreover, although alkovirs inhibit HBV replication, they do not target the viral polymerase, as do most nucleoside analogues. Thus, alkovirs should be effective against lamivudine "resistant" HBV mutants. The objectives of this "fast track" proposal are intended to be straightforward and defined by clear milestones: In phase I, the Alkovir(s) with the most potent anti-HBV activity against wild type virus and lamivudine resistant virus will be selected and tested for in vivo toxicity and pharmacokinetics in a rat model. In Phase II, the efficacy and toxicity of the candidate Alkovir(s) selected in Phase I will be evaluated in the woodchuck model of chronic hepatitis virus infection both as monotherapy and in combination with 3TC-lamivudine. Other work, to be performed in parallel with this study, will explore the precise mechanism of action of alkovirs and possibility that (a) they are effective against other viruses and (b) are a class of compounds to which mutant viruses do not frequently emerge. Accomplishment of these Aims will permit the introduction of alkovirs for human clinical trials. Given the need to find complements to nucleoside analogues, the introduction of new anti-hepatitis B virus agents as described here is extremely important. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NONINJECTED HEROIN USE, HIV AND TRANSITIONS TO INJECTION Principal Investigator & Institution: Ouellet, Lawrence J.; Epidemiology and Biostatistics; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2001; Project Start 20-SEP-2000; Project End 31-AUG-2005 Summary: (adapted from the applicant's abstract): Growing cohorts of young noninjecting heroin users (NIHU) are making choices regarding drug injection that promise to shape the AIDS epidemic in Chicago and other U.S. cites for years to come. Despite the potential impact of NIHU on future AIDS trends, published research on this group in the U.S. is scarce and little is known about their transitions into injection. To help fill this void, we propose a five-year, longitudinal study of NIHU in Chicago that has three major aims: (1) measure the incidence of transitions by NIHU into drug injection and identify factors predicting this event; (2) measure the incidence and prevalence of HIV, hepatitis C, and hepatitis B infections among NIHU and identify factors associated with infection, and (3) explore the link between heroin use and risky sexual practices. The proposed study is grounded conceptually in social epidemiology, which models disease patterns as the product of interactions between an agent, host, and environment. The study will use a multi-method research design that combines a prospective epidemiologic survey, biologic testing, and qualitative interviewing. This design will enable causal analyses of the impact of independent variables on the outcomes of interest. The sample will consist of 1000 NIHU 16-30 years old recruited through respondent-driven sampling from areas across Chicago and its suburbs. Variable categories thought likely to predict major outcomes of interest are changing conditions in the properties and availability of heroin (agent/drug), individual characteristics (host/set), and the social settings within which drug use occurs (environment/setting). The goal of this study is to better understand current drug use patterns and HIV risk practices, particularly transitions to injection, among NIHU. We anticipate our findings being used to develop intervention strategies aimed at preventing drug injection and
72
Hepatitis B
other HIV related behaviors among NIHU. To increase the scope and generalizability of findings, elements of the proposed study, including the survey questionnaire, have been designed for comparison with an ongoing NIDA-funded, prospective study of NIHU in New York City. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NONINJECTING HEROIN USERS, NEW INJECTORS AND HIV RISK Principal Investigator & Institution: Neaigus, Alan; National Development & Res Institutes Research Institutes, Inc. New York, Ny 10010 Timing: Fiscal Year 2001; Project Start 01-JUL-1995; Project End 31-MAR-2003 Summary: Non-injecting heroin use is widespread in New York City and in many other cities. Non-injecting heroin users (NIUs) are at high risk of becoming injecting drug users (IDUs). Increases in the number of new IDUs can lead to many new infections with HIV, hepatitis B (HBV) and hepatitis C (HCV). This study will continue the "HIV Risk and Transitions from Non- Injecting Heroin Use" (NIU) cohort study of approximately 600 NIUs. It will follow the NIU cohort and a cohort of new IDUs, to determine: (1) the incidence and time-trends in transitions to injecting; (2) behavioral and network risks for transitions to injecting and other drug use outcomes; (3) separately, for new IDUs and for NIUs, the incidence and time-trends in HIV, HBV and HCV seroconversions; (4) among NIUs, sexual and other non- injecting risk behaviors and networks predicting HIV, HBV and HCV seroconversion; (5) among new IDUs, drug injecting and sexual risk behaviors and risk networks predicting HIV, HBV and HCV seroconversion; (6) time-trends in the prevalence of drug and sexual risk behaviors and risk networks, and factors predicting these trends; and (7) the impact of changes in the quality and availability of heroin, and in other community factors, on modes of drug administration and other drug and sexual risk behaviors and risk networks. The sample will include: NIUs from the parent study; new IDUs recruited from a supplemental study of network risks for HIV, HBV and HCV infection; and NIUs and new IDUs recruited during the study continuation. Participants will be interviewed and tested for HIV, HBV, and HCV. Ethnography will be used to study the impact of drug markets. Analyses of risk factors for transitions to injecting and seroconversions will explore the "network facilitation" hypothesis by examining the extent to which network characteristics, in interaction with risk behaviors, facilitate transitions to injecting or the cessation of heroin use and other drug use outcomes, and seroconversions. This approach will advance our knowledge of the interaction between network processes and risk behaviors, and can be used to develop interventions to change both risk behaviors and risk networks, and to prevent transitions to injecting and the risk of HIV, HBV and HCV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OCCULT HEPATITIS B Principal Investigator & Institution: Torbenson, Michael S.; Pathology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 30-JUN-2008 Summary: (provided by applicant): The goal of this proposal is to provide Michael Torbenson, MD with a period of mentorship in the proper scientific environment so that he can acquire the necessary skills to become an independent clinician-scientist. Dr. Torbenson has a strong background in diagnostic liver pathology and has a specific interest in viral hepatitis. This proposal focuses on occult hepatitis B, an emerging
Studies
73
infectious entity of potentially large medical significance. Occult hepatitis B has been associated with advanced liver fibrosis, coinfection with hepatitis C, IFN alpha resistance in treatment of hepatitis C, and hepatocellular carcinoma. The overall aim of Dr. Torbenson's proposal is to assess the prevalence and clinical significance of occult hepatitis B in high risk patient population of injection drug users. This study utilizes the unique resources of a pre-existing longitudinal collection of sera and liver tissue from the mentor's ongoing research, allowing assessment of the prevalence of occult hepatitis B over time and estimation of the rate of fibrosis progression in these individuals. The first aim examines the overall prevalence of occult hepatitis B and investigates the impact of Human Immunodeficiency Virus status on the presence of occult hepatitis B. The second aim assess the clinical significance of occult hepatitis B by correlating the presence of occult hepatitis B with the amount of inflammation and fibrosis on liver biopsy. The rate of fibrosis progression will be investigated by comparing the amount of fibrosis on initial liver biopsy to that on follow-up biopsies. In addition, aim 2 will examine the role of occult hepatitis B in HIV progression. The third aim focuses on potential mechanisms of occult hepatitis B and seeks to identify relevant hepatitis B gene mutations. As a final element of this aim, carefully selected (based on known involvement in typical hepatitis B viral infection) signaling pathways will be investigated by analysis of mRNA and protein expression to investigate host-viral interactions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF GROUND GLASS CELLS IN HEPATITIS B Principal Investigator & Institution: Yen, T.S. Benedict.; Professor; Northern California Institute Res & Educ San Francisco, Ca 941211545 Timing: Fiscal Year 2001; Project Start 05-MAR-1992; Project End 31-MAR-2006 Summary: (Adapted from the Investigator's abstract): Hepatitis B virus (HBV) causes chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC), and is especially common among minorities such as African Americans and Asian Americans. The mechanism by which HBV causes HCC is unclear, but it is likely that HCC results from both specific viral factors and non-specific mutagenesis due to constant cell turnover. One candidate viral factor is the large surface protein, since expression of this protein in transgenic mice results in HCC. We have recently shown that large surface protein can activate cellular genes at the transcriptional level, apparently by forming non-secretable particles in the endoplasmic reticulum (ER) and activating ER stress. Further preliminary data indicate that large surface protein causes cell death, probably by apoptosis. Since hepatocytes containing large surface protein particles within the ER ("ground glass cells") are seen in the livers of people with chronic hepatitis B, our results point to a specific mechanism whereby HBV may cause HCC. However, the reason for ground glass cell formation in infected livers is still unclear. For the next cycle of this project, we propose to study events both up-stream and down-stream of the formation of ground glass cells. First, we wish to validate our hypothesis that mutations in the viral genome can lead to ground glass cells, and determine if two common naturally occurring viral mutants can cause ground glass cells and HCC in transgenic mice. Second, we will clone out HBV genomes from human ground glass cells, and look for additional mutations that may be responsible for ground glass cell formation. Third, we will determine how large surface protein causes cell death, and whether it is by apoptosis. We will also determine if there is increased apoptosis of ground glass cells in transgenic mice, and look for activation of apoptotic pathways in human livers with
74
Hepatitis B
ground glass cells. These experiments should give novel insights into the mechanism by which HBV causes liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOGENESIS OF LIVER DISEASE IN HEPATITIS Principal Investigator & Institution: Chisari, Francis V.; Professor & Head; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2001; Project Start 01-JUL-1983; Project End 30-JUN-2003 Summary: (adapted from the investigator's abstract) During the current funding interval Dr. Chisari established the technology required to detect, quantitative and characterize the cytotoxic T lymphocyte (CTL) response to the hepatitis B and C viruses. Using this technology he defined the salient features of the host-virus relationship during the acute and chronic phases of these infections and, in the process, established the rationale and identified the immunological targets for antigen-specific immunotherapy of chronic hepatitis. Despite these advances, the very early aspects of the host-virus relationship during HBV and HCV infection are completely unexplored because, for practical and ethical reasons, it is extremely difficult to access the incubation period in infected patients. Nonetheless, these early host-virus interactions are likely to be key determinants of the outcome of these infections. In the next funding interval, he will examine the virological, immunological and pathological features of the host-virus relationship from the moment of HBV and HCV infection until their final outcome in experimentally infected chimpanzees. As in humans, almost all adult onset HBV infections in chimps are self limited, while only half of chimp HCV infections are self limited and the rest become persistent. Thus, he will compare and contrast the early intrahepatic T cell responses to HBV and HCV to test the hypothesis that the outcome of these infections is determined by the kinetics, vigor, diversity and cytokine profiles of the intrahepatic T cell response and the ability of the virus to spread and to evade immune recognition during the early incubation period of each infection. Thanks to the close relatedness of chimps and humans, most of the reagents and techniques required to define the intrahepatic antigen specific T cell response to these viruses are already available. The information forthcoming from these studies will, for the first time, define the virological and immunological features of early HBV and HCV infection and determine the extent to which they influence viral clearance and disease pathogenesis in these diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PSYCHOLOGICAL STRESS AND IMMUNE RESPONSE TO VACCINATION Principal Investigator & Institution: Marsland, Anna L.; Pathology; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, Pa 15260 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-MAY-2008 Summary: (provided by applicant): It is widely proposed that the influence of stress on immune function is the primary biological pathway linking stress to increased infectious disease susceptibility. However, the literature is missing empirical evidence for this pathway, in part because of a failure to focus on immune measures that are relevant for the development of host resistance. The broad objective of the proposed study is to identify pathways linking psychological stress to in vivo immune processes that are clinically relevant for the development and maintenance of resistance to infectious disease. For this purpose, a hepatitis B vaccination model is employed. This model
Studies
75
permits the systematic exploration of behavioral and biological pathways linking stress to ability to mount and maintain primary and secondary antibody responses following exposure to a novel antigen. It also allows the exploration of the role that individual differences in the magnitude of biological responses to stress play in vulnerability to stress-immune relationship. In this regard, it has been demonstrated that individuals vary consistently in the magnitude of their cortisol and immune responses to acute stress, conceivably rending them more or less able to mount an antibody response to vaccination. One hundred and eight-two healthy males and females aged 40-60 years will be recruited to participate in the proposed longitudinal research, which includes a laboratory based physiological reactivity phase, a prospective surveillance phase and a follow-up period. In the reactivity phase, participant's immune and cortisol responses to an acute laboratory stressor will be measured to determine individual differences in the magnitude of immunologic reactivity to stress. During this phase, participants will also complete self-report measures of recent life stress and trait negative affect. In the surveillance phase, participants will be administered the three does of hepatitis B vaccine by standard protocol. They will also complete daily stress diaries for the seven days surrounding each dose of vaccine to assess levels of acute stress. Saliva samples for the assessment of cortisol levels will be collected at the time of each vaccination. Antibody responses will be measured at the time of the second and third does of vaccine and, during the follow-up period, 6 and 12 months following completion of the vaccination series. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECOMBINANT ATTENUATED SALMONELLA VACCINES FOR HUMANS Principal Investigator & Institution: Curtiss, Roy Iii.; Professor; Biology; Washington University Lindell and Skinker Blvd St. Louis, Mo 63130 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-DEC-2007 Summary: (provided by applicant): Of the 18.9 million annual deaths (1997) due to infectious diseases, about 7.5 million, in addition to significant morbidity, are the result of infections by Salmonella typhi, S. paratyphi A, hepatitis B virus (HBV), Plasmodium falciparum, Streptococcus pneumoniae and Mycobacterium tuberculosis. In the belief that improving health, nutrition and economic well-being (the later dependant on the first two) provides the best means to enhance the quality of life globally and thus reduces conditions that result in warlike and terrorist behavior, we propose a vaccine development program based on our recent technical developments in using recombinant attenuated Salmonella vaccines. Our objectives include: (a) to design, construct and evaluate an attenuated derivative of S. paratyphi A that will serve as an antigen delivery vector by exhibiting regulated delayed lysis within effector lymphoid tissues in the immunized individual to release hepatitis B virus (HBV) core particles encoding (i) HBV pre $1, pre $2 and T-cell epitopes as a preventative/therapeutic vaccine against HBV and (ii) P. falciparum circumsporozoite epitopes as a vaccine against malaria; (b) to construct and evaluate the contribution of strain background and the RpoS* phenotype on immunogenicity of a recombinant antigen expressed by attenuated S. typhi vaccine strains; and (c) to design, construct and evaluate recombinant attenuated S. typhi vaccines to express and deliver protective antigens specified by genetic information from (i) S. pneumoniae to prevent pneumococcal disease caused by strains with diverse capsular serotypes and (ii) M. tuberculosis as a preventative/therapeutic vaccine. The S. paratyphi A and S. typhi recombinant vaccines should also provide immunity to infection by S. paratyphi A and S. typhL We will also
76
Hepatitis B
develop our Master File, prepare and fully characterize candidate vaccine Master Seeds for stability and safety, prepare and submit protocols for IRB approvals, submit information necessary to obtain INDs, and perform any other work needed to arrange that the best candidate vaccines be clinically evaluated in human volunteers. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION Principal Investigator & Institution: Lok, Anna S.; Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2001; Project Start 01-JUN-2001; Project End 31-MAY-2008 Summary: Hepatitis B accounts for approximately 5000 deaths/yr in the United States. Early results with orthotopic liver transplantation (OLT) for hepatitis B were poor with recurrence rates of >80% and 2-year mortality rates of 50%. Recent studies found that continuous high dose IV hepatitis B immune globulin (HBIG) can decrease the rate of reinfection to <20%. However, high dose HBIG is very expensive ($30,000-$50,000/yr) and the efficacy is low in patients with replicative infection pre-OLT. Pilot studies showed that lamivudine (LAM, an oral nucleoside analog which costs $1,200-$1,500 per yr) can decrease the rate of recurrent hepatitis B to <30% during the first post-OLT year but the long-term efficacy is limited by drug resistant mutants. Three pilot studies reported that combination therapy of HBIG and LAM is more effective than either agent alone with recurrence rates <5%, but it is not clear how long HBIG needs to be administered. Given the high costs and the inconvenience of life-long HBIG therapy, there is a need for a prospective, randomized controlled trial to determine if prophylaxis with LAM and short-term HBIG is as effective as LAM and long-term HBIG in the prevention of recurrent hepatitis B post-OLT. The use of antiviral agents with potential activity against LAM resistant HBV mutants, such as adefovir dipivoxil, also needs to be evaluated. The specific aims of our study are: (1) To compare the safety, efficacy and cost-effectiveness of combination therapy with LAM and a 6-month course of HBIG with LAM and a 3-yr course of HBIG in the prevention of recurrent hepatitis B postOLT. (2) To identify the epidemiological, clinical and virological factors that are associated with recurrent hepatitis B post-OLT. (3) To determine the safety and efficacy of adefovir dipivoxil in the suppression of HBV replication in patients who have developed LAM resistant HBV mutants and to compare the rate of recurrent hepatitis B post-OLT in patients with and without LAM resistant mutants prior to transplant. This is a prospective, randomized, multi-center clinical trial involving 20 liver transplant centers in N. America, to be conducted under an investigator IND 59,167. 290 patients with hepatitis B who are listed for OLT as UNOS status 1 or 2 will be enrolled. Open label LAM will be administered to decrease virus load pre-OLT. Patients will be randomized after OLT to Group I: LAM and 3 yr-course of HBIG or Group II: LAM and 6-month course of HBIG. Patients who develop LAM resistant mutants pre- or postOLT will additionally receive adefovir dipivoxil. The primary end-point of this trial is the rate of recurrent hepatitis B during the first 3 yr post-OLT. This trial will provide definitive answers whether combination therapy with LAM and a 6-mon course of HBIG is as efficacious and more cost-effective than LAM and a 3-yr course of HBIG in the prevention of recurrent hepatitis B post-OLT. In addition, crucial data will be generated on the efficacy of pre-OLT LAM in virus clearance, incidence and outcome of silent allograft infection, clinical outcome of patients with LAM resistant HBV mutants, and management of patients with LAM resistant mutants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
77
Project Title: REGULATION OF HBV REPLICATION BY OTHER HUMAN PATHOGENS Principal Investigator & Institution: Guidotti, Luca G.; Associate Professor; Scripps Research Institute Tpc7 La Jolla, Ca 92037 Timing: Fiscal Year 2001; Project Start 01-JAN-1997; Project End 31-DEC-2001 Summary: The hepatitis B virus (HBV) causes acute and chronic necroinflammatory liver disease and hepatocellular carcinoma. Over 300 million people worldwide are persistently infected by HBV, representing an enormous reservoir for horizontal and vertical spread of this virus to others. The long term objective of this application is to understand the host- virus interactions responsible for HBV persistence with the ultimate hope that this knowledge will lead to the development of new therapeutic strategies to terminate persistent infection and its attendant costs and complications. Using transgenic mice that replicate HBV at high levels in the liver as recipients of HBVspecific CTL and hepatotropic viruses such as lymphocytic choriomeningitis virus (LCMV), we have shown that HBV replication is abolished by these agents, noncytopathically, as a result of the intrahepatic induction of interferon alpha, interferon gamma and tumor necrosis factor alpha (type 1 cytokines). We now propose to examine the antiviral regulatory networks that are activated in the LCMV-infected liver in order to identify the ligand-receptor interactions that trigger the hepatocyte to suppress HBV gene expression and replication in vivo. Since the intrahepatic macrophage (Kupffer cell) is an important and well placed source of potentially active antiviral mediators in this system, we will determine whether physiological and pharmacological activation of the Kupffer cell is sufficient to clear HBV from the hepatocyte in vivo. if successful, these studies would establish the concept that inducible cellular crosstalk can control viral infection, perhaps leading to the development of an entirely new area of viral immunotherapeutics. Finally, in view of our findings it is possible that HBV persistence might be favored by inflammatory responses dominated by type 2 cytokines (eg interleukins 4, 5 and 10). To explore this hypothesis, we will determine whether intrahepatic type 2 inflammatory responses initiated by schistosomal and leishmanial infection are able to clear HBV from the liver of these animals. The results of these experiments will not only provide insight into the basic immunological processes that may determine HBV persistence, but additionally they may also shed light on the basis for the more aggressive liver disease that occurs in millions of patients with chronic HBV infection who are superinfected by these parasites in developing countries throughout the world. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION OF TBP BY HBV X ON TRANSFORMATION Principal Investigator & Institution: Johnson, Deborah L.; Associate Professor; Molecular Pharm & Toxicology; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 10-MAY-1997; Project End 31-JAN-2005 Summary: (Adapted from the investigator's abstract) The Hepatitis B virus (HBV) is a common infectious agent. The HBV protein product, X, has shown to be essential for viral replication, and it is strongly implicated in the development of hepatocellular carcinoma in chronically infected HBV patients, yet its role in these events is not wellunderstood. Our previous work has comprehensively defined the mechanism for how X transactivated RNA polymerase I and III promoters. We made the interesting discovery that X induces the promoters by activating the Ras signal transduction pathway which
78
Hepatitis B
then increases the cellular levels of the central transcription factor, TATA-binding protein (TBP). Increases in cellular TBP augment RNA pol I and III transcription and differentially regulate RNA pol II promoters. Our research plan will clearly delineate how X, an oncogenic Ras, increase cellular TBP levels. The proposed aims will rigorously investigate each event in the TBP gene expression process that gives rise to the final TBP product. By examining the individual contribution of each process, and how it differs when either X or oncegenic Ras is expressed in cells, we will obtain a good quantitative picture of how this X- and oncogenic Ras-mediated increase in TBP occurs. We have promising new data indicating that a key step leading to the increase in TBP is due to an increase in TBP promoter activity. Therefore, a major focus of the proposed studies will be to examine how the TBP promoter is regulated by X and by oncogenic Ras. We will comprehensively define the X-mediated signaling events downstream of Ras to the promoter that modulate TBP promoter activity. Since X has been shown to transform cells, and Ras is strongly oncegenic, we will also determine how alterations in the cellular levels of TBP can affect the transformation potential of cells. Focus formation, growth in soft agar, and mouse tumorigenesis assays will be used to assess whether directly overexpressing TBP can enhance transforming activity or whether down-regulating its production in cells can prevent Ras-induced transformation. Using mutant TBP proteins that are specifically defective in RNA pol II or pol III transcription, we will define specific changes in cellular gene expression occurring in TBPoverexpressing cells that contribute to transformation. These studies promise to make unique and important new contributions to our understanding of the function of the HBV X protein and oncegenic Ras, the regulation of TBP, and their consequences on cellular gene activity that leads to cellular transformation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REPLICATION AND PATHOGENESIS OF HEPATITIS B VIRUS Principal Investigator & Institution: Ou, Jing-Hsiung J.; Professor; Molecular Microbiol and Immun; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2001; Project Start 10-APR-1998; Project End 31-JAN-2002 Summary: Dr. Ou proposes to study three aspects of the HBV pathogenesis and its replication cycle: core protein phosphorylation, C gene transcription controls, and the role of the X gene in replication. Aim 1 will evaluate the model that core protein phosphorylation blocks virus assembly. Virions will be analyzed for phosphorylation; virus infection will be reconstituted with core proteins mutated to block phosphorylation at specific residues. Viral regulation, packaging efficiency, and virion production will be analyzed. Aim 2 deals with transcriptional regulation of the core gene, which actually encodes both precore and core proteins by initiating from two different transcription start sites. The study will focus on a critical regulatory site that binds COUP, HNF4, PPAR-RXR, and when mutated, HNF1. Preliminary studies have also characterized an upstream negative regulatory element (NRE) that binds RFX1/MDBP1 and MIBP1. The NRE will be further analyzed in Aim 3. Finally, Aim 4 will evaluate whether the X protein activates cell cycle-dependent genes to support HBV regulation. For these studies, a transgenic mouse will be constructed to incorporate a functional HBV genome, but with a defective X gene. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
79
Project Title: ROLE OF GLYCINE DECARBOXYLASE IN HEPADNAVIRAL INFECTION Principal Investigator & Institution: Li, Jisu; Assistant Professor; Rhode Island Hospital (Providence, Ri) Providence, Ri 02903 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: Hepatitis B virus is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC). A better understanding of the viral life cycle may provide targets for the intervention of HBV infection, thus reducing the risk of HBV-related HCC. However, the early stages of the viral life cycle and viral-host interactions that contribute to viral infection and pathogenicity are poorly understood. This 421 exploratory proposal focuses on studies on a hepadna virus interacting protein, p120/glycine decarboxylase. We have previous found that p120 is a binding partner of an avian hepatitis B virus envelope protein. It is expressed only in the virus infectable tissues and its expression level is directly correlated with the cellular susceptibility to virus infection. It is expressed only in the virus infectable tissues and its expression level is directly correlated with the cellular susceptibility to virus infection. Moreover, viral mutants with an ablated p120-binding site showed reduced infectivity despite wild-type replication capacity. These findings suggest that p120 is associated with the early stage of the viral life cycle. Therefore, we plan to further establish its role in the viral life cycle by genetic approaches. Specific Aim #1 will determine if inhibition of p120 expression or function in well-differentiated duck hepatocytes will reduce susceptibility to viral infection. Specific Aim #2 will examine whether reconstitution of p120 in dedifferentiated duck hepatocytes will restore productive viral infection. In addition, we will determine if p120 is defective in Muscovy ducks, a duck species resistant to hepadnavirus. We will also explore the possibility to restore viral infection by p120 derived from a susceptible Pekin ducks. These studies will provide further information on virus-cell interactions and may lead to development of novel anti-viral strategies for prevention of HBV induced liver cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ROLE OF HBX PROTEIN IN HBV REPLICATION Principal Investigator & Institution: Schneider, Robert J.; Professor; Biochemistry; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2001; Project Start 01-APR-1992; Project End 31-MAR-2006 Summary: (provided by applicant): The long term objectives of this proposal are to understand the roles of the hepatitis B virus (HBV) HBx gene in viral infection. Please note that the title of this grant has been changed from "Transcription and Transformation by Hepatitis B Virus HBx Protein," to" Role of HBx protein in HBV replication" to reflect the progression of our studies on HBx. AIM 1: Molecular mechanism for human hepatitis B virus (HBV) HBx protein action. HBx activates cytoplasmic signal transduction pathways. HBx activation of the Pyk2-Src tyrosine kinase signalling pathway represents an important activity for viral replication in hepatocytic cell lines. Studies are outlined to understand the molecular mechanism for HBx activation of Pyk2-Src signal transduction, since it is tightly linked to HBx stimulation of viral replication. In addition, HBx appears to possess nuclear functions that may stimulate viral transcription. Studies will also investigate the mechanism by which HBx functions in viral transcription, including a possible role in the nucleus, and its impact on viral replication. AIM 2: Role of HBx protein in HBVreplication. Studies are proposed to determine the molecular basis for HBx activation of HBV reverse
80
Hepatitis B
transcription and DNA replication. Model systems have been developed for delivery of hepadnavirus genomes to differentiated hepatocytic cell lines and rodent primary hepatocytes in culture, that permit viral replication in an HBx-dependent manner. Studies will investigate the role of HBx in viral replication in a biologically relevant system, focusing on HBx induction of HBV core protein phosphorylation, control of the cell cycle, and induction of nucleotide metabolism. HBx-dependent HBV replication will also be studied in primary hepatocytes prepared from mice that are deficient in genes that impact on HBV replication, including knockouts of Src and Pyk2 kinases, to better understand their importance for viral replication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SELF CLEAVING RNA AND TRANS ACTING RIBOZYMES Principal Investigator & Institution: Been, Michael D.; Professor; Biochemistry; Duke University Durham, Nc 27706 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-AUG-2002 Summary: The objective of the proposed research is to understand the structure, mechanism, and biological role of self-processing RNA (ribozymes). The ribozymes being studied are self-cleaving sequence associated with the genomic and antigenomic RNA of hepatitis delta virus (HDV). HDV is a human pathogen but is always found in association with hepatitis B virus. The combination leads to serious liver damage with a higher fatality rate that in patients infected only with hepatitis B virus. Thus, in populations where hepatitis B is endemic, HDV can be a serious health threat. It can either be co-transmitted with hepatitis B causing the acute form of the disease or it can infect hepatitis B carriers; the later tends to be more serious. The ribozyme activity is thought to be essential to the replication of the RNA genome of this virus. A greater understanding of the ribozyme structure, cleavage mechanism, and role in replication could lead to a method to block viral replication. In addition because the self-cleaving RNA from HDV is the first clear example of a self-cleaving RNA that functions naturally in human cells; an understanding those features that are unique to this RNA may facilitate the design of ribozymes to be used in therapeutics. The specific aims of the proposal are: (1) To generate and refine a three dimensional model for the HDV ribozyme and utilize the models to evaluate biochemical and genetic data on the ribozyme structure and mechanism. Molecular modeling programs, some of which are designed Specifically for RNA, will be used to generate models that are consistent with constraints on the structure established experimentally. Data gathered from physical methods will also be used, and towards this end methods for making large quantities of circular RNA will be used to produce RNA for crystallography. (2) To test and refine the structure through biochemical and genetic approaches. Methods include chemical protection, substitution interference, in vitro mutagenesis and in vitro selection. (3) To define the mechanism and requirements of the reaction. A complete kinetic scheme for the trans-reaction will developed and the stereochemistry of the reaction will defined. (4) To characterize and define cis-acting sequences that interfere with cleavage activity and may limit ribozyme cleavage to the nascent transcript. As part of this study templates for making concatameric RNA sequences that mimic replication of the RNA from a circular template will be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SEXUAL HEALTH PRACTICES OF HOMELESS ADOLESCENTS Principal Investigator & Institution: Rew, Donna L.; Professor; None; University of Texas Austin 101 E. 27Th/Po Box 7726 Austin, Tx 78712
Studies
81
Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-MAR-2002 Summary: This study is in response to the program announcement, Health Risk Reduction: Community-Based Strategies, and is an essential step in developing culturally relevant interventions to promote positive sexual health practices and outcomes among homeless adolescents. The specific aims are to 1) describe the sexual health practices, including prevalence and incidence of STD testing, diagnosis, and treatment as well as the prevalence and incidence of immunizations for hepatitis B, of homeless adolescents; 2) examine the relationships among variables in the conceptual model of sexual health practices: sociodemographics, sexual history, culture of homelessness, cognitive perceptual factors, behavioral factors, and individual sexual health practices of homeless adolescents; 3) determine the indirect effects of sociodemographics, sexual history, and culture of homelessness, and the direct effects of cognitive perceptual factors and behavioral factors on individual sexual health practices of homeless adolescents; and 4) explore with homeless adolescents the feasibility of developing culturally relevant interventions to promote positive sexual practices in this population through (a) focus groups that explore their perceptions of factors that are culturally relevant, and (b) comparing characteristics of those subjects who remain connected to the project site for periods of 3, 6, 9, and 12 months and characteristics of those who leave the area during these time intervals. A convenience sample of 460 homeless youth will be surveyed to describe their sexual health practices and to examine relationships among theoretical variables through structural equation modeling. A subsample of 40 homeless youth will participate in focus groups to provide their perspectives on community-based interventions to reduce the risk of sexually transmitted diseases (STDs) that would be culturally relevant and feasible for them. The expected outcomes of the study are the refinement of a theoretical model of sexual health practices that will provide a framework for interventions to reduce the prevalence and incidence of STDs in vulnerable homeless adolescents. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SOCIAL CAPITAL, SELF EFFICACY, AND SEX WORKER HEALTH Principal Investigator & Institution: Cohan, Deborah; Ob, Gyn and Reproductive Scis; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 94122 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Deborah Cohan, MD, MPH is a full-time faculty member in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of California San Francisco (UCSF) and medical director of St. James Infirmary, a peer-based, multi-service clinic for male, female, and transgender sex workers. Dr. Cohan has just completed a two-year fellowship in Reproductive Infectious Disease and her Masters in Public Health. She proposes to build on her research skills by learning ethnographic techniques and advanced biostatistical methods, with the ultimate goal of becoming an independent clinical researcher. Dr. Cohan proposes to conduct a multi-level study to identify individual-level psychological factors and population-level network characteristics associated with risk of prevalent HIV-1, sexually transmitted infections (STIs), and hepatitis B (HBV) and C (HCV) among female sex workers in San Francisco. The study combines qualitative and quantitive methods, including ethnography, a cross-sectional survey using venue-based probability sampling, and social network analysis, to describe the sociopolitical, environmental, and psychological forces that underlie sexual and drug-using behavior among sex workers. She proposes three specific aims: (1) to characterize sexual and drug-using behavior and prevalence of HIV, STIs, HBV, and HCV, and to examine
82
Hepatitis B
psychological risk factors associated with these infections among female sex workers in San Francisco; (2) to characterize social capital among networks of female sex workers in San Francisco; and (3) to investigate whether diminished social capital is associated with increased risk of prevalent HIV, STI and hepatitis among these networks. With these data, Dr. Cohan intends to develop and evaluate culturally-appropriate, communitydriven prevention interventions for sex workers. Dr. Cohan has assembled a multidisciplinary team spanning the fields of epidemiology, psychology, and medical anthropology to ensure success of this project. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STRUCTURE/FUNCTION STUDIES OF S100 PROTEINS AND P53 Principal Investigator & Institution: Weber, David J.; Associate Professor; Biochem and Molecular Biology; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2003; Project Start 01-FEB-1999; Project End 31-JAN-2007 Summary: (provided by applicant): During the last 3 years, (i) high yields (>30 mg purified protein/liter media) of S 100B, S 100A 1, S 100A3, CAN19, mtsl, p53, p53(324393), p53(303-393), p53(303-367), hepatitis B viral protein X (HBVX), SUMO-1, Cterminal fragment of myosin IIA(1900-1961), and the HMG A box of the high mobility group protein- 1 (HMG-1) were prepared in minimal media as necessary for isotopic labeling (2H, 13C, 15N, etc). (ii) We determined the solution structures of apo-S 100B, apo-S 100A 1, calcium-bound S 100B, and calcium-bound S 100B in a complex with the negative regulatory domain of p53 (residues 367-388). (iii) We showed that dimeric S 100B is the physiologically relevant oligomerization state of S 100B, and that S 100B inhibits protein kinase C (PKC) phosphorylation of p53. (iv) We developed cellularbased assays for p53 and showed that p53 function is inhibited in tumor cell lines as a result of the calcium-dependent p53-S 100B interaction. This interaction includes both the oligomerization and negative regulatory domains at the C-terminus of p53. We plan to continue characterizing the calcium-dependent interaction of S 100B with the tumor suppressor protein p53. The effects that p53 phosphorylation, acetylation, and sumoylation have on S 100B binding will be examined. The binding of zinc to S 100B and heterodimer formation (i.e. S 100A 1/S 100B, CaN 19/S 100B and mts 1/S 100B etc.) will also be characterized. These data are necessary to determine whether covalent modifications of p53 and/or other S100B binding events affect S100B-p53 complex formation and function We will also determine the 3D structure of calcium-bound S100B complexed with a larger construct of p53 that includes both the oligomerization and the C-terminal regulatory domains of p53 (residues 324-393; Kd=24nM). Heteronuclear relaxation measurements for backbone and sidechain resonances are planned for all of the structures that we solve (or have solved) in order to clarify how calcium and p53 binding affects the dynamics of S100B (and p53). These dynamic data will be used in a search for small molecule inhibitors of the S 100B-p53 interaction. Lastly, the 3D solution structures of other proteins that bind the C-terminus of p53 will be examined including the metastasis protein 1 (mts 1), S100A3, the CaN 19 tumor suppressor, the hepatitis B viral protein (HBVX), the p53 binding domain of BLM, and the A box ofHMG-1. It will be interesting to determine whether these or other p53-binding proteins enhance and/or compete with the S 100B-p53 interaction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
83
Project Title: TARGETED GENE DELIVERY AND EXPRESSION IN HEPATOCYTES Principal Investigator & Institution: Wu, George Y.; Chief, Div of Gastroenterology; Medicine; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, Ct 060302806 Timing: Fiscal Year 2001; Project Start 01-JAN-1990; Project End 31-JAN-2006 Summary: (Adapted from the Applicant's Abstract): In the previous grant period, we developed a multicomponent DNA carrier that, through the incorporation of endosomolytic peptides, is capable of releasing targeted nucleic acids directly to the cytoplasm of hepatocytes. Using multicomponent carriers, the efficiency of delivery of nucleic acids into cells was increased by 3 orders of magnitude, and the amount of DNA introduced into the nuclei in animals was increased 1 to 2 orders of magnitude compared to the originally described system. Recently, we have developed new approaches to enhance integration of targeted genes in cell culture resulting in persistent transgene expression. The objective of the current project is to take advantage of these advances to evaluate a novel therapeutic strategy against hepatitis B viral infection: transfection-mediated therapeutic selection. The hypothesis is: integrative transfection of antiviral genes will result in continuous inhibition of HBV gene expression, and block production of viral antigens. Under the pressure of host cellmediated immune response against cells bearing HBV antigens, there will be a selective survival advantage to transfected cells and their progeny. The antiviral agents are proposed to be generated from genes whose products are directed against unique features of the HBV life cycle, blocking translation, and replication. These areas distinguish viral processes from those of the mammalian host in order to achieve efficacy without toxicity. Candidates will be screened using stable HBV expression models in cell culture first to identify optimal constructs. Agents will be targeted to liver by complexation with multicomponent carriers, and also by genetic engineering into chimeric adeno-associated viral vectors all with integration enhancement capability. After optimization and comparison in an HBV cell culture model system, antiviral agents will be used to test the therapeutic approach in an animal model of HBV infection. Agents will be prepared against analogous sequences in the Woodchuck Hepatitis Virus (WHV), a homologous hepadna virus. Efficacy of long-term inhibition of HBV gene expression and replication, and evidence of selective survival advantage of cells bearing integrated antiviral genes will be determined over the time course, and optimal agents compared. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TRANSCRIPTION ACTIVATION BY HIV, TAT, HTLV TAX & HBV PX Principal Investigator & Institution: Green, Michael R.; Professor; Molecular Medicine; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2001; Project Start 01-SEP-1990; Project End 31-AUG-2005 Summary: (from investigator's abstract): This is a competitive renewal application. The previous grant was for studying how the trancriptional regulatory proteins of three pathogenic viruses activate transcription, specifically, the Tat protein of human immunodeficiency virus type 1 (HIV-1), the Tax protein of human T-cell leukemia virus type 1 (HTLV-1), and the pX protein of hepatitis B virus (HBV). In this application, the applicant seeks to understand in greater detail the mechanism of action of these viral regulatory proteins and their role in viral replication and human disease. The rationale
84
Hepatitis B
for the proposal relies heavily on two relatively new technologies. First, the chromatin immunoprecipitation (ChIP) assay, which allows for the detection of specific proteins that are physically associated with DNA in living cells. Second, the genome-wide expression analysis using high density DNA microarrays, which enables the analysis of transcription profiles of a large array of human genes. The specific aims are: (1) To understand in greater detail how HIV-1 Tat stimulates transcription in vitro and in vivo. The investigator has identified a Tat cofactor, Tat-SF1, and has shown that it is a general transcription elongation factor. A second elongation factor has been implicated, AIEF, and remains to be identified. Tat-SF1 and AIEF and the mechanisms of Tat activation in vivo will be investigated further. (2) To study how HTLV-1 Tax and HBV pX regulates DNA binding of cellular bZIP proteins. The investigator has shown that Tax and pX dramatically increase the DNA binding activity and alter the target selectivity of a wide variety of cellular proteins that possess a basic region-leucine zipper (bZIP) DNA binding domain, through promotion of dimerization. Experiments are proposed to undersstand the basis of altered DNA binding specificity, the cellular proteins involved, and details of the DNA-protein interactions. (3) To analyze how HTLV-1 Tax and HBV pX activate transcription in vivo and transform cells. To test the prediction of different models of how these proteins activate transcription, to identify cellular proteins involved in the activation, and to identify cellular genes activated that may contribute to disease. (4) To understand the mechanism of BEF action. The investigator has identified a nuclear protein BEF (for bZIP-enhancing factor) which is required for bZIP prtoein functions, work synergistically with Tax and pX. However, BEF works by a different mechanism, as a molecular chaperone. Experiments are proposed to further study the mechanism of BEF action. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSIENT GLUCOSYLATION OF GLYCOPROTEINS Principal Investigator & Institution: Parodi, Armando J.; Instituto De Investigaciones Bioquimicas Bioquimicas Fundacion Campomar Buenos Aires, Timing: Fiscal Year 2001; Project Start 15-AUG-1990; Project End 31-MAY-2003 Summary: Protein glycosylation is initiated in the endoplasmic reticulum (ER) by transfer of an oligosaccharide (Glc3Man9GlcNAc2) to nascent polypeptide chains. Processing of the oligosaccharide by glucosidases I and II yields unglucosylated oligosaccharides that are reglucosylated by the UDP-Glc:glycoprotein glucosyltransferase (GT) only if the protein moieties of glycoproteins are not properly folded, as GT behaves as a sensor of glycoprotein conformations. Interaction of monoglucosylated glycoproteins (created by partialdeglucosylation of the transferred compound or by GT-mediated reglucosylation) with ER lectins (calnexin and calreticulin) facilitates acquisition of the proper tertiary structures and prevents secretion of not yet properly folded species. Folding facilitation mediated by the interaction of monoglucosylated glycoproteins and ER lectins is necessary for production of infective viral particles (vesicular stomatitis virus, HIV, hepatitis B virus) and also for the viability of yeasts when under severe ER stress conditions. The long term objective of the proposal is to gain thorough information of the structural features leading to the monoglucosylated glycoprotein-lectin interaction as this knowledge will undoubtedly provide useful information for understanding and/or preventing production of the etiological agents of several diseases. Within this long term objective, the Specific Aims of the proposed research are: a) to define the structural elements exclusively exposed in misfolded glycoproteins whose recognition is required for GTmediated glucosylation; b) to define GT domains responsible for substrate donor (UDP-
Studies
85
Glc), and substrate acceptor (N-oligosaccharide) recognition and for the exclusive glucosylation of misfolded species and c) to study the possibility that folding facilitation mediated by the interaction of cruzipain, a cysteine proteinase from the protozoan parasite Trypanosoma cruzi and ER lectins could be absolutely necessary for parasite infectivity. T. cruzi is the causative agent of a disease endemic in Latin America (Chagas's disease) that affects about 16 million people. Cruzipain has been identified as one of the T. cruzi virulence factors and has been found to be the only glycoprotein interacting with ER lectins in the protozoon. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIRAL INDUCED HCC?
ANTIGEN
GLYCOSYLATION--MARKER
FOR
HBV
Principal Investigator & Institution: Block, Timothy M.; Professor and Director; Biochem & Molecular Pharmacol; Thomas Jefferson University Office of Research Administration Philadelphia, Pa 191075587 Timing: Fiscal Year 2002; Project Start 01-APR-2002; Project End 31-MAR-2004 Summary: (provided by applicant): In this exploratory program we propose to test the hypothesis that oligosaccharides associated with serum proteins can accurately serve as biomarkers. Oligosaccharide profiles of hepatitis B surface antigens (HBsAg), purified from patient sera of different clinical populations, will be generated using novel HPLC sequencing technology that can reproducibly quantitate greater than 0.1 percent of an individual oligosaccharide in a glycan pool. Our sample population will consist of patients at risk for, or diagnosed with, hepatocellular carcinoma (HCC). The data generated will allow HBsAg oligosaccharides to be compared between different patient populations and the potential diagnostic value to be assessed. Alteration in the oligosaccharides associated with glycoproteins is one of the many molecular changes that accompany malignant transformations. In the case of HCC, an increase in fucosylation of secreted liver proteins is a common alteration. This increase in fucosylation has been postulated as a marker for HCC, however, the proteins of interest that show this alteration are typically found in low abundance (e.g. alpha fetoprotein). Our hypothesis is that, in cases where infection with hepatitis B virus (HBV) leads to the development of HCC, the viral glycoproteins (present up to mg/ml concentration) themselves may display aberrant oligosaccharides that could serve as early detection markers for HCC. Infection with HBV is the major etiology of HCC and, although HCC is a less common cancer in the USA, recent studies have shown that the incidence of HCC is rising both in the USA and worldwide. In addition, HCC is one of the most aggressive malignancies with prognosis being poor due to the late diagnosis. With the paucity of organ donors for liver transplantation and the small number of treatable patients (due to, in part, late diagnosis), early diagnosis will allow intervention at an earlier stage. We expect that this pilot study will firstly generate preliminary data to support the stated hypothesis; secondly, the study will allow the feasibility of a larger study to be determined, and thirdly, the parameters required to design a larger study to determine the value of oligosaccharide structures as potential markers of disease status will be obtained. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VIRUSES AND CANCER Principal Investigator & Institution: Courtney, Richard J.; Professor; Microbiology and Immunology; Pennsylvania State Univ Hershey Med Ctr 500 University Dr Hershey, Pa 17033
86
Hepatitis B
Timing: Fiscal Year 2001; Project Start 06-MAY-1994; Project End 31-MAR-2004 Summary: Defining the complex mechanisms of viral oncogenesis requires a broad understanding in at least three areas of research: molecular and cellular biology, immunology, and virology. It is the goal of the proposed training program to provide graduate students and postdoctoral fellows a challenging and enriched scientific environment in which both formal and informal training within these three broad, but interrelated areas can occur. The breadth of the scientific interests of the training faculty create a blend of research areas, many of which incorporate virus systems to dissect the molecular events that occur within the normal versus the cancer cell. The specific research programs include (a) molecular and cellular biology-regulation of cell growth and gene expression, oncogenes, signal transduction, and mechanisms of neoplastic transformation; (b) immunology-expression, oncogenes, signal transduction, and mechanisms of neoplastic transformation; (b) immunology; and (c) virology-molecular studies of virus replication, assembly, oncogenesis, pathogenesis, latency, and gene regulation using adeno, cytomegalo, hepatitis B, herpes simplex, papilloma, papova, and retroviruses. The trainers associated with the proposed training grant have their primary academic appointments within the Department of Microbiology and Immunology. However, each of the trainers is associated with multiple interdisciplinary graduate programs which cross departmental and college boundaries. Graduate students eligible for appointment on the training grant may be associated with one of several graduate programs including Chemical Biology, Cell and Molecular Biology, Genetics, Microbiology and Immunology, Molecular Medicine, and Neurosciences. The potential of the trainers to recruit students from such a variety of programs helps to insure that a significant pool of highly qualified students will be available for appointment to the training grant. The training program for graduate students and postdoctoral fellows includes a dynamic research environment that has excellent research and core support facilities and faculty research laboratories with productive and well funded research programs. The research and training environment is further enhanced by numerous interactions among the various laboratories as well as journal clubs, student seminars, and visiting scientist seminar programs. Finally, the research areas of emphasis within the training program provide a broad foundation on which a creative student and postdoctoral fellow can base a productive career in research in the area of citruses and cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VITAMIN A THERAPY IN PRETERM INFANTS: VACCINE RESPONSE Principal Investigator & Institution: Ballow, Mark; Professor of Pediatrics; Pediatrics; State University of New York at Buffalo Suite 211 Ub Commons Amherst, Ny 14228 Timing: Fiscal Year 2001; Project Start 15-SEP-1999; Project End 31-AUG-2003 Summary: The role of vitamin A as an immune modulatory factor has been the focus of many studies both in animals and man. Epidemiologic studies emphasize that vitamin A is essential for supporting the immune system against infection. Despite many therapeutic improvements in recent years, infection still remains a major problem in very low birth weight (VLBW) pre-term infants. Pre-term infants have lower plasma vitamin A (retinol) levels and limited hepatic reserves compared to full term infants. Vitamin A deficiency may lead to increased susceptibility to infection in pre-term infants. Hepatitis B immunization in the neonatal period offers an excellent opportunity to determine what effects vitamin A supplementation has in pre-term infants on their antibody immune response to this vaccine. VLBW pre-term infants less than 1500g (less
Studies
87
than 32 weeks gestation) will be randomized into two treatment groups: vitamin A supplemented and placebo (saline). The vitamin A treatment group will receive 2000 IU of retinyl palmitate by intramuscular injection starting on postnatal day 2 and thereafter on alternate days for 28 days. Plasma vitamin A levels will be closely monitored for toxicity. Plasma immunoglobulins and antibodies to HbsAg and tetanus toxoid will be quantified by ELISA after the second and third doses of hepatitis B vaccine. These results will be correlated with changes in CD4+ T-cell subsets as defined by their cytokine secretion profile and the proportion of naive (CD45RA) to memory (CD45R0) T-cells as analyzed by flow cytometry. Acceleration in the maturation of T-cells (naive to memory), and augmentation in the proportion of intracellular cytokine producing Tcells will provide a mechanism for the enhancement in the humoral immune responses to hepatitis B vaccine by vitamin A supplementation. Finally, the type and number of infections in the NICU and to 9 months of age will be recorded to determine if vitamin A supplementation affects the incidence and severity of infection in early infancy. Vitamin A supplementation may be useful in pre-term infants in augmenting B-cell immune responses to infectious agents and in their response to vaccines. These factors could lead to decreased morbidity and mortality of pre-term infants during early postnatal life. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: WOMEN DRUG USERS, THEIR MALE PARTNERS AND HIV RISK Principal Investigator & Institution: Tortu, Stephanie A.; Associate Professor; National Development & Res Institutes Research Institutes, Inc. New York, Ny 10010 Timing: Fiscal Year 2001; Project Start 15-DEC-1999; Project End 30-NOV-2003 Summary: In the US, the number of women drug users diagnosed with AIDS continues to increase, and levels of sexual risk behaviors remain high. Theoretical and empirical work has indicated that drug using women's relationships with male sex partners are focal points of risky sexual behavior and drug use. To inform HIV prevention efforts, there is a need to explore women's relationship with their main sexual partners, and determine how relationship factors affect HIV risk. Drug using women (primarily African-American and Puerto Rican) will be recruited from the streets of East Harlem. Those who report use of crack/cocaine, injected drugs, of 360 couples (n=720) will complete structured interviews. In addition to demographic and socioeconomic characteristics, drug use, and HIV risk behaviors, the interview will measure: 1) dyadic factors (e.g., characteristics of the relationship, drug use patterns, interpersonal processes); 2) individual attributes (e.g., history of physical/sexual abuse, psychological functioning, HIV serostatus); and 3) situation specific variables in most recent sex events. HIV, hepatitis B, and Hepatitis C testing and counseling will be offered. Multivariate statistical techniques will be used to determine the effects of dyadic factors, individual attributes, and their interaction on HIV risk behaviors. The prevalence of HIV, HBV, and HCV infections will be assessed, as will the couples will be compared in terms of drug use patterns, interpersonal processes, relationship satisfaction, and partner support. Results of this project will be used to develop interventions targeted at drug using couples to reduce HIV risk behaviors and assist those who are living with HIV. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
88
Hepatitis B
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “hepatitis B” (or synonyms) into the search box. This search gives you access to full-text articles. The following is a sample of items found for hepatitis B in the PubMed Central database: •
(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes. by Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR.; 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163151
•
2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. by Zoulim F, Dannaoui E, Borel C, Hantz O, Lin TS, Liu SH, Trepo C, Cheng YC.; 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163132
•
A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis. by Nassal M, Rieger A.; 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190133
•
A Defective Interference-Like Phenomenon of Human Hepatitis B Virus in Chronic Carriers. by Yuan TT, Lin MH, Chen DS, Shih C.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109410
•
A Dose Ranging Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of Lamivudine in Children and Adolescents with Chronic Hepatitis B. by Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson M, Barber J, Dallow N, Boxall E, Kelly D.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89731
•
A family cluster of an immune escape variant of hepatitis B virus infecting a mother and her two fully immunized children. by Ho MS, Lu CF, Kuo J, Mau YC, Chao WH.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=170234
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
89
•
A Frequent, Naturally Occurring Mutation (P130T) of Human Hepatitis B Virus Core Antigen Is Compensatory for Immature Secretion Phenotype of Another Frequent Variant (I97L). by Yuan TT, Shih C.; 2000 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112021
•
A Hepatitis B Virus Pre-S-Retinoic Acid Receptor [beta] Chimera Transforms Erythrocytic Progenitor Cells In vitro. by Garcia M, de The H, Tiollais P, Samarut J, Dejean A.; 1993 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45605
•
A host factor that binds near the termini of hepatitis B virus pregenomic RNA. by Perri S, Ganem D.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190725
•
A Metastable Form of the Large Envelope Protein of Duck Hepatitis B Virus: Low-pH Release Results in a Transition to a Hydrophobic, Potentially Fusogenic Conformation. by Grgacic EV, Schaller H.; 2000 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110864
•
A Modified Hepatitis B Virus Core Particle Containing Multiple Epitopes of the Plasmodium falciparum Circumsporozoite Protein Provides a Highly Immunogenic Malaria Vaccine in Preclinical Analyses in Rodent and Primate Hosts. by Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=133050
•
A Multicenter Study Evaluation of the Digene Hybrid Capture II Signal Amplification Technique for Detection of Hepatitis B Virus DNA in Serum Samples and Testing of EUROHEP Standards. by Niesters HG, Krajden M, Cork L, de Medina M, Hill M, Fries E, Osterhaus AD.; 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86750
•
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. by Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189390
•
A plant signal peptide --hepatitis B surface antigen fusion protein with enhanced stability and immunogenicity expressed in plant cells. by Sojikul P, Buehner N, Mason HS.; 2003 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151319
•
A Recombinant Measles Virus Expressing Hepatitis B Virus Surface Antigen Induces Humoral Immune Responses in Genetically Modified Mice. by Singh M, Cattaneo R, Billeter MA.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112525
•
A revised secondary structure model for the 3'-end of hepatitis B virus pregenomic RNA. by Kidd AH, Kidd-Ljunggren K.; 1996 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=146111
90
Hepatitis B
•
A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. by Bruss V.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230238
•
A Short N-Proximal Region in the Large Envelope Protein Harbors a Determinant That Contributes to the Species Specificity of Human Hepatitis B Virus. by Chouteau P, Le Seyec J, Cannie I, Nassal M, Guguen-Guillouzo C, Gripon P.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114743
•
A Short Sequence within Domain C of Duck Carboxypeptidase D Is Critical for Duck Hepatitis B Virus Binding and Determines Host Specificity. by Spangenberg HC, Lee HB, Li J, Tan F, Skidgel R, Wands JR, Tong S.; 2001 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114645
•
A Single Amino Acid in the Reverse Transcriptase Domain of Hepatitis B Virus Affects Virus Replication Efficiency. by Lin X, Yuan ZH, Wu L, Ding JP, Wen YM.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114769
•
A Small Molecule Inhibits and Misdirects Assembly of Hepatitis B Virus Capsids. by Zlotnick A, Ceres P, Singh S, Johnson JM.; 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136179
•
A t(3;8) chromosomal translocation associated with hepatitis B virus intergration involves the carboxypeptidase N locus. by Pineau P, Marchio A, Terris B, Mattei MG, Tu ZX, Tiollais P, Dejean A.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190789
•
A Trans-Activator Function is Generated by Integration of Hepatitis B Virus PreS/S Sequences in Human Hepatocellular Carcinoma DNA. by Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R.; 1990 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=53815
•
A Truncated Mutant (Residues 58-140) of the Hepatitis B Virus X Protein Retains Transactivation Function. by Kumar V, Jayasuryan N, Kumar R.; 1996 May 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39302
•
Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. by Lu X, Mehta A, Dadmarz M, Dwek R, Blumberg BS, Block TM.; 1997 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20096
•
Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. by Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J.; 1999 Jul 31; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=28181
•
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ Tcell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. by Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, Frosner G, Will H, Pape GR.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189048
Studies
91
•
Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. by Xu Z, Jensen G, Yen TS.; 1997 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=192084
•
Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database. by Soldan K, Ramsay M, Collins M.; 1999 Jan 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27683
•
Acute Hepatitis in Rats Expressing Human Hepatitis B Virus Transgenes. by Takahashi H, Fujimoto J, Hanada S, Isselbacher KJ.; 1995 Feb 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42541
•
Altered DNA Mutation Spectrum in Aflatoxin B1-Treated Transgenic Mice That Express the Hepatitis B Virus X Protein. by Madden CR, Finegold MJ, Slagle BL.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136763
•
Amplification of Full-Length Hepatitis B Virus Genomes from Samples from Patients with Low Levels of Viremia: Frequency and Functional Consequences of PCRIntroduced Mutations. by Gunther S, Sommer G, Von Breunig F, Iwanska A, Kalinina T, Sterneck M, Will H.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104572
•
An 80-Kilodalton Protein That Binds to the Pre-S1 Domain of Hepatitis B Virus. by Ryu CJ, Cho DY, Gripon P, Kim HS, Guguen-Guillouzo C, Hong HJ.; 2000 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111519
•
Analysis of Duck Hepatitis B Virus Reverse Transcription Indicates a Common Mechanism for the Two Template Switches during Plus-Strand DNA Synthesis. by Havert MB, Ji L, Loeb DD.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135997
•
Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro. by Diepolder HM, Jung MC, Wierenga E, Hoffmann RM, Zachoval R, Gerlach TJ, Scholz S, Heavner G, Riethmuller G, Pape GR.; 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190822
•
Antenatal Screening for Hepatitis B and Antibodies to Toxoplasma gondii and Rubella Virus: Evaluation of Two Commercial Immunoassay Systems. by Diepersloot RJ, Dunnewold-Hoekstra H, Kruit-den Hollander J, Vlaspolder F.; 2001 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=96143
•
Antigenic Diversity of Hepatitis B Virus Strains of Genotype F in Amerindians and Other Population Groups from Venezuela. by Blitz L, Pujol FH, Swenson PD, Porto L, Atencio R, Araujo M, Costa L, Monsalve DC, Torres JR, Fields HA, Lambert S, Van Geyt C, Norder H, Magnius LO, Echevarria JM, Stuyver L.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104602
•
Antigenicity and Immunogenicity of Novel Chimeric Hepatitis B Surface Antigen Particles with Exposed Hepatitis C Virus Epitopes. by Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ.; 2001 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114797
92
Hepatitis B
•
Anti-Hepatitis B Virus Activity and Metabolism of 2[prime prime or minute],3[prime prime or minute]-Dideoxy-2[prime prime or minute],3[prime prime or minute]Didehydro-[beta]-l([minus sign])-5-Fluorocytidine. by Zhu YL, Dutschman GE, Liu SH, Bridges EG, Cheng YC.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105687
•
Antiviral Activities of MCC-478, a Novel and Specific Inhibitor of Hepatitis B Virus. by Kamiya N, Kubota A, Iwase Y, Sekiya K, Ubasawa M, Yuasa S.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127398
•
Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection. by Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A, Tennant B, Korba B, Cote P, Marion P, Cretton-Scott E, Schinazi RF, Sommadossi JP.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90266
•
Assessment of Hepatitis B Virus DNA Stability in Serum by the Chiron Quantiplex Branched-DNA Assay. by Krajden M, Comanor L, Rifkin O, Grigoriew A, Minor JM, Kapke GF.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104546
•
Assessment of the COBAS Amplicor HBV Monitor Test for Quantitation of Serum Hepatitis B Virus DNA Levels. by Lopez VA, Bourne EJ, Lutz MW, Condreay LD.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130700
•
Automated Multiplex Assay System for Simultaneous Detection of Hepatitis B Virus DNA, Hepatitis C Virus RNA, and Human Immunodeficiency Virus Type 1 RNA. by Meng Q, Wong C, Rangachari A, Tamatsukuri S, Sasaki M, Fiss E, Cheng L, Ramankutty T, Clarke D, Yawata H, Sakakura Y, Hirose T, Impraim C.; 2001 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88264
•
Automated Quantitative Analysis of Hepatitis B Virus DNA by Using the Cobas Amplicor HBV Monitor Test. by Noborg U, Gusdal A, Pisa EK, Hedrum A, Lindh M.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85382
•
Avian Hepatitis B Virus Infection Is Initiated by the Interaction of a Distinct Pre-S Subdomain with the Cellular Receptor gp180. by Urban S, Breiner KM, Fehler F, Klingmuller U, Schaller H.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110146
•
Baculovirus Expression of Chimeric Hepatitis B Virus Core Particles with Hepatitis E Virus Epitopes and Their Use in a Hepatitis E Immunoassay. by Touze A, Enogat N, Buisson Y, Coursaget P.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84333
•
Carboxypeptidase D (gp180), a Golgi-Resident Protein, Functions in the Attachment and Entry of Avian Hepatitis B Viruses. by Breiner KM, Urban S, Schaller H.; 1998 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110147
•
Carboxypeptidase D Is an Avian Hepatitis B Virus Receptor. by Tong S, Li J, Wands JR.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112890
•
Carrier-Mediated Delivery of 9-(2-Phosphonylmethoxyethyl)Adenine to Parenchymal Liver Cells: a Novel Therapeutic Approach for Hepatitis B. by de Vrueh RL, Rump ET,
Studies
93
van de Bilt E, van Veghel R, Balzarini J, Biessen EA, van Berkel TJ, Bijsterbosch MK.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89714 •
CD8 + T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection. by Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140637
•
Cell Cycle Regulation of Nuclear Localization of Hepatitis B Virus Core Protein. by Yeh C, Wong SW, Fung Y, Ou J.; 1993 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46951
•
Cellular Receptor Traffic Is Essential for Productive Duck Hepatitis B Virus Infection. by Breiner KM, Schaller H.; 2000 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111701
•
Changes in the Antigenicity of a Hepatitis B Virus Mutant Stemming from Lamivudine Therapy. by Chen WN, Oon CJ.; 2000 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89956
•
Characteristics of Hepatitis B Virus Isolates of Genotype G and Their Phylogenetic Differences from the Other Six Genotypes (A through F). by Kato H, Orito E, Gish RG, Sugauchi F, Suzuki S, Ueda R, Miyakawa Y, Mizokami M.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136184
•
Characterization of a Conformational Epitope on Hepatitis B Virus Core Antigen and Quasiequivalent Variations in Antibody Binding. by Conway JF, Watts NR, Belnap DM, Cheng N, Stahl SJ, Wingfield PT, Steven AC.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155010
•
Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. by Townsend K, Sallberg M, O'Dea J, Banks T, Driver D, Sauter S, Chang SM, Jolly DJ, Mento SJ, Milich DR, Lee WT.; 1997 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191480
•
Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens. by Sallberg M, Townsend K, Chen M, O'Dea J, Banks T, Jolly DJ, Chang SM, Lee WT, Milich DR.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191766
•
Characterization of Novel Human Hepatoma Cell Lines with Stable Hepatitis B Virus Secretion for Evaluating New Compounds against Lamivudine- and PenciclovirResistant Virus. by Fu L, Cheng YC.; 2000 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90212
•
Characterization of Nuclear RNases That Cleave Hepatitis B Virus RNA near the La Protein Binding Site. by Heise T, Guidotti LG, Chisari FV.; 2001 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114415
•
Characterization of the Antiviral Effect of 2[prime prime or minute],3[prime prime or minute]-Dideoxy-2[prime prime or minute], 3[prime prime or minute]-Didehydro[beta]-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model. by Le
94
Hepatitis B
Guerhier F, Pichoud C, Guerret S, Chevallier M, Jamard C, Hantz O, Li XY, Chen SH, King I, Trepo C, Cheng YC, Zoulim F.; 2000 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89636 •
Characterization of Unusual Escape Variants of Hepatitis B Virus Isolated from a Hepatitis B Surface Antigen-Negative Subject. by Grethe S, Monazahian M, Bohme I, Thomssen R.; 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110046
•
Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions. by Chambers MA, Dougan G, Newman J, Brown F, Crowther J, Mould AP, Humphries MJ, Francis MJ, Clarke B, Brown AL, Rowlands D.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190284
•
Clinical and Virological Aspects of Blood Donors Infected with Hepatitis B Virus Genotypes B and C. by Kao JH, Chen PJ, Lai MY, Chen DS.; 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120125
•
Cloning and Characterization of a Novel Hepatitis B Virus x Binding Protein That Inhibits Viral Replication. by Melegari M, Scaglioni PP, Wands JR.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109461
•
Combinatorial Screening and Intracellular Antiviral Activity of Hairpin Ribozymes Directed against Hepatitis B Virus. by zu Putlitz J, Yu Q, Burke JM, Wands JR.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112594
•
Comparative Evaluation of Semiautomated COBAS AMPLICOR Hepatitis B Virus (HBV) MONITOR Test and Manual Microwell Plate-Based AMPLICOR HBV MONITOR Test. by Marin IJ, Poljak M, Seme K, Meglic-Volkar J, Maticic M, Lesnicar G, Brinovec V.; 2001 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87814
•
Comparison of a Chemiluminescent Immunoassay with Two Microparticle Enzyme Immunoassays for Detection of Hepatitis B Virus Surface Antigen. by Diepersloot RJ, van Zantvliet-van Oostrom Y, Gleaves CA.; 2000 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95975
•
Comparison of Anti-Hepatitis B Virus Activities of Lamivudine and Clevudine by a Quantitative Assay. by Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Cable EE, Isom HC.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=148955
•
Comparison of hepatitis B virus DNA extractions from serum by the QIAamp blood kit, GeneReleaser, and the phenol-chloroform method. by Kramvis A, Bukofzer S, Kew MC.; 1996 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229395
•
Comparison of methods for extraction of nucleic acid from hemolytic serum for PCR amplification of hepatitis B virus DNA sequences. by Klein A, Barsuk R, Dagan S, Nusbaum O, Shouval D, Galun E.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229868
•
Comparison of Sequence Analysis and the INNO-LiPA HBV DR Line Probe Assay for Detection of Lamivudine-Resistant Hepatitis B Virus Strains in Patients under
Studies
95
Various Clinical Conditions. by Aberle SW, Kletzmayr J, Watschinger B, Schmied B, Vetter N, Puchhammer-Stockl E.; 2001 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88061 •
Comparison of the Second-Generation Digene Hybrid Capture Assay with the Branched-DNA Assay for Measurement of Hepatitis B Virus DNA in Serum. by Ho SK, Chan TM, Cheng IK, Lai KN.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85256
•
Comparison of Three Different Sensitive Assays for Hepatitis B Virus DNA in Monitoring of Responses to Antiviral Therapy. by Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87356
•
Concentrations of Cytokines, Soluble Interleukin-2 Receptor, and Soluble CD30 in Sera of Patients with Hepatitis B Virus Infection during Acute and Convalescent Phases. by Monsalve-de Castillo F, Romero TA, Estevez J, Costa LL, Atencio R, Porto L, Callejas D.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130099
•
Core Protein Phosphorylation Modulates Pregenomic RNA Encapsidation to Different Extents in Human and Duck Hepatitis B Viruses. by Gazina EV, Fielding JE, Lin B, Anderson DA.; 2000 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111994
•
CpG Oligodeoxynucleotides with Hepatitis B Surface Antigen (HBsAg) for Vaccination in HBsAg-Transgenic Mice. by Malanchere-Bres E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML.; 2001 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114371
•
Critical Roles of Nuclear Receptor Response Elements in Replication of Hepatitis B Virus. by Yu X, Mertz JE.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114721
•
Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. by Delaney WE IV, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, Isom HC, Bock CT, Manns MP, Trautwein C, Locarnini S.; 2001 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90535
•
Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures. by Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137053
•
Cytotoxic T Lymphocytes Inhibit Hepatitis B Virus Gene Expression by a Noncytolytic Mechanism in Transgenic Mice. by Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV.; 1994 Apr 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43662
•
DDB2 Induces Nuclear Accumulation of the Hepatitis B Virus X Protein Independently of Binding to DDB1. by Nag A, Datta A, Yoo K, Bhattacharyya D, Chakrabortty A, Wang X, Slagle BL, Costa RH, Raychaudhuri P.; 2001 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114612
96
Hepatitis B
•
Degenerate Immunogenicity of an HLA-A2-Restricted Hepatitis B Virus Nucleocapsid Cytotoxic T-Lymphocyte Epitope That Is Also Presented by HLA-B51. by Thimme R, Chang KM, Pemberton J, Sette A, Chisari FV.; 2001 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114890
•
Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes. by Sitia G, Isogawa M, Kakimi K, Wieland SF, Chisari FV, Guidotti LG.; 2002 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129753
•
Detection and Sequence Analysis of Hepatitis B Virus Integration in Peripheral Blood Mononuclear Cells. by Laskus T, Radkowski M, Wang LF, Nowicki M, Rakela J.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103945
•
Detection of Duck Hepatitis B Virus DNA on Filter Paper by PCR and SYBR Green Dye-Based Quantitative PCR. by Wang CY, Giambrone JJ, Smith BF.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120600
•
Detection of Hepatitis B Virus DNA in Sera from Patients with Chronic Hepatitis B Virus Infection by DNA Microarray Method. by Kawaguchi K, Kaneko S, Honda M, Kawai HF, Shirota Y, Kobayashi K.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153866
•
Detection of Hepatitis B Virus Infection in Wild-Born Chimpanzees (Pan troglodytes verus): Phylogenetic Relationships with Human and Other Primate Genotypes. by MacDonald DM, Holmes EC, Lewis JC, Simmonds P.; 2000 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111941
•
Development and comparison of procedures for the selection of delta ribozyme cleavage sites within the hepatitis B virus. by Bergeron LJ, Perreault JP.; 2002 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135815
•
Development of a Quantitative Real-Time Detection Assay for Hepatitis B Virus DNA and Comparison with Two Commercial Assays. by Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87141
•
Different Levels of T-Cell Receptor Triggering Induce Distinct Functions in Hepatitis B and Hepatitis C Virus-Specific Human CD4 + T-Cell Clones. by Diepolder HM, Gruener NH, Gerlach JT, Jung MC, Wierenga EA, Pape GR.; 2001 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115022
•
Different Regions of Hepatitis B Virus X Protein Are Required for Enhancement of bZip-Mediated Transactivation versus Transrepression. by Barnabas S, Andrisani OM.; 2000 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111516
•
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. by Rehermann B, Chang KM, McHutchinson J, Kokka R, Houghton M, Rice CM, Chisari FV.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190761
•
Differential Regulation of Hepatitis B Virus Gene Expression by the Sp1 Transcription Factor. by Li J, Ou JH.; 2001 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115085
Studies
97
•
Differential regulation of the pre-C and pregenomic promoters of human hepatitis B virus by members of the nuclear receptor superfamily. by Yu X, Mertz JE.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230240
•
Direct Association and Nuclear Import of the Hepatitis B Virus X Protein with the NF-[kappa]B Inhibitor I[kappa]B[alpha]. by Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C, Brechot C, Israel A.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84605
•
Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. by Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA.; 1995 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=188796
•
Discontinuous Epitopes of Hepatitis B Surface Antigen Derived from a Filamentous Phage Peptide Library. by Chen YJ, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W.; 1996 Mar 5; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39898
•
Distinct Modes of Regulation of Transcription of Hepatitis B Virus by the Nuclear Receptors HNF4[alpha] and COUP-TF1. by Yu X, Mertz JE.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=141100
•
Distribution of Hepatitis B Virus Genotypes among American Blood Donors Determined with a PreS2 Epitope Enzyme-Linked Immunosorbent Assay Kit. by Moriya T, Kuramoto IK, Yoshizawa H, Holland PV.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120221
•
Distribution of Hepatitis B Virus Genotypes in Two Different Pediatric Populations from Argentina. by Mbayed VA, Lopez JL, Telenta PF, Palacios G, Badia I, Ferro A, Galoppo C, Campos R.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105331
•
DNA Vaccine for Hepatitis B: Evidence for Immunogenicity in Chimpanzees and Comparison with Other Vaccines. by Davis HL, McCluskie MJ, Gerin JL, Purcell RH.; 1996 Jul 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38962
•
DNA-Mediated Immunization in a Transgenic Mouse Model of the Hepatitis B Surface Antigen Chronic Carrier State. by Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel M.; 1996 Oct 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38020
•
DNA-Mediated Immunization to the Hepatitis B Surface Antigen in Mice: Aspects of the Humoral Response Mimic Hepatitis B Viral Infection in Humans. by Michel M, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen RG.; 1995 Jun 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41683
98
Hepatitis B
•
dNTP versus NTP discrimination by phenylalanine 451 in duck hepatitis B virus P protein indicates a common structure of the dNTP-binding pocket with other reverse transcriptases. by Beck J, Vogel M, Nassal M.; 2002 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101827
•
Dose Range Study of Pharmacokinetics, Safety, and Preliminary Antiviral Activity of Emtricitabine in Adults with Hepatitis B Virus Infection. by Gish RG, Leung NW, Wright TL, Trinh H, Lang W, Kessler HA, Fang L, Wang LH, Delehanty J, Rigney A, Mondou E, Snow A, Rousseau F.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127249
•
Double-Stranded Linear Duck Hepatitis B Virus (DHBV) Stably Integrates at a Higher Frequency than Wild-Type DHBV in LMH Chicken Hepatoma Cells. by Gong SS, Jensen AD, Chang CJ, Rogler CE.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103974
•
Duck Hepatitis B Virus Expresses a Regulatory HBx-Like Protein from a Hidden Open Reading Frame. by Chang SF, Netter HJ, Hildt E, Schuster R, Schaefer S, Hsu YC, Rang A, Will H.; 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113909
•
Duck Hepatitis B Virus Nucleocapsids Formed by N-Terminally Extended or CTerminally Truncated Core Proteins Disintegrate during Viral DNA Maturation. by Kock J, Wieland S, Blum HE, von Weizsacker F.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110329
•
Duck Hepatitis B Virus Replication in Primary Bile Duct Epithelial Cells. by Lee JY, Culvenor JG, Angus P, Smallwood R, Nicoll A, Locarnini S.; 2001 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115000
•
Effect of Multiple Freeze-Thaw Cycles on Hepatitis B Virus DNA and Hepatitis C Virus RNA Quantification as Measured with Branched-DNA Technology. by Krajden M, Minor JM, Rifkin O, Comanor L.; 1999 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84922
•
Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. by Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190601
•
Effects of Genomic Length on Translocation of Hepatitis B Virus Polymerase-Linked Oligomer. by Ho TC, Jeng KS, Hu CP, Chang C.; 2000 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102097
•
Effects of mutations within and adjacent to the terminal repeats of hepatitis B virus pregenomic RNA on viral DNA synthesis. by Perri S, Ganem D.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=192307
•
Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model. by Seigneres B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trepo C, Zoulim F.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155836
Studies
99
•
Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro. by Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, Colonno RJ.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127388
•
Efficacy of the Carbocyclic 2[prime prime or minute]-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection. by Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, Colonno RJ, Standring DN, Clark JM.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106024
•
Efficient Extraction of Virus DNA by NucliSens Extractor Allows Sensitive Detection of Hepatitis B Virus by PCR. by Gobbers E, Oosterlaken TA, van Bussel MJ, Melsert R, Kroes AC, Claas EC.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88546
•
Efficient Infection of Primary Tupaia Hepatocytes with Purified Human and Woolly Monkey Hepatitis B Virus. by Kock J, Nassal M, MacNelly S, Baumert TF, Blum HE, von Weizsacker F.; 2001 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114913
•
Elimination of Duck Hepatitis B Virus RNA-Containing Capsids in Duck InterferonAlpha-Treated Hepatocytes. by Schultz U, Summers J, Staeheli P, Chisari FV.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112602
•
Enhancement of Hepatitis B Virus Infection by Noninfectious Subviral Particles. by Bruns M, Miska S, Chassot S, Will H.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124627
•
Enhancement of Hepatitis B Virus Replication by Its X Protein in Transgenic Mice. by Xu Z, Yen TS, Wu L, Madden CR, Tan W, Slagle BL, Ou JH.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153824
•
Enrichment of a Precore-Minus Mutant of Duck Hepatitis B Virus in Experimental Mixed Infections. by Zhang YY, Summers J.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104136
•
Envelope Protein-Mediated Down-Regulation of Hepatitis B Virus Receptor in Infected Hepatocytes. by Breiner KM, Urban S, Glass B, Schaller H.; 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113907
•
Epidemiology of Hepatitis B, C, E, and G Virus Infections and Molecular Analysis of Hepatitis G Virus Isolates in Bolivia. by Konomi N, Miyoshi C, La Fuente Zerain C, Li TC, Arakawa Y, Abe K.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85549
•
Epidermal Powder Immunization Induces both Cytotoxic T-Lymphocyte and Antibody Responses to Protein Antigens of Influenza and Hepatitis B Viruses. by Chen D, Weis KF, Chu Q, Erickson C, Endres R, Lively CR, Osorio J, Payne LG.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114750
•
European Proficiency Testing Program for Molecular Detection and Quantitation of Hepatitis B Virus DNA. by Valentine-Thon E, van Loon AM, Schirm J, Reid J, Klapper PE, Cleator GM.; 2001 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88557
100 Hepatitis B
•
Evaluation of a New Rapid Test for the Combined Detection of Hepatitis B Virus Surface Antigen and Hepatitis B Virus e Antigen. by Clement F, Dewint P, LerouxRoels G.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154615
•
Evaluation of enzyme immunoassay for hepatitis B virus DNA based on anti-doublestranded DNA. by Garcia F Jr, Garcia F, Bernal MC, Leyva A, Piedrola G, Maroto MC.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=227958
•
Evaluation of immunochromatographic assay systems for rapid detection of hepatitis B surface antigen and antibody, Dainascreen HBsAg and Dainascreen Ausab. by Sato K, Ichiyama S, Iinuma Y, Nada T, Shimokata K, Nakashima N.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229035
•
Evaluation of Quantitative PCR and Branched-Chain DNA Assay for Detection of Hepatitis B Virus DNA in Sera from Hepatocellular Carcinoma and Liver Transplant Patients. by Chen T, Luk JM, Cheung ST, Yu WC, Fan ST.; 2000 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86641
•
Evaluation of SHARP signal system for enzymatic detection of amplified hepatitis B virus DNA. by Valentine-Thon E.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=227970
•
Evaluation of Two New Automated Assays for Hepatitis B Virus Surface Antigen (HBsAg) Detection: IMMULITE HBsAg and IMMULITE 2000 HBsAg. by Weber B, Dengler T, Berger A, Doerr HW, Rabenau H.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149549
•
Evidence for Increased in vitro Recombination with Insertion of Human Hepatitis B Virus DNA. by Hino O, Tabata S, Hotta Y.; 1991 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52691
•
Evidence that the 5[prime prime or minute]-End Cap Structure Is Essential for Encapsidation of Hepatitis B Virus Pregenomic RNA. by Jeong JK, Yoon GS, Ryu WS.; 2000 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112035
•
Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates. by Gong Y, Yao E, Tavis JE.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=37354
•
Export of hepatitis B virus RNA on a Rev-like pathway: inhibition by the regenerating liver inhibitory factor IkappaB alpha. by Roth J, Dobbelstein M.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=192368
•
Expression of Functional Hepatitis B Virus Polymerase in Yeast Reveals it to be the Sole Viral Protein Required for Correct Initiation of Reverse Transcription. by Tavis JE, Ganem D.; 1993 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46455
Studies
101
•
Expression of Hepatitis B Virus X Protein Does Not Alter the Accumulation of Spontaneous Mutations in Transgenic Mice. by Madden CR, Finegold MJ, Slagle BL.; 2000 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110881
•
Expression of the Terminal Protein Region of Hepatitis B Virus Inhibits Cellular Responses to Interferons [alpha] and [gamma] and Double-Stranded RNA. by Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR.; 1991 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51345
•
Extensive Mutagenesis of the Hepatitis B Virus Core Gene and Mapping of Mutations That Allow Capsid Formation. by Koschel M, Thomssen R, Bruss V.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104460
•
Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. by Budkowska A, Bedossa P, Groh F, Louise A, Pillot J.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=188650
•
Formation of a Functional Hepatitis B Virus Replication Initiation Complex Involves a Major Structural Alteration in the RNA Template. by Beck J, Nassal M.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109213
•
Functional Analysis of a Liver-Specific Enhancer of the Hepatitis B Virus. by Trujillo MA, Letovsky J, Maguire HF, Lopez-Cabrera M, Siddiqui A.; 1991 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51540
•
Functional Characterization of Naturally Occurring Variants of Human Hepatitis B Virus Containing the Core Internal Deletion Mutation. by Yuan TT, Lin MH, Qiu SM, Shih C.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109512
•
Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. by Alcantara FF, Tang H, McLachlan A.; 2002 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113846
•
Functions of the internal pre-S domain of the large surface protein in hepatitis B virus particle morphogenesis. by Bruss V, Vieluf K.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189574
•
Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'thiacytidine] in vitro. by Fischer KP, Tyrrell DL.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163451
•
Generation of Replication-Competent Hepatitis B Virus Nucleocapsids in Insect Cells. by Seifer M, Hamatake R, Bifano M, Standring DN.; 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109721
102 Hepatitis B
•
Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. by Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155849
•
Genetic Immunization of BALB/c mice with a Plasmid Bearing the Gene Coding for a Hybrid Merozoite Surface Protein 1-Hepatitis B Virus Surface Protein Fusion Protects Mice against Lethal Plasmodium chabaudi chabaudi PC1 Infection. by Wunderlich G, Moura IC, del Portillo HA.; 2000 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101545
•
Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection. by Kao JH, Chen PJ, Lai MY, Chen DS.; 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140384
•
Glucagon Treatment Interferes with an Early Step of Duck Hepatitis B Virus Infection. by Hild M, Weber O, Schaller H.; 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109694
•
Half-Life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool In Vivo following Inhibition of Viral Replication. by Addison WR, Walters KA, Wong WW, Wilson JS, Madej D, Jewell LD, Tyrrell DL.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136192
•
Hepatitis B immunisation in renal units in the United Kingdom: questionnaire study. by Ray S, Samuel T, Hawker J, Smith S.; 2002 Apr 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=101399
•
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients. by Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combernoux A, Morlat P, Le Moing V, Riviere C, Chene G, Leport C.; 2000 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90223
•
Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: Evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. by Mehta A, Lu X, Block TM, Blumberg BS, Dwek RA.; 1997 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20001
•
Hepatitis B Virus (HBV) Mutations Associated with Resistance to Lamivudine in Patients Coinfected with HBV and Human Immunodeficiency Virus. by Thibault V, Benhamou Y, Seguret C, Bochet M, Katlama C, Bricaire F, Opolon P, Poynard T, Agut H.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85438
•
Hepatitis B Virus (HBV) Virion and Covalently Closed Circular DNA Formation in Primary Tupaia Hepatocytes and Human Hepatoma Cell Lines upon HBV Genome Transduction with Replication-Defective Adenovirus Vectors. by Ren S, Nassal M.; 2001 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114016
•
Hepatitis B Virus Biology. by Seeger C, Mason WS.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=98986
Studies
103
•
Hepatitis B Virus Capsid Particles are Assembled from Core-Protein Dimer Precursors. by Zhou S, Standring DN.; 1992 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50274
•
Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model. by Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sallberg M, Leroux-Roels G.; 2001 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114358
•
Hepatitis B Virus Core Gene Mutations Which Block Nucleocapsid Envelopment. by Koschel M, Oed D, Gerelsaikhan T, Thomssen R, Bruss V.; 2000 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111506
•
Hepatitis B Virus DNA in Blood Samples Positive for Antibodies to Core Antigen and Negative for Surface Antigen. by Gutierrez C, Leon G, Loureiro CL, Uzcategui N, Liprandi F, Pujol FH.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95771
•
Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. by Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ.; 2003 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150268
•
Hepatitis B Virus HBx Protein Activates Ras-GTP Complex Formation and Establishes a Ras, Raf, MAP Kinase Signaling Cascade. by Benn J, Schneider RJ.; 1994 Oct 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45017
•
Hepatitis B virus HBx protein activates transcription factor NF-kappaB by acting on multiple cytoplasmic inhibitors of rel-related proteins. by Su F, Schneider RJ.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190392
•
Hepatitis B Virus HBx Protein Activation of Cyclin A --Cyclin-Dependent Kinase 2 Complexes and G1 Transit via a Src Kinase Pathway. by Bouchard M, Giannakopoulos S, Wang EH, Tanese N, Schneider RJ.; 2001 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114170
•
Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. by Benn J, Su F, Doria M, Schneider RJ.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190451
•
Hepatitis B virus infected physicians and disclosure of transmission risks to patients: A critical analysis. by Barrigar DL, Flagel DC, Upshur RE.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59900
•
Hepatitis B Virus Large Envelope Protein Interacts with [gamma]2-Adaptin, a Clathrin Adaptor-Related Protein. by Hartmann-Stuhler C, Prange R.; 2001 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114939
•
Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. by Gerelsaikhan T, Tavis JE, Bruss V.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190358
104 Hepatitis B
•
Hepatitis B Virus of Genotype B with or without Recombination with Genotype C over the Precore Region plus the Core Gene. by Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Ueda R, Miyakawa Y, Mizokami M.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136227
•
Hepatitis B Virus pX Targets TFIIB in Transcription Coactivation. by Haviv I, Shamay M, Doitsh G, Shaul Y.; 1998 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108871
•
Hepatitis B virus replication is cell cycle independent during liver regeneration in transgenic mice. by Guidotti LG, Matzke B, Chisari FV.; 1997 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191703
•
Hepatitis B Virus RNA-Binding Proteins Associated with Cytokine-Induced Clearance of Viral RNA from the Liver of Transgenic Mice. by Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103854
•
Hepatitis B Virus Surface Antigen (HBsAg) Mutants in Singapore Adults and Vaccinated Children with High Anti-Hepatitis B Virus Antibody Levels but Negative for HBsAg. by Chen WN.; 2000 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87037
•
Hepatitis B Virus Transactivator Protein, HBx, Associates with the Components of TFIIH and Stimulates the DNA Helicase Activity of TFIIH. by Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A.; 1996 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38195
•
Hepatitis B Virus X Protein Acts as a Tumor Promoter in Development of Diethylnitrosamine-Induced Preneoplastic Lesions. by Madden CR, Finegold MJ, Slagle BL.; 2001 Apr 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114876
•
Hepatitis B Virus X Protein and Simian Virus 5 V Protein Exhibit Similar UV-DDB1 Binding Properties To Mediate Distinct Activities. by Leupin O, Bontron S, Strubin M.; 2003 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154990
•
Hepatitis B Virus X Protein Colocalizes to Mitochondria with a Human VoltageDependent Anion Channel, HVDAC3, and Alters Its Transmembrane Potential. by Rahmani Z, Huh KW, Lasher R, Siddiqui A.; 2000 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111774
•
Hepatitis B virus X protein induces RNA polymerase III-dependent gene transcription and increases cellular TATA-binding protein by activating the Ras signaling pathway. by Wang HD, Trivedi A, Johnson DL.; 1997 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=232540
•
Hepatitis B Virus X Protein Interferes with Cellular DNA Repair. by Becker SA, Lee TH, Butel JS, Slagle BL.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109372
Studies
105
•
Hepatitis B Virus X Protein Is both a Substrate and a Potential Inhibitor of the Proteasome Complex. by Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104247
•
Hepatitis B virus, the vaccine, and the control of primary cancer of the liver. by Blumberg BS.; 1997 Jul 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=33676
•
Hepatitis B Virus-Mediated Changes of Apolipoprotein mRNA Abundance in Cultured Hepatoma Cells. by Norton PA, Gong Q, Mehta AS, Lu X, Block TM.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153946
•
Hepatitis D Virus Genotypes in Intravenous Drug Users in Taiwan: Decreasing Prevalence and Lack of Correlation with Hepatitis B Virus Genotypes. by Kao JH, Chen PJ, Lai MY, Chen DS.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120675
•
Hepatocyte Nuclear Factor 3[beta] Inhibits Hepatitis B Virus Replication In Vivo. by Banks KE, Anderson AL, Tang H, Hughes DE, Costa RH, McLachlan A.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136732
•
High-level hepatitis B virus replication in transgenic mice. by Guidotti LG, Matzke B, Schaller H, Chisari FV.; 1995 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189513
•
HLA Class I-Restricted Human Cytotoxic T Cells Recognize Endogenously Synthesized Hepatitis B Virus Nucleocapsid Antigen. by Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, schlicht HJ, Fowler P, Guilhot S, Chisari FV.; 1991 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52945
•
Horizontal Transmission of a Hepatitis B Virus Surface Antigen Mutant. by Chen WN, Oon CJ, Koh S.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86257
•
Host Cell-Virus Cross Talk: Phosphorylation of a Hepatitis B Virus Envelope Protein Mediates Intracellular Signaling. by Rothmann K, Schnolzer M, Radziwill G, Hildt E, Moelling K, Schaller H.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110552
•
Hsp90 is Required for the Activity of a Hepatitis B Virus Reverse Transcriptase. by Hu J, Seeger C.; 1996 Feb 6; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40030
•
Human Hepatitis B Virus Polymerase Interacts with the Molecular Chaperonin Hsp60. by Park SG, Jung G.; 2001 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114424
106 Hepatitis B
•
Human Immunodeficiency Virus (HIV) Type 1 Reverse Transcriptase Resistance Mutations in Hepatitis B Virus (HBV)-HIV-Coinfected Patients Treated for HBV Chronic Infection Once Daily with 10 Milligrams of Adefovir Dipivoxil Combined with Lamivudine. by Delaugerre C, Marcelin AG, Thibault V, Peytavin G, Bombled T, Bochet MV, Katlama C, Benhamou Y, Calvez V.; 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127167
•
Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection. by Yang PL, Althage A, Chung J, Chisari FV.; 2002 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=129782
•
Identification of a Hepatitis B Virus Genome in Wild Chimpanzees (Pan troglodytes schweinfurthi) from East Africa Indicates a Wide Geographical Dispersion among Equatorial African Primates. by Vartanian JP, Pineau P, Henry M, Hamilton WD, Muller MN, Wrangham RW, Wain-Hobson S.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136620
•
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. by Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163937
•
Identification of Different States of Hepatitis B Virus Infection with a Quantitative PCR Assay. by Kessler HH, Preininger S, Stelzl E, Daghofer E, Santner BI, Marth E, Lackner H, Stauber RE.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95865
•
Identification of hepatitis B virus indigenous to chimpanzees. by Hu X, Margolis HS, Purcell RH, Ebert J, Robertson BH.; 2000 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26492
•
Identification of Multiple Transcription Factors, HLF, FTF, and E4BP4, Controlling Hepatitis B Virus Enhancer II. by Ishida H, Ueda K, Ohkawa K, Kanazawa Y, Hosui A, Nakanishi F, Mita E, Kasahara A, Sasaki Y, Hori M, Hayashi N.; 2000 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111458
•
Identification of SRPK1 and SRPK2 as the Major Cellular Protein Kinases Phosphorylating Hepatitis B Virus Core Protein. by Daub H, Blencke S, Habenberger P, Kurtenbach A, Dennenmoser J, Wissing J, Ullrich A, Cotten M.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155132
•
Immunisation of infants at risk of perinatal transmission of hepatitis B: retrospective audit of vaccine uptake. by Wallis DE, Boxall EH.; 1999 Apr 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27844
•
Immunogenicity and Tolerogenicity of Hepatitis B Virus Structural and Nonstructural Proteins: Implications for Immunotherapy of Persistent Viral Infections. by Kakimi K, Isogawa M, Chung J, Sette A, Chisari FV.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136410
•
Impact of Hepatitis B and Hepatitis C Virus Infections in a Hematology-Oncology Unit at a Children's Hospital in Nicaragua, 1997 to 1999. by Visona K, Baez F, Taylor L, Berrios R, Leon B, Pacheco C, Jiron R, Luftig RB, Somarriba MM.; 2002 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=119972
Studies
107
•
Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women. by Dawar M, Patrick DM, Bigham M, Cook D, Krajden M, Ng H.; 2003 Mar 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154915
•
Improved Detection of Hepatitis B Virus Surface Antigen by a New Rapid Automated Assay. by Weber B, Bayer A, Kirch P, Schluter V, Schlieper D, Melchior W.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85302
•
Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. by Chow YH, Huang WL, Chi WK, Chu YD, Tao MH.; 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191037
•
In Vitro Reconstitution of a Functional Duck Hepatitis B Virus Reverse Transcriptase: Posttranslational Activation by Hsp90. by Hu J, Anselmo D.; 2000 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112423
•
In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to ([minus sign])-[beta]-d-2,6-Diaminopurine Dioxolane and 2[prime prime or minute]-Fluoro-5Methyl-[beta]-l-Arabinofuranosyluracil. by Chin R, Shaw T, Torresi J, Sozzi V, Trautwein C, Bock T, Manns M, Isom H, Furman P, Locarnini S.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=90683
•
In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation. by Billet O, Grimber G, Levrero M, Seye KA, Briand P, Joulin V.; 1995 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189474
•
In Vivo Inhibition of Anti-Hepatitis B Virus Core Antigen (HBcAg) Immunoglobulin G Production by HBcAg-Specific CD4 + Th1-Type T-Cell Clones in a hu-PBLNOD/SCID Mouse Model. by Cao T, Meuleman P, Desombere I, Sallberg M, LerouxRoels G.; 2001 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114731
•
In Vivo Regulation of Hepatitis B Virus Replication by Peroxisome Proliferators. by Guidotti LG, Eggers CM, Raney AK, Chi SY, Peters JM, Gonzalez FJ, McLachlan A.; 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113093
•
Increased prevalence of genotype F hepatitis B virus isolates in Buenos Aires, Argentina. by Telenta PF, Poggio GP, Lopez JL, Gonzalez J, Lemberg A, Campos RH.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229861
•
Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. by Ladner SK, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeger C, King RW.; 1997 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163991
108 Hepatitis B
•
Infection of a human hepatoma cell line by hepatitis B virus. by Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, GuguenGuillouzo C.; 2002 Nov 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137772
•
Infection of Ducklings with Virus Particles Containing Linear Double-Stranded Duck Hepatitis B Virus DNA: Illegitimate Replication and Reversion. by Yang W, Summers J.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110285
•
Infection Process of the Hepatitis B Virus Depends on the Presence of a Defined Sequence in the Pre-S1 Domain. by Le Seyec J, Chouteau P, Cannie I, GuguenGuillouzo C, Gripon P.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104448
•
Influence of a Putative Intermolecular Interaction between Core and the Pre-S1 Domain of the Large Envelope Protein on Hepatitis B Virus Secretion. by Le Pogam S, Shih C.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136289
•
Inhibition of Duck Hepatitis B Virus Replication by 9-(2Phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue. by Nicoll AJ, Colledge DL, Toole JJ, Angus PW, Smallwood RA, Locarnini SA.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106011
•
Inhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2by Ojwang JO, fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidine. Bhattacharya BK, Marshall HB, Korba BE, Revankar GR, Rando RF.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162987
•
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-Larabinofuranosyl uracil. by Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC.; 1996 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163120
•
Inhibition of Hepatitis B Virus Replication by Interferon Requires Proteasome Activity[dagger]. by Robek MD, Wieland SF, Chisari FV.; 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136040
•
Inhibition of Hepatitis B Virus Replication by the Interferon-Inducible MxA Protein. by Gordien E, Rosmorduc O, Peltekian C, Garreau F, Brechot C, Kremsdorf D.; 2001 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115893
•
Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice. by Cavanaugh VJ, Guidotti LG, Chisari FV.; 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109701
•
Inhibition of Human Hepatitis B Virus Replication by AT-61, a Phenylpropenamide Derivative, Alone and in Combination with ([minus sign])[beta]-l-2[prime prime or minute],3[prime prime or minute]-Dideoxy-3[prime prime or minute]-Thiacytidine. by King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=106020
Studies
109
•
Inhibition of replication of hepatitis B virus by cytallene in vitro. by Zhu YL, Pai SB, Liu SH, Grove KL, Jones BC, Simons C, Zemlicka J, Cheng YC.; 1997 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163999
•
Inhibition of the Replication of Hepatitis B Virus in vitro by 2',3'-Dideoxy-3'Thiacytidine and Related Analogues. by Doong S, Tsai C, Schinazi RF, Liotta DC, Cheng Y.; 1991 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52535
•
Inhibitory Effect of 2[prime prime or minute]-Fluoro-5-Methyl-[beta]-lArabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication. by Aguesse-Germon S, Liu SH, Chevallier M, Pichoud C, Jamard C, Borel C, Chu CK, Trepo C, Cheng YC, Zoulim F.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105416
•
Inhibitory Effect of Adefovir on Viral DNA Synthesis and Covalently Closed Circular DNA Formation in Duck Hepatitis B Virus-Infected Hepatocytes In Vivo and In Vitro. by Delmas J, Schorr O, Jamard C, Gibbs C, Trepo C, Hantz O, Zoulim F.; 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127044
•
Insertions within the hepatitis B virus capsid protein influence capsid formation and RNA encapsidation. by Beames B, Lanford RE.; 1995 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189596
•
Integrated Hepatitis B Virus DNA Preserves the Binding Sequence of Transcription Factor Yin and Yang 1 at the Virus-Cell Junction. by Nakanishi-Matsui M, Hayashi Y, Kitamura Y, Koike K.; 2000 Jun 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112043
•
Interaction between Hepatitis B Virus Core Protein and Reverse Transcriptase. by Lott L, Beames B, Notvall L, Lanford RE.; 2000 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112427
•
Interaction between STAT-3 and HNF-3 Leads to the Activation of Liver-Specific Hepatitis B Virus Enhancer 1 Function. by Waris G, Siddiqui A.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135980
•
Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer. by Blake M, Niklinski J, Zajac-Kaye M.; 1996 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190627
•
Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. by Protzer U, Nassal M, Chiang PW, Kirschfink M, Schaller H.; 1999 Sep 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=17966
•
Interferon-Regulated Pathways That Control Hepatitis B Virus Replication in Transgenic Mice. by Guidotti LG, Morris A, Mendez H, Koch R, Silverman RH, Williams BR, Chisari FV.; 2002 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135990
110 Hepatitis B
•
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. by Cavanaugh VJ, Guidotti LG, Chisari FV.; 1997 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191456
•
Interleukin-18 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice. by Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136645
•
Intracellular Hepatitis B Virus Nucleocapsids Survive Cytotoxic T-LymphocyteInduced Apoptosis. by Pasquetto V, Wieland S, Chisari FV.; 2000 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112416
•
Intracellular Retention of Hepatitis B Virus Surface Proteins Reduces Interleukin-2 Augmentation after Genetic Immunizations. by Geissler M, Bruss V, Michalak S, Hockenjos B, Ortmann D, Offensperger WB, Wands JR, Blum HE.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104209
•
Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. by Xu Z, Yen TS.; 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189797
•
Intrahepatic Induction of Alpha/Beta Interferon Eliminates Viral RNA-Containing Capsids in Hepatitis B Virus Transgenic Mice. by Wieland SF, Guidotti LG, Chisari FV.; 2000 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111931
•
Is a Function of the Secreted Hepatitis B e Antigen to Induce Immunologic Tolerance in utero? by Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A.; 1990 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54584
•
Kinetic Analysis of Wild-Type and YMDD Mutant Hepatitis B Virus Polymerases and Effects of Deoxyribonucleotide Concentrations on Polymerase Activity. by Gaillard RK, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L, Allen MI, Condreay P, Miller WH, Condreay LD.; 2002 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127103
•
La Autoantigen Specifically Recognizes a Predicted Stem-Loop in Hepatitis B Virus RNA. by Heise T, Guidotti LG, Chisari FV.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112637
•
Lack of Tumor Necrosis Factor Alpha Induces Impaired Proliferation of Hepatitis B Virus-Specific Cytotoxic T Lymphocytes. by Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, Ohnishi H, Seishima M, Kakumu S, Moriwaki H.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=141095
•
Leptomycin B Inhibits Equine Infectious Anemia Virus Rev and Feline Immunodeficiency Virus Rev Function but Not the Function of the Hepatitis B Virus Posttranscriptional Regulatory Element. by Otero GC, Harris ME, Donello JE, Hope TJ.; 1998 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110012
Studies
111
•
Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy. by Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, Rossau R.; 2000 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86181
•
Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: Implications for morphogenesis and organization of encapsidated RNA. by Zlotnick A, Cheng N, Stahl SJ, Conway JF, Steven AC, Wingfield PT.; 1997 Sep 2; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=23216
•
Localization of the N terminus of hepatitis B virus capsid protein by peptide-based difference mapping from cryoelectron microscopy. by Conway JF, Cheng N, Zlotnick A, Stahl SJ, Wingfield PT, Steven AC.; 1998 Dec 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=24499
•
Long PCR and its application to hepatitis viruses: amplification of hepatitis A, hepatitis B, and hepatitis C virus genomes. by Tellier R, Bukh J, Emerson SU, Miller RH, Purcell RH.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229463
•
Long-Term Therapy with the Guanine Nucleoside Analog Penciclovir Controls Chronic Duck Hepatitis B Virus Infection In Vivo. by Lin E, Luscombe C, Colledge D, Wang YY, Locarnini S.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105885
•
Low frequency of mutations in the core promoter and precore regions of hepatitis B virus in anti-HBe positive Brazilian carriers. by Castro LD, Niel C, Gomes SA.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=35280
•
Low-Level Secretion of Human Hepatitis B Virus Virions Caused by Two Independent, Naturally Occurring Mutations (P5T and L60V) in the Capsid Protein. by Le Pogam S, Yuan TT, Sahu GK, Chatterjee S, Shih C.; 2000 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=102108
•
Low-Level Viremia and Intracellular Expression of Hepatitis B Surface Antigen (HBsAg) in HBsAg Carriers with Concurrent Hepatitis C Virus Infection. by Chu CM, Yeh CT, Liaw YF.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104984
•
Mapping of Amino Acid Side Chains on the Surface of Hepatitis B Virus Capsids Required for Envelopment and Virion Formation. by Ponsel D, Bruss V.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140605
•
Mapping of Homologous Interaction Sites in the Hepatitis B Virus Core Protein. by Konig S, Beterams G, Nassal M.; 1998 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110062
•
Mapping of the Hepatitis B Virus Reverse Transcriptase TP and RT Domains by Transcomplementation for Nucleotide Priming and by Protein-Protein Interaction. by Lanford RE, Kim YH, Lee H, Notvall L, Beames B.; 1999 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104429
112 Hepatitis B
•
Markedly Prolonged Incubation Period of Hepatitis B in a Chimpanzee Passively Immunized with a Human Monoclonal Antibody to the a Determinant of Hepatitis B Surface Antigen. by Ogata N, Ostberg L, Ehrlich PH, Wong DC, Miller RH, Purcell RH.; 1993 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46227
•
Mechanism of Suppression of Hepatitis B Virus Precore RNA Transcription by a Frequent Double Mutation. by Li J, Buckwold VE, Hon MW, Ou JH.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=103946
•
Mechanisms of Inhibition of Nuclear Hormone Receptor-Dependent Hepatitis B Virus Replication by Hepatocyte Nuclear Factor 3[beta]. by Tang H, McLachlan A.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136416
•
Members of the nuclear receptor superfamily regulate transcription from the hepatitis B virus nucleocapsid promoter. by Raney AK, Johnson JL, Palmer CN, McLachlan A.; 1997 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191157
•
Metabolic Labeling of Woodchuck Hepatitis B Virus X Protein in Naturally Infected Hepatocytes Reveals a Bimodal Half-Life and Association with the Nuclear Framework. by Dandri M, Petersen J, Stockert RJ, Harris TM, Rogler CE.; 1998 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110361
•
Metabolic Studies on BMS-200475, a New Antiviral Compound Active against Hepatitis B Virus. by Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89048
•
Mimovirus: a Novel Form of Vaccine That Induces Hepatitis B Virus-Specific Cytotoxic T-Lymphocyte Responses In Vivo. by Wu YZ, Zhao JP, Wan Y, Jia ZC, Zhou W, Bian J, Ni B, Zou LY, Tang Y.; 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136564
•
Mitochondrially Associated Hepatitis B Virus X Protein Constitutively Activates Transcription Factors STAT-3 and NF-[kappa]B via Oxidative Stress. by Waris G, Huh KW, Siddiqui A.; 2001 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=99943
•
Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells. by Lazdina U, Cao T, Steinbergs J, Alheim M, Pumpens P, Peterson DL, Milich DR, Leroux-Roels G, Sallberg M.; 2001 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114359
•
Molecular Chaperone GRP78/BiP Interacts with the Large Surface Protein of Hepatitis B Virus In Vitro and In Vivo. by Cho DY, Yang GH, Ryu CJ, Hong HJ.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=141094
•
Molecular Characteristic-Based Epidemiology of Hepatitis B, C, and E Viruses and GB Virus C/Hepatitis G Virus in Myanmar. by Nakai K, Win KM, Oo SS, Arakawa Y, Abe K.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87966
Studies
113
•
Molecular Cloning of a Rat Chromosome Putative Recombinogenic Sequence Homologous to the Hepatitis B Virus Encapsidation Signal. by Aoki H, Kajino K, Arakawa Y, Hino O.; 1996 Jul 9; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=38978
•
Molecular Epidemiology of an Outbreak of Fulminant Hepatitis B. by Petrosillo N, Ippolito G, Solforosi L, Varaldo PE, Clementi M, Manzin A.; 2000 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87163
•
Molecular Epidemiology of Hepatitis B Virus Variants in Nonhuman Primates. by Grethe S, Heckel JO, Rietschel W, Hufert FT.; 2000 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110896
•
Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC). by Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, Arnold E.; 2001 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114232
•
Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay. by Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E.; 2002 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130856
•
Monitoring the Emergence of Hepatitis B Virus Polymerase Gene Variants during Lamivudine Therapy Using the LightCycler. by Whalley SA, Brown D, Teo CG, Dusheiko GM, Saunders NA.; 2001 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87954
•
Multiple Liver-Specific Factors Bind to the Hepatitis B Virus Core/ Pregenomic Promoter: Trans-Activation and Repression by CCAAT/Enhancer Binding Protein. by Lopez-Cabrera M, Letovsky J, Hu K, Siddiqui A.; 1990 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54263
•
Murine Retroviral Pseudotype Virus Containing Hepatitis B Virus Large and Small Surface Antigens Confers Specific Tropism for Primary Human Hepatocytes: a Potential Liver-Specific Targeting System. by Sung VM, Lai MM.; 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136820
•
Mutations in the Carboxyl-Terminal Domain of the Small Hepatitis B Virus Envelope Protein Impair the Assembly of Hepatitis Delta Virus Particles. by Jenna S, Sureau C.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104099
•
Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. by Fallows DA, Goff SP.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189007
•
Mutations in the Pre-Core Region of Hepatitis B Virus Serve to Enhance the Stability of the Secondary Structure of the Pre-Genome Encapsidation Signal. by Lok AS, Akarca U, Greene S.; 1994 Apr 26; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43726
114 Hepatitis B
•
Mutations That Increase In Situ Priming Also Decrease Circularization for Duck Hepatitis B Virus. by Loeb DD, Tian R.; 2001 Jul 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114372
•
Naturally Occurring Mutations Define a Novel Function of the Hepatitis B Virus Core Promoter in Core Protein Expression. by Baumert TF, Marrone A, Vergalla J, Liang TJ.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109887
•
New Enzyme Immunoassay for Detection of Hepatitis B Virus Core Antigen (HBcAg) and Relation between Levels of HBcAg and HBV DNA. by Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, Maki N.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=154683
•
New Hepatitis B Virus of Cranes That Has an Unexpected Broad Host Range. by Prassolov A, Hohenberg H, Kalinina T, Schneider C, Cova L, Krone O, Frolich K, Will H, Sirma H.; 2003 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140978
•
Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4 + T-Cell Repertoire in Chronic Hepatitis B Virus Infection. by Chen M, Sallberg M, Thung SN, Hughes J, Jones J, Milich DR.; 2000 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112280
•
Novel and frequent mutations of hepatitis B virus coincide with a major histocompatibility complex class I-restricted T-cell epitope of the surface antigen. by Tai PC, Banik D, Lin GI, Pai S, Pai K, Lin MH, Yuoh G, Che S, Hsu SH, Chen TC, Kuo TT, Lee CS, Yang CS, Shih C.; 1997 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191713
•
Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus. by Ono-Nita SK, Kato N, Shiratori Y, Carrilho FJ, Omata M.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127322
•
Nuclear Covalently Closed Circular Viral Genomic DNA in the Liver of Hepatocyte Nuclear Factor 1[alpha]-Null Hepatitis B Virus Transgenic Mice. by Raney AK, Eggers CM, Kline EF, Guidotti LG, Pontoglio M, Yaniv M, McLachlan A.; 2001 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115916
•
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. by Schirmbeck R, Bohm W, Ando K, Chisari FV, Reimann J.; 1995 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189487
•
Nucleic Acid-Based Cross-Linking Assay for Detection and Quantification of Hepatitis B Virus DNA. by Lai VC, Guan R, Wood ML, Lo SK, Yuen MF, Lai CL.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84196
•
Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. by Lanford RE, Notvall L, Beames B.; 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189185
Studies
115
•
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. by Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A.; 2002 Sep 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124550
•
Occult Hepatitis B Virus Infection and Clinical Outcomes of Patients with Chronic Hepatitis C. by Kao JH, Chen PJ, Lai MY, Chen DS.; 2002 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=139665
•
Oral immunization with hepatitis B surface antigen expressed in transgenic plants. by Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y.; 2001 Sep 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=58765
•
Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus. by Chen IH, Huang CJ, Ting LP.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189080
•
p53-Mediated Cellular Response to DNA Damage in Cells with Replicative Hepatitis B Virus. by Puisieux A, Ji J, Guillot C, Legros Y, Soussi T, Isselbacher K, Ozturk M.; 1995 Feb 28; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42515
•
Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: An alternative mechanism of HBx-related pathogenesis. by Tralhao JG, Roudier J, Morosan S, Giannini C, Tu H, Goulenok C, Carnot F, Zavala F, Joulin V, Kremsdorf D, Brechot C.; 2002 May 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124516
•
Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. by Korba BE, Boyd MR.; 1996 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163310
•
Pharmacology of [beta]-l-Thymidine and [beta]-l-2[prime prime or minute]Deoxycytidine in HepG2 Cells and Primary Human Hepatocytes: Relevance to Chemotherapeutic Efficacy against Hepatitis B Virus. by Hernandez-Santiago B, Placidi L, Cretton-Scott E, Faraj A, Bridges EG, Bryant ML, Rodriguez-Orengo J, Imbach JL, Gosselin G, Pierra C, Dukhan D, Sommadossi JP.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127241
•
Phenotypic mixing of rodent but not avian hepadnavirus surface proteins into human hepatitis B virus particles. by Gerhardt E, Bruss V.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=188693
•
Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro. by Delaney IV WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=127422
•
Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-betaD-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. by Wang J, Eriksson S.; 1996 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=163369
116 Hepatitis B
•
Phosphorylation of the Core Protein of Hepatitis B Virus by a 46-Kilodalton Serine Kinase. by Kau JH, Ting LP.; 1998 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109602
•
Phylogenetic Origin of Hepatitis B Virus Strains with Precore C-1858 Variant. by Alestig E, Hannoun C, Horal P, Lindh M.; 2001 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88319
•
Posttranscriptional Clearance of Hepatitis B Virus RNA by Cytotoxic T LymphocyteActivated Hepatocytes. by Tsui LV, Guidotti LG, Ishikawa T, Chisari FV.; 1995 Dec 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=40365
•
Posttranscriptional regulation of hepatitis B virus replication by the precore protein. by Scaglioni PP, Melegari M, Wands JR.; 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191057
•
Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus Replication. by Marion PL, Salazar FH, Winters MA, Colonno RJ.; 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=126982
•
Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. by Chu CM, Yeh CT, Chiu CT, Sheen IS, Liaw YF.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229124
•
Precore Stop Mutant in HBeAg-Positive Patients with Chronic Hepatitis B: Clinical Characteristics and Correlation with the Course of HBeAg-to-Anti-HBe Seroconversion. by Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF.; 2002 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=120083
•
Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. by Milich DR, Peterson DL, Schodel F, Jones JE, Hughes JL.; 1995 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=188971
•
Pretreatment of Whole Blood for Use in Immunochromatographic Assays for Hepatitis B Virus Surface Antigen. by Shin HS, Kim CK, Shin KS, Chung HK, Heo TR.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=96004
•
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. by Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, Parry JV.; 2001 Nov 24; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=59992
•
Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. by Allwright S, Bradley F, Long J, Barry J, Thornton L, Parry JV.; 2000 Jul 8; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=27426
•
Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study. by Koulentaki M, Ergazaki M, Moschandrea J, Spanoudakis S, Tzagarakis N, Drandakis PE, Spandidos DA, Kouroumalis EA.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=64645
Studies
117
•
Promoters for synthesis of the pre-C and pregenomic mRNAs of human hepatitis B virus are genetically distinct and differentially regulated. by Yu X, Mertz JE.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190967
•
Properties of Monoclonal Antibodies Directed against Hepatitis B Virus Polymerase Protein. by zu Putlitz J, Lanford RE, Carlson RI, Notvall L, de la Monte SM, Wands JR.; 1999 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104198
•
Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line. by Lu X, Block TM, Gerlich WH.; 1996 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190069
•
Proteasome complex as a potential cellular target of hepatitis B virus X protein. by Huang J, Kwong J, Sun EC, Liang TJ.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190518
•
Protective Efficacy of DNA Vaccines against Duck Hepatitis B Virus Infection. by Triyatni M, Jilbert AR, Qiao M, Miller DS, Burrell CJ.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109352
•
Quantitation of Hepatitis B Virus Genomic DNA by Real-Time Detection PCR. by Abe A, Inoue K, Tanaka T, Kato J, Kajiyama N, Kawaguchi R, Tanaka S, Yoshiba M, Kohara M.; 1999 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85408
•
Quantitative assay of PCR-amplified hepatitis B virus DNA using a peroxidaselabelled DNA probe and enhanced chemiluminescence. by Erhardt A, Schaefer S, Athanassiou N, Kann M, Gerlich WH.; 1996 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229147
•
Quantitative Detection of Hepatitis B Virus by Transcription-Mediated Amplification and Hybridization Protection Assay. by Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S.; 1999 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84293
•
Quantitative Detection of Hepatitis B Virus DNA by Real-Time Nucleic Acid Sequence-Based Amplification with Molecular Beacon Detection. by Yates S, Penning M, Goudsmit J, Frantzen I, van de Weijer B, van Strijp D, van Gemen B.; 2001 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88403
•
Quantitative Detection of Hepatitis B Virus DNA in Two International Reference Plasma Preparations. by Heermann KH, Gerlich WH, Chudy M, Schaefer S, Thomssen R.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84170
•
Rapid and Specific Genotyping System for Hepatitis B Virus Corresponding to Six Major Genotypes by PCR Using Type-Specific Primers. by Naito H, Hayashi S, Abe K.; 2001 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87732
118 Hepatitis B
•
Rate of Hepatitis B Virus Infection in Pregnant Women Determined by a Monoclonal Hepatitis B Surface Antigen Immunoassay. by Gotstein MG, Aide PM, Coleman PF, Sanborn MR.; 2002 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=130673
•
Rebound of Hepatitis B Virus Replication in HepG2 Cells after Cessation of Antiviral Treatment. by Abdelhamed AM, Kelley CM, Miller TG, Furman PA, Isom HC.; 2002 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=155168
•
Recent High Incidence of Fulminant Hepatitis in Samara, Russia: Molecular Analysis of Prevailing Hepatitis B and D Virus Strains. by Flodgren E, Bengtsson S, Knutsson M, Strebkova EA, Kidd AH, Alexeyev OA, Kidd-Ljunggren K.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=87379
•
Recombinant Duck Interferon Gamma Inhibits Duck Hepatitis B Virus Replication in Primary Hepatocytes. by Schultz U, Chisari FV.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104078
•
Reconstitution of a Functional Duck Hepatitis B Virus Replication Initiation Complex from Separate Reverse Transcriptase Domains Expressed in Escherichia coli. by Beck J, Nassal M.; 2001 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114976
•
Reduced antibody reactivity to hepatitis C virus antigens in hemodialysis patients coinfected with hepatitis B virus. by Devesa M, Khudyakov YE, Capriles F, Blitz L, Fields HA, Liprandi F, Pujol FH.; 1997 Nov; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=170632
•
Regulation of Hepatitis B Virus Gene Expression by Its Two Enhancers. by Su H, Yee J.; 1992 Apr 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=48731
•
Regulation of Hepatocyte Nuclear Factor 1 Activity by Wild-Type and Mutant Hepatitis B Virus X Proteins. by Li J, Xu Z, Zheng Y, Johnson DL, Ou JH.; 2002 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136206
•
Regulation of RNA Polymerase I-Dependent Promoters by the Hepatitis B Virus X Protein via Activated Ras and TATA-Binding Protein. by Wang HD, Trivedi A, Johnson DL.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109290
•
Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines. by McClary H, Koch R, Chisari FV, Guidotti LG.; 2000 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111707
•
Reliability of methods for hepatitis B virus DNA detection. by Quint WG, Heijtink RA, Schirm J, Gerlich WH, Niesters HG.; 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=227915
•
Replication Advantage and Host Factor-Independent Phenotypes Attributable to a Common Naturally Occurring Capsid Mutation (I97L) in Human Hepatitis B Virus. by Suk FM, Lin MH, Newman M, Pan S, Chen SH, Liu JD, Shih C.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136898
Studies
119
•
Replication of the Wild Type and a Natural Hepatitis B Virus Nucleocapsid Promoter Variant Is Differentially Regulated by Nuclear Hormone Receptors in Cell Culture. by Tang H, Raney AK, McLachlan A.; 2001 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114462
•
Residues Critical for Duck Hepatitis B Virus Neutralization Are Involved in Host Cell Interaction. by Sunyach C, Rollier C, Robaczewska M, Borel C, Barraud L, Kay A, Trepo C, Will H, Cova L.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104011
•
Retinoid X receptor alpha transactivates the hepatitis B virus enhancer 1 element by forming a heterodimeric complex with the peroxisome proliferator-activated receptor. by Huan B, Kosovsky MJ, Siddiqui A.; 1995 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=188608
•
Retinoid X Receptor RXR[alpha] Binds to and Trans-Activates the Hepatitis B Virus Enhancer. by Huan B, Siddiqui A.; 1992 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50064
•
Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil. by Lewis-Ximenez LL, do O KM, Ginuino CF, Silva JC, Schatzmayr HG, Stuver S, Yoshida CF.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140010
•
RMP, a Novel RNA Polymerase II Subunit 5-Interacting Protein, Counteracts Transactivation by Hepatitis B Virus X Protein. by Dorjsuren D, Lin Y, Wei W, Yamashita T, Nomura T, Hayashi N, Murakami S.; 1998 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109335
•
Role for Calnexin and N-Linked Glycosylation in the Assembly and Secretion of Hepatitis B Virus Middle Envelope Protein Particles. by Werr M, Prange R.; 1998 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=109435
•
Role of B cells in antigen presentation of the hepatitis B core. by Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL.; 1997 Dec 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=25082
•
Role of N Glycosylation of Hepatitis B Virus Envelope Proteins in Morphogenesis and Infectivity of Hepatitis Delta Virus. by Sureau C, Fournier-Wirth C, Maurel P.; 2003 May; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153980
•
Role of NF-[kappa]B and Myc Proteins in Apoptosis Induced by Hepatitis B Virus HBx Protein. by Su F, Theodosis CN, Schneider RJ.; 2001 Jan 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113915
•
Role of Polypyrimidine Tract Binding Protein in the Function of the Hepatitis B Virus Posttranscriptional Regulatory Element. by Zang WQ, Li B, Huang PY, Lai MM, Yen TS.; 2001 Nov 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114659
•
Role of the hepatitis B virus posttranscriptional regulatory element in export of intronless transcripts. by Huang ZM, Yen TS.; 1995 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230626
120 Hepatitis B
•
Role of the Pre-S2 Domain of the Large Envelope Protein in Hepatitis B Virus Assembly and Infectivity. by Le Seyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110210
•
Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asdbalanced lethal vector system. by Tacket CO, Kelly SM, Schodel F, Losonsky G, Nataro JP, Edelman R, Levine MM, Curtiss R 3rd.; 1997 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=175478
•
Searching for Interferon-Induced Genes That Inhibit Hepatitis B Virus Replication in Transgenic Mouse Hepatocytes. by Wieland SF, Vega RG, Muller R, Evans CF, Hilbush B, Guidotti LG, Sutcliffe JG, Schultz PG, Chisari FV.; 2003 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=140855
•
Secretion of Human Hepatitis B Virus is Inhibited by the Imino Sugar NButyldeoxynojirimycin. by Block TM, Lu X, Platt FM, Foster GR, Gerlich WH, Blumberg BS, Dwek RA.; 1994 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43345
•
Selection of Peptide Inhibitors of Interactions Involved in Complex Protein Assemblies: Association of the Core and Surface Antigens of Hepatitis B Virus. by Dyson MR, Murray K.; 1995 Mar 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42450
•
Semiautomated Quantification of Hepatitis B Virus DNA in a Routine Diagnostic Laboratory. by Kessler HH, Stelzl E, Daghofer E, Santner BI, Marth E, Lackner H, Stauber RE.; 2000 Sep; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=95971
•
Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load. by Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, Maki N.; 2002 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=153363
•
Signals for Bidirectional Nucleocytoplasmic Transport in the Duck Hepatitis B Virus Capsid Protein. by Mabit H, Breiner KM, Knaust A, Zachmann-Brand B, Schaller H.; 2001 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=115143
•
Simultaneous Detection of Multiplex-Amplified Human Immunodeficiency Virus Type 1 RNA, Hepatitis C Virus RNA, and Hepatitis B Virus DNA Using a Flow Cytometer Microsphere-Based Hybridization Assay. by Defoort JP, Martin M, Casano B, Prato S, Camilla C, Fert V.; 2000 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=86341
•
Specific hepatitis B virus minus-strand DNA synthesis requires only the 5' encapsidation signal and the 3'-proximal direct repeat DR1. by Rieger A, Nassal M.; 1996 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=189849
Studies
121
•
Structure-Activity Relationship of a New Class of Anti-Hepatitis B Virus Agents. by Mehta A, Conyers B, Tyrrell DL, Walters KA, Tipples GA, Dwek RA, Block TM.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=132742
•
Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen. by Yuan TT, Tai PC, Shih C.; 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113064
•
Sustained Activation of Mitogen-Activated Protein Kinases and Activator Protein 1 by the Hepatitis B Virus X Protein in Mouse Hepatocytes In Vivo. by Nijhara R, Jana SS, Goswami SK, Rana A, Majumdar SS, Kumar V, Sarkar DP.; 2001 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114609
•
The apical stem --loop of the hepatitis B virus encapsidation signal folds into a stable tri --loop with two underlying pyrimidine bulges. by Flodell S, Schleucher J, Cromsigt J, Ippel H, Kidd-Ljunggren K, Wijmenga S.; 2002 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=135823
•
The Binding Site of Transcription Factor YY1 Is Required for Intramolecular Recombination between Terminally Repeated Sequences of Linear Replicative Hepatitis B Virus DNA. by Hayashi Y, Kitamura Y, Nakanishi M, Koike K.; 2000 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112376
•
The degrees of hepatocyte nuclear but not cytoplasmic expression of hepatitis B core antigen reflect the level of viral replication in chronic hepatitis B virus infection. by Chu CM, Yeh CT, Chien RN, Sheen IS, Liaw YF.; 1997 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=229519
•
The Duck Hepatitis B Virus Polymerase Is Activated by Its RNA Packaging Signal, [var epsilon]. by Tavis JE, Massey B, Gong Y.; 1998 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110380
•
The Dynamics of Hepatitis B Virus Infection. by Payne RJ, Nowak MA, Blumberg BS.; 1996 Jun 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39060
•
The Enhancer I Core Region Contributes to the Replication Level of Hepatitis B Virus In Vivo and In Vitro. by Bock CT, Malek NP, Tillmann HL, Manns MP, Trautwein C.; 2000 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=111700
•
The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. by Al-Mekhaizeem KA, Miriello M, Sherker AH.; 2001 Oct 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=81543
•
The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. by Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, Chisari FV.; 1996 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190756
122 Hepatitis B
•
The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. by Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL.; 1997 Mar; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191326
•
The Hepatitis B Virus Core Promoter Is Strongly Activated by the Liver Nuclear Receptor Fetoprotein Transcription Factor or by Ectopically Expressed Steroidogenic Factor 1. by Gilbert S, Galarneau L, Lamontagne A, Roy S, Belanger L.; 2000 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=110855
•
The hepatitis B virus post-transcriptional regulatory element contains two conserved RNA stem-loops which are required for function. by Smith GJ 3rd, Donello JE, Luck R, Steger G, Hope TJ.; 1998 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=147918
•
The hepatitis B virus posttranscriptional regulatory element is composed of two subelements. by Donello JE, Beeche AA, Smith GJ 3rd, Lucero GR, Hope TJ.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190367
•
The hepatitis B virus X protein promotes tumor cell invasion by inducing membranetype matrix metalloproteinase-1 and cyclooxygenase-2 expression. by Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, Mira E, Iniguez MA, Fresno M, Martinez-A. C, Arroyo AG, Lopez-Cabrera M.; 2002 Dec 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151651
•
The Hepatitis B Virus X Protein Targets the Basic Region-Leucine Zipper Domain of CREB. by Williams JS, Andrisani OM.; 1995 Apr 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42053
•
The Hepatitis B Virus X Protein Transactivates Viral Core Gene Expression In Vivo. by Reifenberg K, Wilts H, Lohler J, Nusser P, Hanano R, Guidotti LG, Chisari FV, Schlicht HJ.; 1999 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113095
•
The M539V Polymerase Variant of Human Hepatitis B Virus Demonstrates Resistance to 2[prime prime or minute]-Deoxy-3[prime prime or minute]-Thiacytidine and a Reduced Ability to Synthesize Viral DNA. by Ladner SK, Miller TJ, King RW.; 1998 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=105884
•
The Majority of Duck Hepatitis B Virus Reverse Transcriptase in Cells Is Nonencapsidated and Is Bound to a Cytoplasmic Structure. by Yao E, Gong Y, Chen N, Tavis JE.; 2000 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=116376
•
The Mechanism of an Immature Secretion Phenotype of a Highly Frequent Naturally Occurring Missense Mutation at Codon 97 of Human Hepatitis B Virus Core Antigen. by Yuan TT, Sahu GK, Whitehead WE, Greenberg R, Shih C.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=112633
•
The myc intron-binding polypeptide associates with RFX1 in vivo and binds to the major histocompatibility complex class II promoter region, to the hepatitis B virus
Studies
123
enhancer, and to regulatory regions of several distinct viral genes. by Reinhold W, Emens L, Itkes A, Blake M, Ichinose I, Zajac-Kaye M.; 1995 Jun; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=230535 •
The Pre-S Domain of the Large Viral Envelope Protein Determines Host Range in Avian Hepatitis B Viruses. by Ishikawa T, Ganem D.; 1995 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41497
•
The PreS2 activator MHBst of hepatitis B virus activates c-raf-1 /Erk2 signaling in transgenic mice. by Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH.; 2002 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=125852
•
The Role of Envelope Proteins in Hepatitis B Virus Assembly. by Bruss V, Ganem D.; 1991 Feb 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50954
•
The small envelope protein is required for secretion of a naturally occurring hepatitis B virus mutant with pre-S1 deleted. by Melegari M, Scaglioni PP, Wands JR.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191785
•
The X protein of hepatitis B virus coactivates potent activation domains. by Haviv I, Vaizel D, Shaul Y.; 1995 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=232011
•
Transactivation by Hepatitis B Virus X Protein is Promiscuous and Dependent on Mitogen-Activated Cellular Serine/Threonine Kinases. by Cross JC, Wen P, Rutter WJ.; 1993 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47291
•
Trans-Activation Function of a 3' Truncated X Gene-Cell Fusion Product from Integrated Hepatitis B Virus DNA in Chronic Hepatitis Tissues. by Takada S, Koike K.; 1990 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54380
•
Trans-Activation of HLA-DR Gene by Hepatitis B Virus X Gene Product. by Hu K, Vierling JM, Siddiqui A.; 1990 Sep 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54699
•
Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase. by Lanford RE, Notvall L, Lee H, Beames B.; 1997 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191428
124 Hepatitis B
•
Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. by Stoll-Becker S, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M, Lampert F, Gerlich WH.; 1997 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=191779
•
Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. by Tang H, McLachlan A.; 2001 Feb 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29344
•
Transcriptional Repression of Human Hepatitis B Virus Genes by a bZIP Family Member, E4BP4. by Lai CK, Ting LP.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=104083
•
Transfer of Hepatitis B Virus Genome by Adenovirus Vectors into Cultured Cells and Mice: Crossing the Species Barrier. by Sprinzl MF, Oberwinkler H, Schaller H, Protzer U.; 2001 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=114916
•
Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-[kappa]B. by Biermer M, Puro R, Schneider RJ.; 2003 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=150632
•
Turnover of Hepatitis B Virus X Protein Is Regulated by Damaged DNA-Binding Complex. by Bergametti F, Sitterlin D, Transy C.; 2002 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136256
•
Two Sensitive PCR-Based Methods for Detection of Hepatitis B Virus Variants Associated with Reduced Susceptibility to Lamivudine. by Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD.; 1999 Oct; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=85560
•
Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. by Gunther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H.; 1996 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=190919
•
Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection. by Mahoney FJ.; 1999 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=88921
•
Up-Regulation of Intercellular Adhesion Molecule 1 Transcription by Hepatitis B Virus X Protein. by Hu K, Yu C, Vierling JM.; 1992 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50567
•
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. by Chu CK, Ma T, Shanmuganathan K, Wang C, Xiang Y, Pai SB, Yao GQ, Sommadossi JP, Cheng YC.; 1995 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=162665
Studies
125
•
Use of Real-Time PCR and Fluorimetry To Detect Lamivudine Resistance-Associated Mutations in Hepatitis B Virus. by Cane PA, Cook P, Ratcliffe D, Mutimer D, Pillay D.; 1999 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89331
•
Use of the Hepatitis B Virus Recombinant Baculovirus-HepG2 System to Study the Effects of ([minus sign])-[beta]-2[prime prime or minute],3[prime prime or minute]Dideoxy-3[prime prime or minute]-Thiacytidine on Replication of Hepatitis B Virus and Accumulation of Covalently Closed Circular DNA. by Delaney WE IV, Miller TG, Isom HC.; 1999 Aug; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=89407
•
Viral Cross Talk: Intracellular Inactivation of the Hepatitis B Virus during an Unrelated Viral Infection of the Liver. by Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MB, Chisari FV.; 1996 May 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39321
•
Viral Dynamics in Hepatitis B Virus Infection. by Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H.; 1996 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39549
•
Viral Superinfection in Previously Unrecognized Chronic Carriers of Hepatitis B Virus with Superimposed Acute Fulminant versus Nonfulminant Hepatitis. by Chu CM, Yeh CT, Liaw YF.; 1999 Jan; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=84220
•
Virus-Specific CD8 + Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C. by Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, Ferrari C.; 2002 Dec; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=136708
•
Wild-Type and e Antigen-Minus Hepatitis B Viruses and Course of Chronic Hepatitis. by Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H, Bonino F.; 1991 May 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=51623
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals.
6 PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
126 Hepatitis B
To generate your own bibliography of studies dealing with hepatitis B, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “hepatitis B” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for hepatitis B (hyperlinks lead to article summaries): •
A rapid immunochromatographic assay for hepatitis B virus screening. Author(s): Lau DT, Ma H, Lemon SM, Doo E, Ghany MG, Miskovsky E, Woods GL, Park Y, Hoofnagle JH. Source: Journal of Viral Hepatitis. 2003 July; 10(4): 331-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823602&dopt=Abstract
•
A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine. Author(s): Ide T, Kumashiro R, Koga Y, Tanaka E, Hino T, Hisamochi A, Murashima S, Ogata K, Tanaka K, Kuwahara R, Sata M. Source: The American Journal of Gastroenterology. 2003 September; 98(9): 2048-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14499786&dopt=Abstract
•
A review of the case for hepatitis B vaccination of high-risk adults. Author(s): Rich JD, Ching CG, Lally MA, Gaitanis MM, Schwartzapfel B, Charuvastra A, Beckwith CG, Flanigan TP. Source: The American Journal of Medicine. 2003 March; 114(4): 316-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12681460&dopt=Abstract
•
A statewide hepatitis B vaccination program for school children in Hawaii: vaccination series completion and participation rates over consecutive school years. Author(s): Dilraj A, Strait-Jones J, Nagao M, Cui K, Terrell-Perica S, Effler PV. Source: Public Health Reports (Washington, D.C. : 1974). 2003 March-April; 118(2): 12733. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690066&dopt=Abstract
•
A survey of community pharmacists on prevention of HIV and hepatitis B and C: current practice and attitudes in Grampian. Author(s): Watson L, Bond C, Gault C. Source: Journal of Public Health Medicine. 2003 March; 25(1): 13-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12669912&dopt=Abstract
•
Acceptance of hepatitis B vaccine by workers in a Nigerian teaching hospital. Author(s): Fatusi AO, Fatusi OA, Esimai AO, Onayade AA, Ojo OS. Source: East Afr Med J. 2000 November; 77(11): 608-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12862107&dopt=Abstract
Studies
127
•
Activation and inhibition of cellular calcium and tyrosine kinase signaling pathways identify targets of the HBx protein involved in hepatitis B virus replication. Author(s): Bouchard MJ, Puro RJ, Wang L, Schneider RJ. Source: Journal of Virology. 2003 July; 77(14): 7713-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12829810&dopt=Abstract
•
Acute hepatitis B and isolated thrombocytopenia. Author(s): Ozaras R, Celik AD, Kisacik B, Mert A, Aki H, Ozturk R, Tabak F. Source: Journal of Clinical Gastroenterology. 2003 July; 37(1): 87-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12811220&dopt=Abstract
•
Acute hepatitis B infection and hepatitis B surface antigen positivity reported in the Department of Veterans Affairs: occurrence in a population seeking medical assistance. Author(s): Kralovic SM, Danko LH, Simbartl LA, Roselle GA. Source: Military Medicine. 2003 June; 168(6): 493-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12834144&dopt=Abstract
•
Aeromonas veronii biovar veronii septicaemia and acute suppurative cholangitis in a patient with hepatitis B. Author(s): Mencacci A, Cenci E, Mazzolla R, Farinelli S, D'Alo F, Vitali M, Bistoni F. Source: Journal of Medical Microbiology. 2003 August; 52(Pt 8): 727-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867570&dopt=Abstract
•
Agents in clinical development for the treatment of chronic hepatitis B. Author(s): Raney AK, Hamatake RK, Hong Z. Source: Expert Opinion on Investigational Drugs. 2003 August; 12(8): 1281-95. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882617&dopt=Abstract
•
Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Author(s): Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM, Matsuda M, Fujii H, Scoazec JY, Ohgaki H. Source: International Journal of Cancer. Journal International Du Cancer. 2003 September 1; 106(3): 334-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12845670&dopt=Abstract
•
An infectious clone of woolly monkey hepatitis B virus. Author(s): Lanford RE, Chavez D, Barrera A, Brasky KM. Source: Journal of Virology. 2003 July; 77(14): 7814-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12829821&dopt=Abstract
128 Hepatitis B
•
Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. Author(s): Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, Su CW, Wang YJ, Chang FY, Lee SD. Source: Journal of Viral Hepatitis. 2003 July; 10(4): 277-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823594&dopt=Abstract
•
Analysis of complement-bound hepatitis B virus complexes by an immuno-capture polymerase chain reaction method. Author(s): Wang SY, Liu R, Zhang JY, Lian QZ, Peng XX. Source: Scandinavian Journal of Immunology. 2003 July; 58(1): 112-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12828566&dopt=Abstract
•
Analysis of hepatitis B virus-immunoglobulin isotype complexes by a novel immunocapture polymerase chain reaction method. Author(s): Zhou YL, Wang SY, Zhang JY, Peng XX. Source: Scandinavian Journal of Immunology. 2003 April; 57(4): 391-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12662303&dopt=Abstract
•
Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Author(s): Elefsiniotis IS, Diamantis ID, Dourakis SP, Kafiri G, Pantazis K, Mavrogiannis C. Source: European Journal of Gastroenterology & Hepatology. 2003 July; 15(7): 721-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12811301&dopt=Abstract
•
Antisense RNAs transcribed from the upstream region of the precore/core promoter of hepatitis B virus. Author(s): Moriyama K, Hayashida K, Shimada M, Nakano S, Nakashima Y, Fukumaki Y. Source: The Journal of General Virology. 2003 July; 84(Pt 7): 1907-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12810886&dopt=Abstract
•
Are we ready for marginal hepatitis B core antibody-positive living liver donors? Author(s): Fontana RJ, Merion RM. Source: Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2003 August; 9(8): 833-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12884196&dopt=Abstract
Studies
129
•
Auditing delivery of first dose of hepatitis B immunization to at risk groups may be more important than subsequent doses. Author(s): Sathia UL, McOwan A. Source: International Journal of Std & Aids. 2003 February; 14(2): 140-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12662396&dopt=Abstract
•
Bacterial expression, purification, and in vitro N-myristoylation of fusion hepatitis B virus preS1 with the native-type N-terminus. Author(s): Ma HH, Yang L, Yang XY, Xu ZP, Li BL. Source: Protein Expression and Purification. 2003 January; 27(1): 49-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12509984&dopt=Abstract
•
Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Author(s): Hoeprich S, Zhou Q, Guo S, Shu D, Qi G, Wang Y, Guo P. Source: Gene Therapy. 2003 August; 10(15): 1258-67. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858191&dopt=Abstract
•
Baruch Blumberg--hepatitis B and beyond. Interviewed by Pam Das. Author(s): Blumberg BS. Source: The Lancet Infectious Diseases. 2002 December; 2(12): 767-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12467696&dopt=Abstract
•
Baruch Blumberg--work on hepatitis B virus. Author(s): Shampo MA, Kyle RA. Source: Mayo Clinic Proceedings. 2003 September; 78(9): 1186. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12962173&dopt=Abstract
•
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Author(s): Kao JH, Chen PJ, Lai MY, Chen DS. Source: Gastroenterology. 2003 February; 124(2): 327-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12557138&dopt=Abstract
•
Beneficial effect of lamivudine for hepatitis B transplant recipients. Author(s): Mutimer D. Source: Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2002 May; 8(5): 440-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12004343&dopt=Abstract
130 Hepatitis B
•
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Author(s): Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, Paterlini-Brechot P, Brechot C, Kremsdorf D. Source: Cancer Research. 2001 November 1; 61(21): 7803-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11691796&dopt=Abstract
•
Brain metastasis from hepatocellular carcinoma associated with hepatitis B virus. Author(s): Frati A, Salvati M, Giarnieri E, Santoro A, Rocchi G, Frati L. Source: J Exp Clin Cancer Res. 2002 September; 21(3): 321-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12385572&dopt=Abstract
•
Can serum HBV-DNA be used as a primary end point to assess efficacy of new treatments for chronic hepatitis B? Author(s): Alberti A. Source: Hepatology (Baltimore, Md.). 2003 July; 38(1): 18-20. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12829981&dopt=Abstract
•
Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. Author(s): Chami M, Ferrari D, Nicotera P, Paterlini-Brechot P, Rizzuto R. Source: The Journal of Biological Chemistry. 2003 August 22; 278(34): 31745-55. Epub 2003 June 10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12799372&dopt=Abstract
•
Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Author(s): Julander JG, Colonno RJ, Sidwell RW, Morrey JD. Source: Antiviral Research. 2003 August; 59(3): 155-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12927305&dopt=Abstract
•
Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Author(s): Lin YL, Shiao MS, Mettling C, Chou CK. Source: Virology. 2003 September 15; 314(1): 253-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14517078&dopt=Abstract
•
Chronic hepatitis B with flare due to co-infection of hepatitis delta virus during lamivudine therapy. Author(s): Joh R, Hasegawa K, Tokushige K, Hashimoto E, Torii N, Yamashiro T, Enomoto N, Watanabe M, Hayashi N. Source: Intern Med. 2003 July; 42(7): 581-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12879950&dopt=Abstract
Studies
131
•
Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. Author(s): Rokuhara A, Tanaka E, Matsumoto A, Kimura T, Yamaura T, Orii K, Sun X, Yagi S, Maki N, Kiyosawa K. Source: Journal of Viral Hepatitis. 2003 July; 10(4): 324-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823601&dopt=Abstract
•
Clinical features of hepatitis B virus genotype A in Japanese patients. Author(s): Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Hosaka T, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Kumada H. Source: Journal of Gastroenterology. 2003; 38(7): 656-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12898358&dopt=Abstract
•
Coexistence of two distinct secretion mutations (P5T and I97L) in hepatitis B virus core produces a wild-type pattern of secretion. Author(s): Chua PK, Wen YM, Shih C. Source: Journal of Virology. 2003 July; 77(13): 7673-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12805468&dopt=Abstract
•
Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Author(s): Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R. Source: Transplantation Proceedings. 2003 March; 35(2): 609-11. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12644066&dopt=Abstract
•
Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus. Author(s): Ohmoto K, Tsuduki M, Yamamoto S. Source: The American Journal of Gastroenterology. 2003 May; 98(5): 1215-6; Author Reply 1217. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809863&dopt=Abstract
•
Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Author(s): Sousa JM, Pareja F, Serrano J, Gomez MA, Garcia I, Tamayo MJ, Diaz C, Martin C, Pascasio JM, Hinojosa R, Perez-Bernal JB, Canas E, Sayago M, Bernardos A. Source: Transplantation Proceedings. 2003 March; 35(2): 723-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12644112&dopt=Abstract
132 Hepatitis B
•
Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Author(s): Yalcin K, Degertekin H, Yildiz F, Celik Y. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 June 15; 36(12): 1516-22. Epub 2003 Jun 06. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802750&dopt=Abstract
•
Comparison of clinical features and survival of patients with hepatitis B- and hepatitis C-associated hepatocellular carcinoma in Thailand. Author(s): Tangkijvanich P, Suwangool P, Mahachai V. Source: J Med Assoc Thai. 2003 June; 86 Suppl 2: S250-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12929997&dopt=Abstract
•
Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Author(s): Ikeda K, Arase Y, Kobayashi M, Someya T, Saitoh S, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. Source: Intervirology. 2003; 46(2): 96-104. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684548&dopt=Abstract
•
Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Author(s): Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Source: Clinical Transplantation. 2003 June; 17(3): 254-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12780677&dopt=Abstract
•
Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. Author(s): Pwu RF, Chan KA. Source: J Formos Med Assoc. 2002 September; 101(9): 632-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12645191&dopt=Abstract
•
Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha. Author(s): Babu S. Source: Natl Med J India. 2003 May-June; 16(3): 175; Author Reply 175-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12929872&dopt=Abstract
Studies
133
•
Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha. Author(s): Nagral A. Source: Natl Med J India. 2003 May-June; 16(3): 175; Author Reply 175-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12929871&dopt=Abstract
•
Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha. Author(s): Desai HG. Source: Natl Med J India. 2003 May-June; 16(3): 175; Author Reply 175-6. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12929870&dopt=Abstract
•
Current status and prospects of studies on human genetic alleles associated with hepatitis B virus infection. Author(s): Wang FS. Source: World Journal of Gastroenterology : Wjg. 2003 April; 9(4): 641-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679901&dopt=Abstract
•
De novo infection in a renal transplant recipient caused by novel mutants of hepatitis B virus despite the presence of protective anti-hepatitis B surface antibody. Author(s): Lu M, Lorentz T. Source: The Journal of Infectious Diseases. 2003 April 15; 187(8): 1323-6. Epub 2003 March 26. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12696014&dopt=Abstract
•
Decompensated hepatitis B virus-related cirrhosis successfully treated with lamivudine allowing surgery for hepatocellular carcinoma. Author(s): Nakanishi S, Michitaka K, Miyake T, Hidaka S, Yoshino I, Konishi I, Iuchi H, Horiike N, Onji M. Source: Intern Med. 2003 May; 42(5): 416-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12793712&dopt=Abstract
•
Depression and anxiety in chronic hepatitis B: effect of hepatitis B virus infection on psychological state in childhood. Author(s): Arslan N, Buyukgebiz B, Ozturk Y, Akay AP. Source: Turk J Pediatr. 2003 January-March; 45(1): 26-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718367&dopt=Abstract
•
Detection of hepatitis B virus DNA in sera from patients with chronic hepatitis B virus infection by DNA microarray method. Author(s): Kawaguchi K, Kaneko S, Honda M, Kawai HF, Shirota Y, Kobayashi K. Source: Journal of Clinical Microbiology. 2003 April; 41(4): 1701-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12682163&dopt=Abstract
134 Hepatitis B
•
Detection of mutations in the hepatitis B virus polymerase gene. Author(s): Kessler HH, Stelzl E, Marth E, Stauber RE. Source: Clinical Chemistry. 2003 June; 49(6 Pt 1): 989-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12766008&dopt=Abstract
•
Detection of T lymphocyte subsets and mIL-2R on surface of PBMC in patients with hepatitis B. Author(s): Wang KX, Peng JL, Wang XF, Tian Y, Wang J, Li CP. Source: World Journal of Gastroenterology : Wjg. 2003 September; 9(9): 2017-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12970897&dopt=Abstract
•
Determination of the fine epitope specificity of an anti-hepatitis B virus X protein monoclonal antibody using microanalytical and molecular biological methods. Author(s): Pal J, Czompoly T, Nyarady Z, Marczinovits I, Janaky T, Kele Z, Felici F, Nemeth P. Source: Molecular Immunology. 2003 September; 40(5): 241-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12943796&dopt=Abstract
•
Developing partnerships in Washington State to prevent hepatitis B virus infection in Asian Americans and Pacific Islanders. Author(s): Chen AL, Kuss TT, McKeirnan S, Gleason CJ. Source: Asian Am Pac Isl J Health. 2001 Summer-Fall; 9(2): 195-204. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11846365&dopt=Abstract
•
Development of a candidate polyvalent live vaccine against human immunodeficiency, hepatitis B, and orthopox viruses. Author(s): Shchelkunov SN, Nesterov AE, Ryazankin IA, Ignat'ev GM, Sandakhchiev LS. Source: Doklady. Biochemistry and Biophysics. 2003 May-June; 390: 180-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12959074&dopt=Abstract
•
Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. Author(s): Wolters LM, Niesters HG, Hansen BE, van der Ende ME, Kroon FP, Richter C, Brinkman K, Meenhorst PL, de Man RA. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2002 April; 24(3): 173-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11856618&dopt=Abstract
Studies
135
•
Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity. Author(s): Ogata N, Ichida T, Aoyagi Y, Kitajima I. Source: Rinsho Byori. 2003 April; 51(4): 313-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12747252&dopt=Abstract
•
Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. Author(s): Nakayoshi T, Maeshiro T, Nakayoshi T, Nakasone H, Sakugawa H, Kinjo F, Orito E, Mizokami M. Source: Journal of Medical Virology. 2003 July; 70(3): 350-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12766996&dopt=Abstract
•
Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications. Author(s): Perez-Olmeda M, Nunez M, Garcia-Samaniego J, Rios P, Gonzalez-Lahoz J, Soriano V. Source: Aids Research and Human Retroviruses. 2003 August; 19(8): 657-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13678467&dopt=Abstract
•
Distribution of hepatitis B virus in the liver of chronic hepatitis C patients with occult hepatitis B virus infection. Author(s): Rodriguez-Inigo E, Mariscal L, Bartolome J, Castillo I, Navacerrada C, OrtizMovilla N, Pardo M, Carreno V. Source: Journal of Medical Virology. 2003 August; 70(4): 571-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794719&dopt=Abstract
•
Do patients who fail to complete a hepatitis A or hepatitis B vaccination series have to restart it? Author(s): Alter MJ. Source: Cleve Clin J Med. 2003 March; 70(3): 234. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12678213&dopt=Abstract
•
Dominant mutations of hepatitis B virus variants in hepatoma accumulate in B-cell and T-cell epitopes of the HBx antigen. Author(s): Hwang GY, Huang CJ, Lin CY, Wu CC. Source: Virus Research. 2003 April; 92(2): 157-64. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12686424&dopt=Abstract
136 Hepatitis B
•
Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. Author(s): Chan HL, Sung JJ, Fong WF, Chim AM, Yung PP, Hui AY, Fung KP, Leung PC. Source: Alimentary Pharmacology & Therapeutics. 2003 August 1; 18(3): 339-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12895219&dopt=Abstract
•
Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. Author(s): Yao FY. Source: Journal of Clinical Gastroenterology. 2003 May-June; 36(5): 440-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702990&dopt=Abstract
•
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Author(s): Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. Source: Hepatology (Baltimore, Md.). 2003 April; 37(4): 748-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668966&dopt=Abstract
•
Durable clearance of hepatitis B virus after allogeneic blood stem cell transplantation by adoptive immunity transfer and antiviral chemotherapy. Author(s): Groll AH, Baumann-Kohler M, Storkebaum B, Kuhn J, Jurgens H, Vormoor J. Source: The Pediatric Infectious Disease Journal. 2003 August; 22(8): 753-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12938680&dopt=Abstract
•
Early-onset acute transverse myelitis following hepatitis B vaccination and respiratory infection: case report. Author(s): Fonseca LF, Noce TR, Teixeira ML, Teixeira AL Jr, Lana-Peixoto MA. Source: Arquivos De Neuro-Psiquiatria. 2003 June; 61(2A): 265-8. Epub 2003 June 09. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12806509&dopt=Abstract
•
Economic analysis of promotion of hepatitis B vaccinations among VietnameseAmerican children and adolescents in Houston and Dallas. Author(s): Zhou F, Euler GL, McPhee SJ, Nguyen T, Lam T, Wong C, Mock J. Source: Pediatrics. 2003 June; 111(6 Pt 1): 1289-96. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12777543&dopt=Abstract
•
Effect of long-term lamivudine therapy on histological outcome in chronic hepatitis B. Author(s): De Ridder RJ, Stronkhorst A. Source: Gastroenterology. 2003 October; 125(4): 1286-7; Author Reply 1287. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14552322&dopt=Abstract
Studies
137
•
Effects of hepatitis B virus infection on human sperm chromosomes. Author(s): Huang JM, Huang TH, Qiu HY, Fang XW, Zhuang TG, Liu HX, Wang YH, Deng LZ, Qiu JW. Source: World Journal of Gastroenterology : Wjg. 2003 April; 9(4): 736-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12679922&dopt=Abstract
•
Effects of marker for hepatic fibrosis and viral status on recurrence after resection of hepatitis B virus-related hepatocellular carcinoma. Author(s): Kubo S, Tsukamoto T, Kawai S, Hirohashi K, Tanaka H, Shuto T, Takemura S, Nishiguchi S, Kinoshita H. Source: Hepatogastroenterology. 2003 March-April; 50(50): 497-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12749255&dopt=Abstract
•
Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure--results of a prospective, randomized trial. Author(s): Singh NP, Mandal SK, Thakur A, Kapoor D, Anuradha S, Prakash A, Kohli R, Agarwal SK. Source: Renal Failure. 2003 March; 25(2): 255-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12739832&dopt=Abstract
•
Efficacy of interferon alpha-2b and lamivudine therapy for chronic hepatitis B in children. Author(s): Bahar A, Iscan S, Karademir F, Gocmen I. Source: Chinese Medical Journal. 2003 April; 116(4): 593-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875729&dopt=Abstract
•
Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Author(s): Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Takagi K, Kumada H. Source: Intervirology. 2003; 46(3): 182-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867757&dopt=Abstract
•
Efficacy of selective antenatal screening for hepatitis B among pregnant women in Denmark: is selective screening still an acceptable strategy in a low-endemicity country? Author(s): Jensen L, Heilmann C, Smith E, Wantzin P, Peitersen B, Weber T, Krogsgaard K. Source: Scandinavian Journal of Infectious Diseases. 2003; 35(6-7): 378-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12953948&dopt=Abstract
138 Hepatitis B
•
Emergency living related liver transplantation for fulminant reactivation of hepatitis B virus after unrelated marrow transplantation. Author(s): Au WY, Lau GK, Lie AK, Liang R, Lo CM, Fan ST, Liu CL, Hawkins BR, Ng IO, Kwong YL. Source: Clinical Transplantation. 2003 April; 17(2): 121-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12709077&dopt=Abstract
•
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. Author(s): Schilling R, Ijaz S, Davidoff M, Lee JY, Locarnini S, Williams R, Naoumov NV. Source: Journal of Virology. 2003 August; 77(16): 8882-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12885906&dopt=Abstract
•
Entecavir: a potent new antiviral drug for hepatitis B. Author(s): Honkoop P, De Man RA. Source: Expert Opinion on Investigational Drugs. 2003 April; 12(4): 683-8. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12665423&dopt=Abstract
•
Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Author(s): Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu S, Ishida T, Chutaputti A, Lai CL, Gish RG, Ueda R, Miyakawa Y, Mizokami M. Source: Gastroenterology. 2003 April; 124(4): 925-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12671889&dopt=Abstract
•
Epidermal cis-urocanic acid levels correlate with lower specific cellular immune responses after hepatitis B vaccination of ultraviolet B-exposed humans. Author(s): Sleijffers A, Kammeyer A, de Gruijl FR, Boland GJ, van Hattum J, van Vloten WA, van Loveren H, Teunissen MB, Garssen J. Source: Photochemistry and Photobiology. 2003 March; 77(3): 271-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685654&dopt=Abstract
•
Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system. Author(s): Romero MR, Martinez-Diez MC, Larena MG, Macias RI, Dominguez M, Garcia-Monzon C, Serrano MA, Marin JJ. Source: Antivir Chem Chemother. 2002 November; 13(6): 371-80. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12718409&dopt=Abstract
Studies
139
•
Evolutionary history of Hepatitis B virus genotype F: an in-depth analysis of Argentine isolates. Author(s): Pineiro y Leone FG, Mbayed VA, Campos RH. Source: Virus Genes. 2003 August; 27(1): 103-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12913363&dopt=Abstract
•
Excellent outcome of Lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. Author(s): Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Source: Journal of Clinical Gastroenterology. 2003 July; 37(1): 64-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12811212&dopt=Abstract
•
Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. Author(s): Ben-Ari Z, Mor E, Tur-Kaspa R. Source: Journal of Internal Medicine. 2003 May; 253(5): 544-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12702032&dopt=Abstract
•
Expression of bile duct-type cytokeratin in noncancerous hepatocytes in patients with hepatitis B virus-related hepatocellular carcinoma. Author(s): Uenishi T, Kubo S, Hirohashi K, Yamamoto T, Ogawa M, Tanaka H, Shuto T, Kinoshita H. Source: Hepatogastroenterology. 2003 July-August; 50(52): 1101-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12845990&dopt=Abstract
•
Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFNgamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. Author(s): Mihm S, Schweyer S, Ramadori G. Source: Journal of Medical Virology. 2003 August; 70(4): 562-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794718&dopt=Abstract
•
Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Author(s): Aristegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL. Source: International Journal of Infectious Diseases : Ijid : Official Publication of the International Society for Infectious Diseases. 2003 June; 7(2): 143-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839717&dopt=Abstract
140 Hepatitis B
•
Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Author(s): Stroffolini T, Bianco E, Szklo A, Bernacchia R, Bove C, Colucci M, Cristina Coppola R, D'Argenio P, Lopalco P, Parlato A, Ragni P, Simonetti A, Zotti C, Mele A. Source: Vaccine. 2003 March 7; 21(11-12): 1246-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12559805&dopt=Abstract
•
Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Author(s): Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ. Source: Journal of Medical Virology. 2002 October; 68(2): 182-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12210406&dopt=Abstract
•
Factors influencing hepatitis B vaccine uptake in injecting drug users. Author(s): McGregor J, Marks PJ, Hayward A, Bell Y, Slack RC. Source: Journal of Public Health Medicine. 2003 June; 25(2): 165-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12848409&dopt=Abstract
•
Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. Author(s): Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, Haspolat K. Source: Journal of Gastroenterology and Hepatology. 2003 February; 18(2): 218-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12542609&dopt=Abstract
•
False-reactive test for hepatitis B surface antigen following administration of granulocyte-colony-stimulating factor. Author(s): Warren K, Eastlund T. Source: Vox Sanguinis. 2002 October; 83(3): 247-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12366767&dopt=Abstract
•
Familial clustering of hepatitis B infection: study of a family. Author(s): Verma G, Dalai P, Bapat M, Rathi P, Abraham P. Source: Indian J Gastroenterol. 2003 January-February; 22(1): 22-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12617448&dopt=Abstract
•
Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Author(s): Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Source: Scandinavian Journal of Gastroenterology. 2002 March; 37(3): 366-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11916202&dopt=Abstract
Studies
141
•
Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Author(s): Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Source: Gut. 2002 October; 51(4): 597-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12235087&dopt=Abstract
•
Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Author(s): Westhoff TH, Jochimsen F, Schmittel A, Stoffler-Meilicke M, Schafer JH, Zidek W, Gerlich WH, Thiel E. Source: Blood. 2003 September 1; 102(5): 1930. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930732&dopt=Abstract
•
Fatal outcome of SARS in a patient with reactivation of chronic hepatitis B. Author(s): Hui AY, Chan HL, Liew CT, Chan PK, To KF, Chan CP, Sung JJ. Source: The American Journal of Medicine. 2003 September; 115(4): 334-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12967706&dopt=Abstract
•
Fatal reactivation of hepatitis B virus following cytotoxic chemotherapy for acute myelogenous leukemia: fibrosing cholestatic hepatitis. Author(s): Kojima H, Abei M, Takei N, Mukai Y, Hasegawa Y, Iijima T, Nagasawa T. Source: European Journal of Haematology. 2002 August; 69(2): 101-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12366713&dopt=Abstract
•
Fetal meconium peritonitis in the infant of a woman with fulminant hepatitis B. A case report. Author(s): Su WH, Wang PH, Yuan CC, Chang SP. Source: J Reprod Med. 2002 November; 47(11): 952-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12497690&dopt=Abstract
•
Fibrosing cholestatic hepatitis-like syndrome in a hepatitis B virus and hepatitis C virus-negative renal transplant recipient: a case report with autopsy findings. Author(s): Duseja A, Nada R, Kalra N, Acharya SK, Minz M, Joshi K, Chawla Y. Source: Trop Gastroenterol. 2003 January-March; 24(1): 31-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12974214&dopt=Abstract
•
Fidelity of hepatitis B virus polymerase. Author(s): Park SG, Kim Y, Park E, Ryu HM, Jung G. Source: European Journal of Biochemistry / Febs. 2003 July; 270(14): 2929-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12846825&dopt=Abstract
142 Hepatitis B
•
First dose of hepatitis B vaccine in infants. Author(s): Mathew A. Source: Indian Pediatrics. 2002 October; 39(10): 981-2; Author Reply 982-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12428054&dopt=Abstract
•
Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Author(s): Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Source: Blood. 2002 October 1; 100(7): 2637-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12239179&dopt=Abstract
•
Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Author(s): Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, Gomes SA. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2003 February; 22(2): 92-8. Epub 2003 February 18. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12627282&dopt=Abstract
•
Fulminant hepatic failure caused by hepatitis B virus activation after chemotherapy for breast cancer treated with liver transplantation: a case report. Author(s): Hung CM, Jeng LB, Lee WC, Yu MC, Kuo LM, Chen MF. Source: Transplantation Proceedings. 2003 February; 35(1): 387-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591453&dopt=Abstract
•
Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. Author(s): Michel M, Duvoux C, Hezode C, Cherqui D. Source: The Journal of Rheumatology. 2003 July; 30(7): 1624-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858469&dopt=Abstract
•
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Author(s): Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L. Source: Antimicrobial Agents and Chemotherapy. 2003 June; 47(6): 1936-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12760870&dopt=Abstract
•
Genetic variability in hepatitis B viruses. Author(s): Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Source: The Journal of General Virology. 2002 June; 83(Pt 6): 1267-80. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12029141&dopt=Abstract
Studies
143
•
Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. Author(s): Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS. Source: Journal of Medical Virology. 2002 November; 68(3): 319-27. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12226817&dopt=Abstract
•
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. Author(s): Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, Khan N, Trepo C, Wands J, Tong S. Source: Journal of Virology. 2003 June; 77(12): 6601-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12767980&dopt=Abstract
•
Genomic mutations with amino acid substitutions of circulating hepatitis B virus found in non-B, non-C patients with hepatocellular carcinoma. Author(s): Nakamoto N, Saito H, Ebinuma H, Tada S, Saito Y, Kurita S, Kitamura K, Ishii H. Source: Intern Med. 2003 April; 42(4): 322-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12729320&dopt=Abstract
•
Genotype analysis, using PCR with type-specific primers, of hepatitis B virus isolates from patients coinfected with hepatitis delta virus genotype II from Miyako Island, Japan. Author(s): Moriyama M, Taira M, Matsumura H, Aoki H, Mikuni M, Kaneko M, Shioda A, Iwaguchi K, Arai S, Ichijima S, Iwasaki H, Tanaka N, Abe K, Arakawa Y. Source: Intervirology. 2003; 46(2): 114-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684550&dopt=Abstract
•
Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Author(s): Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, Sung JJ. Source: The American Journal of Gastroenterology. 2002 October; 97(10): 2629-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12385451&dopt=Abstract
•
Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. Author(s): Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Source: The Journal of General Virology. 2002 August; 83(Pt 8): 2059-73. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12124470&dopt=Abstract
144 Hepatitis B
•
Genotype mixtures of hepatitis B virus in patients treated with interferon. Author(s): Hannoun C, Krogsgaard K, Horal P, Lindh M; Interpred trial group. Source: The Journal of Infectious Diseases. 2002 September 15; 186(6): 752-9. Epub 2002 August 28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12198608&dopt=Abstract
•
Genotype, serotype, and phylogenetic characterization of the complete genome sequence of hepatitis B virus isolates from Malawian chronic carriers of the virus. Author(s): Sugauchi F, Orito E, Kato H, Suzuki S, Kawakita S, Sakamoto Y, Fukushima K, Akiba T, Yoshihara N, Ueda R, Mizokami M. Source: Journal of Medical Virology. 2003 January; 69(1): 33-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12436475&dopt=Abstract
•
Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. Author(s): Kao JH, Chen PJ, Lai MY, Chen DS. Source: Journal of Clinical Microbiology. 2002 April; 40(4): 1207-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11923332&dopt=Abstract
•
Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. Author(s): Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal AA, Zaid MA, Agha S, Mizokami M. Source: Journal of Medical Virology. 2003 August; 70(4): 529-36. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794714&dopt=Abstract
•
Genotypes and S-gene variability of Mexican hepatitis B virus strains. Author(s): Sanchez LV, Maldonado M, Bastidas-Ramirez BE, Norder H, Panduro A. Source: Journal of Medical Virology. 2002 September; 68(1): 24-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12210427&dopt=Abstract
•
Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Author(s): Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R. Source: The American Journal of Gastroenterology. 2003 January; 98(1): 151-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12526951&dopt=Abstract
•
Genotyping study of hepatitis B virus in its intrauterine transmission. Author(s): Guo PF, Zhong M, Hou JL. Source: Di Yi June Yi Da Xue Xue Bao. 2002 April; 22(4): 303-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12390728&dopt=Abstract
Studies
145
•
Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries. Author(s): Ding X, Park YN, Taltavull TC, Thung SN, Jin X, Jin Y, Trung NS, Edamoto Y, Sata T, Abe K. Source: Japanese Journal of Infectious Diseases. 2003 February; 56(1): 12-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12711820&dopt=Abstract
•
Global control of hepatitis B virus infection. Author(s): Kao JH, Chen DS. Source: The Lancet Infectious Diseases. 2002 July; 2(7): 395-403. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12127351&dopt=Abstract
•
Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan. Author(s): Kane MA. Source: Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2003 January; 12(1): 2-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12540496&dopt=Abstract
•
Global progress toward universal childhood hepatitis B vaccination, 2003. Author(s): Centers for Disease Control and Prevention (CDC). Source: Mmwr. Morbidity and Mortality Weekly Report. 2003 September 12; 52(36): 86870. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12970620&dopt=Abstract
•
Gulliane Barre syndrome following vaccination with hepatitis B vaccine. Author(s): Seti NK, Reddi R, Anand I, Sethi PK. Source: J Assoc Physicians India. 2002 July; 50: 989. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126370&dopt=Abstract
•
Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles. Author(s): Souza KP, Luz JA, Teles SA, Carneiro MA, Oliveira LA, Gomes AS, Dias MA, Gomes SA, Yoshida CF, Martins RM. Source: Memorias Do Instituto Oswaldo Cruz. 2003 July; 98(5): 599-603. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=13677340&dopt=Abstract
146 Hepatitis B
•
Hepatitis B and you: a patient education resource for pregnant women and new mothers. Author(s): Wilson HR. Source: Journal of Women's Health (2002). 2003 June; 12(5): 437-41. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869290&dopt=Abstract
•
Hepatitis B immune globulin preparations and use in liver transplantation. Author(s): Terrault NA, Vyas G. Source: Clinics in Liver Disease. 2003 August; 7(3): 537-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509525&dopt=Abstract
•
Hepatitis B knowledge and practices among Chinese Canadian women in Vancouver, British Columbia. Author(s): Thompson MJ, Taylor VM, Yasui Y, Hislop TG, Jackson JC, Kuniyuki A, Teh C. Source: Canadian Journal of Public Health. Revue Canadienne De Sante Publique. 2003 July-August; 94(4): 281-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12873087&dopt=Abstract
•
Hepatitis B surface antigen (HbsAg) in the sera of medical, nursing and microbiology students in Ibadan, Nigeria. Author(s): Odemuyiwa SO, Oyedele OI, Forbi JC, Elemuwa CO, Ibeh MA, Kfutwah AK, Uche LN, Anibaba AA. Source: Afr J Med Med Sci. 2001 December; 30(4): 333-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14510114&dopt=Abstract
•
Hepatitis B vaccination for sex workers: do outreach programmes perform better? Author(s): Mak R, Traen A, Claeyssens M, Van Renterghem L, Leroux-Roels G, Van Damme P. Source: Sexually Transmitted Infections. 2003 April; 79(2): 157-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690142&dopt=Abstract
•
Hepatitis B vaccination of incarcerated women: a pilot program. Author(s): Clarke J, Schwartzapfel B, Pomposelli J, Allen S, Spaulding A, Rich JD. Source: Journal of Health Care for the Poor and Underserved. 2003 August; 14(3): 31823. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12955912&dopt=Abstract
•
Hepatitis B vaccination: myths and controversies. Author(s): Mittal SK. Source: Indian J Pediatr. 2003 June; 70(6): 499-502. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12921320&dopt=Abstract
Studies
147
•
Hepatitis B vaccine and risk of multiple sclerosis. Author(s): DeStefano F, Verstraeten T, Chen RT. Source: Expert Rev Vaccines. 2002 December; 1(4): 461-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12901584&dopt=Abstract
•
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. Author(s): Gunson RN, Shouval D, Roggendorf M, Zaaijer H, Nicholas H, Holzmann H, de Schryver A, Reynders D, Connell J, Gerlich WH, Marinho RT, Tsantoulas D, Rigopoulou E, Rosenheim M, Valla D, Puro V, Struwe J, Tedder R, Aitken C, Alter M, Schalm SW, Carman WF; European Consensus Group. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2003 August; 27(3): 213-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878084&dopt=Abstract
•
Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. Author(s): Fernandez M, Quiroga JA, Carreno V. Source: The Journal of General Virology. 2003 August; 84(Pt 8): 2073-82. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867637&dopt=Abstract
•
Hepatitis B virus genotypes in the United States: results of a nationwide study. Author(s): Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, Carey W, Brown RS Jr, Luketic VA, Terrault N, Lok AS. Source: Gastroenterology. 2003 August; 125(2): 444-51. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12891547&dopt=Abstract
•
Hepatitis B virus molecular diversity in Indonesia. Author(s): Handojo Muljono D, Soemohardjo S. Source: Advances in Experimental Medicine and Biology. 2003; 531: 163-76. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916788&dopt=Abstract
•
Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. Author(s): Shirakata Y, Koike K. Source: The Journal of Biological Chemistry. 2003 June 13; 278(24): 22071-8. Epub 2003 April 03. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12676947&dopt=Abstract
148 Hepatitis B
•
Hepatitis B virus X protein induces TNF-alpha expression via down-regulation of selenoprotein P in human hepatoma cell line, HepG2. Author(s): Yi YS, Park SG, Byeon SM, Kwon YG, Jung G. Source: Biochimica Et Biophysica Acta. 2003 July 30; 1638(3): 249-56. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878326&dopt=Abstract
•
Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States. Author(s): Edlich RF, Diallo AO, Buchanan L, Martin ML. Source: Journal of Long-Term Effects of Medical Implants. 2003; 13(2): 117-25. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14510285&dopt=Abstract
•
Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Author(s): Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H, Broelsch CE, Gerken G. Source: Immunology. 2003 August; 109(4): 487-95. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12871214&dopt=Abstract
•
Hepatitis B: Implications for the oral health worker. Author(s): Naidoo S. Source: Sadj. 2003 June; 58(5): 196-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14596264&dopt=Abstract
•
Hepatocellular carcinoma in a patient with primary biliary cirrhosis and seronegativity for markers of hepatitis B virus and hepatitis C virus: report of a case. Author(s): Sunagawa H, Takayama H, Yamashiro T, Sasaki H, Sashida Y, Matsuura K, Kayou M. Source: Surgery Today. 2003; 33(3): 219-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12658391&dopt=Abstract
•
Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Author(s): Suzuki Y, Arase Y, Ikeda K, Saitoh S, Tsubota A, Suzuki F, Kobayashi M, Akuta N, Someya T, Miyakawa Y, Kumada H. Source: Intervirology. 2003; 46(3): 164-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867754&dopt=Abstract
Studies
149
•
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Author(s): Bienzle U, Gunther M, Neuhaus R, Vandepapeliere P, Vollmar J, Lun A, Neuhaus P. Source: Hepatology (Baltimore, Md.). 2003 October; 38(4): 811-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14512868&dopt=Abstract
•
Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to colombian infants after a birth dose of hepatitis B vaccine. Author(s): Lopez P, Rubiano L, del Pilar Rubio M, David MP, Safary A. Source: Expert Rev Vaccines. 2002 October; 1(3): 277-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12901568&dopt=Abstract
•
Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Author(s): Samuel D, Kimmoun E. Source: Clinics in Liver Disease. 2003 August; 7(3): 667-81. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509533&dopt=Abstract
•
Impact of the introduction of a combined Haemophilus B conjugate vaccine and hepatitis B recombinant vaccine on vaccine coverage rats in a large West Coast health maintenance organization. Author(s): Davis RL, Coplan P, Mell L, Black S, Shinefield H, Lewis E. Source: The Pediatric Infectious Disease Journal. 2003 July; 22(7): 657-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12886895&dopt=Abstract
•
Impact of the thimerosal controversy on hepatitis B vaccine coverage of infants born to women of unknown hepatitis B surface antigen status in Michigan. Author(s): Biroscak BJ, Fiore AE, Fasano N, Fineis P, Collins MP, Stoltman G. Source: Pediatrics. 2003 June; 111(6 Pt 1): E645-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12777580&dopt=Abstract
•
Impact of universal preadolescent vaccination against hepatitis B on antenatal seroprevalence of hepatitis B markers in British Columbia women. Author(s): Dawar M, Patrick DM, Bigham M, Cook D, Krajden M, Ng H. Source: Cmaj : Canadian Medical Association Journal = Journal De L'association Medicale Canadienne. 2003 March 18; 168(6): 703-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12642425&dopt=Abstract
150 Hepatitis B
•
Implementation of universal antenatal screening for HIV and hepatitis B--lessons for future work. Author(s): Baird J, Hammond M, Barker M. Source: Journal of Public Health Medicine. 2003 June; 25(2): 171-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12848410&dopt=Abstract
•
Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. Author(s): Weber O, Siegling A, Friebe A, Limmer A, Schlapp T, Knolle P, Mercer A, Schaller H, Volk HD. Source: The Journal of General Virology. 2003 July; 84(Pt 7): 1843-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12810878&dopt=Abstract
•
Infection with hepatitis B and C viruses and human retroviruses (HTLV-I and HIV) among high-risk Lebanese patients. Author(s): Ramia S, Klayme S, Naman R. Source: Annals of Tropical Medicine and Parasitology. 2003 March; 97(2): 187-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12803874&dopt=Abstract
•
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia. Author(s): Sarmati L, Andreoni M, Suligoi B, Bugarini R, Uccella I, Pozio E, Rezza G. Source: The American Journal of Tropical Medicine and Hygiene. 2003 April; 68(4): 5012. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12875304&dopt=Abstract
•
Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. Author(s): Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, Mizokami M. Source: Journal of Medical Virology. 2003 August; 70(4): 537-44. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794715&dopt=Abstract
•
Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues. Author(s): Wu JM, Lin JS, Xie N, Liang KH. Source: World Journal of Gastroenterology : Wjg. 2003 August; 9(8): 1840-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12918134&dopt=Abstract
•
Inhibition of hepatitis B virus expression and replication by RNA interference. Author(s): Shlomai A, Shaul Y. Source: Hepatology (Baltimore, Md.). 2003 April; 37(4): 764-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668968&dopt=Abstract
Studies
151
•
Integrating behavioral theory to understand hepatitis B vaccination among men who have sex with men. Author(s): Rhodes SD, Grimley DM, Hergenrather KC. Source: American Journal of Health Behavior. 2003 July-August; 27(4): 291-300. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12882423&dopt=Abstract
•
Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Author(s): Ferber MJ, Montoya DP, Yu C, Aderca I, McGee A, Thorland EC, Nagorney DM, Gostout BS, Burgart LJ, Boix L, Bruix J, McMahon BJ, Cheung TH, Chung TK, Wong YF, Smith DI, Roberts LR. Source: Oncogene. 2003 June 12; 22(24): 3813-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802289&dopt=Abstract
•
Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses. Author(s): Tabor E. Source: Dig Liver Dis. 2003 May; 35(5): 297-305. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12846400&dopt=Abstract
•
Interferon therapy in hepatitis B e antigen-negative chronic hepatitis B. Author(s): Colli A, Massironi S, Anreoletti M. Source: Hepatology (Baltimore, Md.). 2003 September; 38(3): 779-80; Author Reply 780. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12939609&dopt=Abstract
•
Intrafamilial transmission of hepatitis B virus in the eastern Anatolian region of Turkey. Author(s): Erol S, Ozkurt Z, Ertek M, Tasyaran MA. Source: European Journal of Gastroenterology & Hepatology. 2003 April; 15(4): 345-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12655252&dopt=Abstract
•
Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Author(s): Forgues M, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, Valerie K, Fukasawa K, Wang XW. Source: Molecular and Cellular Biology. 2003 August; 23(15): 5282-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12861014&dopt=Abstract
152 Hepatitis B
•
Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type1-infected individuals. Author(s): Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, Ukomadu C. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 June 15; 36(12): 1602-5. Epub 2003 Jun 06. Erratum In: Clin Infect Dis. 2003 July 1; 37(1): 157. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12802762&dopt=Abstract
•
Kala azar in a case of chronic hepatitis B with cirrhosis of liver. Author(s): Dhar MC, Chaudhuri S, Pain S, Sau TJ, Bagchi SR. Source: J Assoc Physicians India. 2001 November; 49: 1127. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11868875&dopt=Abstract
•
Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Author(s): Gaillard RK, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L, Allen MI, Condreay P, Miller WH, Condreay LD. Source: Antimicrobial Agents and Chemotherapy. 2002 April; 46(4): 1005-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11897582&dopt=Abstract
•
Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. Author(s): Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Source: Journal of Medical Virology. 2003 March; 69(3): 313-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12526040&dopt=Abstract
•
Lack of epidemiological evidence for a role of resolved hepatitis B virus infection in hepatocarcinogenesis in patients infected with hepatitis C virus in Japan. Author(s): Hiraoka T, Katayama K, Tanaka J, Ohno N, Joko K, Komiya Y, Kumagai J, Mizui M, Hino K, Miyakawa Y, Yoshizawa H. Source: Intervirology. 2003; 46(3): 171-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867755&dopt=Abstract
•
Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. Author(s): Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2003 May; 27(1): 111-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12727536&dopt=Abstract
Studies
153
•
Lamivudine plasma levels in chronic hepatitis B patients. Author(s): Wolters LM, Geerlings CJ, van Dijk L, Niesters HG, Vulto AG, de Man RA. Source: The Netherlands Journal of Medicine. 2003 January; 61(1): 9-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12688563&dopt=Abstract
•
Lamivudine therapy for hepatitis B in renal transplantation. Author(s): Santos FR, Haiashi AR, Araujo MR, Abensur H, Romao Junior JE, Noronha IL. Source: Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas / Sociedade Brasileira De Biofisica. [et Al.]. 2002 February; 35(2): 199-203. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11847523&dopt=Abstract
•
Lamivudine therapy in renal allograft recipients with hepatitis B virus infection. Author(s): Tsang WK, Tong KL, Chan HW. Source: Transplantation Proceedings. 2003 February; 35(1): 278-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591398&dopt=Abstract
•
Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. Author(s): van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Source: Journal of Viral Hepatitis. 2003 July; 10(4): 294-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12823596&dopt=Abstract
•
Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Author(s): Hartman C, Berkowitz D, Shouval D, Eshach-Adiv O, Hino B, Rimon N, Satinger I, Kra-Oz T, Daudi N, Shamir R. Source: The Pediatric Infectious Disease Journal. 2003 March; 22(3): 224-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12634582&dopt=Abstract
•
Lethal liver failure in an elderly patient with hepatitis B superinfected with EpsteinBarr virus. Author(s): Jimenez-Saenz M, Perez-Pozo JM, Leal-Luna A, Herrerias-Gutierrez JM. Source: European Journal of Gastroenterology & Hepatology. 2002 November; 14(11): 1283-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12439128&dopt=Abstract
154 Hepatitis B
•
Levels of plasma malondialdehyde and erythrocyte antioxidant enzyme activities in patients with chronic hepatitis B. Author(s): Demirdag K, Yilmaz S, Ozdarendeli A, Ozden M, Kalkan A, Kilic SS. Source: Hepatogastroenterology. 2003 May-June; 50(51): 766-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12828081&dopt=Abstract
•
Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients. Author(s): Ohnishi M, Kanda Y, Takeuchi T, Won Kim S, Hori A, Niiya H, Chizuka A, Nakai K, Saito T, Makimoto A, Tanosaki R, Watanabe T, Kobayashi Y, Tobinai K, Takaue Y, Mineishi S. Source: Transplantation. 2002 March 15; 73(5): 812-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11907433&dopt=Abstract
•
Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Author(s): Williams IT, Goldstein ST, Tufa J, Tauillii S, Margolis HS, Mahoney FJ. Source: The Pediatric Infectious Disease Journal. 2003 February; 22(2): 157-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12586980&dopt=Abstract
•
Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy. Author(s): Akuta N, Suzuki F, Tsubota A, Arase Y, Suzuki Y, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. Source: Digestive Diseases and Sciences. 2002 February; 47(2): 405-14. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11855559&dopt=Abstract
•
Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. Author(s): Marx G, Martin SR, Chicoine JF, Alvarez F. Source: The Journal of Infectious Diseases. 2002 August 1; 186(3): 295-301. Epub 2002 July 17. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12134225&dopt=Abstract
•
Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Author(s): Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M. Source: Hepatology (Baltimore, Md.). 2003 May; 37(5): 1172-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12717399&dopt=Abstract
Studies
155
•
Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. Author(s): Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Source: The Journal of Infectious Diseases. 2003 January 1; 187(1): 134-8. Epub 2002 December 13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12508157&dopt=Abstract
•
Long-term outcome of kidney transplantation in patients with hepatitis B or C positive. Author(s): Lezaic V, Djukanovic Lj, Blagojevic R, Radivojevic D. Source: Clinical Transplantation. 2003 February; 17(1): 75-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12588326&dopt=Abstract
•
Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Author(s): Esposito S, Faldella G, Giammanco A, Bosis S, Friscia O, Clerici M, Principi N. Source: Vaccine. 2002 July 26; 20(23-24): 2928-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12126904&dopt=Abstract
•
Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study. Author(s): Akuta N, Tsubota A, Suzuki F, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Source: Journal of Hepatology. 2003 January; 38(1): 91-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12480565&dopt=Abstract
•
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24month interferon therapy. Author(s): Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M. Source: Hepatology (Baltimore, Md.). 2003 April; 37(4): 756-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12668967&dopt=Abstract
•
Low prevalence of hepatitis B and C markers in non-amazonian indigenous population. Author(s): Aguiar JI, de Souza JA, Aguiar ES, Oliveira JM, de Lemos ER, Yoshida CF. Source: The Brazilian Journal of Infectious Diseases : an Official Publication of the Brazilian Society of Infectious Diseases. 2002 October; 6(5): 269-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12495611&dopt=Abstract
156 Hepatitis B
•
Management of chronic hepatitis B. Author(s): Conjeevaram HS, Lok AS. Source: Journal of Hepatology. 2003; 38 Suppl 1: S90-103. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591188&dopt=Abstract
•
Management of hepatitis B and C in HIV co-infected patients. Author(s): Rockstroh JK. Source: Journal of Acquired Immune Deficiency Syndromes (1999). 2003 September; 34 Suppl 1: S59-65. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14562859&dopt=Abstract
•
Management of hepatitis B and C in renal failure and renal transplant recipients. Author(s): Amarapurkar D, Das HS. Source: Trop Gastroenterol. 2002 April-June; 23(2): 49-53. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12632966&dopt=Abstract
•
Management of hepatitis B virus infected health care workers based on HBV DNA levels. Author(s): Schalm SW, Buster EH. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2003 August; 27(3): 231-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12878085&dopt=Abstract
•
Management of HIV and hepatitis B or C co-infection in 15 HIV treatment centres. Disparity between protocols and practice. Author(s): Brook MG, Jones K, Dale AW, Miller RF. Source: International Journal of Std & Aids. 2003 July; 14(7): 469-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12869227&dopt=Abstract
•
Management of occupational exposure to hepatitis B, hepatitis C, and human immunodeficiency virus. Author(s): Bednarsh H, Eklund K. Source: Compend Contin Educ Dent. 2002 June; 23(6): 561-6, 568-9; Quiz 570. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12789970&dopt=Abstract
•
Markers of disease activity in chronic hepatitis B virus infection. Author(s): Yalcin K, Degertekin H, Yildiz F, Celik Y. Source: Clinical and Investigative Medicine. Medecine Clinique Et Experimentale. 2003 February; 26(1): 27-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12659467&dopt=Abstract
Studies
157
•
Modified protocol for hepatitis B virus DNA isolation and detection. Author(s): Khaja MN, Poduri CD, Habibullah CM. Source: Analytical Biochemistry. 2003 March 1; 314(1): 142-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12633613&dopt=Abstract
•
Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. Author(s): Hsia CC, Scudamore CH, Di Bisceglie AM, Tabor E. Source: Journal of Medical Virology. 2003 May; 70(1): 20-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12629639&dopt=Abstract
•
Molecular aspects of hepatitis B viral infection and the viral carcinogenesis. Author(s): Ryu WS. Source: J Biochem Mol Biol. 2003 January 31; 36(1): 138-43. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12542984&dopt=Abstract
•
Molecular chaperone GRP78/BiP interacts with the large surface protein of hepatitis B virus in vitro and in vivo. Author(s): Cho DY, Yang GH, Ryu CJ, Hong HJ. Source: Journal of Virology. 2003 February; 77(4): 2784-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12552023&dopt=Abstract
•
Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B virus carriers negative for HBsAg but positive for anti-HBs and anti-HBc. Author(s): Oon CJ, Chen WN, Goh KT, Mesenas S, Ng HS, Chiang G, Tan C, Koh S, Teng SW, Toh I, Moh MC, Goo KS, Tan K, Leong AL, Tan GS. Source: Journal of Gastroenterology and Hepatology. 2002 December; 17 Suppl: S491-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534784&dopt=Abstract
•
Molecular epidemiology and immunology of hepatitis B virus infection - an update. Author(s): Pumpens P, Grens E, Nassal M. Source: Intervirology. 2002; 45(4-6): 218-32. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12566704&dopt=Abstract
•
Molecular epidemiology and transmission of hepatitis B virus in close family contacts of HBV-related chronic liver disease patients. Author(s): Thakur V, Kazim SN, Guptan RC, Malhotra V, Sarin SK. Source: Journal of Medical Virology. 2003 August; 70(4): 520-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12794713&dopt=Abstract
158 Hepatitis B
•
Molecular epidemiology of gibbon hepatitis B virus transmission. Author(s): Noppornpanth S, Haagmans BL, Bhattarakosol P, Ratanakorn P, Niesters HG, Osterhaus AD, Poovorawan Y. Source: The Journal of General Virology. 2003 January; 84(Pt 1): 147-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12533711&dopt=Abstract
•
Molecular epidemiology of hepatitis B viral serotypes and genotypes in taiwan. Author(s): Liu CJ, Kao JH, Chen PJ, Lai MY, Chen DS. Source: Journal of Biomedical Science. 2002 March-April; 9(2): 166-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11914584&dopt=Abstract
•
Molecular epidemiology of hepatitis viruses and genotypic distribution of hepatitis B and C viruses in Harbin, China. Author(s): Ding X, Gu H, Zhong ZH, Zilong X, Tran HT, Iwaki Y, Li TC, Sata T, Abe K. Source: Japanese Journal of Infectious Diseases. 2003 February; 56(1): 19-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12711821&dopt=Abstract
•
Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. Author(s): Crook PD, Jones ME, Hall AJ. Source: International Journal of Epidemiology. 2003 February; 32(1): 118-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690022&dopt=Abstract
•
Mutations within the hepatitis B virus genome among chronic hepatitis B patients with hepatocellular carcinoma. Author(s): Blackberg J, Kidd-Ljunggren K. Source: Journal of Medical Virology. 2003 September; 71(1): 18-23. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858404&dopt=Abstract
•
Natural history and prognosis of hepatitis B. Author(s): Fattovich G. Source: Seminars in Liver Disease. 2003 February; 23(1): 47-58. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12616450&dopt=Abstract
•
Natural history of hepatitis B and outcomes after liver transplantation. Author(s): Huang MA, Lok AS. Source: Clinics in Liver Disease. 2003 August; 7(3): 521-36. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509524&dopt=Abstract
Studies
159
•
New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. Author(s): Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, Maki N. Source: Journal of Clinical Microbiology. 2003 May; 41(5): 1901-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12734224&dopt=Abstract
•
New immunization initiatives and progress toward the global control of hepatitis B. Author(s): Kane MA, Brooks A. Source: Current Opinion in Infectious Diseases. 2002 October; 15(5): 465-9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12686877&dopt=Abstract
•
New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Author(s): Feld J, Lee JY, Locarnini S. Source: Hepatology (Baltimore, Md.). 2003 September; 38(3): 545-53. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12939579&dopt=Abstract
•
Non-responders to hepatitis B vaccination: a review. Author(s): Kubba AK, Taylor P, Graneek B, Strobel S. Source: Commun Dis Public Health. 2003 June; 6(2): 106-12. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12889288&dopt=Abstract
•
Novel assay of competitively differentiated polymerase chain reaction for screening point mutation of hepatitis B virus. Author(s): Peng XM, Chen XJ, Li JG, Gu L, Huang YS, Gao ZL. Source: World Journal of Gastroenterology : Wjg. 2003 August; 9(8): 1743-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12918112&dopt=Abstract
•
Nuclear import of hepatitis B virus capsids and release of the viral genome. Author(s): Rabe B, Vlachou A, Pante N, Helenius A, Kann M. Source: Proceedings of the National Academy of Sciences of the United States of America. 2003 August 19; 100(17): 9849-54. Epub 2003 Aug 08. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12909718&dopt=Abstract
•
Nucleoside analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Author(s): Yu AS, Keeffe EB. Source: Clinics in Liver Disease. 2003 August; 7(3): 551-72. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509526&dopt=Abstract
160 Hepatitis B
•
Nursing staff knowledge of the hepatitis B virus including attitudes and acceptance of hepatitis B vaccination: development of an effective program. Author(s): McGrane J, Staines A. Source: Aaohn Journal : Official Journal of the American Association of Occupational Health Nurses. 2003 August; 51(8): 347-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12934862&dopt=Abstract
•
Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Author(s): Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A. Source: Bmj (Clinical Research Ed.). 2002 September 14; 325(7364): 569. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12228132&dopt=Abstract
•
Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. Author(s): Kao JH, Chen PJ, Lai MY, Chen DS. Source: Journal of Clinical Microbiology. 2002 November; 40(11): 4068-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12409376&dopt=Abstract
•
Occult hepatitis B virus infection in HIV/hepatitis C virus co-infected patients. Author(s): Fabris P, Giordani MT, Tositti G, Rassu M, De Lalla F. Source: Aids (London, England). 2003 July 4; 17(10): 1581-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12824807&dopt=Abstract
•
Occult hepatitis B. Author(s): Torbenson M, Thomas DL. Source: The Lancet Infectious Diseases. 2002 August; 2(8): 479-86. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12150847&dopt=Abstract
•
Occupational risk of infection by human immunodeficiency and hepatitis B viruses among health workers in south-eastern Nigeria. Author(s): Ansa VO, Udoma EJ, Umoh MS, Anah MU. Source: East Afr Med J. 2002 May; 79(5): 254-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12638809&dopt=Abstract
•
Offering the vaccine and accepting it: an audit of hepatitis B vaccination in West Midlands region. Author(s): Jaleel H, Allan PS, Huengsberg M, Natin D; West Midlands Regional Audit Committee. Source: International Journal of Std & Aids. 2003 September; 14(9): 632-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14511502&dopt=Abstract
Studies
161
•
One two tandem of lamivudine and inferferon might work for patients with chronic hepatitis B who failed inferferon monotherapy. Author(s): Kaplan DD, Reddy KR. Source: The American Journal of Gastroenterology. 2002 September; 97(9): 2465-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12358276&dopt=Abstract
•
Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study. Author(s): Bozkaya H, Yurdaydin C, Bozdayi AM, Erkan O, Karayalcin S, Uzunalimoglu O. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2002 October 15; 35(8): 960-5. Epub 2002 September 25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12355383&dopt=Abstract
•
Overexpression and purification of the hepatitis B e antigen precursor. Author(s): Laine S, Salhi S, Rossignol JM. Source: Journal of Virological Methods. 2002 May; 103(1): 67-74. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11906734&dopt=Abstract
•
Overview: past and future of immunologic intervention in the pathogenesis, prophylaxis and therapeusis of hepatitis B. Author(s): Hilleman MR. Source: Journal of Gastroenterology and Hepatology. 2002 December; 17 Suppl: S449-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12534776&dopt=Abstract
•
Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. Author(s): Zhang W, Hacker HJ, Tokus M, Bock T, Schroder CH. Source: Journal of Medical Virology. 2003 September; 71(1): 24-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858405&dopt=Abstract
•
Peripheral neurological symptoms after hepatitis B virus vaccination. Author(s): Bantz PM, Peiser C, Groneberg DA. Source: Qjm : Monthly Journal of the Association of Physicians. 2003 August; 96(8): 611. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12897348&dopt=Abstract
162 Hepatitis B
•
Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. Author(s): Yu MW, Yang SY, Pan IJ, Lin CL, Liu CJ, Liaw YF, Lin SM, Chen PJ, Lee SD, Chen CJ. Source: Journal of the National Cancer Institute. 2003 October 1; 95(19): 1485-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14519756&dopt=Abstract
•
Precore wild-type hepatitis B virus with G1896 in the resolution of persistent hepatitis B virus infection. Author(s): Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Hosaka T, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y, Kumada H. Source: Intervirology. 2003; 46(3): 157-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867753&dopt=Abstract
•
Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. Author(s): Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Source: Journal of Virology. 2003 September; 77(17): 9511-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12915565&dopt=Abstract
•
Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. Author(s): Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Source: The Journal of Infectious Diseases. 2003 August 15; 188(4): 571-7. Epub 2003 Aug 05. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12898445&dopt=Abstract
•
Prevalence of hepatitis B virus markers in surgeons in Lagos, Nigeria. Author(s): Belo AC. Source: East Afr Med J. 2000 May; 77(5): 283-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12858922&dopt=Abstract
•
Previous hepatitis B virus infection is associated with worse disease stage and occult hepatitis B virus infection has low prevalence and pathogenicity in hepatitis C viruspositive patients. Author(s): Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Ansaldi F, Durando P, Risso D, Lantieri PB, Icardi GC, Testa R. Source: Liver International : Official Journal of the International Association for the Study of the Liver. 2003 February; 23(1): 12-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12640722&dopt=Abstract
Studies
163
•
Prognostic factors in severe exacerbation of chronic hepatitis B. Author(s): Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, Doutreloigne J, Bogaerts V, Wong BC, Fan ST, Lai CL. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 April 15; 36(8): 979-84. Epub 2003 Apr 02. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12684909&dopt=Abstract
•
Psychosocial predictors of hepatitis B vaccination among young African-American gay men in the deep south. Author(s): Rhodes SD, Diclemente RJ. Source: Sexually Transmitted Diseases. 2003 May; 30(5): 449-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916138&dopt=Abstract
•
Quantification and genotyping in management of chronic hepatitis B and C. Author(s): Zoulim F. Source: Virus Research. 2002 January 30; 82(1-2): 45-52. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11885949&dopt=Abstract
•
Quantitative analysis of hepatitis B virus DNA by real-lime amplification. Author(s): Zanella I, Rossini A, Domenighini D, Albertini A, Cariani E. Source: European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology. 2002 January; 21(1): 22-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11913497&dopt=Abstract
•
Quantitative detection of hepatitis B virus DNA in serum by a new rapid real-time fluorescence PCR assay. Author(s): Jardi R, Rodriguez F, Buti M, Costa X, Cotrina M, Valdes A, Galimany R, Esteban R, Guardia J. Source: Journal of Viral Hepatitis. 2001 November; 8(6): 465-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11703579&dopt=Abstract
•
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Author(s): Chu CJ, Hussain M, Lok AS. Source: Hepatology (Baltimore, Md.). 2002 December; 36(6): 1408-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12447866&dopt=Abstract
•
Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. Author(s): Bruno R, Sacchi P, Zocchetti C, Ciappina V, Puoti M, Filice G. Source: Aids (London, England). 2003 March 28; 17(5): 783-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12646813&dopt=Abstract
164 Hepatitis B
•
Re: Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. Author(s): Sung YM, Tang NL, Lai PB, Chan PK, Chan FK. Source: Journal of the National Cancer Institute. 2003 April 2; 95(7): 559-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12671025&dopt=Abstract
•
Recombinant hepatitis B vaccination in renal failure patients. Author(s): Vlassopoulos D. Source: Current Pharmaceutical Biotechnology. 2003 April; 4(2): 141-51. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12678888&dopt=Abstract
•
Recurrent hepatitis B flares in an HIV-positive patient. Author(s): Jenny-Avital ER. Source: Aids Clin Care. 2003 January; 15(1): 4-5. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12685421&dopt=Abstract
•
Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3. Author(s): Leach JK, Qiao L, Fang Y, Han SL, Gilfor D, Fisher PB, Grant S, Hylemon PB, Peterson D, Dent P. Source: Journal of Gastroenterology and Hepatology. 2003 April; 18(4): 376-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12653885&dopt=Abstract
•
Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B. Author(s): Mihm U, Sarrazin C, Herrmann E, Teuber G, von Wagner M, Kronenberger B, Zeuzem S. Source: Zeitschrift Fur Gastroenterologie. 2003 March; 41(3): 249-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12664345&dopt=Abstract
•
Rising incidence of hepatocellular carcinoma: the role of hepatitis B and C; the impact on transplantation and outcomes. Author(s): Kaplan DE, Reddy KR. Source: Clinics in Liver Disease. 2003 August; 7(3): 683-714. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14509534&dopt=Abstract
•
Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Author(s): Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, Lai CL. Source: Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 2003 August 15; 37(4): 593-7. Epub 2003 July 29. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12905145&dopt=Abstract
Studies
165
•
Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. Author(s): Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LT. Source: World Journal of Gastroenterology : Wjg. 2003 September; 9(9): 2004-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12970894&dopt=Abstract
•
Routine hepatitis B immunization in India: cost effectiveness needs reassessment. Author(s): Puliyel JM, Mittal R, Tyagi V, Gupta S. Source: Indian J Pediatr. 2003 February; 70(2): 188. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12661821&dopt=Abstract
•
Safety of immunisation and adverse events following vaccination against hepatitis B. Author(s): Duclos P. Source: Expert Opinion on Drug Safety. 2003 May; 2(3): 225-31. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12904102&dopt=Abstract
•
Selection of a secretion-incompetent mutant in the serum of a patient with severe hepatitis B. Author(s): Kalinina T, Riu A, Fischer L, Santantonio T, Will H, Sterneck M. Source: Gastroenterology. 2003 October; 125(4): 1077-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14517791&dopt=Abstract
•
Selective inhibition of hepatitis B virus replication by RNA interference. Author(s): Ying C, De Clercq E, Neyts J. Source: Biochemical and Biophysical Research Communications. 2003 September 19; 309(2): 482-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12951075&dopt=Abstract
•
Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control. Author(s): Abebe A, Nokes DJ, Dejene A, Enquselassie F, Messele T, Cutts FT. Source: Epidemiology and Infection. 2003 August; 131(1): 757-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12948377&dopt=Abstract
•
Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. Author(s): Song le H, Binh VQ, Duy DN, Kun JF, Bock TC, Kremsner PG, Luty AJ. Source: Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology. 2003 September; 28(1): 93-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12927756&dopt=Abstract
166 Hepatitis B
•
Serum zinc as a factor predicting response to interferon-alpha2b therapy in children with chronic hepatitis B. Author(s): Ozbal E, Helvaci M, Kasirga E, Akdenizoglu F, Kizilgunesler A. Source: Biological Trace Element Research. 2002 Winter; 90(1-3): 31-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12666823&dopt=Abstract
•
Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Author(s): Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H. Source: Digestive Diseases and Sciences. 2003 September; 48(9): 1786-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14561002&dopt=Abstract
•
Spontaneous viral clearance after 6-21 years of hepatitis B and C viruses coinfection in high HBV endemic area. Author(s): Fan CL, Wei L, Jiang D, Chen HS, Gao Y, Li RB, Wang Y. Source: World Journal of Gastroenterology : Wjg. 2003 September; 9(9): 2012-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12970896&dopt=Abstract
•
Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus. Author(s): Chen X, Kern ER, Drach JC, Gullen E, Cheng YC, Zemlicka J. Source: Journal of Medicinal Chemistry. 2003 April 10; 46(8): 1531-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12672254&dopt=Abstract
•
Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine. Author(s): Chiba T, Yokosuka O, Goto S, Fukai K, Imazeki F, Shishido H, Narita M, Saisho H. Source: European Journal of Haematology. 2003 September; 71(3): 220-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12930325&dopt=Abstract
•
The delivery of hepatitis B vaccine. Author(s): Chislett L. Source: Nurs Times. 2003 February 18-24; 99(7): 50-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12655755&dopt=Abstract
•
The efficacy of a two-dose hepatitis B vaccination scheme. Author(s): Boland GJ, van Bommel T, Rulos-van den Berg A, van den Berg JP, van Loon AM, van Hattum J. Source: Advances in Experimental Medicine and Biology. 2003; 531: 185-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916790&dopt=Abstract
Studies
167
•
The T(1858) variant predisposing to the precore stop mutation correlates with one of two major genotype F hepatitis B virus clades. Author(s): Norder H, Arauz-Ruiz P, Blitz L, Pujol FH, Echevarria JM, Magnius LO. Source: The Journal of General Virology. 2003 August; 84(Pt 8): 2083-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12867638&dopt=Abstract
•
Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Author(s): Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, Ozkan T, Ozeke T, Yagci RV, Haspolat K. Source: The Pediatric Infectious Disease Journal. 2003 April; 22(4): 345-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12690275&dopt=Abstract
•
Transcriptional repression of the human p53 gene by hepatitis B viral core protein (HBc) in human liver cells. Author(s): Kwon JA, Rho HM. Source: Biological Chemistry. 2003 February; 384(2): 203-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12675512&dopt=Abstract
•
Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Author(s): Lindemann M, Barsegian V, Runde V, Fiedler M, Heermann KH, Schaefer UW, Roggendorf M, Grosse-Wilde H. Source: Transplantation. 2003 March 27; 75(6): 833-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12660511&dopt=Abstract
•
Transient hepatitis B surface antigenemia in a blood donor after a combination hepatitis A and B vaccine. Author(s): Davis AR, Brotchie HL, Mundkur BA, Ismay SL. Source: Transfusion. 2003 April; 43(4): 545. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12662290&dopt=Abstract
•
Transmission of hepatitis B and C viruses in outpatient settings--New York, Oklahoma, and Nebraska, 2000-2002. Author(s): Centers for Disease Control and Prevention (CDC). Source: Mmwr. Morbidity and Mortality Weekly Report. 2003 September 26; 52(38): 9016. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=14508437&dopt=Abstract
168 Hepatitis B
•
Transmission profile of hepatitis B virus infection in the Batam region, Indonesia. Evidence for a predominantly horizontal transmission profile. Author(s): van Hattum J, Boland GJ, Jansen KG, Kleinpenning AS, van Bommel T, van Loon AM, Abdurachman SA, Yusuf H, Rulos-van den Berg A, van den Berg J. Source: Advances in Experimental Medicine and Biology. 2003; 531: 177-83. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12916789&dopt=Abstract
•
Treatment of chronic hepatitis B in 2002. Author(s): Husa P, Husova L. Source: Bratisl Lek Listy. 2003; 104(2): 59-63. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12839213&dopt=Abstract
•
Ultrapure dialysis fluid and response to hepatitis B vaccine. Author(s): Schiffl H, Wendinger H, Lang SM. Source: Nephron. 2002 July; 91(3): 530-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12119493&dopt=Abstract
•
Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned? Author(s): Yee LJ, Rhodes SD. Source: Sexually Transmitted Infections. 2002 October; 78(5): 374-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12407244&dopt=Abstract
•
Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. Author(s): Bramley JC, Wallace LA, Ahmed S, Duff R, Carman WF, Cameron SO, Kitchin NR, Watson MW, Goldberg DJ. Source: Commun Dis Public Health. 2002 December; 5(4): 318-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12564249&dopt=Abstract
•
Update on hepatitis B treatment. Author(s): Firpi RJ, Martin P. Source: Medgenmed [electronic Resource] : Medscape General Medicine. 2002 September 24; 4(3): 9. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12466752&dopt=Abstract
•
Update on the management of chronic hepatitis B. Author(s): Davis GL. Source: Reviews in Gastroenterological Disorders. 2002 Summer; 2(3): 106-15. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12227214&dopt=Abstract
Studies
169
•
Use of hepatitis B core antibody-positive donors for liver transplantation. Author(s): Munoz SJ. Source: Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2002 October; 8(10 Suppl 1): S82-7. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12362304&dopt=Abstract
•
Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Author(s): Burton JR Jr, Shaw-Stiffel TA. Source: Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2003 August; 9(8): 837-42. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12884197&dopt=Abstract
•
Use of lidocaine-prilocaine patch to decrease intramuscular injection pain does not adversely affect the antibody response to diphtheria-tetanus-acellular pertussisinactivated poliovirus-Haemophilus influenzae type b conjugate and hepatitis B vaccines in infants from birth to six months of age. Author(s): Halperin BA, Halperin SA, McGrath P, Smith B, Houston T. Source: The Pediatric Infectious Disease Journal. 2002 May; 21(5): 399-405. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12150176&dopt=Abstract
•
Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Author(s): Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG. Source: Transplantation. 2003 April 27; 75(8): 1179-86. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12717200&dopt=Abstract
•
Use of the organ donor with prior hepatitis B infection: a safe option? Author(s): Fabrizi F, Bunnapradist S, Martin P. Source: Int J Artif Organs. 2003 January; 26(1): 6-11. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12602463&dopt=Abstract
•
Vaccinating Asian Pacific Islander children against hepatitis B: ethnic-specific influences and barriers. Author(s): Pulido MJ, Alvarado EA, Berger W, Nelson A, Todoroff C. Source: Asian Am Pac Isl J Health. 2001 Summer-Fall; 9(2): 211-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11846367&dopt=Abstract
170 Hepatitis B
•
Vaccination against hepatitis B in patients on chronic haemodialysis. Author(s): Kovacic V. Source: Int J Clin Pract. 2003 April; 57(3): 161-2. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12723714&dopt=Abstract
•
Vaccine induced protection against hepatitis B. Author(s): Van Damme P, Banatvala JE. Source: Bmj (Clinical Research Ed.). 2003 January 11; 326(7380): 105. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12521983&dopt=Abstract
•
Vacuolization in hepatitis B virus-infected hepatocytes. Author(s): Roingeard P. Source: Hepatology (Baltimore, Md.). 2003 May; 37(5): 1223-4; Author Reply 1224. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12717405&dopt=Abstract
•
Validation of an in vitro potency test for the Cuban hepatitis B vaccine. Author(s): Landys Chovel Cuervo M, Reyes Huerta N. Source: Dev Biol (Basel). 2002; 111: 305-12. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12678254&dopt=Abstract
•
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Author(s): Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS. Source: American Journal of Epidemiology. 2003 March 1; 157(5): 467-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12615611&dopt=Abstract
•
Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. Author(s): Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Suzuki F, Akuta N, Someya T, Matsuda M, Sato J, Takagi K, Miyakawa Y, Kumada H. Source: Journal of Medical Virology. 2002 December; 68(4): 522-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12376960&dopt=Abstract
•
Virological and histological outcome of a patient with chronic hepatitis B transplanted with liver from hepatitis C virus-positive donor. Author(s): Chan HL, Chui AK, Chan FK, Rao AR, Wong J, Lau WY. Source: Transplantation Proceedings. 2003 February; 35(1): 423-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12591470&dopt=Abstract
Studies
171
•
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. Author(s): Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, Ferrari C. Source: Journal of Virology. 2002 December; 76(24): 12423-34. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12438568&dopt=Abstract
•
Vitamin K and hepatitis B vaccine. Author(s): O'Bryant C. Source: Midwifery Today Int Midwife. 2001 Spring; (57): 66; Author Reply 66-7. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12596416&dopt=Abstract
•
Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Author(s): Westland CE, Yang H, Delaney WE 4th, Gibbs CS, Miller MD, Wulfsohn M, Fry J, Brosgart CL, Xiong S; 437 and 438 Study Teams. Source: Hepatology (Baltimore, Md.). 2003 July; 38(1): 96-103. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12829991&dopt=Abstract
•
What is the optimal therapy for chronic hepatitis B? Author(s): Lyra AC, Di Bisceglie AM. Source: Minerva Med. 2001 December; 92(6): 431-4. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11740431&dopt=Abstract
•
Why can't Chinese Han drink alcohol? Hepatitis B virus infection and the evolution of acetaldehyde dehydrogenase deficiency. Author(s): Lin YP, Cheng TJ. Source: Medical Hypotheses. 2002 August; 59(2): 204-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12208210&dopt=Abstract
•
Why do gay men want to be vaccinated against hepatitis B? An assessment of psychosocial determinants of vaccination intention. Author(s): Schutten M, de Wit JB, van Steenbergen JE. Source: International Journal of Std & Aids. 2002 February; 13(2): 86-90. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11839162&dopt=Abstract
•
Wild-type and 'a' epitope variants in chronic hepatitis B virus carriers positive for hepatitis B surface antigen and antibody. Author(s): Mesenas SJ, Chow WC, Zhao Y, Lim GK, Oon CJ, Ng HS. Source: Journal of Gastroenterology and Hepatology. 2002 February; 17(2): 148-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11966944&dopt=Abstract
172 Hepatitis B
•
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. Author(s): Funk ML, Rosenberg DM, Lok AS. Source: Journal of Viral Hepatitis. 2002 January; 9(1): 52-61. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11851903&dopt=Abstract
173
CHAPTER 2. NUTRITION AND HEPATITIS B Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and hepatitis B.
Finding Nutrition Studies on Hepatitis B The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “hepatitis B” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7 Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
174 Hepatitis B
The following information is typical of that found when using the “Full IBIDS Database” to search for “hepatitis B” (or a synonym): •
A case history of plant-derived drug research: phyllanthus and hepatitis B virus. Source: Blumberg, B.S. Medicinal plants their role in health and biodiversity /. Philadelphia : University of Pennsylvania Press, c1998. page 3-10. ISBN: 0812234316 (cloth : alk paper)
•
A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. Author(s): The Hospital for Rheumatic Diseases, Hanyang University, 17 Haengdongdong, Seongdong-gu, Seoul 133-792, Korea. Source: Lee, Seung Won Kim, Ki Chan Oh, Dong Ho Jung, Sung Soo Yoo, Dae Hyun Kim, Seong Yoon Choe, Gheeyoung Kim, Tae Hwan J-Korean-Med-Sci. 2002 February; 17(1): 141-3 1011-8934
•
A comparative study of Phyllanthus amarus compound and interferon in the treatment of chronic viral hepatitis B. Author(s): Tropical Medicine Institute, Guangzhou University of Traditional Chinese Medicine, Guangdong, People's Republic of China. Source: Xin Hua, W Chang Qing, L Xing Bo, G Lin Chun, F Southeast-Asian-J-TropMed-Public-Health. 2001 March; 32(1): 140-2 0125-1562
•
A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. Author(s): Department of Infectious Diseases, The First Affiliated Hospital of Kunming Medical College, 153# Xi Chang Road, Kunming 650032, Yunnan Province, China. Source: You, J Zhuang, L Tang, B Z Yang, W B Ding, S Y Li, W Wu, R X Zhang, H L Zhang, Y M Yan, S M Zhang, L World-J-Gastroenterol. 2001 June; 7(3): 411-4 1007-9327
•
Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. Author(s): Department of Molecular Virology and Microbiology. Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA. Source: Madden, C R Finegold, M J Slagle, B L J-Virol. 2002 November; 76(22): 11770-4 0022-538X
•
Characterization of a 120-kilodalton pre-S-binding protein as a candidate duck hepatitis B virus receptor. Source: Li, J.S. Tong, S.P. Wands, J.R. J-virol. Washington, D.C. : American Society for Microbiology. Sept 1996. volume 70 (9) page 6029-6035. 0022-538X
•
Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection. Author(s): The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Dept. 7701, H:S Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark, DK-2100.
[email protected] Source: Liu, J P McIntosh, H Lin, H Cochrane-Database-Syst-Revolume 2001; (2): CD002231 1469-493X
•
Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. Author(s): Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
[email protected] Source: Liu, P Hu, Y Y Liu, C Zhu, D Y Xue, H M Xu, Z Q Xu, L M Liu, C H Gu, H T Zhang, Z Q World-J-Gastroenterol. 2002 August; 8(4): 679-85 1007-9327
Nutrition
175
•
Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBepositive chronic hepatitis B in Turkey. Author(s): Department of Gastroenterology, Celal Bayar University, School of Medicine, Manisa, Turkey.
[email protected] Source: Saruc, M Yuceyar, H Kucukmetin, N Demir, M A Kandiloglu, A R Hepatogastroenterology. 2002 May-June; 49(45): 798-802 0172-6390
•
Critical roles of nuclear receptor response elements in replication of hepatitis B virus. Author(s): McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706-1599, USA. Source: Yu, X Mertz, J E J-Virol. 2001 December; 75(23): 11354-64 0022-538X
•
Detecting the replication of the hepatitis B virus using the ImmunoMax technique following treatment with interferon-alpha in children with chronic hepatitis. Author(s): Department of Histology and Embryology, Medical University of Poznan, Poland.
[email protected] Source: Kasprzak, Aldona Wysocki, Jacek Zabel, Maciej Surdyk Zasada, Joanna MedSci-Monit. 2002 January; 8(1): PR1-7 1234-1010
•
Determination of hepatic zinc content in chronic liver disease due to hepatitis B virus. Author(s): Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Ankara-Turkey. Source: Gur, G Bayraktar, Y Ozer, D Ozdogan, M Kayhan, B Hepatogastroenterology. 1998 Mar-April; 45(20): 472-6 0172-6390
•
Effects of acupuncture on the immunological functions in hepatitis B virus carriers. Author(s): First Municipal Hospital, Zhuzhou, Hunan Province. Source: Chen, J Chen, M Zhao, B Wang, Y J-Tradit-Chin-Med. 1999 December; 19(4): 26872 0254-6272
•
Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. Author(s): The Cochrane Hepato-Biliary Group, The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, Copenhagen, Denmark.
[email protected] Source: Liu, J Lin, H McIntosh, H J-Viral-Hepat. 2001 September; 8(5): 358-66 1352-0504
•
Hepatitis B infection in China. Author(s): University Department of Medicine, Queen Mary Hospital, Hong Kong, SAR, China.
[email protected] Source: Lau, G K Clin-Liver-Dis. 2001 May; 5(2): 361-79 1089-3261
•
Hepatitis B virus surface antigen suppresses the activation of monocytes through interaction with a serum protein and a monocyte-specific receptor. Author(s): Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium.
[email protected] Source: Vanlandschoot, Peter Van Houtte, Freya Roobrouck, Annelies Farhoudi, Ali Leroux Roels, Geert J-Gen-Virol. 2002 June; 83(Pt 6): 1281-9 0022-1317
•
Identification of two separable modules in the duck hepatitis B virus core protein. [Erratum: Apr 1997, v. 71 (4), p. 3363.]. Source: Weizsacker, F. von Wieland, S. Blum, H.E. J-virol. Washington, D.C. : American Society for Microbiology. April 1995. volume 69 (4) page 2704-2707. 0022-538X
176 Hepatitis B
•
Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Author(s): Department of Rheumatology, University Hospital Gent, Belgium.
[email protected] Source: De Keyser, F Naeyaert, J M Hindryckx, P Elewaut, D Verplancke, P Peene, I Praet, M Veys, E Clin-Exp-Rheumatol. 2000 Jan-February; 18(1): 81-5 0392-856X
•
In vitro anti-hepatitis B virus activities of 5”-O-myristoyl analogue derivatives of 3”fluoro-2”,3”-dideoxythymidine (FLT) and 3”-azido-2”,3”-dideoxythymidine (AZT). Author(s): Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada. Source: Knaus, E E Parang, K Wiebe, L I Huang, J S Tyrrell, D L J-Pharm-Pharm-Sci. 1998 Sep-December; 1(3): 108-14 1482-1826
•
Inhibition of hepatitis B virus by oxymatrine in vivo. Author(s): Department of Cell Biology, the Second Military Medical University, Shanghai 200433,China.
[email protected] Source: Chen, X S Wang, G J Cai, X Yu, H Y Hu, Y P World-J-Gastroenterol. 2001 February; 7(1): 49-52 1007-9327
•
Interaction of fucoidan from Pelvetia fastigiata with surface antigens of hepatitis B and woodchuck hepatitis viruses. Source: Venkateswaran, P.S. Millman, I. Blumberg, B.S. Plant-Med. Stuttgart, W. Ger. : Georg Thieme Verlag. June 1989. volume 55 (3) page 265-270. 0032-0943
•
Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus rev function but not the function of the hepatitis B virus posttranscriptional regulatory element. Author(s): Infectious Disease Laboratory, The Salk Institute for Biological Studies, La Jolla, California 92037, USA. Source: Otero, G C Harris, M E Donello, J E Hope, T J J-Virol. 1998 September; 72(9): 7593-7 0022-538X
•
L-Homoserine: a novel excreted metabolic marker of hepatitis B abnormally produced in liver from methionine. Author(s): Department of Molecular Biology and Biotechnology, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico D. F., Mexico.
[email protected] Source: Gazarian, K G Gening, L V Gazarian, T G Med-Hypotheses. 2002 April; 58(4): 279-83 0306-9877
•
Management of chronic hepatitis B infection: an update. Author(s): Department of Gastroenterology, VIMS, RKM Seva Pratisthan, Calcutta. Source: Mazumdar, T N J-Indian-Med-Assoc. 2001 June; 99(6): 306-8, 310 0019-5847
•
Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Author(s): The Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, H:S Rigshospitalet, Denmark. Source: Liu, J Kjaergard, L L Gluud, C Am-J-Chin-Med. 2002; 30(1): 173-6 0192-415X
•
Nutritional therapy of chronic hepatitis by whey protein (non-heated). Author(s): Third Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Toyama, Japan.
Nutrition
177
Source: Watanabe, A Okada, K Shimizu, Y Wakabayashi, H Higuchi, K Niiya, K Kuwabara, Y Yasuyama, T Ito, H Tsukishiro, T Kondoh, Y Emi, N Kohri, H J-Med. 2000; 31(5-6): 283-302 0025-7850 •
One year follow-up of patients treated with misoprostol in acute phase of viral hepatitis B. Author(s): Department of Infectious Diseases, Medical Academy of Bialystok, Zurawia Str 14, 15-540, Bialystok, Poland.
[email protected] Source: Flisiak, R Prokopowicz, D Prostaglandins-Other-Lipid-Mediat. 2000 March; 60(4-6): 161-5 1098-8823
•
Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. Author(s): Department of Medicine, University of Toronto, Canada. Source: Hyman, A Yim, C Krajden, M Read, S Basinski, A S Wanless, I Levy, G Heathcote, J J-Viral-Hepat. 1999 July; 6(4): 329-36 1352-0504
•
Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids. Author(s): University Hospital Freiburg, Department of Internal Medicine II, Molecular Biology, Hugstetter Str. 55, D-79107 Freiburg, Germany. Source: Beterams, G Bottcher, B Nassal, M FEBS-Lett. 2000 September 15; 481(2): 169-76 0014-5793
•
Phenotypic mixing of rodent but not avian hepadnavirus surface proteins into human hepatitis B virus particles. Source: Gerhardt, E. Bruss, V. J-virol. Washington, D.C. : American Society for Microbiology. February 1995. volume 69 (2) page 1201-1208. 0022-538X
•
Possible role of retinoids in hepatitis B virus-associated liver damage. Author(s): Public Health Program, Des Moines University Osteopathic Medical Center, 3200 Grand Avenue, Des Moines, Iowa 50312, USA.
[email protected] Source: Mawson, A R Steele, T A Exp-Biol-Med-(Maywood). 2001 September; 226(8): 734-9 1535-3702
•
Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. Author(s): Department of Hepatology, Kunming Third Municipal People's Hospital, 319 Wu Jin Road, Kunming 650041,Yunnan Province, China. Source: Zhuang, L You, J Tang, B Z Ding, S Y Yan, K H Peng, D Zhang, Y M Zhang, L World-J-Gastroenterol. 2001 June; 7(3): 407-10 1007-9327
•
Production in yeast versus mammalian cells of the first recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine. Source: Stephenne, J. Adv-Biotechnol-Processes. New York, N.Y. : Allan R. Liss. 1990. volume 14 page 279-299. ill. 0736-2293
•
Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Author(s): Institute of Oncology, Ljubljana, Slovenia.
[email protected] Source: Markovic, S Drozina, G Vovk, M Fidler Jenko, M Hepatogastroenterology. 1999 Sep-October; 46(29): 2925-30 0172-6390
•
Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. Author(s): Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
178 Hepatitis B
Source: Tang, H Raney, A K McLachlan, A J-Virol. 2001 October; 75(19): 8937-48 0022538X •
Selected mutations of the duck hepatitis B virus P gene RNase H domain affect both RNA packaging and priming of minus-strand DNA synthesis. Source: Chen, Y. Robinson, W.S. Marion, P.L. J-virol. Washington, D.C. : American Society for Microbiology. August 1994. volume 68 (8) page 5232-5238. 0022-538X
•
Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Author(s): The Copenhagen Trial Unit, Copenhagen University Hospital, H:S Rigshospitalet, Blegdamsvej 9, Copenhagen, Denmark, DK-2100.
[email protected] Source: Mellerup, M T Krogsgaard, K Mathurin, P Gluud, C Poynard, T CochraneDatabase-Syst-Revolume 2002; (2): CD000345 1469-493X
•
Serum level of interferon alpha in patients with acute viral hepatitis B. Author(s): Department of Infectious Diseases, Epidemiology and Parasitology, Higher Medical Institute, Plovdiv, Bulgaria. Source: Geneva Popova, M Folia-Med-(Plovdiv). 1998; 40(1): 46-51 0204-8043
•
Sustained activation of mitogen-activated protein kinases and activator protein 1 by the hepatitis B virus X protein in mouse hepatocytes in vivo. Author(s): Department of Biochemistry, University of Delhi South Campus, New Delhi110021, India. Source: Nijhara, R Jana, S S Goswami, S K Rana, A Majumdar, S S KuMarch, V Sarkar, D P J-Virol. 2001 November; 75(21): 10348-58 0022-538X
•
The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B. Author(s): Department of Gastroenterology, School of Medicine, Hacettepe University, Ankara, Turkey. Source: Bayraktar, Y Saglam, F Temizer, A Uzunalimodlu, B van Thiel, D H Hepatogastroenterology. 1998 Nov-December; 45(24): 2322-7 0172-6390
•
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Author(s): Unite de Recombinaison et Expression Genetique (INSERM U163), Institut Pasteur, Paris, France. Source: Bergametti, F Prigent, S Luber, B Benoit, A Tiollais, P Sarasin, A Transy, C Oncogene. 1999 May 6; 18(18): 2860-71 0950-9232
•
Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. Author(s): Department of Internal Medicine, Liver Research Institute, Seoul National University Hospital, Chongno-gu, Korea.
[email protected] Source: Lee, H S Kim, K M Yoon, J H Lee, T R Suh, K S Lee, K U Chung, J W Park, J H Kim, C Y J-Clin-Oncol. 2002 November 15; 20(22): 4459-65 0732-183X
•
Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Author(s): Division of Gastroenterology, Department of Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Nutrition
179
Source: Mutchnick, M G Lindsay, K L Schiff, E R Cummings, G D Appelman, H D Peleman, R R Silva, M Roach, K C Simmons, F Milstein, S Gordon, S C Ehrinpreis, M N J-Viral-Hepat. 1999 September; 6(5): 397-403 1352-0504 •
Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. Author(s): Departments of Medicine and Pathology, Queen Mary Hospital Clinical Trials Centre, The Institute of Molecular Biology, The University of Hong Kong, Hong Kong SAR, China.
[email protected] Source: Lau, G K Nanji, A Hou, J Fong, D Y Au, W S Yuen, S T Lin, M Kung, H F Lam, S K J-Viral-Hepat. 2002 July; 9(4): 280-7 1352-0504
•
Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan. Author(s): Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan.
[email protected] Source: Kobayashi, M Arase, Y Ikeda, K Tsubota, A Suzuki, Y Saitoh, S Kobayashi, M Suzuki, F Akuta, N Someya, T Matsuda, M Sato, J Takagi, K Miyakawa, Y Kumada, H JMed-Virol. 2002 December; 68(4): 522-8 0146-6615
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
180 Hepatitis B
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMD®Health: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to hepatitis B; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Vitamin E Source: Prima Communications, Inc.www.personalhealthzone.com
•
Minerals Selenium Source: Prima Communications, Inc.www.personalhealthzone.com
181
CHAPTER 3. ALTERNATIVE MEDICINE AND HEPATITIS B Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to hepatitis B. At the conclusion of this chapter, we will provide additional sources.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to hepatitis B and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “hepatitis B” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to hepatitis B: •
A comparative study of Phyllanthus amarus compound and interferon in the treatment of chronic viral hepatitis B. Author(s): Xin-Hua W, Chang-Qing L, Xing-Bo G, Lin-Chun F. Source: Southeast Asian J Trop Med Public Health. 2001 March; 32(1): 140-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11485076&dopt=Abstract
•
A large outbreak of acupuncture-associated hepatitis B. Author(s): Kent GP, Brondum J, Keenlyside RA, LaFazia LM, Scott HD. Source: American Journal of Epidemiology. 1988 March; 127(3): 591-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3341362&dopt=Abstract
•
A novel oral adjuvant for hepatitis B virus (HBV) vaccines. Author(s): Ishizaka S, Kuriyama S, Kikuchi E, Nishimura K, Tsujii T.
182 Hepatitis B
Source: Journal of Hepatology. 1990 November; 11(3): 326-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2290023&dopt=Abstract •
A plant-derived edible vaccine against hepatitis B virus. Author(s): Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. Source: The Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology. 1999 October; 13(13): 1796-9. Erratum In: Faseb J 1999 December; 13(15): 2339. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10506582&dopt=Abstract
•
A randomized controlled trial of kurorinone versus interferon-alpha2a treatment in patients with chronic hepatitis B. Author(s): Chen C, Guo SM, Liu B. Source: Journal of Viral Hepatitis. 2000 May; 7(3): 225-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10849265&dopt=Abstract
•
A two-stage clinical trial of Phyllanthus amarus in hepatitis B carriers: failure to eradicate the surface antigen. Author(s): Doshi JC, Vaidya AB, Antarkar DS, Deolalikar R, Antani DH. Source: Indian J Gastroenterol. 1994 January; 13(1): 7-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8119752&dopt=Abstract
•
Active compounds from Saussurea lappa Clarks that suppress hepatitis B virus surface antigen gene expression in human hepatoma cells. Author(s): Chen HC, Chou CK, Lee SD, Wang JC, Yeh SF. Source: Antiviral Research. 1995 May; 27(1-2): 99-109. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7486962&dopt=Abstract
•
Acupuncture and possible hepatitis B infection. Author(s): Li FP, Shiang EL. Source: Jama : the Journal of the American Medical Association. 1980 April 11; 243(14): 1423. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7359710&dopt=Abstract
•
Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma. Author(s): Sato T, Kato J, Kawanishi J, Kogawa K, Ohya M, Sakamaki S, Niitsu Y. Source: Journal of Gastroenterology. 1997 October; 32(5): 668-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9349995&dopt=Abstract
Alternative Medicine 183
•
Acute hepatic injury after discontinuation of chemotherapy in a patient with nonHodgkin's lymphoma and chronic hepatitis B virus infection. Author(s): Haanen JB, Bieger R, van't Wout JW. Source: The Netherlands Journal of Medicine. 1996 December; 49(6): 239-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8990863&dopt=Abstract
•
Aflatoxin exposure, hepatitis B virus infection and liver cancer in Swaziland. Author(s): Peers F, Bosch X, Kaldor J, Linsell A, Pluijmen M. Source: International Journal of Cancer. Journal International Du Cancer. 1987 May 15; 39(5): 545-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3570547&dopt=Abstract
•
AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Author(s): Perez-Garcia R, Perez-Garcia A, Verbeelen D, Bernstein ED, Villarrubia VG, Alvarez-Mon M. Source: Kidney International. 2002 May; 61(5): 1845-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11967036&dopt=Abstract
•
AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons. Author(s): Sanchez L, Pena E, Civantos A, Sada G, Alvarez MM, Chirigos MA, Villarrubia VG. Source: Journal of Hepatology. 1995 January; 22(1): 119-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7751580&dopt=Abstract
•
An acupuncture-associated outbreak of hepatitis B in Jerusalem. Author(s): Slater PE, Ben-Ishai P, Leventhal A, Zahger D, Bashary A, Moses A, Costin C, Shouval D. Source: European Journal of Epidemiology. 1988 September; 4(3): 322-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3181383&dopt=Abstract
•
Anti-hepatitis B virus effects of wogonin isolated from Scutellaria baicalensis. Author(s): Huang RL, Chen CC, Huang HL, Chang CG, Chen CF, Chang C, Hsieh MT. Source: Planta Medica. 2000 December; 66(8): 694-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11199123&dopt=Abstract
•
Antiviral activities of extracts isolated from Terminalis chebula Retz., Sanguisorba officinalis L., Rubus coreanus Miq. and Rheum palmatum L. against hepatitis B virus. Author(s): Kim TG, Kang SY, Jung KK, Kang JH, Lee E, Han HM, Kim SH. Source: Phytotherapy Research : Ptr. 2001 December; 15(8): 718-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11746867&dopt=Abstract
184 Hepatitis B
•
Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed. Author(s): Berk L, de Man RA, Schalm SW, Labadie RP, Heijtink RA. Source: Journal of Hepatology. 1991 May; 12(3): 405-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1940272&dopt=Abstract
•
Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials. Author(s): McCulloch M, Broffman M, Gao J, Colford JM Jr. Source: American Journal of Public Health. 2002 October; 92(10): 1619-28. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12356611&dopt=Abstract
•
Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection. Author(s): Liu JP, McIntosh H, Lin H. Source: Cochrane Database Syst Rev. 2001; (2): Cd002231. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11406038&dopt=Abstract
•
Chinese medicinal herbs for chronic hepatitis B. Author(s): Liu JP, McIntosh H, Lin H. Source: Cochrane Database Syst Rev. 2001; (1): Cd001940. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11279742&dopt=Abstract
•
Chinese medicinal herbs for chronic hepatitis B: a systematic review. Author(s): Liu J, McIntosh H, Lin H. Source: Liver. 2001 August; 21(4): 280-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11454192&dopt=Abstract
•
Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. Author(s): Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ. Source: World Journal of Gastroenterology : Wjg. 2002 August; 8(4): 679-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12174378&dopt=Abstract
•
Clinical study on the treatment of liver fibrosis due to hepatitis B by IFN-alpha(1) and traditional medicine preparation. Author(s): Cheng ML, Wu YY, Huang KF, Luo TY, Ding YS, Lu YY, Liu RC, Wu J. Source: World Journal of Gastroenterology : Wjg. 1999 June; 5(3): 267-269. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11819444&dopt=Abstract
•
Combined lamivudine and interferon-alpha therapy for chemotherapy-induced reactivation of hepatitis B virus. Author(s): Ohmoto K, Tsuduki M, Yamamoto S.
Alternative Medicine 185
Source: The American Journal of Gastroenterology. 2003 May; 98(5): 1215-6; Author Reply 1217. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12809863&dopt=Abstract •
Complement-mediated changes in morphology of hepatitis B antigen-antibody complexes. Author(s): Hirschman SZ, Kochwa S, Rosenfield R, Schwartz J. Source: Vox Sanguinis. 1974 March; 26(3): 222-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=4209321&dopt=Abstract
•
Detection of hepatitis B and woodchuck hepatitis viral DNA in plasma and mononuclear cells from heparinized blood by the polymerase chain reaction. Author(s): Pardoe IU, Michalak TI. Source: Journal of Virological Methods. 1995 February; 51(2-3): 277-88. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7738148&dopt=Abstract
•
Development of an enzyme immunoassay for the detection of hepatitis B surface antigen employing monoclonal antibodies. Author(s): Toplikar E, Carlomagno A, Rojkin LF, Gariglio R, Lorenzo LE. Source: Journal of Clinical Laboratory Analysis. 1993; 7(6): 324-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8277356&dopt=Abstract
•
Disclosure of trauma and immune response to a hepatitis B vaccination program. Author(s): Petrie KJ, Booth RJ, Pennebaker JW, Davison KP, Thomas MG. Source: Journal of Consulting and Clinical Psychology. 1995 October; 63(5): 787-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7593871&dopt=Abstract
•
Do bedbugs transmit hepatitis B? Author(s): Mayans MV, Hall AJ, Inskip HM, Lindsay SW, Chotard J, Mendy M, Whittle HC. Source: Lancet. 1994 March 26; 343(8900): 761-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7907732&dopt=Abstract
•
Double-blinded placebo-controlled study of Phyllanthus urinaris for the treatment of chronic hepatitis B. Author(s): Chan HL, Sung JJ, Fong WF, Chim AM, Yung PP, Hui AY, Fung KP, Leung PC. Source: Alimentary Pharmacology & Therapeutics. 2003 August 1; 18(3): 339-45. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12895219&dopt=Abstract
•
Downregulation of hepatitis B surface antigen expression in human hepatocellular carcinoma cell lines by HD-03, a polyherbal formulation. Author(s): Yeh SF, Gupta M, Sarma DN, Mitra SK.
186 Hepatitis B
Source: Phytotherapy Research : Ptr. 2003 January; 17(1): 89-91. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12557256&dopt=Abstract •
Duck hepatitis B virus model for screening of antiviral agents from medicinal herbs. Author(s): Mi Z, Chen H, Zhang X, Shao X, Li Z, Wu X. Source: Chinese Medical Journal. 1995 September; 108(9): 660-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8575230&dopt=Abstract
•
Effect of an extract from Phyllanthus amarus on hepatitis B surface antigen gene expression in human hepatoma cells. Author(s): Yeh SF, Hong CY, Huang YL, Liu TY, Choo KB, Chou CK. Source: Antiviral Research. 1993 March; 20(3): 185-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8470882&dopt=Abstract
•
Effect of lymphatic and splenic pump techniques on the antibody response to hepatitis B vaccine: a pilot study. Author(s): Jackson KM, Steele TF, Dugan EP, Kukulka G, Blue W, Roberts A. Source: J Am Osteopath Assoc. 1998 March; 98(3): 155-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9558831&dopt=Abstract
•
Effect of misoprostol on serum beta2-microglobulin in the course of viral hepatitis B. Author(s): Flisiak R, Prokopowicz D. Source: European Journal of Gastroenterology & Hepatology. 1999 November; 11(11): 1227-30. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10563531&dopt=Abstract
•
Effect of misoprostol on the course of viral hepatitis B. Author(s): Flisiak R, Prokopowicz D. Source: Hepatogastroenterology. 1997 September-October; 44(17): 1419-25. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9356866&dopt=Abstract
•
Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Author(s): Brook MG. Source: Lancet. 1988 October 29; 2(8618): 1017-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2902445&dopt=Abstract
•
Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. Author(s): Thyagarajan SP, Subramanian S, Thirunalasundari T, Venkateswaran PS, Blumberg BS. Source: Lancet. 1988 October 1; 2(8614): 764-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2901611&dopt=Abstract
Alternative Medicine 187
•
Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo. Author(s): Niu JZ, Wang YY, Qiao M, Gowans E, Edwards P, Thyagarajan SP, Gust I, Locarnini S. Source: Journal of Medical Virology. 1990 December; 32(4): 212-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2081970&dopt=Abstract
•
Effect of sho-saiko-to(xiao-chai-hu-tang) on HBeAg clearance in children with chronic hepatitis B virus infection and with sustained liver disease. Author(s): Tajiri H, Kozaiwa K, Ozaki Y, Miki K, Shimuzu K, Okada S. Source: The American Journal of Chinese Medicine. 1991; 19(2): 121-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1816724&dopt=Abstract
•
Effect of sizofiran, a polysaccharide, on interferon gamma, antibody production and lymphocyte proliferation specific for hepatitis B virus antigen in patients with chronic hepatitis B. Author(s): Kakumu S, Ishikawa T, Wakita T, Yoshioka K, Ito Y, Shinagawa T. Source: International Journal of Immunopharmacology. 1991; 13(7): 969-75. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1761362&dopt=Abstract
•
Effect of thymic extract on allogeneic MLR and mitogen-induced responses in patients with chronic active hepatitis B. Author(s): Zeman K, Dworniak D, Tchorzewski H, Pokoca L, Majewska E. Source: Immunological Investigations. 1991 December; 20(7): 545-55. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1836778&dopt=Abstract
•
Effectiveness of thymostimulin treatment in hepatitis B surface antigen-positive chronic active liver disease. Results of a randomized clinical trial. Author(s): Romeo F, Arcoria D, Palmisano L, Polosa P. Source: Arzneimittel-Forschung. 1985; 35(8): 1317-22. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3907642&dopt=Abstract
•
Effects of acupuncture on the immunological functions in hepatitis B virus carriers. Author(s): Chen J, Chen M, Zhao B, Wang Y. Source: J Tradit Chin Med. 1999 December; 19(4): 268-72. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10921130&dopt=Abstract
•
Effects of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies. Author(s): Venkateswaran PS, Millman I, Blumberg BS. Source: Proceedings of the National Academy of Sciences of the United States of America. 1987 January; 84(1): 274-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3467354&dopt=Abstract
188 Hepatitis B
•
Effects of Phyllanthus plant extracts on duck hepatitis B virus in vitro and in vivo. Author(s): Shead A, Vickery K, Pajkos A, Medhurst R, Freiman J, Dixon R, Cossart Y. Source: Antiviral Research. 1992 June; 18(2): 127-38. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1416905&dopt=Abstract
•
Effects of TJ-9 Sho-saiko-to (kampo medicine) on interferon gamma and antibody production specific for hepatitis B virus antigen in patients with type B chronic hepatitis. Author(s): Kakumu S, Yoshioka K, Wakita T, Ishikawa T. Source: International Journal of Immunopharmacology. 1991; 13(2-3): 141-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1906436&dopt=Abstract
•
Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers. Author(s): Thamlikitkul V, Wasuwat S, Kanchanapee P. Source: J Med Assoc Thai. 1991 September; 74(9): 381-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1791391&dopt=Abstract
•
Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus. Author(s): Shinada M, Azuma M, Kawai H, Sazaki K, Yoshida I, Yoshida T, Suzutani T, Sakuma T. Source: Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.). 1986 February; 181(2): 205-10. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3080754&dopt=Abstract
•
Enzyme-antibody conjugation by a heterobifunctional reagent and its application in enzyme-linked immunosorbent assay (ELISA) for the detection of hepatitis B surface antigen. Author(s): Gadkari DA, Fields HA, Maynard JE. Source: Journal of Virological Methods. 1985 March; 10(3): 215-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3886682&dopt=Abstract
•
Epidemiology of hepatitis B virus infection in the Asia-Pacific region. Author(s): Chen CJ, Wang LY, Yu MW. Source: Journal of Gastroenterology and Hepatology. 2000 May; 15 Suppl: E3-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10921373&dopt=Abstract
•
Essential fatty acid supplementation in chronic hepatitis B. Author(s): Jenkins AP, Green AT, Thompson RP. Source: Alimentary Pharmacology & Therapeutics. 1996 August; 10(4): 665-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8853774&dopt=Abstract
Alternative Medicine 189
•
Evaluation of anti-hepadnavirus activity of Phyllanthus amarus and Phyllanthus maderaspatensis in duck hepatitis B virus carrier Pekin ducks. Author(s): Munshi A, Mehrotra R, Ramesh R, Panda SK. Source: Journal of Medical Virology. 1993 December; 41(4): 275-81. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8106861&dopt=Abstract
•
Evaluation of Phyllanthus amarus and Phyllanthus maderaspatensis as agents for postexposure prophylaxis in neonatal duck hepatitis B virus infection. Author(s): Munshi A, Mehrotra R, Panda SK. Source: Journal of Medical Virology. 1993 May; 40(1): 53-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8515247&dopt=Abstract
•
Exacerbation of hepatitis in hepatitis B carriers following chemotherapy for haematological malignancies. Author(s): Wong GC, Tan P, Goh YT, Ng HS, Chong R, Lee LH. Source: Ann Acad Med Singapore. 1996 July; 25(4): 500-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8893918&dopt=Abstract
•
Experimental studies on the inhibition effects of 1000 Chinese medicinal herbs on the surface antigen of hepatitis B virus. Author(s): Zheng M, Zheng Y. Source: J Tradit Chin Med. 1992 September; 12(3): 193-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1453758&dopt=Abstract
•
Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus. Author(s): Milne A, Hopkirk N, Lucas CR, Waldon J, Foo Y. Source: N Z Med J. 1994 June 22; 107(980): 243. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8208497&dopt=Abstract
•
Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers. Author(s): Leelarasamee A, Trakulsomboon S, Maunwongyathi P, Somanabandhu A, Pidetcha P, Matrakool B, Lebnak T, Ridthimat W, Chandanayingyong D. Source: Lancet. 1990 June 30; 335(8705): 1600-1. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1972525&dopt=Abstract
•
Familial clustering of hepatitis B and C viruses in Korea. Author(s): Kim YS, Ahn YO, Kim DW. Source: Journal of Korean Medical Science. 1994 December; 9(6): 444-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7786439&dopt=Abstract
190 Hepatitis B
•
Functional and structural similarity between the X protein of hepatitis B virus and nucleoside diphosphate kinases. Author(s): De-Medina T, Shaul Y. Source: Febs Letters. 1994 September 12; 351(3): 423-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8082807&dopt=Abstract
•
Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. Author(s): Liu J, Lin H, McIntosh H. Source: Journal of Viral Hepatitis. 2001 September; 8(5): 358-66. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11555193&dopt=Abstract
•
HBsAg-like structures in immunosuppressed mice inoculated with human hepatitis B virus. Author(s): Schaff Z, Pohl O, Bencsath M, Brojnas J, Lapis K, Kopper L, Hollos I. Source: Virchows Arch B Cell Pathol Incl Mol Pathol. 1982 August; 40(2): 249-61. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6127839&dopt=Abstract
•
Hepatitis after withdrawal of chemotherapy in a patient with chronic hepatitis B. Author(s): Schofield K, Morris D, Klapper P. Source: The Journal of Infection. 1993 July; 27(1): 101-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7690376&dopt=Abstract
•
Hepatitis B and C virus prevalence in a rural area of South Korea: the role of acupuncture. Author(s): Shin HR, Kim JY, Kim JI, Lee DH, Yoo KY, Lee DS, Franceschi S. Source: British Journal of Cancer. 2002 July 29; 87(3): 314-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12177801&dopt=Abstract
•
Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Author(s): Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, Ahn YO, Shigemastu T. Source: International Journal of Epidemiology. 1996 October; 25(5): 933-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8921477&dopt=Abstract
•
Hepatitis B antigen, alpha-fetoglobulins and primary hepatocellular carcinoma in Ethiopia. Author(s): Tsega E, Gold P, Shuster J, Whittemore B, Lester FT. Source: J Trop Med Hyg. 1976 October; 79(10): 230-4. No Abstract Available. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=64619&dopt=Abstract
•
Hepatitis B control in China: knowledge and practices among village doctors. Author(s): Clayton S, Yang H, Guan J, Lin Z, Wang R.
Alternative Medicine 191
Source: American Journal of Public Health. 1993 December; 83(12): 1685-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8259795&dopt=Abstract •
Hepatitis B epidemiology and cultural practices in Amerindian populations of Amazonia: the Tupi-Monde and the Xavante from Brazil. Author(s): Coimbra Junior CE, Santos RV, Yoshida CF, Baptista ML, Flowers NM, do Valle AC. Source: Social Science & Medicine (1982). 1996 June; 42(12): 1735-43. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8783434&dopt=Abstract
•
Hepatitis B in Nuremberg, Germany. Epidemiology of a drug-associated epidemic. Among US Army soldiers. Author(s): Cates W Jr, Warren JW. Source: Jama : the Journal of the American Medical Association. 1975 December 1; 234(9): 930-4. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1242490&dopt=Abstract
•
Hepatitis B infection and renal transplantation: the absence of anti-delta antibodies and the possible beneficial effect of silymarin during acute episodes of hepatic dysfunction. Author(s): Chan MK, Chan PC, Wong KK, Cheng IK, Li MK, Chang WK. Source: Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association. 1989; 4(4): 297-301. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2502738&dopt=Abstract
•
Hepatitis B infection in China. Author(s): Lau GK. Source: Clinics in Liver Disease. 2001 May; 5(2): 361-79. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11385968&dopt=Abstract
•
Hepatitis B infection in patients with lymphomas. Author(s): Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Source: Hematological Oncology. 1990 September-October; 8(5): 261-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1701155&dopt=Abstract
•
Hepatitis B vaccination in the skin penetration industry. Author(s): Bouwman R, Cannata S, Fett MJ. Source: The Medical Journal of Australia. 1994 February 7; 160(3): 165. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8295594&dopt=Abstract
•
Hepatitis B virus and hepatocellular carcinoma--treatment of HBV carriers with Phyllanthus amarus. Author(s): Blumberg BS, Millman I, Venkateswaran PS, Thyagarajan SP.
192 Hepatitis B
Source: Cancer Detection and Prevention. 1989; 14(2): 195-201. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2559794&dopt=Abstract •
Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with Phyllanthus amarus. Author(s): Blumberg BS, Millman I, Venkateswaran PS, Thyagarajan SP. Source: Vaccine. 1990 March; 8 Suppl: S86-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2158192&dopt=Abstract
•
Hepatitis B: therapeutic perspectives. Author(s): Rizzetto M, Lagget M. Source: Forum (Genova). 2001 April-June; 11(2): 137-50. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11948359&dopt=Abstract
•
Hepatocellular carcinoma, hepatic cirrhosis, and hepatitis B virus infection in Nigeria. Author(s): Otu AA. Source: Cancer. 1987 November 15; 60(10): 2581-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2822223&dopt=Abstract
•
Herbs of the genus Phyllanthus in the treatment of chronic hepatitis B: observations with three preparations from different geographic sites. Author(s): Wang M, Cheng H, Li Y, Meng L, Zhao G, Mai K. Source: The Journal of Laboratory and Clinical Medicine. 1995 October; 126(4): 350-2. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7561442&dopt=Abstract
•
High cytoplasmic expression in E. coli, purification, and in vitro refolding of a single chain Fv antibody fragment against the hepatitis B surface antigen. Author(s): Sanchez L, Ayala M, Freyre F, Pedroso I, Bell H, Falcon V, Gavilondo JV. Source: Journal of Biotechnology. 1999 June 11; 72(1-2): 13-20. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10406095&dopt=Abstract
•
History of blood transfusion, tattooing, acupuncture and risk of hepatitis B surface antigenaemia among Chinese men in Singapore. Author(s): Phoon WO, Fong NP, Lee J. Source: American Journal of Public Health. 1988 August; 78(8): 958-60. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3389434&dopt=Abstract
•
Identification of a protein kinase C (PKC) activator, daphnoretin, that suppresses hepatitis B virus gene expression in human hepatoma cells. Author(s): Chen HC, Chou CK, Kuo YH, Yeh SF.
Alternative Medicine 193
Source: Biochemical Pharmacology. 1996 October 11; 52(7): 1025-32. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8831721&dopt=Abstract •
Immunogenicity and safety of low doses of recombinant yeast-derived hepatitis B vaccine. Author(s): Tan KL, Oon CJ, Goh KT, Wong LY, Chan SH. Source: Acta Paediatr Scand. 1990 June-July; 79(6-7): 593-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2143619&dopt=Abstract
•
In vitro studies on the effect of certain natural products against hepatitis B virus. Author(s): Mehrotra R, Rawat S, Kulshreshtha DK, Patnaik GK, Dhawan BN. Source: The Indian Journal of Medical Research. 1990 April; 92: 133-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2370093&dopt=Abstract
•
Influence of perceived psychological stress and distress on antibody response to low dose rDNA hepatitis B vaccine. Author(s): Jabaaij L, Grosheide PM, Heijtink RA, Duivenvoorden HJ, Ballieux RE, Vingerhoets AJ. Source: Journal of Psychosomatic Research. 1993 May; 37(4): 361-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8510062&dopt=Abstract
•
Inhibition of hepatitis B surface antigen secretion on human hepatoma cells. Components from Rubia cordifolia. Author(s): Ho LK, Don MJ, Chen HC, Yeh SF, Chen JM. Source: Journal of Natural Products. 1996 March; 59(3): 330-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8882438&dopt=Abstract
•
Interaction of fucoidan from Pelvetia fastigiata with surface antigens of hepatitis B and woodchuck hepatitis viruses. Author(s): Venkateswaran PS, Millman I, Blumberg BS. Source: Planta Medica. 1989 June; 55(3): 265-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2544915&dopt=Abstract
•
Lamivudine and rapid regeneration of the atrophic liver in decompensated cirrhosis due to hepatitis B. Author(s): Saito T, Shinzawa H, Watanabe H, Sugahara K, Okumoto K, Togashi H, Kawata S. Source: The American Journal of Gastroenterology. 2002 February; 97(2): 493-5. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11866301&dopt=Abstract
•
Leeches and hepatitis B. Author(s): Narendranathan M.
194 Hepatitis B
Source: Lancet. 1992 May 30; 339(8805): 1362. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1350029&dopt=Abstract •
Misuse of randomization: a review of Chinese randomized trials of herbal medicines for chronic hepatitis B. Author(s): Liu J, Kjaergard LL, Gluud C. Source: The American Journal of Chinese Medicine. 2002; 30(1): 173-6. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12067091&dopt=Abstract
•
Modulation of immune response to rDNA hepatitis B vaccination by psychological stress. Author(s): Jabaaij L, van Hattum J, Vingerhoets JJ, Oostveen FG, Duivenvoorden HJ, Ballieux RE. Source: Journal of Psychosomatic Research. 1996 August; 41(2): 129-37. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8887826&dopt=Abstract
•
Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy. Author(s): Webster GJ, Hallett R, Whalley SA, Meltzer M, Balogun K, Brown D, Farrington CP, Sharma S, Hamilton G, Farrow SC, Ramsay ME, Teo CG, Dusheiko GM. Source: Lancet. 2000 July 29; 356(9227): 379-84. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10972370&dopt=Abstract
•
New treatments for hepatitis B and C [antigen-specific transfer for A, B & C (chisolm biologicals) and thymate]. Author(s): Konlee M. Source: Posit Health News. 1998 Fall; (No 17): 19-21. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11366548&dopt=Abstract
•
Obstacles to hepatitis B vaccine uptake by health care staff. Author(s): Briggs MJ, Thomas J. Source: Public Health. 1994 March; 108(2): 137-48. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8183969&dopt=Abstract
•
Occurrence of hepatitis and hepatitis B surface antigen in adult patients with acute leukemia. Author(s): Cowan DH, Kouroupis GM, Leers WD. Source: Can Med Assoc J. 1975 March 22; 112(6): 693-7. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1054615&dopt=Abstract
•
Osthole increases glycosylation of hepatitis B surface antigen and suppresses the secretion of hepatitis B virus in vitro. Author(s): Huang RL, Chen CC, Huang YL, Hsieh DJ, Hu CP, Chen CF, Chang C.
Alternative Medicine 195
Source: Hepatology (Baltimore, Md.). 1996 September; 24(3): 508-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8781315&dopt=Abstract •
Outbreak of hepatitis B associated with acupuncture. Author(s): Stryker WS, Gunn RA, Francis DP. Source: The Journal of Family Practice. 1986 February; 22(2): 155-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3944549&dopt=Abstract
•
Outbreak of hepatitis B in an acupuncture clinic. Author(s): Walsh B, Maguire H, Carrington D. Source: Commun Dis Public Health. 1999 June; 2(2): 137-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10402750&dopt=Abstract
•
Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA. Author(s): McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. Source: Fems Immunology and Medical Microbiology. 2002 February 18; 32(3): 179-85. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11934561&dopt=Abstract
•
Phyllanthus amarus and hepatitis B. Author(s): Thyagarajan SP, Jayaram S, Valliammai T, Madanagopalan N, Pal VG, Jayaraman K. Source: Lancet. 1990 October 13; 336(8720): 949-50. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1976968&dopt=Abstract
•
Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication. Author(s): Lee CD, Ott M, Thyagarajan SP, Shafritz DA, Burk RD, Gupta S. Source: European Journal of Clinical Investigation. 1996 December; 26(12): 1069-76. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9013081&dopt=Abstract
•
Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer I and cellular transcription factors. Author(s): Ott M, Thyagarajan SP, Gupta S. Source: European Journal of Clinical Investigation. 1997 November; 27(11): 908-15. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=9395786&dopt=Abstract
•
Potent synergistic effect of sho-saiko-to, a herbal medicine, during vaccine therapy in a murine model of hepatitis B virus carrier. Author(s): Akbar SM, Yamamoto K, Abe M, Ninomiya T, Tanimoto K, Masumoto T, Michitaka K, Horiike N, Onji M.
196 Hepatitis B
Source: European Journal of Clinical Investigation. 1999 September; 29(9): 786-92. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10469167&dopt=Abstract •
Pretreatment of whole blood for use in immunochromatographic assays for hepatitis B virus surface antigen. Author(s): Shin HS, Kim CK, Shin KS, Chung HK, Heo TR. Source: Clinical and Diagnostic Laboratory Immunology. 2001 January; 8(1): 9-13. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11139189&dopt=Abstract
•
Prevalence of hepatitis B and C viruses in healthy Indonesian blood donors. Author(s): Sulaiman HA, Julitasari, Sie A, Rustam M, Melani W, Corwin A, Jennings GB. Source: Trans R Soc Trop Med Hyg. 1995 March-April; 89(2): 167-70. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7539951&dopt=Abstract
•
Prevalence of syphilis and hepatitis B among homosexual men in two saunas in Amsterdam. Author(s): Bleeker A, Coutinho RA, Bakker-Kok J, Tio D, de Koning GA. Source: Br J Vener Dis. 1981 June; 57(3): 196-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7237084&dopt=Abstract
•
Prevention and therapy of hepatitis B. Author(s): Tao Q, Feng B. Source: Chinese Medical Journal. 1999 October; 112(10): 942-6. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11717982&dopt=Abstract
•
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Author(s): Rossi G, Pelizzari A, Motta M, Puoti M. Source: British Journal of Haematology. 2001 October; 115(1): 58-62. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11722410&dopt=Abstract
•
Prophylactic effect of interferon-alpha for exacerbation of hepatitis B after high-dose chemotherapy. Author(s): Matano S, Kobayashi K, Ohta H, Minouchi K, Sanada T, Sugimoto T. Source: Acta Haematologica. 2001; 106(3): 138-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11713383&dopt=Abstract
•
Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine. Author(s): Simpson ND, Simpson PW, Ahmed AM, Nguyen MH, Garcia G, Keeffe EB, Ahmed A.
Alternative Medicine 197
Source: Journal of Clinical Gastroenterology. 2003 July; 37(1): 68-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12811213&dopt=Abstract •
Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. Author(s): Liu J, Zhu M, Shi R, Yang M. Source: The American Journal of Chinese Medicine. 2003; 31(3): 337-54. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12943166&dopt=Abstract
•
Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. Author(s): Araneo BA, Woods ML 2nd, Daynes RA. Source: The Journal of Infectious Diseases. 1993 April; 167(4): 830-40. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8450248&dopt=Abstract
•
Screening of 25 compounds isolated from Phyllanthus species for anti-human hepatitis B virus in vitro. Author(s): Huang RL, Huang YL, Ou JC, Chen CC, Hsu FL, Chang C. Source: Phytotherapy Research : Ptr. 2003 May; 17(5): 449-53. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12748977&dopt=Abstract
•
Seroconversion rate, hepatitis B vaccination, hemodialysis, and zinc supplementation. Author(s): Rawer P, Willems WR, Breidenbach T, Guttmann W, Pabst W, Schutterle G. Source: Kidney International. Supplement. 1987 October; 22: 149-52. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3481000&dopt=Abstract
•
Simultaneous extraction of hepatitis C virus (HCV), hepatitis B virus, and HIV-1 from plasma and detection of HCV RNA by a reverse transcriptase-polymerase chain reaction assay designed for screening pooled units of donated blood. Author(s): Sun R, Schilling W, Jayakar H, Ku J, Wang J, Rosenstraus M, Spadoro J. Source: Transfusion. 1999 October; 39(10): 1111-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10532606&dopt=Abstract
•
Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Author(s): Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Source: Science. 1985 December 6; 230(4730): 1160-3. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=3865370&dopt=Abstract
•
Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Author(s): Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen
198 Hepatitis B
WC, Hsu CH, Tien HF, Chao TY, Chen LT, Whang-Peng J; Lymphoma Committee of Taiwan Cooperative Oncology Group. Source: Hepatology (Baltimore, Md.). 2003 June; 37(6): 1320-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=12774010&dopt=Abstract •
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma. Author(s): Cheng AL. Source: Blood. 1996 February 1; 87(3): 1202. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8562950&dopt=Abstract
•
Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene. Author(s): Magnius LO, Norder H. Source: Intervirology. 1995; 38(1-2): 24-34. Review. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8666521&dopt=Abstract
•
Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine. Author(s): Csatary LK, Schnabel R, Bakacs T. Source: Anticancer Res. 1999 January-February; 19(1B): 629-33. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10216467&dopt=Abstract
•
Suppressive effects of metabolites from Alternaria brassicaea on the hepatitis B surface antigen. Author(s): Sun CM, Chen HC, Yeh SF. Source: Planta Medica. 1994 February; 60(1): 87-8. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=8134423&dopt=Abstract
•
The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis B surface antigen. Author(s): Nixon-George A, Moran T, Dionne G, Penney CL, Lafleur D, Bona CA. Source: Journal of Immunology (Baltimore, Md. : 1950). 1990 June 15; 144(12): 4798-802. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=2351829&dopt=Abstract
•
The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. Author(s): Treichel U, Meyer zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G. Source: The Journal of General Virology. 1994 November; 75 ( Pt 11): 3021-9. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=7964611&dopt=Abstract
•
The effect of long-term thymosine factor x/TFx/treatment on T lymphocyte subpopulations and peripheral blood mononuclear cell cytotoxicity in chronic active
Alternative Medicine 199
hepatitis B. Author(s): Baj Z, Pokoca L, Tchorzewski H, Dworniak D, Tkacz B. Source: J Investig Allergol Clin Immunol. 1991 August; 1(4): 239-46. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=1669583&dopt=Abstract •
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. Author(s): Rizzetto M, Shih JW, Gerin JL. Source: Journal of Immunology (Baltimore, Md. : 1950). 1980 July; 125(1): 318-24. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=6769999&dopt=Abstract
•
The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. Author(s): Lee YI, Kang-Park S, Do SI, Lee YI. Source: The Journal of Biological Chemistry. 2001 May 18; 276(20): 16969-77. Epub 2001 March 01. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=11278872&dopt=Abstract
•
The proapoptotic effect of hepatitis B virus HBx protein correlates with its transactivation activity in stably transfected cell lines. Author(s): Bergametti F, Prigent S, Luber B, Benoit A, Tiollais P, Sarasin A, Transy C. Source: Oncogene. 1999 May 6; 18(18): 2860-71. http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_ uids=10362257&dopt=Abstract
•
The witch-doctor and tribal scarification of t